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vForeword
This report presents the first national burden of disease study for Australia. It uses the
disability-adjusted life year or DALY to measure the total impact of mortality and non-fatal
health outcomes in a consistent way across a comprehensive range of diseases and illnesses.
The DALY was developed for the Global Burden of Disease Study (GBD), undertaken in the
first half of the 1990s by researchers at the Harvard School of Public Health and the World
Health Organization. The GBD has generated considerable interest among health policy
makers and researchers, and an increasing number of national burden of disease studies are
now underway.
Over the last 18 months, AIHW has undertaken an Australian burden of disease study with
the assistance of funding from the Commonwealth Department of Health and Aged Care.
This study builds on Australian and international work to generate summary population
health information using the DALY metric and provide inputs on the size and causes of
health problems in Australia to assist national and State planning and priority setting for
public health, health services and research.
This report addresses the need for comprehensive and comparable information on the
causes of loss of health in the Australian population. The study provides the first detailed
and internally consistent estimates for Australia of the incidence, prevalence, duration,
mortality and disease burden for more than 175 disease and injury categories. It has also
taken first steps towards quantifying the burden associated with a range of risk factors and
health determinants, and with socieconomic disadvantage.
Burden of disease analysis provides a unique perspective on health—one that integrates
fatal and non-fatal outcomes, yet allows the two classes of outcomes to be examined
separately as well. This study is a first step towards exploring the usefulness of burden of
disease methods for Australia. The estimates published here should be seen as provisional
and developmental. If the types of information provided by burden of disease analysis are
seen to be useful, there will need to be further work to refine and further develop these
analyses, and to explore how to assess the disability associated with health conditions in the
Australian context.
Richard Madden
Director
November 1999
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Highlights
This report provides an overview of results from the Australian Burden of Disease and
Injury Study undertaken by the AIHW during 1998 and 1999. The Study uses the methods
developed for the Global Burden of Disease Study, adapted to the Australian context and
drawing extensively on Australian sources of population health data. It provides a
comprehensive assessment of the amount of ill health and disability, the ‘burden of disease’
in Australia in 1996.
Mortality, disability, impairment, illness and injury arising from 176 diseases, injuries and
risk factors are measured using a common metric, the Disability-Adjusted Life Year or
DALY. One DALY is a lost year of ‘healthy’ life and is calculated as a combination of years
of life lost due to premature mortality (YLL) and equivalent ‘healthy’ years of life lost due to
disability (YLD). This report provides estimates of the contribution of fatal and non-fatal
health outcomes to the total burden of disease and injury measured in DALYs in Australia
in 1996.
Key findings—mortality (YLL)
· Life expectancy at birth in 1996 was 75.6 years for Australian males and 81.3 years for
Australian females. Male life expectancy is six years lower than female life expectancy.
· Australia ranks around 10th in the world in terms of total life expectancy at birth.
Australia ranks fifth best in the world, behind Japan, Greece, Sweden and Italy in terms
of the probability of dying between ages 15 and 59.
· Males lost 26% more years of life than females. Cardiovascular disease, cancers and
injury were responsible for 72% of the total mortality burden in both males and females.
· In people aged 75 years and over, cardiovascular diseases account for more than half the
years of life lost, whereas cancers are a more important cause than cardiovascular
disease for all ages below 75. Injuries are the main cause of lost years of life in young
adults and children aged 5-14 years, and neonatal conditions the main cause in children
aged under five.
· Overall, the age-adjusted mortality burden in Australia has declined by 27% in the 15
years between 1981 and 1996. There have been substantial declines in the mortality
burden of cardiovascular diseases, road traffic accidents, low birthweight, and stomach
cancer for both males and females.
· The burden of smoking-related diseases has decreased in males but increased
substantially in females. In the 15 years from 1981 to 1996, the per capita mortality
burden for lung cancer and chronic obstructive pulmonary disease (COPD) decreased by
15% and 16% respectively for males, but increased by 62% and 70% respectively for
females.
· The largest increases in mortality burden have occurred for HIV/AIDS, suicide and
prostate cancer in males, and for senile dementias and heroin dependence and abuse in
both sexes, and for lung cancer and COPD in women.
· The mortality burden is significantly higher among socioeconomically disadvantaged
people. The most disadvantaged quintile of the Australian population lost 35% more
years of life than the least disadvantaged quintile in 1996.
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Figure 1: Probability of dying between ages
25 and 65, by quintile of socioeconomic
disadvantage and sex, Australia 1995-97
· Between 1986 and 1996, these socioeconomic differentials have remained similar for
females and for adult and older males, but have widened for boys and young men aged
15-24 years, particularly for motor vehicle accidents and suicide. They have narrowed for
drug overdose deaths (rates have increased faster in the top quintile than the bottom
between 1986 and 1996).
Key findings—disability (YLD)
· Mental disorders are the leading cause of years of life lost due to disability (YLD),
accounting for nearly 30% of the non-fatal burden of disease in Australia.
· Nervous system and sense organ disorders are each responsible for 16% of the disability
burden.
· Depression is the leading cause of non-fatal disease burden in Australia, causing 8% of
the total YLD in 1996. Hearing loss and alcohol dependence and harmful use are the
second and third leading contributors to non-fatal burden for males. Dementia and
osteoarthritis are the second and third leading contributors for females (Figure 2).
· In contrast to the mortality burden, the disability burden is almost identical for males
and females. The non-fatal burden of nervous system disorders, mental disorders and
musculoskeletal disorders are all higher for females than for males. The male burden is
higher for cardiovascular disease, diabetes, chronic respiratory diseases and cancers.
· Australian males born in 1996 can expect to live the equivalent of 68.7 years of good
health, compared to 73.6 years for females. Approximately 9% of total life expectancy at
birth is ‘lost’ due to disability for both males and females in Australia.
· For Australians aged less than 65, the
differential burden between the lowest
and highest quintile is even greater,
with a 60% excess burden in the most
disadvantaged group.
· The overall inequality in mortality
burden is 50% larger for males than
females in Australia. When analysed by
disease group, the inequality in
mortality burden is greatest for
maternal mortality, followed by ill-
defined conditions (sudden infant death
syndrome) in both sexes, followed by
digestive system diseases and injuries
in males.
· Men in the bottom quintile of
socioeconomic disadvantage have a
40% higher chance of dying between
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Figure 2: Leading causes of years of life lost due to disability (YLD), Australia 1996
Key findings—burden of disease and injury (DALYs)
· Inclusion of non-fatal health outcomes provides a substantially different picture to that
provided by traditional mortality statistics: mental disorders are now the third leading
cause of overall burden (14% of total) after cardiovascular diseases (20%) and cancers
(19%). Central nervous system and chronic respiratory conditions are almost as large a
contributor to total burden as injuries.
· The male burden (in total DALYs) is 13% higher than the female burden.
· The ten leading causes of the burden of disease in Australia for males and females are
shown below.
Males
Contribution to total burden
(per cent of total DALYs)   Females
Contribution to total burden
(per cent of total DALYs)
1 Ischaemic heart disease 13.6 1 Ischaemic heart disease 11.1
2 Stroke 4.8 2 Stroke 6.1
3 Lung cancer 4.5 3 Depression 4.8
4 COPD 4.2 4 Dementia 4.7
5 Suicide and self-inflicted injuries 3.3 5 Breast cancer 4.6
6 Road traffic accidents 3.0 6 COPD 3.2
7 Diabetes mellitus 3.0 7 Asthma 3.1
8 Depression 2.7 8 Diabetes mellitus 3.0
9 Colorectal cancer 2.7 9 Osteoarthritis 2.9
10 Dementia 2.5 10 Colorectal cancer 2.7
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· The total burden of disease and injury in Australia in 1996 is estimated to be 2.5 million
DALYs or 137 DALYs lost per 1,000 population. In other words, among each 1,000
people in the Australian population, during 1996 the lost years of healthy life
represented 13.7% of the total life years lived.
· Ischaemic heart disease and stroke lead the list, together causing nearly 18% of the total
disease burden. Chronic obstructive pulmonary disease and lung cancer (also smoking-
related diseases) are the third and fifth leading cause of disease burden, accounting for
another 7.3% of the total burden. Depression is the fourth leading cause of disease
burden in Australia, accounting for nearly 4% of the total burden.
· Inclusion of the attributable burden of cardiovascular disease due to diabetes increases
the burden of diabetes from 3% to 5% of total DALYs. Inclusion of the attributable
burden of suicide and ischaemic heart disease increases the total burden of depression
also from 3% to 5%, so that depression and diabetes are equal third leading causes of
burden of disease in Australia.
· The six National Health Priority Areas account for 70% of the total burden of disease
and injury in Australia, comprising 81% of the YLL and 57% of the YLD.
· Seven cancers have been identified as the focus of the cancer priority area—lung cancer,
skin cancer, cancer of the cervix, breast cancer, colorectal cancer, prostate cancer and
non-Hodgkin’s lymphoma. These cancers together account for around 61% of the
burden of cancer (DALYs) for men and 63% for women.
· The burden of mental disorders in Australia is dominated by affective disorders,
substance use disorders and anxiety disorders. Substance use disorders are the leading
cause of mental disorder for males, accounting for 33% of their mental health DALYs.
Alcohol abuse accounts for 59% of male substance use disorder DALYs. The major cause
of mental disorder for women is affective disorders, accounting for 39% of women’s
mental health DALYs. This is almost entirely depression (87%).
· The injury burden in Australia is dominated by suicide and self-inflicted injuries and
road traffic accidents, each of which accounts for 27% of the total injury burden. These
two causes, together with accidental falls, account for 64% of the total injury burden.
· Overall, diabetes causes almost as much disability burden (43% of total DALYs) as
mortality burden. The burden is relatively evenly shared between males and females,
with males responsible for 54% of the total burden of diabetes. Below age 55, the burden
is predominantly due to diabetes and its complications. Over age 55, more than 60% of
the burden is due to cardiovascular disease (heart disease, stroke and peripheral
vascular disease) attributable to diabetes.
· Asthma is responsible for 4.8% of YLD (non-fatal burden) and 2.6% of DALYs (total
burden) in Australia. The majority of the asthma burden is incident in childhood.
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Key findings—attributable burden of risk factors
· Risk factors such as smoking, physical inactivity, obesity, high blood pressure and high
cholesterol are responsible for a sizable proportion of the total burden of disease in
Australia as shown in Figure 3.
· To the extent possible, these estimates are based on studies that examined each risk
factor independent of other risk factors, but it is likely that the complexity of the
interaction between risk factors has not been captured fully. Therefore, caution is
warranted in the interpretation of these results. Despite these reservations, the
conclusion remains that each of these risk factors is responsible for large amounts of ill
health, ranking in size with the top-ten diseases. This suggests that large health gains
can be expected from effective public health interventions.
· Tobacco smoking is the risk factor responsible for the greatest burden of disease in
Australia, responsible for about 12% of the total burden of disease in males and 7% in
females.
· Physical inactivity is responsible for about 7% of the total burden of disease and
overweight and obesity for more than 4%.
· Hypertension causes over 5% of the total burden of disease and injury, and high blood
cholesterol nearly 3%.
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Figure 3: Proportion of total burden attributed to selected risk factors, by sex, Australia 1996
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· Inadequate fruit and vegetable intake is also responsible for around 3% of the total
disease burden. This burden relates to average consumption of less than 5 serves of fruit
or vegetables per day. Inadequate fruit and vegetable intake causes an estimated 11% of
the total cancer burden in Australia.
· The net harm associated with alcohol consumption is around 2.2% of total burden, as the
injury and chronic disease burden associated with harmful and hazardous levels of
alcohol consumption are offset by the burden of cardiovascular disease prevented by
alcohol consumption. The protective effect is only relevant after age forty-five, whereas
the harmful effects of alcohol are apparent at all ages.
· Illicit drugs are responsible for a similar level of harm to alcohol for males, at 2.2% of
total male burden. Just over half this burden is due to premature mortality, the other
half to YLD resulting from drug dependence or harmful use. Illicit drugs account for
about 1.3% of the total female burden.
· Unsafe sex is responsible for around 1% of the total burden of disease in Australia in
1996. HIV/AIDs accounts for 58% of the total burden of disease that is attributable to
unsafe sex, followed by cervix cancer (23%) and other sexually transmitted diseases
(8%). Table 7.18 shows the proportion of the total for males (1.1%) and females (0.8%).
· Occupational exposures to toxic chemicals and injury risks were responsible for an
estimated total of 2,005 deaths in Australia in 1996—1.6% of total deaths. Because many
of these deaths occur at younger ages, the mortality burden is a somewhat higher
proportion (2.0%) of the total mortality burden. The attributable burden of occupational
exposures is 1.7% of the total burden of disease and injury in 1996. Cancers are
responsible for 41% of this attributable burden, followed by injuries (33%) and other
chronic diseases (25%).
Conclusions
This report has addressed the need for comprehensive and comparable information on the
causes of loss of health in the Australian population.
· The study provides the first detailed and internally consistent estimates for Australia of
the incidence, prevalence, duration, mortality and disease burden for an exhaustive and
mutually exclusive set of disease and injury categories.
· It has also taken first steps towards quantifying the burden associated with a range of
risk factors and health determinants, including socioeconomic disadvantage.
While every attempt has been made to identify the best available information in relation to
each disease, injury and risk factor category, and to consult as widely as possible, it must be
emphasised that the estimates published here should be seen as provisional and
developmental. It is hoped that others will contribute to future improvements in data,
disease models and disability weights.
Burden of disease analysis provides a unique perspective on health—one that integrates
fatal and non-fatal outcomes, yet allows the two classes of outcomes to be examined
separately as well. This study, together with the parallel Victorian study (DHS 1999) are a
first step towards exploring the usefulness of burden of disease methods to provide
information to assist in health planning and priority setting in Australia.
11 Introduction
1.1 Purpose and background
Mortality and fertility rates are decreasing across the globe, resulting in ageing populations
and higher life expectancies. Developments in knowledge and medical technology are
contributing to a growing demand for health services and, in some cases, to higher costs of
providing these services. These and other factors are placing increasing pressure on health
budgets. In Australia and elsewhere there will be increasing focus on making choices, while
seeking both optimum health gain for health expenditure and fair and equitable access to
health interventions. Additionally, there is increasing public and policy concern to ensure
that non-fatal conditions (such as mental health problems and musculoskeletal disorders)
are appropriately reflected in health planning and priority setting.
Evidence-based evaluation of policies to improve health and reduce inequalities, and the
prioritising and resourcing of these policies, requires four basic types of information:
· a detailed assessment of the magnitude and impact of health problems in the
population, including information on the causes of loss of health in the population
(both in terms of diseases and injury, and risk factors or broader determinants), in order
to address the questions of what can be done to improve health and what are the best
buys for the health dollar;
· information on health expenditure and health infrastructure (a national system of
health accounts) detailing the availability of resources for health improvement and what
the resources are currently used for;
· information on the cost-effectiveness of available technologies and strategies for
improving health; and
· information on inequalities in health status, health determinants, and access to and use
of health services (including both prevention and treatment services).
Good information is available in Australia on disease causes of mortality, but these data
provide, at best, only indirect information on the health of the living and the causes of poor
health. Most ‘health’ data in Australia relate to the health care system, and then mainly its
inputs and throughputs. We know far more about the costs of health care and the numbers
of patients treated than we do about the health impacts of the treatments and the health of
the population in general.
This report addresses the first of these information needs by providing the first detailed and
internally consistent estimates for Australia of the incidence, prevalence, duration, mortality
and disease burden for an exhaustive and mutually exclusive set of disease and injury
categories. It uses a summary measure for disease burden which can also be used to
measure the health outcomes for cost-effectiveness analyses, allowing the linkage of
information on burden of disease, costs and health outcomes. This report also takes first
steps towards addressing the fourth of these needs with an analysis of inequalities in
mortality burden according to socioeconomic status.1 1
                                                  
1 Superscript numbers refer to technical notes in Appendix A. These contain additional explanatory
or technical information.
2Murray and Lopez (1996a) developed a new summary measure of population health, the
Disability-Adjusted Life Year or DALY, to provide information to support health policy and
priority setting at a global level. This was used to provide a comprehensive assessment of
the global burden of disease and injury in 1990 (World Bank 1993, Murray & Lopez 1996a,
1996b) and has been adopted by the World Health Organization (WHO) to inform global
health planning (WHO 1999a). The DALY was designed:
• to allow estimates of health impact to be mapped to causes, whether in terms of disease
and injury, or risk factors and broader social determinants;
• to provide a common metric for estimating population health impact and cost-
effectiveness of interventions;
• to use common values and health standards for all regions of the world2; and
• to provide a common metric for fatal and non-fatal health outcomes.
Box 1.1: Is it useful to know the size of health problems?
Some health economists have expressed concerns that burden of disease analyses may tempt planners
to set priorities in terms of size of problem, arguing that priority setting requires knowledge only of
cost-effectiveness ratios at the margins of current activity (Williams 1999, Mooney et al. 1997).
While it is certainly true that burden of disease estimates without economic analyses are insufficient
to make decisions on resource allocation, there are good reasons to do both.
First, a vast amount of work is needed to evaluate the cost-effectiveness of the myriad of existing and
potential health interventions. A lot of this work will need to be replicated in different countries to
incorporate context-specific effectiveness and costing data. Burden of disease assessments help to
choose those interventions for cost-effectiveness analyses that potentially can result in large health
gains3. The DALY was explicitly designed to address this need (Bobadilla et al. 1994, Murray and
Lopez 1996a, Ad Hoc Committee on Health Research Relating to Future Intervention Options 1996).
Burden of disease analysis will be particularly important for attempts at the macro-evaluation and
planning models required to make big steps in addressing the evaluation backlog. Burden of disease
studies of the type reported here provide a good understanding of how to model diseases in a
consistent way—this is very important for achieving standard approaches to modelling health
outcomes in cost-effectiveness studies.
Secondly, the size of problem is very relevant to monitoring and evaluating progress towards societal
goals. If our goal is to reduce unemployment, we need to monitor the level of unemployment as well
as the marginal cost of creating or finding jobs. Similarly, societal priorities are informed by the
burden of disease and injury as well the marginal costs of interventions.
Thirdly, where there are large or lumpy fixed costs associated with doing each additional activity, it
is not only the marginal cost-effectiveness that needs to be taken into account, but also the size of
each of the problems that can potentially be addressed. Examples where this occurs include policy
attention for major national health priorities, training of health professionals and research and
development.
According to economic theory, the greatest benefit is obtained from the intervention where there is the
greatest net present value. This does not always correspond with the highest cost-effectiveness ratio
as it reflects both the ratio and the absolute magnitude of the program. Burden of disease analysis
may provide a good first approximation to the potential magnitude of the benefit.
The size of the health problem is also very relevant to priority setting if equity is to be taken into
consideration. For example, suppose decision makers were told that an additional year of Indigenous
life could be purchased for $5,500 and an additional year of non-Indigenous life could be purchased
for $5,000 at the margin. They would surely also wish to know the relative size of the burden of
disease in each population and, after financing the health program or shifting some resources, the
changes in the overall burden of disease for each population.
3Increasingly, there is recognition that future progress in population health must address
health-related quality of life as well as quantity of life. In the last decade, health policy
makers have shown a marked increase in interest in the development, calculation and use of
summary health measures that combine mortality and morbidity (see Section 1.3). The
DALY methodology provides a way to link information on disease causes and occurrence to
information on both short-term and long-term health outcomes, including impairments,
functional limitations (disability) and, potentially, restrictions in participation in usual roles
(handicap), and death. The burden of disease methodology is designed to inform health
policy in relation to the prevention and treatment (cure or reduction in severity) of adverse
health outcomes. It is not designed to inform policy for the provision of social support or
welfare services for people with long-term disability or handicap.
1.2 Australian Burden of Disease and Injury Study
The Australian Burden of Disease and Injury Study has been carried out by the Australian
Institute of Health and Welfare (AIHW) using methods largely based on those developed
for the Global Burden of Disease study. The project commenced in June 1998 and part-
funding was contributed by the Commonwealth Department of Health and Aged Care. The
Victorian Department of Human Services has also carried out a state-level analysis of the
burden of disease for Victoria under the leadership of Dr Theo Vos. The two project teams
have worked closely together and shared methods and analyses. The Australian studies
have adapted the DALY methodology to suit the Australian context and the need for greater
detail in measuring the size of health problems that are important in Australia.
The Australian Burden of Disease and Injury project had three major aims:
• to review the Global Burden of Disease (GBD) methodology and its applicability for
Australian analyses and, where possible, improve the methods to make full use of
Australia’s relatively rich sources of population health data;
• to systematically compile and assess data on incidence, prevalence, case fatality and
severity for diseases and injury; and
• to estimate the burden of disease in Australia for diseases and injury, key risk factors
and selected priority populations (quintiles of socioceconomic disadvantage in the first
instance).
This report presents a detailed analysis of the findings of the Australian Burden of Disease
and Injury project. Details of the methods are presented in Chapter 2, which may be
skipped on first reading by those readers more interested in the results. Chapters 3 and 4
provide overviews of the burden of mortality and disability respectively. Chapters 5 and 6
provide an overview of the total burden of disease and injury in Australia, by cause, age
and sex. Chapter 7 provides estimates of the burden of disease and injury attributable to
selected risk factors in Australia.
The Australian Burden of Disease and Injury Study is the first attempt in Australia to carry
out a systematic and comprehensive national analysis of the incidence, prevalence,
remission, case fatality and severity of diseases, ensuring internal consistency and using a
common currency to measure the burden of mortality and morbidity. This report provides
estimates of burden for 176 disease and injury categories involving analysis of 1,260 stages,
severity levels and/or sequelae.
While every attempt has been made to identify the best available information in relation to
each disease and injury category, and to consult as widely as possible, it must be
4emphasised that the estimates published here should be seen as provisional and
developmental. For some conditions, it was not possible to go beyond simple models and
assumptions about some key parameters, in the time frame available. For many conditions,
all required information was not available and analyses drew on overseas studies or expert
opinion. The analyses carried out for this study will provide a framework for more detailed
analysis of particular conditions and guidance in identifying data gaps and deficiencies. It is
hoped that further improvements over time in methods, models and data will result in
increasing accuracy and certainty in estimates of burden of disease in Australia.
Box 1.2: Comments and feedback
Comments and feedback on methods and assumptions or on estimates presented in this report are
welcome and are a crucial input to improving future estimates. Comments should be sent to:
Australian Burden of Disease and Injury Study
Australian Institute of Health and Welfare
GPO Box 570, Canberra, ACT 2601
Australia
or e-mailed to: bod@aihw.gov.au
1.3 Disability-Adjusted Life Years
In order to include the impact of both premature death and health problems among those
who are alive, a common currency or metric is required. The DALY uses time as a common
currency, as do most other summary measures developed to date. The DALY extends the
concept of potential years of life lost due to premature death (PYLL) to include equivalent
years of ‘healthy’ life lost by virtue of being in states of poor health or disability. DALYs for
a disease or health condition are calculated as the sum of the years of life lost due to
premature mortality (YLL) in the population and the years lost due to disability (YLD) for
incident cases of the health condition:
 YLD YLL=DALY  +
The loss of healthy life due to non-fatal health conditions (YLD) requires estimation of the
incidence of the health condition (disease or injury) in the specified time period. For each
new case, the number of years of healthy life lost is obtained by multiplying the average
duration of the condition (to remission or death) by a severity weight that quantifies the
equivalent loss of healthy years of life due to living
with the health condition or its sequelae. The DALY
is described in detail in Murray and Lopez (1996a).
The Australian studies depart from the GBD
methods in the following areas (see Chapter 2 for
further details):
· Australian cohort life expectancies for 1996 are used to calculate years of life lost due to
mortality;
· age weights are not used;
One DALY is one lost
year of ‘healthy’ life.
5· disability weights for non-fatal health outcomes are derived from a recent Dutch study,
supplemented by weights used in the Global Burden of Disease Study for some
conditions; and
· some adjustments are made for the effects of comorbidity between conditions.
1.4 Summary measures of health
The simplest and most widely used method for producing population health statistics is to
aggregate data on individuals in order to generate statistics like the proportion of the
population (or of a particular age–sex group) suffering from a particular health problem or
in a particular health state. This approach rapidly becomes unwieldy when a number of
problems are being monitored and we want to make comparisons over time, across
population groups, or before and after some health intervention. We are then faced with an
explosion in the numbers of statistics that must be compared.
Summary measures of population health are measures that combine information on
mortality and non-fatal health outcomes to represent population health in a single number
(Field and Gold 1998). In the past decade, there has been a marked increase in interest in
the development, calculation and use of summary measures. Their range of potential
applications include:
· comparing of health conditions or overall health status between two populations or the
same population over time;
· quantifying health inequalities;
· ensuring that non-fatal health outcomes receive appropriate policy attention;
· measuring the magnitude of different health problems using a common currency;
· analysing the benefits of health interventions for use in cost-effectiveness studies;
· providing information to assist in setting priorities for health planning, public health
programs, research and development, and professional training (Murray, Salomon &
Mathers 1999).
Two classes of summary measure have been developed: health expectancies (e.g. disability-
free life expectancy, active life expectancy) and health gaps (disability-adjusted life years,
healthy life years etc.). Both classes of summary measure use time (lived in health states or
lost through premature death) as an appropriate common metric for measuring the impact
of mortality and non-fatal health outcomes.
Health expectancies are population indicators that estimate the average time (in years) that a
person could expect to live in a defined state of health. Examples include disability-free life
expectancy (DFLE), active life expectancy and disability-adjusted life expectancy. These
extend the concept of life expectancy to refer to expectations of various states of health, not
just of life per se. During the last ten years, the International Network on Health Expectancy
(REVES) has promoted and developed the concept and methods and it is now widely used
at national level and by the Organization for Economic Co-operation and Development
(OECD) to report on population health (Mathers & Robine 1993, OECD 1998).
Measures of potential years of life lost due to premature mortality have been used for many
years to measure the mortality burden of various causes of death. These all measure the gap
in years between age at death and some arbitrary standard age before which death is
considered ‘premature’ (typically 65 years or 75 years). Health gaps extend the notion of
mortality gaps to include time lived in states other than excellent health. The most widely
6Box 1.3: Health gaps and health expectancies
The relationship between health expectancies and health gaps can be illustrated using a population
survival curve (Mathers 1997a). The survival curves in Figure 1.1 are constructed by following a
birth cohort over time and plotting for each year (age) the proportion who are still alive and the
proportion who are in good health. The curve bounding area C is the usual survival curve of the type
typically used to construct a lifetable and the total area (A+B) underneath it represents life
expectancy at birth. Health expectancies are measures of the area underneath the survival curve that
either give zero weight to years lived in the area labelled B (as in DFLE) or take some proportion of
area B to represent its equivalent years of good health. Health gaps measure the difference between
the population experience and some ideal or goal for population health. Thus if the ideal was taken to
be 95 years of good health followed by death, then the mortality gap would be area C in Figure 1.1.
The health gap would be area C plus some proportion of area B representing the equivalent lost years
of good health.
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Figure 1.1: Population survival curves, health expectancies and health gaps
known of these is the disability-adjusted life year or DALY. These have been used to guide
World Bank investment policies for health and to inform global priority setting for health
research and international health programs (World Bank 1993, Ad Hoc Committee on
Health Research Relating to Future Intervention Options 1996, WHO 1999a). Time-based
health gap measures offer the possibility of using a common metric for population health
and for the outcomes of interest in randomised control trials, in cohort studies and in some
health services administrative datasets.
Figure 1.2 shows a simplified schema relating causes (determinants, diseases and injuries) to
impairments and disability. DALY calculations start from information on diseases and
injuries (incidence, prevalence and duration) and estimate the associated impairments and
disability in order to quantify the total burden. Using attributable fraction methods, it is also
possible to estimate the attributable burden of specific risk factors or health determinants.
Health expectancy calculations, on the other hand, have generally started with population
data on disabilities (the right-most box in Figure 1.2) in order to estimate expectations of
years lived in various health states. Attempts have been made to relate health expectancies
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Figure 1.2: Relating causes to outcomes
back to disease and risk factor causes using data from population disability surveys on the
health conditions contributing to the disability (Mathers 1992, Bone et al. 1995, Nusselder et
al. 1996, Mathers 1997b). However, there are severe problems with the quality and compar-
ability of self-reported data on the disease and injury causes of disability which limit the
usefulness of such data for analysis of the non-fatal outcomes for most diseases and injury
(Mathers 1997b, 1999b).
All summary measures of population health involve explicit or implicit social value choices.
For example, mortality-based indicators do not evaluate non-fatal loss of health, potential
years of life lost indicators ignore deaths beyond an arbitrary age (e.g. 65 years), and
disability-free life expectancy indicators do not place any positive value on years lived with
disability.
In particular, health gap measures such as the DALY measure the gap between a
population’s actual health status and some ‘ideal’ or reference status. In developing the
DALY indicator, Murray and Lopez (1996a) identified five value choices that should be
explicitly made:
· How long ‘should’ people in good health expect to live? This must be decided in order
to calculate how many years are lost through death at any given age (see Section 2.4).
· How should we compare years of life lost through death with years lived with poor
health or disability of various levels of severity? Issues involved in making these ‘health
state valuation’ choices are discussed in the next section (Section 1.5).
· Is a year of healthy life gained now worth more to society than a year of healthy life
gained in 20 years’ time? This value choice (the discount rate) is discussed in Section
1.6.
· Are lost years of healthy life valued more at some ages than others? Is a year of life at
young adult ages valued more than in old age or infancy? This value choice is discussed
in Section 1.7.
· Are all people equal? Should these values be determined at local or national level for
country analyses and at national or international level for cross-national comparisons?
Murray (1996) explicitly sought to build egalitarian principles into the DALY, and the
Global Burden of Disease Study used the same values for all regions of the world. It used
the same life expectancy ‘ideal’ standard for all population subgroups, whether or not their
current life expectancy was lower than that of other groups. It excluded all non-health
characteristics (such as race, socioeconomic status or occupation) apart from age and sex
from consideration in calculating lost years of healthy life. Most importantly, it used the
8same ‘disability weight’ for everyone living a year in a specified health state. The meaning
and estimation of these disability weights is described in the following section.
1.5 Comparing time lived in different health states
In order to use time as a common currency for non-fatal health states and for years of life
lost due to mortality, we must define, measure and numerically value time lived in non-fatal
health states. The ‘valuation’ of time lived in non-fatal health states formalises and
quantifies social preferences for different states of health as health state weights.
This is a critical step in combining information on mortality and non-fatal health outcomes
into summary measures. Without the use of such weights, summary measures of
population health cannot be responsive to changes in the severity distribution of health
states (Wolfson 1998, Murray, Salomon and Mathers 1999). Depending on how these
weights are derived, they are variously referred to as disability weights, quality-adjusted life
year (QALY) weights, health state valuations, health state preferences or health state
utilities. Most such weights are measured as a number on a scale of 0 to 1, where 0 is
assigned to a state comparable to death and 1 is assigned to a state of ideal health.
While death is not difficult to define, non-fatal health states are. Non-fatal outcomes of
disease are different from each other in their impact on the individual, and the impact on
the individual is mediated by contextual factors including personal characteristics and the
physical and social environment. Non-fatal outcomes of disease involve multiple domains
of health: on what basis can we weight and then aggregate various aspects of an
individual’s health such as mobility, anxiety and pain?
What aspects of health should be included in a weight?
WHO defines health as ‘a state of complete physical, mental and social wellbeing and not
merely the absence of disease or infirmity’ (WHO 1946). This definition is so broad that it
could be read as equating health with total wellbeing or quality of life. The latter concepts
include domains of wellbeing such as economic wellbeing, life satisfaction and spiritual or
existential wellbeing that are usually seen as being distinct from health (although influenced
by it and influencing it). The inclusion of these aspects of wellbeing in the WHO definition
has made the development of practical measures of health difficult to achieve.
One common approach is to describe health as a profile of levels on a series of domains. The
SF-36 is an example of such an instrument, with eight domains covering self-perceived
health, vitality, bodily pain, mental health, physical functioning, social functioning, and role
limitations (Ware & Sherbourne 1992). SF-36 domains are scored on continuous scales from
0 to 100, resulting in a large number of potential health states. Health state profiles intended
for use with health state valuations tend to use a more limited number of levels in each
domain4.
Ideally, any weighting exercise for use in burden of disease analysis or economic evaluation
should measure preferences for clearly defined health states. The Global Burden of Disease
Study asked participants in weighting exercises to make a composite judgement on the
severity distribution of the condition and the preference for time spent in each severity
level5. This was to a large extent necessitated by the lack of population information on the
severity distribution of most conditions at the global and regional level. The Netherlands
has also carried out a project to measure weights for 53 diseases of public health importance
using a methodology consistent with the GBD study (Stouthard et al. 1997). This study used
9more specific disease stages or severity levels so that judgements were not required on the
distribution of disease stages or severity levels in the population. In addition, the Dutch
defined each disease stage in terms of the associated average levels of disability, handicap,
mental wellbeing, pain and cognitive impairment using a modified version of the EuroQol
health status instrument (see Section 2.5 for details). Some examples of disability weights
from the Dutch study are shown in Table 1.1.
Table 1.1: Some examples of disability weights from the Dutch study
Weight Disease stage, severity level or sequela
0.00 – 0.01 Gingivitis, dental caries
0.01 – 0.05 Mild asthma, mild vision loss, mild hearing loss, basal cell skin cancer
0.05 – 0.05 Low back pain, uncomplicated diabetes case, mild stable angina (NYHA 1-2)
0.10 – 0.15 Mild depression, osteoarthritis (radiological grade 2) of hip or knee, epilepsy
0.15 – 0.20 Mild/moderate panic disorder, spina bifida (sacral), HIV seropositive
0.20 – 0.30 Non-invasive breast cancer or tumour < 2 cm (diagnostic/treatment phase),
anorexia, mild/moderate obsessive-compulsive disorder
0.30 – 0.40 Moderate depression, multiple sclerosis in relapsing-remitting phase, severe
asthma, chronic hepatitis B infection with active viral replication, deafness
0.40 – 0.50 Severe vision loss, medium-level spina bifida (L3–L5), osteoarthritis (grade 3–4),
operable small cell lung cancer, moderate intellectual disability (IQ 35–49)
0.50 – 0.65 Paraplegia, AIDS (first stage), severe chronic bronchitis or emphysema
0.65 – 0.80 Disseminated breast cancer, severe depression, moderately severe brain injury
resulting in permanent impairments, extreme intellectual disability (IQ<20)
0.80 – 1.00 Severe schizophrenia, disseminated colorectal cancer, severe dementia, alcoholic
psychosis, quadriplegia, stroke with multiple permanent impairments, end-stage
Parkinson’s disease
Source: Stouthard et al. 1997.
In the terminology of the International Classification of Impairments, Disabilities and
Handicaps (ICIDH), the term disability has referred to functional limitation at the level of
the individual, handicap to the impact of impairments and disabilities in carrying out usual
roles, given the particular social context of the individual (WHO 1980). In the current draft
revision of the ICIDH, the term disability is used more broadly to refer to impairments,
functional limitations and participation restrictions (handicap).6
Following the GBD terminology, and consistent with the proposed revision to ICIDH, the
term disability is used broadly in this report to refer to departures from good or ideal health
in any of the important domains of health. These include mobility, self-care, participation in
usual activities, pain and discomfort, anxiety and depression, and cognitive impairment, as
summarised in the modified EuroQol descriptions used in the Dutch study. The reference
state for good or ideal health is defined as a health state where the individual has:
· no pathological processes (disease or disease precursors);
· no mental health problems, no injuries;
· no impairments resulting from congenital, disease or injury causes; and
· no functional limitations resulting from current or former health problems or
impairments.
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In some contexts, the word ‘healthy’ is understood to mean ‘absence of illness’. In this
document, health is given a broader meaning. As well as implying absence of illness there
are also no impairments or functional limitations due to previous illness or injury.
We thus refer to disability weights and years lost due to disability (YLD) as shorthand terms for
health state preferences and years of healthy life lost due to time lived in states other than
the reference state of good health, respectively. A year of healthy life refers to a year lived in
the reference state of good health. Note that disability (i.e. states other than ideal health)
may be short-term or long-term. A day with a common cold is a day with disability.
How can we obtain weights for time lived in health states?
A number of methods have been developed for measuring preferences for health states.
Four general approaches that involve asking people to compare various health states are
outlined in the box below. The different methods reflect different concepts of what is being
measured (utilities or preferences), differences in application (individual/clinical decision
making or health program planning), and in viewpoint (valuing own health states or those
of others).7
We must ensure that the method used provides the appropriate type of value, is consistent
with the uses to which the resulting summary measures will be put, and summarises the
preferences of the appropriate people. Burden of disease analyses use the person trade-off
(PTO) method, as this more directly attempts to measure social preferences for health states
than the other methods.8 A deliberative approach is used with small groups of people in
order to produce weights that meaningfully reflect social preferences for health states. The
deliberative approach ensures that the people involved understand and are aware of the
implications of their choices.9
Box 1.4: Methods for valuing health states
Rating scales—Two health states are displayed on a chart (sometimes a thermometer) with the most
preferred health state rated 100, and the least preferred state (or sometimes death) rated 0. Subjects
are asked to indicate on the chart where other health states would rank.
Standard gamble—Subjects are asked to consider two alternatives. In one alternative their health
state is certain (e.g. the state under consideration). In the other alternative there are two possible
health states, one better than the certain state (e.g. ideal health) and one worse (e.g. dead) and the
probability that the best state occurs is p. The probability p is varied until the subject is indifferent
between the two alternatives. The probability p at the point of indifference is the ‘utility’ of the health
state under consideration.
Time trade-off—Subjects are asked to choose between one health state for a specified period of time
(say 10 years) or a shorter life in good health. The length of the shorter life is varied until the subject
is indifferent between the two.
Person trade-off—Subjects are asked to choose, as health decision makers or as consumers
purchasing an insurance plan, between a lesser health benefit for a larger number of people against a
larger benefit for a smaller number of people. An example of person trade-off is to ask subjects to
choose between saving a larger number of lives and leaving them in a specified state of less than ideal
health and saving a smaller number of lives and restoring them to ideal health.
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Whose weights should be used?
As well as representative samples of the general population, groups asked to numerically
value health states may include health professionals with knowledge of health states, or
people with direct experience of the health states involved. Whose weights should be used
depends on the purpose for which the weights will be used. There is a growing consensus
among health economists that health state preferences should reflect the preferences of the
general population when they are to be used as part of a process of broad health policy
development, priority setting or resource allocation (Gold et al. 1996, Ubel, Richardson and
Menzel 1999).10 However, the preferences of the individual come into play when deciding
on choices or allocations for an individual client or patient.
The GBD weighting studies used small groups of health experts who were asked to
determine weights for a set of indicator health conditions using PTO methods in a
deliberative process (Murray 1996). Health experts were used for convenience reasons due
to the practical difficulties in ensuring that lay persons fully understood the impact and
severity distribution of the conditions being valued. The Dutch disability weight study
attempted to address this problem by defining the distribution of health states associated
with a disease stage, sequela or severity level using the modified EuroQol health profile to
describe the health states. The Dutch project used three panels of physicians with broad
medical knowledge and experience and one lay panel comprising people with an academic
background but no medical knowledge (Stouthard et al. 1997). Few differences were seen in
the average PTO preferences assigned by the lay panel compared with those of the panels of
medical experts. The Dutch study concluded that it makes little difference whether the
valuation panel is composed of health care experts or lay people, as long as accurate
functional health state descriptions are included in the specifications of the health problems
being valued.
Another aspect of the question of whose weights to use is whether social preferences for
health states vary within or across populations. It seems very possible that health state
preferences could vary markedly between populations that have different cultural beliefs,
conceptualisations of health, and expectations for health and wellbeing. To date, however,
there is little empirical evidence that social preferences for health states derived using
deliberative methods vary markedly across populations. The GBD carried out health state
preference studies in over ten countries and found surprisingly high levels of consistency
between weights for 22 indicator conditions spanning a wide range of severity (Murray &
Lopez 1996a).11
Interpreting disability weights
The disability weights used in DALY calculations quantify societal preferences for different
health states. They range from 0 representing a state of good or ideal health (preferred to all
other states) to 1 representing states equivalent to being dead. These weights do not
represent the lived experience of any disability or health state, or imply any societal value of
the person in a disability or health state. Rather they quantify societal preferences for health
states in relation to the societal ‘ideal’ of good health.
Thus a weight for paraplegia of 0.57 does not mean that a person in this health state is ‘half
dead’, that they experience their life as halfway between life and death, or that society
values them as a person less than anyone else. It means that, on average, society judges a
year with blindness (weight 0.43) to be preferable to a year with paraplegia (weight 0.57),
and a year with paraplegia to be preferable to a year with unremitting unipolar major
depression (weight 0.76). It also means that, on average, society would prefer a person to
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have a year in good health followed by death than a year with paraplegia followed by
death. As well, society would prefer a person to live three years with paraplegia followed by
death than have one year of good health followed by death (3 years x (1-0.57) = 1.3 ‘healthy’
years is greater than 1 year of good health).
All other things being equal, society would prefer to prevent or cure a case of paraplegia
(weight 0.57) rather than a case of low back pain (weight 0.06), if each case could be restored
to full function for the same cost and there were insufficient resources to do both. However,
the use of health state preferences and DALY or QALY measures to quantify loss of health
or health gain carries no implication that society will necessarily choose the maximisation of
health gain as the main or only goal for the health system12. Additionally, the disability
weights should not be further interpreted as giving a value to the maximum benefit
obtained by saving the life of a person with that health problem, but leaving them in the
health state. We should not interpret a weight of 0.5 for paraplegia as meaning that saving
the life of a paraplegic person (but not changing their disability status) is given only half the
value of saving the life of a person in good health (Menzel et al. 1999, Nord et al. 1999).
1.6 Discounting
The DALY measures the future stream of healthy years of life lost due to each incident case
of disease or injury. It is thus an incidence-based measure rather than a prevalence-based
measure. The GBD applied a 3% time discount rate to years of life lost in the future to
estimate the net present value of years of life lost. With this discount rate, a year of healthy
life gained in 10 years’ time is worth 24% less than one gained now.13
Discounting of future benefits is standard practice in economic analysis14 and there are some
specific arguments for applying discounting to the DALY in measuring population health
(Murray and Acharya 1997):
· to be consistent with measurement of health outcomes in cost-effectiveness analyses;
· to prevent giving excessive weight to deaths at younger ages (without discounting, a
death at age zero results in 50% more YLL than a death at age 25 and 100% more than a
death at age 40); and
· the disease eradication/research paradox: assuming that investment in research or
disease eradication has a non-zero chance of succeeding, then without discounting, all
current expenditure should be shifted to such investment because the future stream of
benefits is infinite. This is a particular case of the excessive sacrifice argument.15
A number of people have argued that discounting should not be applied to future health
gains or losses16 and discounting is rarely used by epidemiologists and demographers for
summary health measures. Murray and Acharya (1997) concluded that the strongest
argument for discounting is the disease eradication/research paradox and that the social
discount rate should be smaller than average individual discount rates. They noted,
however, that the choice of a discount rate for health benefits, even if technically desirable,
may result in morally unacceptable allocations between generations. Because the discount
rate issue is not easily resolved, the GBD published discounted and undiscounted estimates
of the global burden.
A discount rate of 5% per annum has been standard in much health economic and other
social policy analyses for many years. Environmentalists and renewable energy analysts
have argued in recent decades for lower discount rates for social decisions17. The World
Bank Disease Control Priorities Study and the Global Burden of Disease project both used a
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3% discount rate.18 The US Panel on Cost-Effectiveness in Health and Medicine recently
recommended that a 3% real discount rate be used in health economic analyses to adjust
both costs and health outcomes (Gold et al. 1996), but that the sensitivity of the results to the
discount rate should be examined. As discussed in Section 2.3, the Australian Burden of
Disease Study has used a 3% discount rate.
1.7 Age weights
The Global Burden of Disease Study weighted a year of healthy life lived at young ages and
older ages lower than for other ages.19 This choice was based on a number of studies that
have indicated there is a broad social preference to value a year lived by a young adult more
highly than a year lived by a young child or at older ages (Murray and Lopez 1996a). Not all
such studies agree that young ages as well as older ages should be given less weight or on
the relative magnitude of the differences.
The age weights are the single most controversial value choice built into the DALY.
Criticisms of the age weights have fallen into five categories:
· age-weighting is unacceptable on equity grounds (every year of life is of equal value
a priori) (Anand and Hanson 1997);
· the age weights are arbitrary and have not been validated for large populations;
· the age weights do not reflect social values (for example the DALY values the life of a
newborn about equally to that of a 20 year old whereas the empirical data suggest a
4-fold difference (Bobadilla 1996);
· when applied to discounted YLL, the age weights result in higher weights being given
to all ages from 0–27 (Barendregt et al. 1996); and
· they add an extra level of complexity to the burden of disease analysis which obscures
the method, and makes little overall difference to the rankings.
Murray and Acharya (1997) have argued that age weights are not in themselves inequitable,
because everyone potentially lives through every age, and that they do reflect legitimate
societal priorities. As discussed in Section 2.3, the Australian burden of disease studies use
uniform age weights so that a year of healthy life is valued equally at all ages.
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2 Methodology
2.1 Overview
The DALY extends the concept of potential years of life lost due to premature death (PYLL)
to include equivalent years of ‘healthy’ life lost by virtue of being in states other than good
health. DALYs for a disease or health condition are calculated as the sum of the years of life
lost due to premature mortality (YLL) in the population and the equivalent ‘healthy’years
lost due to disability for incident cases of the health condition:
 YLD YLL=DALY  +
The loss of healthy life due to non-fatal health conditions (YLD) requires estimation of the
incidence of the health condition (disease or injury) in the specified time period. For each
new case, the number of years of healthy life lost is obtained by multiplying the average
duration of the condition (to remission or death) by a severity weight that measures the loss
of healthy life using an average health state weight. The DALY is described in detail in
Murray and Lopez (1996a).
The Australian study departs from the GBD methodology in the following five areas:
· The GBD uses a standard life table with a life expectancy at birth of 82.5 years for
females and 80.0 years for males to calculate YLL. Australian cohort life expectancies
that take projected future declines in mortality into account are higher than this: 85.7
years for females and 81.5 years for males. The Australian project uses Australian
cohort life expectancies for 1996 to calculate YLL.
· The GBD discounted DALYs using a 3% time discount rate and applied age weights
that gave higher weight to a year of life in young and mid-adult years, and lower
weight to a year of life at very young and older years. The Australian project also uses a
3% discount rate but does not use age weights.
· The Australian study uses a set of Dutch weights for conditions common in developed
countries, supplemented by weights used in the GBD study for other conditions. In
general, the Dutch and GBD weights are reasonably consistent, but in the longer term it
would be desirable to carry out weighting exercises in Australia to examine how
appropriate the weights are in the Australian context.
· The Australian study includes a wider range of disease and injury categories than the
GBD.
· The GBD did not attempt to deal with the effects of comorbidities on YLD estimates for
individual diseases. The Australian study adjusts YLD estimates for comorbidities
between mental disorders and between physical disorders at older ages.
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2.2 Analysis categories
Estimates of burden of disease have been made for a comprehensive set of 176 disease and
injury categories. Following the classification scheme used by the GBD study, disease and
injury categories were grouped in three broad cause groups:
· Group I: Communicable, maternal, neonatal and nutritional conditions;
· Group II: Noncommunicable diseases; and
· Group III: Injuries.
Each of these groups is then subdivided into subcategories (22 in total), most of which
correspond to chapter-level groups of ICD-9 codes. These are further divided into 176
individual disease and injury categories, such as hepatitis B infection, breast cancer, and
accidental falls. Annex Table A lists these categories and defines them in terms of ICD-9
codes.
Estimates of burden of disease have been made for these condition categories using the
following age groups:
0–4, 5–14, 15–24, 25–34, 35–44, 45–54, 55–64, 65–74, 75+.
Detailed estimates for YLL, YLD and DALYs in Annex Tables E–H are presented in terms of
20-year age groups for reasons of space. Full estimates by 10-year age groups are available
on request. Analyses to be carried out for subpopulations below national level are limited at
this stage to population quintiles of relative socioeconomic disadvantage (using a small-
area-based index derived from census data).
2.3 Discounting and age weights
The main results reported here for the burden of disease and injury in Australia use DALYs
calculated with a 3% discount rate (see Section 1.6). The effect of discounting on years of life
lost due to mortality is shown in Figure 2.1 in the following section. The effect of
discounting on the pattern and distribution of disease burden in Australia is examined in
Section 5.5.
As discussed in Section 1.7, the DALY allows for non-uniform age weights. The particular
age weights used in the GBD result in greater weight being given to all deaths below age 38
compared to deaths at older ages for Australia. The Steering Committees for both the
Australian and Victorian burden of disease studies decided that uniform age weights should
be used. All results in the Australian study reported here use uniform age weights (K=0 in
the terminology of the GBD).
2.4 Years of life lost due to mortality
Years of life lost due to mortality (YLL) are the mortality component of DALYs. The GBD
Study calculated the years of life lost due to a death at a given age using the life expectancy
at that age in standard life tables (Coale and Demeny West Model Level 26) with life
expectancy at birth fixed at 82.5 years for females and 80.0 years for males.20 Murray (1996)
argued that there is evidence for an intrinsic biological difference in life expectancy for
males and females, but that it is much less than the approximately 5–7 years observed in
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developed countries. Much of this excess is due to higher male exposure to various risks,
e.g. alcohol, tobacco, occupational exposures—and arguably should not be allowed for in
estimates of the burden of mortality.
The Steering Committee for the Australian Burden of Disease and Injury Study decided that
cohort life expectancies for Australians alive in 1996 should be used to estimate the burden
of premature mortality. Unlike the usually quoted ‘period’ life expectancies (ABS 1999c),
which synthesise the currently observed mortality patterns across all age groups in the
population, cohort life expectancies use projected trends in mortality rates to estimate the
average life expectancies likely to be achieved by people currently alive.
Projections of Australian mortality rates to the year 2051 (ABS 1998a) were used to estimate
cohort life expectancies by age and sex for Australians alive in 1996.21 The projected cohort
life expectancy for infants born in 1996 is 81.5 for males and 85.7 for females, compared to
period life expectancies at birth in 1996 of 75.6 and 81.3 respectively. The male–female
difference is around 4.2 years compared to 5.7 for the period life expectancies and 2.5 for the
GBD.
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Figure 2.1: Years of life lost according to age at
death, Australian cohort life expectancies 1996
and GBD standard life expectancies
The mean life expectancy in each age interval was then discounted using the formula:
 0.03 / 0.03L) exp(  (1 =  YLL --
where L is the life expectancy. The effect of discounting on years of life lost due to mortality
is shown in Figure 2.2. Cohort life expectancies for cohorts alive at various ages in 1996 and
YLLs due to a death at each of these ages are shown in Table 2.1. Note that YLLs are lost
due to deaths at every age. A death at age 95 results in a loss of YLLs. Unlike most potential
years of life lost (PYLL) measures, YLLs do not exclude deaths above a certain age level, or
give zero value to years of life lost above that age level.
Figure 2.1 compares the 1996
Australian cohort life expectancies
with the GBD standards. There is
very little difference (and if
discounting is applied this almost
completely disappears).
If Australian YLL are calculated
using the GBD standard life tables
rather than the cohort life tables, the
differences are small. At 3%
discounting, they become
negligible.
For each age category used in this
study, mean cohort life expectancy
was calculated from the observed
mean age at death in the age
interval and interpolation between
the cohort life expectancy estimates
at the exact ages defining the age
interval.
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Figure 2.2: Effect of discounting on YLL for deaths at various ages
Table 2.1: Projected cohort life expectancies at selected exact ages and discounted YLL due to a
death at each age used in the Australian Burden of Disease and Injury Study
Life expectancy (years) YLLs due to a death at each age (discounted at 3%)
Age (years) Males Females Males Females
0 81.45 85.69 30.44 30.78
5 76.88 81.20 30.01 30.42
15 66.22 70.87 28.76 29.36
25 55.92 60.55 27.11 27.91
35 45.65 50.16 24.86 25.93
45 35.43 39.82 21.82 23.24
66 25.50 29.85 17.82 19.72
65 16.75 20.56 13.17 15.34
75 9.89 12.50 8.55 10.42
85 5.39 6.64 4.97 6.02
95 3.30 3.49 3.14 3.32
2.5 Disability weights
The DALY uses explicit preference weights for health states derived using a deliberative
person trade-off (PTO) method (see Section 1.5). No comprehensive Australian
measurements of disability weights have yet been undertaken. The Netherlands has carried
out a project to measure weights for 53 diseases of public health importance, involving the
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estimation of weights for 175 disease stages, sequelae and severity levels (Stouthard et al.
1997).
The Dutch weights only cover a restricted range of conditions, but they differentiate
between different condition stages and severities. Hence they can be applied more directly
to detailed disease models in estimating YLD and allow Australian information on the
severity distribution of each disease to be taken into account. Further the conditions they
focus on are also those of most relevance to the health of the Australian population.
The Dutch weights also have the great advantage that they define each disease stage or
sequela in terms of a standardised health state description using a variant of the EuroQol 5D
classification, the EQ-5D+, which includes a sixth dimension for cognitive functioning (see
Box 2.1). For many conditions, either there are no standard clinical definitions of severity or
stages, or available Australian population data do not use these definitions. The availability
of standardised health state descriptions in the Dutch study has greatly assisted in defining
and estimating distributions of severity levels from Australian population data. The
estimation of the burden of mental disorders from the 1997 National Mental Health Survey
provides an example of this (see Section 5.2).
The GBD weights cover a wider range of conditions, but generally for less specific disease
and sequelae categories. The exception is injury, where the GBD has a much more
comprehensive set of weights for the short-term and long-term sequelae of 39 types of
injury. For this first Australian Burden of Disease and Injury Study, we have used Dutch
weights where possible. For disease and injury categories where Dutch weights are not
available, we have generally used the GBD weights if these are available.
Box 2.1 The EuroQol 5D+ classification for health status (Stouthard et al. 1997)
Dimension Level Code
Mobility No problems in walking about
Some problems in walking about
Confined to bed
1
2
3
Self-care No problems with washing or dressing self
Some problems with washing or dressing self
Unable to wash or dress self
1
2
3
Usual activities No problems performing usual activities (e.g. work,
study, housework, family, leisure)
Some problems with performing usual activities
Unable to perform daily activities
1
2
3
Pain/discomfort No pain or discomfort
Moderate pain or discomfort
Extreme pain or discomfort
1
2
3
Anxiety/
depression
Not anxious or depressed
Moderately anxious or depressed
Extremely anxious or depressed
1
2
3
Cognition No problems in cognitive functioning (e.g. memory,
concentration, coherence, IQ)
Some problems in cognitive functioning
Extreme problems in cognitive functioning
1
2
3
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Figure 2.3: Comparison of GBD and Dutch weights for 54
comparable disease and injury categories
The two sets of disability weights cannot be directly compared for most conditions because
the disease categories in the Dutch study are more specific.22 There are 54 disease and injury
categories in the Australian study where Dutch weights were used and GBD weights are
also available. Figure 2.2 compares the Dutch and GBD disability weights for these 54
conditions. In some cases, the GBD weight for a disease category has been compared with
the average Dutch weight across a range of disease stages or sequelae using Australian
information on stage/sequelae distributions.
The correlation coefficient for these two sets of disability weights is 0.91 and the line of best
fit (shown in Figure 2.3) has a slope of 0.998 and an intercept of 0.009. This suggests that the
two studies generally valued the same conditions in a similar way, and that it is reasonably
valid to use GBD and Dutch weights in the same study.
There are some disease categories included in the Australian study for which there are no
weights in either the Dutch or GBD studies. To assist in estimating provisional weights for
these, we have fitted a multiplicative regression model23 for the single attribute states
defined by the six dimensions of the EQ-5D+ (see Box 2.1). Figure 2.4 shows the fitted
regression weights plotted against the weights estimated in the Dutch study. The model
explains 92% of the variation in the Dutch weights. Unexplained variance may reflect the
limitations of the EQ-5D+ in fully describing important variations in health status associated
with different diseases or perhaps inconsistencies in the valuations of similar health states.
The EQ-5D+ regression model has been used to estimate disability weights for 33 disease
stages, severity levels or sequelae where empirical evidence or expert opinion could be used
to specify the distribution using the EQ-5D+. The validity of the estimated weights depends
on the accuracy of the EQ-5D+ descriptions and the validity of the fitted regression model.
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Figure 2.4: Comparison of EQ5D+ weights 
(from fitted multiplicative model) with Dutch 
weights for 153 disease stages or sequelae
of the very different methods used to obtain these weights.25 The Dutch weights were for
specific disease states and derived using PTO, a deliberative approach, small expert panels
and one lay panel; whereas the HUI3 study used generic health state descriptions, the
standard gamble approach, no deliberation, and 500 members of the general population.
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Figure 2.5: Comparison of single attribute 
regression weights for EQ-5D+ with single 
attribute weights for the Health Utility
Index Version 3 (HUI3).
Apart from the internal validity of the
model in fitting the Dutch weights, we
have also validated the regression model
by comparing it with a multiplicative
regression model for the Health Utility
Index Version 3 (HUI3).
Furlong et al. (1998) have fitted a multi-
plicative function to measured utility
weights for the HUI3. The HUI3 has
more dimensions and more levels than
the EQ-5D+ but there is reasonable
correspondence between most of these.
Figure 2.5 compares the single attribute
weights for the HUI3 and the EQ-5D+
regression model.24 The correlation coeff-
icient for the two sets of weights is 0.94.
Although the mapping carried out
between HUI3 and EQ-5D+ may over-
state the consistency between the single
attribute weights, there is still a
remarkable level of concordance  in view
Annex Table B lists all the disability
weights used in the Australian Burden
of Disease Study and their sources.
Where Dutch or GBD weights were not
available, and it was not feasible to use
the EQ-5D+ regression model, a Dutch
or GBD weight for a similar condition
was used on a provisional basis. For a
few mental disorders, Australian experts
were asked to assess weights using a
value rating scale to compare them with
Dutch weights for other mental dis-
orders. In any further Australian burden
of disease studies, it would be useful to
do this on a more systematic basis for a
wider range of conditions where
provisional weights have been used. In
the longer term, it may be appropriate to
carry out a full Australian disability
weight study.
Table 2.2 summarises the sources of
weights for the 1260 disease sequelae,
stages and severity levels used in the
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Australian Burden of Disease and Injury Study. These 1260 categories are listed in Annex
Table B, together with disability weights and sources. GBD weights were used for 40
different types of injury. These were used as sequelae for each of the 18 external causes of
injury, so that there were 720 injury categories in total. Dutch weights or the EQ-D5+ were
used for over 75% of the 536 non-injury sequelae. The weights used in this study must be
regarded as provisional pending either the development of internationally accepted
standard weights or suitable Australian weights.
Table 2.2: Sources of disability weights used in the Australian Burden of Disease and Injury
Study
Source of weights Diseases (Groups I and II) Injuries (Group III) Total
Dutch weights(a) 370 — 370
EQ-5D+ regression model 46 — 46
GBD weights(b) 118 720 838
Australian weights 6 — 6
Total 540 720 1,260
(a) Stouthard et al. (1997).
(b) Murray and Lopez (1996a).
2.6 Years lost due to disability
Years lost due to disability are essentially calculated as follows (ignoring the complications
of discounting):
 LDI =  YLD ´´
where I is the number of incident cases in the reference period, D is the disability weight (in
the range 0–1) and L is the average duration of disability (measured in years). With
discounting at rate r, the formula for calculating YLD becomes:
[ ]  r / rL) exp(  1DI =  YLD --´´
In order to make a consistent and meaningful estimate of YLD for a condition, it is crucial to
clearly define the condition under consideration in terms of case or episode, and severity
level or disease stage. It is then necessary to ensure that the disability weight and the
population incidence/prevalence data relate to the same case definition. The most difficult
step in estimating YLD for most diseases is matching existing population data to the disease
stage/severity categories for which the weights are available. Getting this wrong can result
in substantial error in the YLD estimate. Disability weights are discussed further below.
For some conditions, numbers of incident cases are available directly from disease registers
or epidemiological studies but for most conditions, only prevalence data are available. In
these cases, a software program called DISMOD© is used to model incidence and duration
from estimates of prevalence, remission, case fatality and background mortality. 26 The
underlying model is shown in Figure 2.6.
Where remission rates and/or case fatality rates are not known, they are usually estimated
from available evidence. While this affects the age distribution of incident cases and YLD,
total YLD are quite insensitive to these assumptions. This is because YLD are proportional
to incidence multiplied by duration, which approximately equals the prevalence of the
condition. In other words, the combination of incidence and remission rates chosen (and
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Figure 2.6: DISMOD modelling of incidence, prevalence and duration of disease
thus derived durations) does not make a lot of difference to total YLD added across all ages,
if the incidence and duration estimates are being matched to the same prevalence figures.
Locating or modelling information on the incidence (the number of new cases arising in
1996), average duration, and, in some cases severity distribution of 1260 disease and injury
stages and sequelae in the Australian population requires considerable work and creativity.
The sources of data and methods used for each of the major disease and injury groups are
summarised in Section 5.2 in more detail. Due to the large number of categories analysed,
and the paucity of even basic epidemiological information for many of them, many of the
disease models are necessarily simple and approximate. Many different sources of
information were used to calculate YLD. Where no data were available and estimates could
not be found in Australian or international epidemiological and medical literature, expert
judgement was relied on. The resulting YLD estimates should be seen as a first step in a
developmental process. It is hoped that many of these models can be refined and improved
by relevant disease experts and that the data gaps and deficiencies identified by the YLD
analyses carried out for this project will contribute to setting priorities for improving
Australian health information (see Section 8.3).
For most disease and injury groups, Australian experts were consulted during the
development and revision of YLD estimates. Complete worksheets for each disease group
were given to selected experts for comment and assumptions, models and estimates were
revised where necessary.
Worksheets for each disease and injury category detailing data sources, assumptions and
methods used to calculate YLD are available on request as Excel 97 spreadsheets.
2.7 Adjustments for comorbidity
Comorbidity is common between mental disorders and has been taken into account in
analysis of YLD for mental disorders, but not for comorbidity between physical and mental
disorders. In addition, there are significant proportions of older people who will have
comorbidities for some of the common non-fatal conditions of older age (e.g. hearing loss,
osteoarthritis, heart conditions, diabetes etc.). The GBD and Dutch disability weights were
estimated for each condition in isolation and no attempt was made to estimate weights for
comorbid conditions. It is not always sensible to add the weights for such conditions, as it is
then possible to have very severe weights and weights exceeding 1.0. It is unlikely that for
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someone with a severe condition, such as Alzheimer’s disease or cancer, that the additional
weight of 0.02 for mild vision loss is still appropriate.
Weights for prevalent low-severity conditions have been adjusted to take account of
comorbidities. A multiplicative model was used to estimate weights for comorbid conditions
and the change in total weight attributed back to the weight for the milder of the
conditions.27 The most prevalent physical conditions at older ages together with the
comorbidity adjustment factors for weights at ages 65–74 and 75+ are listed in Appendix
A.28
Mental health problems are less prevalent at older ages, apart from dementia, and no
attempt has been at this stage to also adjust for mental-physical comorbidities. The National
Mental Health Survey data could allow this to be done, since it identifies mental–physical
comorbidity (through self-report).
2.8 Socioeconomic inequalities
One of the longer term aims of this study is to develop estimates of the burden of disease for
different groups within the Australian population, including groups defined in terms of
relative socioeconomic status. For this initial report, we have undertaken analyses of
inequalities in the burden of mortality by level of socioeconomic disadvantage, using an
index classifying people according to the average disadvantage of their statistical local area
(SLA) of usual residence.
In keeping with earlier work (Mathers 1994a, 1994b, 1995, 1996), this study uses a small-area
based measure known as the Index of Relative Socioeconomic Disadvantage (IRSD). The
IRSD is one of the socioeconomic indexes for areas (SEIFA indexes) developed by the
Australian Bureau of Statistics (ABS) using data collected in the 1986, 1991 and 1996
population censuses to categorise areas on the basis of their social and economic
characteristics (ABS 1998c). It is constructed using principal components analysis and is
derived from attributes such as low income, low educational attainment, high levels of
public sector housing, high unemployment, and jobs in relatively unskilled occupations.
For the years 1995–97 deceased persons were classified into quintiles of socioeconomic
disadvantage according to the IRSD for their SLA of usual residence29, with the 1st quintile
corresponding to the highest socioeconomic group and the 5th quintile the lowest. SLAs
were grouped into quintiles so that each quintile contained approximately 20% of the total
Australian population.
YLL inequalities
Inequality in mortality burden across the quintiles of socioeconomic disadvantage was
assessed using three measures: the rate ratio, the Gini coefficient, and excess mortality
burden.
Rate ratios. The age standardised YLL rate per 1,000 population for the most
socioeconomically disadvantaged quintile (Q5) is expressed as a multiple of the standardised
rate for the least disadvantaged quintile (Q1). Thus, for example, the rate ratio for all cause
mortality burden in males is 1.41 (YLL RateQ1/YLL RateQ5 = 9598/6802).
Gini coefficient. In recent years, studies examining socioeconomic health inequalities have
made increasing use of the Gini coefficient (Leclerc et al. 1990, Carr-Hill 1990, Kennedy et al.
1996). The Gini coefficient is a summary measure of the degree of inequality in some
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characteristic (such as income) within the population. It is derived from the Lorenz curve
and takes values ranging between 0 (perfect equality) to 1 (complete inequality).30
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Figure 2.7: Lorenz curve for inequality in
mortality burden
on the Lorenz curve we have plotted cumulative numbers of age-standardised YLL across
quintiles. The corresponding Gini index measures the degree of mortality inequality across
the quintiles of socioeconomic disadvantage, excluding inequality due purely to population
age structure differences.
The term ‘Gini coefficient’ is used here to refer to a measure of mortality inequality based on
population groups ranked by socioeconomic status rather than health status. Wagstaff et al.
(1991) have referred to these as health or ill-health concentration indices.
Excess mortality. Kunst (1997) has proposed mortality inequality measures that are not only
sensitive to realtive differences between groups but, in addition, take into account the size of
the socioeconomic groups that are compared. These measures address the total impact that
socioeconomic differences have on the mortality level of the general population. We also
present an excess mortality measure which estimates the percentage of YLL that potentially
could be avoided if all quintiles had the same age-standardised YLL rate as the least
disadvantaged quintile.
In effect, the measure identifies the burden of mortality in the Australian population that
may be attributable to socioeconomic disadvantage.31 Note that this measure is only
indicative. Different estimates would be obtained using different reference groups (eg. top
decile rather than top quintile) ior using a different measure of socioeconomic disadvantage
(eg. education level or family income).
YLD inequalities
Inequality in disability burden was assessed for selected mental disorders using data from
the 1997 National Survey of Mental Health and Wellbeing (MHS’97). Survey respondents
were classified into quintiles of socioeconomic disadvantage using the IRSD to classify place
In this study, we use a form of the
Lorenz curve in which cumulative YLL
are plotted against cumulative
population across the five quintiles of
socioeconomic disadvantage (ranked in
terms of decreasing disadvantage). This
is illustrated in Figure 2.7, where the
dashed line represents to cumulative
YLL plotted according to cumulative
population. The straight line is the line
of perfect equality (every quintile has
the same YLL rate) and the area
between the two curves expressed as a
proportion of the area below the
diagonal line gives the Gini coefficient.
Even if age-specific rates of mortality
burden were equal across all quintiles,
there would still be inequality if
population age structures differ across
the quintiles (since there will be more
deaths in older populations). To remove
the effects of  population  age  structure
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of usual residence. The Victorian Burden of Disease project estimated incidence rates for
substance abuse disorders (except heroin), affective disorders, anxiety disorders and
borderline personality disorders. These were modelled by age, sex and quintile of
socioeconomic disadvantage by fitting a logistic regression model to the unit record data
from the MHS’97. Socioeconomic variations in YLD for heroin dependence were assumed to
follow the same pattern as YLL.
Confidence intervals for YLD rate ratios, Gini coefficients and excess burden were estimated
using the @RISK statisical software package (see Section 2.10) based on the standard error
estimates for the incidence rate ratios estimated from logistic models.
DALY inequalities
It has not been possible to complete comprehensive analyses of YLD by quintile of
socioeconomic disadvantage for all disease and injury categories for this first report on the
burden of disease and injury in Australia. Provisional estimates of differentials in burden of
disease measured in DALYs for the main disease and injury groups are included in
Section 5.6. These are based on provisional YLD estimates for main disease groups derived
as follows:
· Data from the 1997 National Survey of Mental Health and Wellbeing were used to
model incidence of selected mental disorders by quintile of socioeconomic disadvantage
(see above).
· Data from the 1995 National Health Survey were used to model prevalence of a number
of low-fatality conditions by quintile of socioeconomic disadvantage. These included
low-fatality infectious diseases, acute respiratory infections, anaemia, childhood mental
disorders, sense organ disorders, ischaemic heart disease, stroke, peripheral vascular
disease, chronic obstructive pulmonary disease (COPD), asthma, digestive system
disorders, genitourinary conditions, skin disorders and musculoskeletal disorders. YLD
differentials by age and sex were modelled from these differentials.
· Oral health problems were modelled from Australian data collected by the AIHW
Dental Statistics Research Unit (AIHW 1992).
· For the remaining conditions, with significant case fatality levels, incidence rates were
assumed to follow the same pattern as mortality rates by level of socioeconomic
disadvantage. YLD differentials for each age-sex group were modelled from death rate
differentials for the corresponding age-sex group.
Confidence intervals for DALY rate ratios were estimated using the @RISK statisical
software package (see Section 2.10). Uncertainties in YLL differentials were modelled
assuming observed deaths followed Poisson distributions. Uncertainties in mental health
YLD differentials were modelled as described above. Uncertainties in other YLD
differentials were estimated based on sampling errors for the 1995 National Health Survey,
where relevant, and uncertainties in YLL differentials.
2.9 Burden attributable to risk factors
The proportions of the burden of disease and injury attributable to various risk factors to
health are estimated in Chapter 7 for ten selected risk factors. Population attributable
fractions (PAF) are calculated for each risk factor from available information on the
prevalence of the risk factor and the relative risks (RR) of incidence or mortality for each
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health condition causally associated with exposure to the risk factor. For some conditions,
direct estimates for PAFs are directly available from surveillance systems or epidemiological
studies (e.g. HIV/AIDS and unsafe sex, motor vehicle accidents and alcohol consumption).
The population attributable fraction is the proportion of the total risk (incidence rate,
mortality rate or burden) in the whole population (including the subpopulations exposed
and unexposed to the risk factor) that is causally attributable to the exposure to the risk
factor. It is derived by comparing the risk (or burden) in the whole population to the risk in
the unexposed group English et al. (1995).
For a risk factor with k exposure categories, the aetiologic fraction for exposure category i is
calculated as follows:
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where pi is the prevalence of exposure to category i of the risk factor,
RRi is the corresponding relative risk for category i of the risk factor relative
to the reference category, and
i=0 is the reference (non-exposed) category.
The attributable fraction is conventionally interpreted as the proportion of current disease
(or mortality) attributable to the risk factor concerned. This is only strictly correct if the
prevalences used to calculate the PAFs reflect the prevalence of the risk factor at an
appropriate period in the past. For some chronic diseases, current disease may be associated
with exposure many years in the past (e.g. occupational asbestos exposure and meso-
thelioma) or with cumulative exposure over a considerable period. For tobacco smoking,
there is a long timelag between exposure to tobacco smoke and some diseases, particularly
cancers and chronic obstructive pulmonary disease. For these diseases, the Peto-Lopez
method was used to calculate PAFs for tobacco smoking (Peto and Lopez 1993). This
method derives an artificial prevalence measure of cumulative tobacco exposure derived
from a comparison between overall lung cancer rates in Australia and lung cancer rates
among non-smokers derived from a large long-term follow-up study in the USA.
2.10 Uncertainty analyses
For a number of comparisons of life expectancy and socioeconomic inequalities, we have
estimated 95% confidence intervals. Although analytical solutions for the confidence
intervals for these measures can be constructed, we used a simulation approach to estimate
95% confidence intervals. Latin hypercube sampling was carried out using the @RISK
software program (Palisade 1996). Observed deaths were assumed to follow Poisson
distributions. Confidence intervals for survey-based estimates were used to estimate
uncertainty in YLD differentials.
This software is also being used to calculate ‘uncertainty’ intervals for some YLD and DALY
estimates based on estimated ranges of uncertainty for various key parameters and
assumptions built into the relevant disease models. It is intended to carry out a more
detailed sensitivity analysis of the DALY estimates in relation to the underlying
epidemiological parameters using simulation methods. The first report examines only the
sensitivity of the results to some of the key value assumptions such as the discount rate.
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3 Years of life lost due to mortality
Australia, like other developed countries, has almost complete registration of deaths and
relatively good information on causes of death. This chapter describes the burden of
premature mortality in Australia in 1996 using years of life lost (YLL). The calculation of
YLL is based on numbers of deaths attributed to each cause at each age. The following
section describes how numbers of deaths were estimated for each cause and the rest of the
chapter presents results for deaths and YLL which identify patterns by age, sex, cause, level
of socioeconomic disadvantage, and time trends over the last 15 years.
3.1 Estimating deaths due to each cause
Registration of deaths in Australia is the responsibility of the State and Territory Registrars
of Births, Deaths and Marriages. Information on the cause of death is supplied by the
medical practitioner certifying the death or by a coroner. Other information about the
deceased is supplied by a relative or other person acquainted with the deceased, or by an
official of the institution where the death occurred. Registration of death is a legal
requirement in Australia, and compliance is virtually complete. The information is provided
by the Registrars to the Australian Bureau of Statistics (ABS) for coding of information and
compilation into national statistics. Estimates of numbers of deaths and mortality burden in
this report were derived from the registration data coded by ABS and provided to the
Institute by the State and Territory Registrars.
There were 128,711 deaths registered in Australia during 1996 (53% of these were for males).
For each of these deaths, the underlying cause of death is coded using the Ninth Revision of
the International Classification of Diseases (ICD-9). This code was used to classify all deaths
registered in 1996 to one of the 175 disease and injury categories used in this study. Full
details of these categories and their corresponding ICD-9 codes are given in Annex Table A.
There were 327 deaths assigned to ill-defined signs and symptoms (ICD-9 codes 780 to 799
excluding the code for sudden infant death syndrome) for Australia in 1996, of which 13
were aged 0–4. This 0.25% of deaths was redistributed proportionally by age and sex to
other causes apart from injuries on the assumption that it is unlikely for injury deaths to be
classified as ill-defined. Note that this differs from the GBD which distributed deaths due to
ill-defined causes across Group I only for ages 0–4 and Group II only for ages 5 and over.
Prior to 1996, HIV/AIDS deaths were only identifiable through the use of a flag indicating
that AIDS was mentioned on the death certificate. In 1996, for the first time, ABS coded
most AIDS deaths to codes 042–044 (HIV/AIDS), and there were 491 male and 15 female
deaths for these causes. There were an additional 55 male and 7 female deaths for which
there was an AIDS flag specified, including 9 male deaths with ICD-9 external cause code
875 (contaminated blood). A total of 479 male and 17 female AIDS deaths which occurred in
1996 were notified by mid-1998 (NCHECR 1998). A total of 500 male and 17 female deaths
were classified to HIV/AIDS in this study, including the nine deaths for E-code 875 with an
AIDS flag, and two additional female deaths with an AIDS flag.
There were 2320 cancer deaths (6.6% of all malignant neoplasms) coded to ICD-9 codes 195–
199 (malignant neoplasm of other and unspecified sites including those whose point of
origin cannot be determined, secondary and unspecified neoplasms). On advice from the
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National Cancer Statistics Clearinghouse at the AIHW, these have been distributed pro-rata
across all malignant neoplasm categories within each age–sex group.
Murray and Lopez (1997b) provided convincing evidence that a significant and varying
proportion of ischaemic heart disease deaths are coded in many countries to ill-defined
codes such as 428 (heart failure). In Australia in 1996, 5.4% of cardiovascular deaths were
coded to heart failure and an additional 1.1% to other so-called ‘garbage’ codes (see
Table 3.1). The GBD used a regression formula to redistribute deaths from garbage codes to
ischaemic heart disease. It mentioned also that some of these deaths might belong to the
inflammatory heart disease group (cardiomyopathy, endocarditis, myocarditis and
pericarditis) but did not redistribute deaths to this group.
Table 3.1: Deaths coded to cardiovascular ‘garbage’ codes, Australia 1996
Garbage code ICD-9 No. deaths
Heart failure 428 2,909
Ill-defined descriptions of heart disease 429.0–429.2 245
Generalised and unspecified atherosclerosis 440.9 214
Cardiac arrest 427.5 123
Ventricular fibrillation and flutter 427.4 18
Ventricular tachycardia 427.1 6
Heart disease, unspecified 429.9 9
Total garbage codes 3,524
Australian cardiovascular disease experts advised that the major cause of heart failure (ICD
code 428) in young adults is cardiomyopathy and in older adults is ischaemic heart disease.
There was only one heart failure death below age 30 in Australia in 1996 (a male aged 10–14
years). It was decided after expert advice to redistribute the majority of cardiovascular
garbage codes to ischaemic heart disease, inflammatory heart disease and hypertensive
heart disease in proportions varying by age as shown in Table 3.2. These redistributions
result in a 10% increase in deaths attributed to ischaemic heart disease in 1996. This is very
similar to the estimate of 10% under-estimation of ischaemic heart disease deaths by
Jamrozik et al. (1999).
Deaths coded as gastric haemorrhage (ICD-9 code 578) were redistributed equally across
peptic ulcer disease and liver cirrhosis as the most likely underlying aetiologies.
There were 139 injury deaths in Australia in 1996 where it was not determined whether the
injury was accidental or intentional (ICD-9 E-codes 980–989). The GBD allocated these
deaths pro-rata to intentional and unintentional injury. Because unintentional injuries in
Australia are dominated by motor vehicle accidents and falls, this has the effect of
reallocating most of the undetermined deaths to accidental deaths.
Table 3.2: Redistribution of deaths coded to cardiovascular ‘garbage’ codes
Garbage code Age group
Ischaemic heart
disease
Inflammatory
heart disease
Hypertensive
heart disease
Heart failure (428) 5–29 — 75% —
30 –44 70% 25% 5%
45 –59 70% 10% 20%
60+ 60% 10% 30%
Other CVD garbage codes (see Table 3.1) 30 –44 75% — —
60+ 80% — —
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However, very few of the undetermined deaths are falls or road traffic accidents: The age–
sex distribution and other characteristics of these ‘undetermined’ injuries are much closer to
suicide than to the relevant accidental injuries. Injury researchers advised that it is likely
that the great majority of the undetermined deaths are suicide, but that the coroner did not
have sufficient evidence to make that finding. Ninety per cent of undetermined poisoning
and drowning deaths were allocated to suicide, and the other 10% to accidental poisoning
and drowning respectively. Undetermined deaths due to other causes were similarly
allocated 90% to intentional causes (suicide for those aged 15 years and over, violence for
the three male deaths under age 15 years) and 10% to other accidental causes excluding road
traffic and transport accidents.
For certain cause groups, deaths have been redistributed back to other cause groups to
ensure consistency with the YLD estimates for sequelae associated with those cause groups.
Liver cancer and liver cirrhosis deaths attributable to hepatitis have been redistributed to the
hepatitis B and hepatitis C categories in this report. Data on the underlying cause of renal
failure from the Australian and New Zealand Register of Dialysis and Transplant Patients
(ANZDATA) have been used to redistribute renal failure deaths to nephritis and nephrosis,
diabetes mellitus, injuries, congenital conditions, cancers and infectious diseases.
Cardiovascular disease mortality attributable to diabetes as a risk factor is included in the
cardiovascular category. Diabetes mortality includes deaths directly due to diabetes and its
complications and diabetic renal failure deaths. The total attributable mortality burden of
diabetes, including the cardiovascular component, is estimated in Section 5.4.
3.2 Deaths in Australia 1996
Due to these various redistributions, the distribution of deaths by age, sex and cause used to
estimate the mortality burden in Australia in 1996 differs slightly from cause of death data
published elsewhere by AIHW and ABS. Annex Table D tabulates the adjusted numbers of
deaths by cause, sex and 20-year age groups for Australia in 1996. These deaths form the
basis for the YLL estimates described in the following section. YLL are calculated as
described in Section 2.4.
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Source: Data for developing and developed regions of the world from Murray and Lopez 1996
Figure 3.1: Deaths by broad cause groups, Australia 1996 compared with developed and
developing regions in 1990 (Murray and Lopez 1996).
Group I Group II Group III
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Deaths by broad cause groups for Australia in 1996 are compared with those for developed
and developing regions in 1990 (Murray & Lopez 1996a) in Figure 3.1. Group I conditions
(infectious, maternal, perinatal and nutritional conditions) are responsible for fewer deaths
in Australia than in other developed countries, as are Group III conditions (injuries). The
non-communicable diseases (Group II) thus account for a larger proportion of deaths in
Australia than in other developed countries as a whole.
Table 3.3 compares the ten leading causes of death for Australia and developed regions of
the world (developed regions include Established Market Economies and Former Socialist
Economies).
Table 3.3: Ten leading causes of death, Australia, 1996 and developed regions of the world, 1990
Australia, 1996
Ranking in
developed
regions
No. of
deaths
Per cent
of total Developed regions, 1990
Ranking
in
Australia
Per cent
of total
1. Ischaemic heart disease 1 32,681 25.4 1. Ischaemic heart disease 1 24.7
2. Stroke 2 12,839 10.0 2. Stroke 2 13.1
3. Lung cancer 3 7,307 5.6 3. Lung cancer 3 4.8
4 COPD(a) 5 6,163 4.8 4. Lower respiratory infections(b) 12 3.5
5. Colorectal cancer 6 4,973 3.9 5. COPD(a) 4 3.0
6. Dementia 14 3,897 3.0 6. Colorectal cancer 5 2.5
7. Diabetes mellitus 10 2,997 2.4 7. Stomach cancer 19 2.2
8. Prostate cancer 15 2,846 2.2 8. Road traffic accidents 11 2.0
9. Breast cancer 11 2,823 2.2 9. Suicide 10 1.8
10. Suicide 9 2,515 1.9 10. Diabetes mellitus 7 1.6
(a) Chronic obstructive pulmonary disease (chronic bronchitis and emphysema).
(b) Influenza, acute bronchitis and pneumonia.
Australia ranks around 10th in the world in terms of total life expectancy at birth (AIHW
1998b). Life expectancy at birth in 1996 was 75.6 years for Australian males and 81.3 years
for Australian females. Another way to compare the mortality risks of Australians with
those in other countries is to calculate the probability of dying between two specific ages if a
person experienced the average mortality risk observed at each age in the population.
Table 3.4 compares the probability of dying between ages 15 and 59 for Australia and
selected other developed countries in 1998. The Australian estimates are based on the 1995–
1997 Australian life tables projected forward to 1998 as described in Section 2.4. Countries
are ranked in increasing probability of dying between ages 15 and 59 for males and females
combined. Australia ranks fifth in the world, behind Japan, Greece, Sweden and Italy.
3.3 Mortality burden in Australia in 1996
In 1996, premature mortality was responsible for 1.35 million years of life lost (discounted at
3% per annum) in Australia. Males lost 26% more years of life than females. If male YLL are
calculated using the cohort life expectancies for females (see Section 2.4), then the male
excess mortality burden rises to 43%.33
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Table 3.4: Probability of dying (%) between ages 15 and 59, by sex, Australia
and selected developed countries, 1998
Country Males Females Persons
Japan 9.9 5.0 7.5
Greece 11.0 4.9 8.0
Sweden 9.7 6.3 8.0
Italy 10.8 5.4 8.1
Australia 10.4 5.9 8.1
Israel 10.2 6.1 8.2
Norway 10.7 5.9 8.3
Netherlands 10.2 6.5 8.4
Canada 10.8 6.1 8.5
Switzerland 11.4 6.0 8.7
UK 11.0 6.9 9.0
Ireland 11.4 6.6 9.0
Spain 12.9 5.4 9.2
Singapore 11.8 7.8 9.8
Germany 13.2 6.6 9.9
New Zealand 12.5 7.9 10.2
France 14.5 6.3 10.4
USA 15.4 7.9 11.7
Denmark 14.1 9.6 11.9
Source: Data for other countries from WHO (1999a)
Cardiovascular disease, cancers and injury were responsible for 72% of the total mortality
burden in both males and females (Figure 3.2). In people aged 75 years and over,
cardiovascular diseases account for more than half the years of life lost, whereas cancers are
a more important cause than cardiovascular disease for all ages below 75. Injuries are the
main cause of lost years of life in young adults and children aged 5–14 years, and neonatal
conditions the main cause in children aged under five (Figure 3.3).
Figure 3.2: Mortality burden (YLL) by sex and broad disease group, Australia, 1996
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Figure 3.3: Years of life lost by age, sex and broad disease group, Australia, 1996
Table 3.5: Top twenty causes of the mortality burden (YLL), by sex, Australia, 1996
Males
YLL
(’000) Females
YLL
(’000) Persons
YLL
(’000)
1 Ischaemic heart disease 158,378 1 Ischaemic heart disease 117,399 1 Ischaemic heart disease 275,778
2 Lung cancer 55,030 2 Stroke 56,660 2 Stroke 98,523
3 Suicide 44,278 3 Breast cancer 40,684 3 Lung cancer 83,146
4 Stroke 41,863 4 Lung cancer 28,117 4 Suicide 55,458
5 Road traffic accidents 33,685 5 Colorectal cancer 26,149 5 Colorectal cancer 55,372
6 COPD(a) 31,429 6 COPD(a) 23,065 6 COPD(a) 54,494
7 Colorectal cancer  29,223 7 Dementia 15,670 7 Road traffic accidents 45,928
8 Prostate cancer  22,474 8 Diabetes mellitus 15,090 8 Breast cancer 40,684
9 Diabetes mellitus 16,019 9 Road traffic accidents 12,243 9 Diabetes mellitus 31,109
10 Cirrhosis of the liver  13,053 10 Ovary cancer 11,699 10 Dementia 23,887
11 HIV/AIDS  11,594 11 Suicide  11,180 11 Prostate cancer 22,474
12 Leukemia  10,045 12 Lymphoma 9,687 12 Lymphoma 19,535
13 Lymphoma  9,848 13 Pancreas cancer 9,474 13 Cirrhosis of the liver 18,824
14 Hypertensive heart
disease 9,686
14 Lower respiratory
tract infections(b) 8,141
14 Pancreas cancer 18,334
15 Brain cancer  9,636 15 Leukemia 7,256 15 Leukemia 17,056
16 Pancreas cancer  8,861 16 Brain cancer 7,076 16 Brain cancer 16,713
17 Stomach cancer  8,646 17 Inflammatory heart 
disease 6,684
17 Lower respiratory
tract infections(b) 15,318
18 Heroin dependence &
harmful use 8,556
18 Nephritis and nephrosis 8,681 18 Inflammatory heart 
disease 15,111
19 Dementia  8,217 19 Cirrhosis of the liver 5,771 19 Stomach cancer 14,400
20 Melanoma  8,164 20 Stomach cancer 5,754 20 Melanoma 13,114
All causes 752,591 All causes 595,642 All causes 1,348,233
(a) Chronic obstructive pulmonary disease (chronic bronchitis and emphysema).
(b) Influenza, acute bronchitis and pneumonia.
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Figure 3.4: Leading causes of mortality burden (YLL), by sex, Australia, 1996
Ischaemic heart disease (IHD) is by far the largest cause of years of life lost in both males
and females (Table 3.5 and Figure 3.4). IHD is followed by stroke and breast cancer in
females, and by lung cancer and suicide in males. Heroin overdose deaths are in the top 20
causes of years of life lost for males, resulting in almost as many years of life lost as
HIV/AIDS or leukemia. State differences in mortality burden are shown in Figure 3.5. A
complete analysis of the mortality burden of disease in Victoria has been carried out by Vos
and coworkers (Department of Human Services 1999a).
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Figure 3.5: Years of life lost per 1,000 population by State and Territory, 1996
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Note that YLL estimates of mortality burden produce a quite different ranking of causes
than the potential years of life lost to age 75 (PYLL) published by AIHW and other health
statistical agencies (see for example, Jelfs et al. 1996). This is because PYLL to age 75 exclude
deaths above age 75 and truncate the years of life lost to age 75. In other words, the
traditional PYLL indicators apply a strong form of age weighting, which gives zero weight
to years of life lost above age 75. Figure 3.6 compares YLL and PYLL estimates for males
and females combined for the top 20 causes of mortality burden in Australia. The PYLL give
greater weight to those causes with a younger average age at death (because there is no
discounting) and lower weight to those causes with relatively high proportion of deaths
occurring above age 75.
0
20
40
60
80
100
120
0 50 100 150 200 250 300
YLL ('000s)
PYLL (’000s)
Figure 3.6: Potential years of life lost to age 75 (PYLL) and years of life lost (YLL),
top twenty causes of mortality burden, Australia, 1996
3.4 Recent trends in mortality burden
The per capita mortality burden in Australia has declined by 44% in the 15 years between
1981 and 1996 (from 88.1 YLL per 1,000 in 1981 to 73.8 YLL per 1,000 in 1996). Table 3.6
shows the disease and injury groups with the largest changes over 15 years in the mortality
burden per 1,000 population (not age-standardised). Overall, the age-adjusted mortality
burden in Australia has declined by 44% in the 15 years between 1981 and 1996, from 94.8
YLL per 1,000 in 1981 to 65.8 YLL per 1,000 in 1996.
There have been substantial declines in the mortality burden of cardiovascular diseases,
road traffic accidents, low birthweight, and stomach cancer for both males and females. The
massive 30-40% decrease in the burden of ischaemic heart disease and stroke over the last 15
years is thought to reflect the successes of primary prevention (through reductions in levels
of tobacco smoking, changes in diet, better control of hypertension and high blood
cholesterol, and other risk factors) and of improvements in treatment (AIHW 1998a). The
more than 50% reduction in the mortality burden for road traffic accidents reflects
Australia’s success in improving road safety over recent decades. The 25% to 30% reduction
Stroke
Prostate cancer
Road traffic accidents
Senile dementia
IHD
Suicide
Lung cancer
Breast cancer
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in the mortality burden for stomach cancer is offset by the increasing burden of colorectal
cancer in males and lung cancer, breast cancer and several other cancers in females.
Note that the burden of smoking-related diseases (lung cancer, COPD) has decreased in
males but increased substantially in females. The largest increases in mortality burden have
occurred for HIV/AIDS, suicide and prostate cancer in males, for senile dementias and
heroin dependence and abuse in both sexes, and for lung cancer and chronic obstructive
pulmonary disease in women. The first death from AIDS in Australia was recorded in 1982,
so there was no mortality burden due to HIV/AIDS in 1981. HIV/AIDS mortality peaked in
1989 and has dropped dramatically since. The large apparent increase in mortality burden
for dementia is likely to be partly due to changes in coding practice that have led to
increasing identification of dementia as an underlying cause of death.
Table 3.6: Causes with largest increase or decrease in mortality burden per 1,000 population,
Australia, 1981–1996
Change Change
Males YLL/1000 % Females YLL/1000 %
Largest decreases in mortality burden per 1,000 population
1. Ischaemic heart disease –12.2 –41 1. Ischaemic heart disease –6.0 –32
2. Road traffic accidents –4.3 –54 2. Stroke –3.3 –35
3. Stroke –2.5 –36 3. Road traffic accidents –1.4 –50
4. Lung cancer –1.1 –15 4. Sudden infant death syndrome –0.4 –57
5. Sudden infant death syndrome –0.7 –63 5. Inflammatory heart disease –0.3 –28
6. COPD –0.7 –16 6. Low birthweight –0.3 –38
7. Cirrhosis of the liver –0.6 –31 7. Cervix cancer –0.2 –30
8. Low birthweight –0.5 –49 8. Stomach cancer –0.2 –25
9. Pneumonia, influenza –0.4 –35 9. Cirrhosis of the liver –0.2 –25
10. Stomach cancer –0.4 –30 10. Colorectal cancer –0.2 –7
Largest increases in mortality burden per 1,000 population
1. HIV/AIDS 1.3 — 1. Dementia 1.2 267
2. Suicide and self-inflicted injuries 1.1 31 2. Lung cancer 1.2 62
3. Prostate cancer 0.9 62 3. COPD 1.0 70
4. Heroin dependence/harmful use 0.7 323 4. Breast cancer 0.4 10
5. Dementia 0.5 145 5. Pancreas cancer 0.3 41
6. Type 2 diabetes 0.5 41 6. Lymphoma 0.2 30
7. Poisoning 0.4 108 7. Type 2 diabetes 0.2 18
8. Colorectal cancer 0.2 8 8. Heroin dependence/harmful use 0.2 356
9. Liver cancer 0.2 59 9. Multiple myeloma 0.2 74
10. Oesophagus cancer 0.2 29 10. Septicaemia 0.1 117
All causes –20.4 –25 All causes –8.4 –13
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3.5 Socioeconomic disadvantage and mortality
There is a marked gradient in the 1996 mortality burden with socioeconomic disadvantage
as defined by a small area index of socioeconomic disadvantage at SLA (local government)
area level (Figure 3.7). The mortality burden in the most disadvantaged (5th) quintile is 41%
higher for males and 26% higher for females than the burden for males and females in the
least disadvantaged (1st) quintile. Inequalities in burden would be much greater for
disadvantaged groups defined in terms of smaller areas (such as census collection districts)
or individual circumstances.
The ratio of the age-standardised YLL rate per 1,000 population for bottom and top quintiles
is a measure of the differential mortality burden between the most disadvantaged and least
disadvantaged groups in Australia, after taking into account differences in the age structure
of the population across quintiles of socioeconomic disadvantage. Figure 3.7 illustrates the
differentials in mortality burden for all causes and major groups of causes of death.
Figure 3.8 illustrates the differentials in mortality burden due to various main causes of
death (on the left) and for selected specific causes of death (on the right). The differentials in
mortality burden between top and bottom quintiles are smaller for infectious diseases and
cancers than for cardiovascular disease, chronic respiratory conditions, digestive system
diseases and injuries (see also Table 3.7).
As described in Section 2.8, the Gini coefficient is a summary measure of the degree of
inequality in mortality burden across all quintiles of socioeconomic disadvantage. Table 3.7
also gives Gini coefficients for the male and female mortality burden for all main cause of
death groups. The overall inequality in mortality burden is 50% larger for males than
females in Australia (with Gini coefficients of 0.06 and 0.04). The inequality in mortality
burden is greatest for maternal mortality and nutritional deficiencies in women (where there
are very small total numbers of deaths), followed by ill-defined conditions (sudden infant
death syndrome) in both sexes, followed by digestive system diseases in males, diabetes in
females, and injuries in males.
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Figure 3.7: Mortality burden (YLL) per 1,000 population by quintile of socioeconomic
disadvantage and major causes, 1995–97
37
   1/2 1    2    4
Infectious
Cancer
Diabetes
Mental disorders
Cardiovascular
Chronic respiratory
Digestive system
Genitourinary
Injuries
All causes
Age-standardised rate ratio
(bottom quintile/top quintile)
Females
Males
   1/2    1    2   4
HIV/AIDS
Neonatal infections
Colorectal cancer
Lung cancer
Breast cancer
Cervix cancer
Prostate cancer
Stroke
COPD
Asthma
Road traffic accidents
Suicide
Homicide
Age-standardised rate ratio
(bottom quintile/top quintile)
Note: The infectious disease category includes acute respiratory infections
Figure 3.8: Differentials in mortality burden top and bottom quintiles of socioeconomic
disadvantage, main causes and selected causes, by sex, 1995–97
Table 3.7 also presents estimates of the proportion of the mortality burden that is
attributable to variability in YLL rates across the quintiles of socioeconomic disadvantage.
Interpretation of these estimates is straightforward. Take for example, diabetes YLL rates for
males for the period 1995–97. If the top four quintiles had the same YLL rate as the most
disadvantaged SES quintile, the overall mortality burden for diabetes would be lower by
approximately one-quarter for males and one-third for females. The excess mortality burden
associated with socioeconomic disadvantage is particularly high for diabetes, chronic
respiratory diseases, unintentional injuries, intentional injuries and acute respiratory
conditions (in males).
Among males, the overall ‘excess’ mortality burden associated with socioeconomic
disadvantage is 19%, considerably higher than the corresponding excess burden of 12% for
females. In other words, if it were possible to reduce death rates in all areas to a level
equivalent to that of the least disadvantaged quintile, the potential savings in years of life
lost due to mortality would range from 12% for females to 19% for males. These are larger
than the attributable mortality burden for risk factors such as tobacco smoking,
hypertension or physical inactivity estimated in Chapter 7. Of course, some of the effects of
socioeconomic disadvantage are mediated by these traditional risk factors (Mathers 1994a)
and so there is some overlap in the estimate of excess mortality burden estimated here with
the burden attributable to various risk factors.
Ischaemic heart disease
38
Table 3.7: Differentials and inequality in mortality burden, by main disease categories
and sex, Australia, 1995-97
   YLL ratio(a)
 (bottom quintile/top quintile)      Gini coefficient           Excess burden(b)
Disease category Male Female Male Female Male Female
A. Infectious and parasitic diseases 1.06* 1.05* –0.015* –0.001* 9.6* –3.9*
B. Acute respiratory infections 1.47* 1.42* 0.078* 0.051* 21.7* 12.6*
C. Maternal conditions —* 2.46* —* 0.255* —* 18.9*
D. Neonatal causes 1.43* 1.40* 0.077* 0.050* 14.4* 7.7*
E. Nutritional deficiencies 0.63* 2.79* –0.074* 0.226* –50.5* 48.7*
F. Malignant neoplasms 1.22* 1.12* 0.036* 0.018* 10.9* 6.7*
G. Other neoplasms 0.95* 1.20* –0.021* 0.033* –0.2* 12.2*
H. Diabetes mellitus 1.63* 2.07* 0.072* 0.117* 24.9* 33.1*
I. Endocrine and metabolic disorders 1.21* 1.52* 0.030* 0.071* 14.7* 21.5*
J. Mental disorders 1.35* 1.52* 0.061* 0.043* 15.7* 19.2*
K. Nervous system disorders 1.12* 0.78* 0.013* –0.050* 3.3* –10.0*
L. Cardiovascular disease 1.41* 1.25* 0.060* 0.043* 19.5* 12.3*
M. Chronic respiratory diseases 1.81* 1.75* 0.098* 0.089* 30.9* 27.5*
N. Diseases of the digestive system 2.13* 1.73* 0.122* 0.098* 38.3* 26.2*
O. Genitourinary diseases 1.41* 1.59* 0.057* 0.078* 16.9* 21.8*
P. Skin diseases 0.83* 0.95* 0.004* 0.013* 21.5* 11.3*
Q. Musculoskeletal diseases 0.90* 1.39* –0.015* 0.040* 7.9* 17.2*
R. Congenital abnormalities 1.34* 1.00* 0.036* 0.028* 12.1* 10.5*
S. Oral health —* —* —* —* —* —*
V. Ill-defined conditions 1.96* 4.06* 0.122* 0.244* 27.1* 58.9*
T. Unintentional injuries 1.84* 1.41* 0.102* 0.056* 31.9* 17.0*
U. Intentional injuries 1.71* 1.49* 0.092* 0.041* 25.0* 19.9*
All causes 1.41* 1.26* 0.059* 0.039* 18.7* 12.0*
(a) Ratio of age-standardised YLL per 1,000 population for bottom quintile of area index of socioeconomic disadvantage to age-standardised
YLL per 1,000 population for top (least disadvantaged) quintile.
(b) Per cent of mortality burden (YLL) that would be avoided if all quintiles had the same YLL rate as the least disadvantaged (1st) quintile.
* Asterisk indicates that rate ratio, Gini coefficient and excess burden differ significantly (p<0.05) from value for no difference (1, 0.0 and 0%
respectively).
These gradients in mortality burden correspond to quite large gradients in the probability of
survival at younger ages and mid-adult ages (Table 3.8 and Figure 3.9). For example, men in
the bottom quintile have a 40% higher chance of dying between ages 25 and 64 than men in
the top quintile. Table 3.9 gives estimates of average life expectancy by quintile of
socioeconomic disadvantage. There is a 3.6 year gap in life expectancy at birth for males
between the top and bottom quintiles, and a 1.9 year gap for females.
In assessing the mortality inequalities reported here, we should keep in mind that the
Australian population has been classified into quintiles using a small area based index of
socioeconomic disadvantage. This index relates to the average disadvantage of all people
living in the area and so the resultant mortality inequalities will be smaller than if the
population were classified using individual socioeconomic status or areas defined at a lower
level than SLA (e.g. census districts). In other words, these measures of inequality will
almost certainly understate the true inequality in mortality burden by level of
socioeconomic disadvantage at the individual level in Australia.
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Table 3.8: Probability of dying between various exact ages, by quintile of socioeconomic
disadvantage, by sex, Australia, 1995–97
1st quintile 2nd quintile 3rd quintile 4th quintile 5th quintile
Between ages 0 and 15
   Males 0.8 0.8 1.0 1.0 1.2
   Females 0.6 0.7 0.8 0.7 0.9
Between ages 15 and 25
   Males 0.7 0.9 1.2 0.9 1.4
   Females 0.3 0.3 0.3 0.3 0.4
Between ages 25 and 65
   Males 11.6 14.7 16.0 16.3 18.1
   Females 7.2 8.3 9.1 9.5 10.2
Between ages 65 and 75
   Males 21.8 24.8 25.3 25.6 27.7
   Females 12.8 13.8 14.7 14.2 15.3
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Figure 3.9: Probability of dying between exact ages 15 and 25, and ages 25 and 65, by quintile of
socioeconomic disadvantage and sex, Australia, 1995–97
Table 3.9: Life expectancy at birth and at age 65, by quintile of socioeconomic disadvantage,
Australia, 1995–97
1st quintile 2nd quintile 3rd quintile 4th quintile 5th quintile
Life expectancy at birth
   Male 77.76 76.01 75.28 75.20 74.12
   Female 82.39 81.45 81.20 81.20 80.48
Life expectancy at age 65 years
   Male 17.08 16.15 16.10 15.95 15.73
   Female 20.26 19.70 19.76 19.82 19.52
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Table 3.10: Trends in mortality differentials and inequality in mortality rates for selected disease
and injury categories, by broad age group and sex, Australia, 1985–87 to 1995–97
Males Females
Gini coefficient Gini coefficient
Disease category 1985–87 1995–97 1985–87 1995–97
0–14 years
   All causes 0.07 0.09**  Ý 0.10 0.07**  ß
   Perinatal conditions 0.08      0.08** 0.13 0.07**  ß
   Sudden infant death syndrome 0.04 0.17**  Ý 0.11 0.19**  Ý
   All injuries 0.11 0.13**  Ý 0.11   0.11**
   Road traffic accidents 0.07 0.16**  Ý 0.14 0.08**  ß
15–24 years
   All causes 0.07 0.10**  Ý 0.09 0.07**  ß
   Drug dependence and harmful use 0.13 0.04**  ß 0.07 0.01**  ß
   All injuries 0.06 0.12**  Ý 0.10 0.07**  ß
   Road traffic accidents 0.05 0.14**  Ý 0.08 0.12**  Ý
   Suicide 0.05 0.09**  Ý 0.03 0.03**
25–64 years
   All causes 0.10 0.09** 0.07 0.07**
   Ischaemic heart disease 0.08 0.11**  Ý 0.14 0.16**  Ý
   Stroke 0.13 0.12** 0.10 0.09**
   Diabetes mellitus 0.12      0.12** 0.18 0.22**  Ý
   All cancers 0.05 0.06** 0.01 0.02**
   Lung cancer 0.08 0.12**  Ý 0.07 0.10**  Ý
   All injuries 0.12 0.09**  ß 0.09 0.06**  ß
   Suicide 0.10 0.06**  ß 0.06 0.01**  ß
   Road traffic accident 0.09 0.15**  Ý 0.08 0.12**  Ý
(a) Age-standardised Gini coefficients for mortality rate per 1,000 population across quintiles of socioeconomic disadvantage defined
using a small area index of relative socioeconomic disadvantage according to place of residence at time of death.
(b) Asterisks attached to the 1995-97 estimates indicate level of significance of the difference from the corresponding 1985–87 value:
* p <0.01, ** p <0.001.  The arrows indicate significant increasing or decreasing trends for Gini coefficients which have changed
by more than 0.01 over the ten year period.
Source: Turrell and Mathers 1999.
As shown in Table 3.9, comparison of death rate differentials for 1995–97 with those for
1985–87 published in earlier AIHW reports (Mathers 1994a, 1995, 1996) shows that the
differentials have remained similar for females and for adult and older males, but have
widened for boys and young men aged 15–24 years (Turrell & Mathers 1999). In the latter
group, the differentials between the top and bottom quintiles have widened for motor
vehicle accidents and suicide, but narrowed for drug overdose deaths as rates have
increased faster in the top quintile than the bottom.
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4 Years lost due to disability
4.1 Overview
In this chapter, we present the final results of the Australian Burden of Disease and Injury
Study for years of life lost due to disability (YLD) by age, sex and cause for 1996. These
results quantify the burden of non-fatal health outcomes using a single measure, DALYs.
Figure 4.1 shows the YLD contributions for the major disease groups and injury to the total
non-fatal burden of disease and injury in Australia in 1996. The non-fatal disease burden
presents a substantially different picture than that provided by traditional mortality
statistics: mental disorders are the leading cause, accounting for nearly 30% of the non-fatal
burden (YLD) in Australia. Mental disorders are followed by nervous system and sense
organ disorders (Figure 4.1). The latter category is dominated by senile dementias and
hearing loss. Table 4.3 shows the top 20 causes of years lost due to disability. Detailed
information on YLD by sex and age group for all disease and injury categories is given in
Annex Table G.
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Figure 4.1: Non-fatal burden of disease (YLD) for major disease groups, Australia, 1996
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4.2 Data and methods
Many sources of information were used to calculate YLD for diseases and injuries in
Australia in 1996. These included national surveillance data and disease registers, health
survey data, hospital and medical service use data and Australian and international
epidemiological studies (see Annex Table C). Section 2.6 describes the general methods and
data sources used for estimating YLD for diseases and injuries. Two examples of YLD
worksheets, for senile dementia and stroke, are given in Appendices B and C to illustrate
the general approach used.
The YLD methods are generally similar to those used in the GBD. Australia has more
comprehensive population health data collections than most other regions of the world.
Together with the use of the more detailed Dutch weights and sequelae, this has enabled the
Australian studies to carry out more detailed analyses of YLD for many diseases, taking into
account Australian data on incidence, prevalence, case fatality and severity of the condition
and its sequelae.
Specialised models and analyses were developed for a number of major disease and injury
groups. These are briefly described below.
Cancers
The basis of YLD estimation for cancer was the calculation of the age-sex specific cure rate
and the age–sex specific average time to death for those not cured. Those who are cured of
the cancer were assumed to have negligible disability after an initial treatment and
remission period. For those who die, the survival time to death was assumed to follow an
exponential distribution, so that the mean survival time was estimated by fitting this
distribution to available survival data.
We developed a model for each cancer based on the cancer stages and sequelae for which
the Dutch study estimated disability weights (Stouthard et al. 1997). The general form of the
model for sites apart from non-melanoma skin cancers (NMSC) is shown in Figure 4.2.
Incidence
State after intentionally curative
primary therapy
DW  0.18–0.38
Diagnosis and
primary therapy
DW  0.19–0.69
Cure
In remission
DW  0.18–0.47
Disseminated
carcinoma
DW  0.75–0.91
Terminal phase
DW  0.19–0.69
Death
12 months or less
Up to 5 years
Variable 12 months or less 1 month
Figure 4.2: General model for cancer YLD estimation, including disability weight (DW)
and duration ranges
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We used the Dutch study weights for this analysis where they were available (Stouthard et
al. 1997). For most cancers there are alternative weights developed by the GBD study
(Murray & Lopez 1996a). The GBD weights distinguish between treated and untreated
cancer but do not address issues of disease stage or severity as the Dutch weights do.
Diagnosed cancers generally do not remain untreated in Australia, so the Dutch approach is
more applicable here. In general the GBD weights are far lower than the Dutch weights.
Where no Dutch weights were available for a specific cancer site, we extrapolated weights
using the Dutch weight for the cancer that it most resembles.
The Dutch study did not derive a weight for the terminal stage of any of the cancers. Instead
we used the Dutch weight for general end-stage disease.
The durations of the initial treatment, disseminated and terminal stages were specified
separately for each cancer site. The duration of the remission stage was taken as the total
mean survival time less the sum of the durations of the initial treatment, disseminated and
terminal stages. The duration of the state after intentionally curative primary therapy was
taken as five years less the duration of the initial treatment stage.
There are two sources of data for the estimation of proportion cured and mean survival time
for those who die:
· Data published by the SA Cancer Registry (SA Cancer Registry 1996)
· These data consist of the estimated proportion of cases surviving by year from diagnosis
for the first five years after diagnosis. These proportions are adjusted for other causes of
death so they represent time till death from the specific cancer under study.
· The National Cancer Statistics Clearing House database
· The National Cancer Statistics Clearing House (NCSCH) database includes records for
all notified cases of cancer in Australia from 1982 to 1991, with data for some States and
Territories up to 1994. Deaths data on this database are incomplete so the entire database
is not suitable for analysis of cancer survival. However, deaths data from the NSW, SA
and WA registries for the period 1982 to 1994 are relatively complete and can be used for
survival analysis. Survival probabilities adjusted for other causes of death were
calculated using the SAS procedure PROC LIFETEST.
For most cancers, the proportion cured for the cancer was taken as the proportion surviving
five years and the YLD estimation for these cancers was based on the SA data. The
exceptions to this were colorectal, lung, melanoma, breast, uterus, prostate, lymph, multiple
myeloma and leukemia, where either the survival time was too long to be estimated from
five years data or the SA data were not sufficiently detailed to apply the disease model. For
these cancers the cure rate was taken as the proportion surviving after the last recorded
death on the NCSCH database. In addition, survival times for gall bladder and bladder
cancer were estimated from the SA data but the cure rate was based on the number of
observed deaths in 1996. NMSC is not included in Australian cancer registry data, so model
parameters were drawn from published results in the academic literature and the observed
number of deaths in 1996.
In each case the mean survival was estimated by finding the exponential distribution which
most closely reproduced the survival probabilities using the maximum likelihood criteria.
The State and Territory cancer registries do not actively follow up cancer cases to record
deaths. Hence it is likely that some deaths will be missed even for those States with good
deaths data, leading to possible over-estimation of the proportion cured. However,
examination of the registry data has shown that this proportion is likely to be small and so
can be neglected for our modelling (Tallis et al. 1988).
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The incidence data for all cancers other than NMSC were calculated from the NCSCH
database. These were projections to 1996 calculated from observed incidence data up to 1994
and made using the NCSCH projection methodology. NMSC incidence estimates were
derived from survey data collected for Australia in 1995 (G. Giles, personal communication
1998). These were adjusted to 1996 values, by assuming a linear trend between 1990 and
1995 survey estimates and projecting this trend to 1996.
Diabetes
YLD estimates were made for Type 1 (insulin-dependent) diabetes mellitus and for Type 2
(non-insulin-dependent) diabetes mellitus. Incidence rates were modelled from prevalence
rates using DISMOD. Prevalence estimates for Type 1 diabetes were derived from GAD
(glutamic acid decarboxylase) auto-immune antibody prevalence in subjects on the
Tasmanian Insulin-Treated Diabetes Registry (McCarty et al. 1996). Approximately 85% of
eligible subjects were tested.
Prevalence estimates for Type 2 diabetes were derived from the rates of self-reported current
diagnosis of diabetes in the 1995 ABS National Health Survey (NHS). The NHS data were
adjusted for undiagnosed cases using an adjustment factor based on the US NHANES III
study for 1988-94 (Harris et al. 1998), which estimated the ratio of undiagnosed to diagnosed
diabetes in subjects 20 years and over to be approximately 50%. Previous diabetes
prevalence adjustments for undiagnosed cases using the NHS have estimated one
undiagnosed case for every diagnosed case (Coliaguri et al. 1998, McCarty et al. 1996). These
estimates were based on an earlier NHANES study (1976–1980) reported by Harris et al.
(1987), which estimated the ratio of undiagnosed to diagnosed diabetes in the 20–74 year
age-group to be approximately 100%.
Seven sequelae were modelled for diabetes: retinopathy, cataracts, glaucoma, nephropathy,
neuropathy, diabetic foot ulcers and amputation. YLD for these sequelae have been
discounted back to age at incidence of diabetes. These sequelae generally occur many years
after the onset of diabetes per se. In order to estimate discounted YLD, quite complex
models were necessary to estimate the average lag time till onset of each sequela, the
incidence per case of the sequela by number of years lived with diabetes, and the average
duration of the sequela. Each sequela has been modelled separately, and comorbidities
between them have not been taken into account.
Renal failure deaths due to diabetes are included with the mortality and YLL estimates for
diabetes. Diabetes is also a risk factor for coronary heart disease and stroke. While the
attributable mortality for these diseases has been taken into account in estimating durations
with diabetes, the attributable YLD for these diseases is not included here but with the
cardiovascular disease categories. Similarly, infections and pregnancy complications due to
diabetes have not been included here but their burden is included in YLDs estimated for
those categories. Section 5.4 estimates the total burden attributable to diabetes in Australia,
including the attributable burden of cardiovascular disease. Section 6.5 also provides a more
detailed picture of the burden of diabetes in Australia.
Mental disorders
This group includes all mental disorders in the corresponding ICD-9 chapter apart from
senile dementias. The latter are included with Alzheimer’s disease in the nervous system
group ‘Dementia’. The primary data sources for the mental disorders included in the
Australian Burden of Disease Study are:
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· ABS National Survey of Mental Health and Wellbeing 1997 (MHS’97)—used for anxiety
disorders, depression, most substance abuse, and borderline personality disorder;
· National Drug Strategy Household Survey 1998—used for heroin and residual ‘other
drugs’ category; and
· reviews of epidemiological studies—used for schizophrenia, bipolar disorder, eating
disorders, childhood disorders.
The MHS’97 was conducted by the Australian Bureau of Statistics (ABS 1999b) from May to
August 1997 from a population sample of 10,600 people aged 18 years and over (a response
rate of 78%). The survey did not include people in health institutions. The survey was
designed to provide information on the prevalence of a range of major mental disorders in
Australia. A modified version of the Composite International Diagnostic Interview (CIDI)
was used to classify respondents according to ICD-10 criteria for those conditions whose
prevalence was expected to be of the order of 1% or greater in the population. For each ICD-
10 diagnostic group included, the MHS’97 estimated the one-year prevalence (any
occurrence of the disorder in the 12 months prior to interview) and the prevalence during
the last two weeks. The survey contained a number of symptom and general disability
scales, including the SF-12, BDQ, GHQ and days out of role.
Many mental disorders are chronic conditions with periods of symptoms and periods of
remission. In general, we used the proportion of the 12-month prevalent cases with
symptoms in the last two weeks as an approximation of the proportion of time
symptomatic. An exception to this was alcohol dependence (as opposed to harmful use) for
which different methods were used to estimate average severity of condition.
There are very high levels of comorbidity between anxiety disorders, affective disorders and
substance abuse. Nearly one in three persons with an anxiety disorder (12-month
prevalence) also had an affective disorder, while one in five also had a substance abuse
disorder. More than half of those with an affective disorder also had a disorder from one of
the other major groupings. In order to avoid double-counting of burden, we have shared
comorbidity between anxiety disorders, affective disorders and borderline personality
disorder equally so that person with 2 disorders is counted 50% in each category.
Comorbidity with harmful substance abuse is attributed 75% to relevant
anxiety/affective/borderline personality category and 25% to substance abuse.
The EuroQol descriptions of the six anxiety disorders in adults distinguish mild/moderate
from severe manifestations mostly in the third domain of usual activities and the fifth
domain of anxiety/depression. The MHS’97 included the SF-12 disability instrument. Six
items relating to usual activities and anxiety or depression were used to match prevalences
from the MHS’97 as closely as possible to the severity levels specified for the Dutch weights.
The mapping was validated by examining its performance in discriminating disability
severity as measured by nine available disability and symptom scales in the MHS’97.
The reader should note therefore that the burden of mental disorders calculated here is
based on prevalence estimates not comparable with those published by the Australian
Bureau of Statistics (ABS 1999b). The YLD estimates have been calculated to take account of
comorbidities (so that each person is counted once), proportion of time symptomatic, and
severity of associated disability whereas the ABS prevalences for mental disorders are
12-month prevalence rates for conditions (not persons).
The methods and data sources are quite different from those used in the GBD. In addition,
different and more detailed disability weights are used that take into account Australian
population data on severity distributions. The overall non-fatal burden of anxiety disorders,
affective disorders and substance abuse disorders are compared for Australia and the
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Established Market Economies (EME) in the GBD in Figure 4.3. The burden of schizophernia
is lower in Australia than the EME because the estimate is based on lower incidence
estimates. The estimated burden of anxiety disorders is substantially larger per 1,000
population because a larger number of disorders are included (7 disorders compared to 3 in
the GBD). However, obsessive-compulsive disorders were overestimated in the GBD (based
on one of the earliest US mental health surveys and later acknowledged to be too high). The
difference in alcohol burden is partly a reflection of the smaller size of the problem in
Australia and in 1996 compared to 1990, but also to differences in modelling which resulted
in use of a lower disability weight for Australia, particularly among younger men.
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Source: EME data from Murray and Lopez 1996a.
Figure 4.3: Comparison of estimated total burden (undiscounted DALYs) for mental disorders
in Australia, 1996 and EME, 1990
Sense organ disorders
Adult-onset hearing loss and age-related vision loss other than cataracts and glaucoma (e.g.
macular degeneration, disorders of accommodation and refraction) were not included in the
Global Burden of Disease Study. YLD estimates for these conditions were based on
Australian population surveys of measured visual acuity with usual glasses (if worn) and
measured hearing loss in the better ear. Hearing loss estimates have been adjusted to take
account of the use of hearing aids. These YLD estimates thus reflect the net disability due to
sight and hearing loss after the effects of aids have been taken into account. They do not
reflect the total disability levels of sight and hearing loss per se.
YLD for the three vision loss disorders included in the Australian study were estimated
using data on the prevalence of mild, moderate and severe vision loss (refer to Annex Table
C for definitions). These data are from the Blue Mountains Eye Study (BMES), which
sampled community residents and also a nursing home sample (Attebo et al. 1996, Mitchell
et al. 1997). The BMES also examined causes of vision loss, allowing estimation of the
contributions of glaucoma and cataracts.
Males Females
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Vision loss was initially modelled as a progressive condition which progresses through
mild, moderate and severe levels, so that the YLD valued using the moderate and severe
weights were discounted back to age of incidence. It was found that the incidence rates for
moderate and severe vision loss could only be consistent with relatively short time lags of
less than 3 years, and so the final estimates treated the mild, moderate and severe vision
loss as separate conditions for simplicity.
Wilson et al. (1998, 1999) have carried out the first Australian population survey of meas-
ured hearing loss using the SA Health Omnibus Survey as a sampling frame. They sampled
both people who reported hearing loss and those who did not. The prevalence of hearing
impairment was measured at a number of theshold hearing levels for the worse ear and the
better ear. The prevalence data for the better ear reflects the prevalence of hearing
impairment and was used here. Threshold levels of 25, 35, 45 and 65 dBHTL (averaged over
0.5, 1, 2, 4kHz) were used as these correspond to the lower boundaries of mild, moderate
and severe hearing loss (Wilson et al. 1999). The level 35 dBHTL corresponds to the lower
boundary of the level at which the person would benefit from wearing a hearing aid.
Hearing loss was modelled as a progressive condition which progresses through mild (25–
34 dBHTL), mild (35–44 dBHTL), moderate and severe levels. Thus cases of prevalent severe
hearing loss at a given age were modelled as cases of mild hearing loss incident at an earlier
age that have progressed through moderate to severe levels. The YLD for mild (35–44
dBHTL), moderate and severe hearing loss were thus discounted back to age of incidence.
Cardiovascular disease
This group includes all diseases classified by ICD-9 as circulatory diseases except for
hypertensive renal disease, which is included as part of the genitourinary diseases group,
and chronic pulmonary heart disease, which is included as part of the chronic respiratory
diseases group. The major data source for YLD estimation was the AIHW national hospital
morbidity database, with incidence and duration data derived using DISMOD with disease
modelling assumptions and published results from the research literature.
The three biggest contributors to YLD in this group are stroke, ischaemic heart disease
(IHD) and peripheral vascular disease (PVD). The disease modelling for stroke was based
on incident cases of first-ever stroke. These were divided into people who died within 28
days, those who survived this period with a permanent disability and those who recovered
completely. The YLD contribution from people who have second and subsequent strokes
was included in the YLD estimate for survivors with permanent disability. Incidence and
duration estimates were derived using DISMOD from the numbers of hospitalised stroke
patients and modelling assumptions drawn from a community stroke study in Perth and a
study of Perth and Auckland population-based stroke registers.
The IHD disease model assumed that the disease may start as either angina pectoris or an
acute myocardial infarction (AMI). Although these two conditions relate to the same disease
process, there were insufficient data to model them together so they were modelled
independently.
Angina pectoris was modelled as recurring attacks over the rest of the person’s life, with
possible remission due to treatment. Angina incidence was derived from the reported
prevalence of current treated angina in the 1989 National Heart Foundation Risk Factor
Survey using DISMOD. Published data was used to estimate case fatality rates and
Australian trends in angina-related hospital inpatient procedures used to estimate remission
rates. Angina incidence rates were assumed to have declined between 1989 and 1996 at the
same rate as the decline in incidence of ischaemic heart disease.
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AMI may result in (1) death, (2) heart failure, or (3) recovery with zero disability weight.
Death was assumed to follow the AMI duration given in the GBD study for EME countries
(Murray & Lopez 1996b). Heart failure was assumed to follow immediately after the AMI
and last for the heart failure duration given for EME countries in the GBD study. The
disease model focused on AMI incidents rather than on people experiencing an AMI, so the
incidence data refer to the number of new AMI incidents in a year rather than people
experiencing AMI for the first time. AMI incidence was derived from hospital data while a
model of the course of the disease was based on published data.
PVD prevalence and disease severity distribution data were derived from the 1993
Australian disability survey. These were used with treatment rates derived from hospital
data and some mortality assumptions to derive disease incidence and duration. There were
no Dutch or GBD disability weights for this condition, so provisional weights were derived
using the EQ-5D+ regression model. Amputation was taken as the major additional sequela
of PVD, with incidence derived directly from the hospital data and duration derived using
DISMOD.
Table 4.1 compares the YLD/YLL ratios for cardiovascular diseases in Australia in 1996 with
the estimates for the EME from the GBD (Murray & Lopez 1996a). The ratios are similar for
ischaemic heart disease and stroke, the two largest contributors to cardiovascular burden,
but substantially higher for other cardiovascular diseases in Australia. This is due to the
explicit estimation of YLD for peripheral vascular disease, for which the disability burden is
more than four times the mortality burden.
Table 4.1: YLD/YLL ratios for cardiovascular diseases, Australia and EME
YLD/YLL ratio
Condition Australia 1996 EME 1990
Ischaemic heart disease 0.084 0.094
Stroke 0.507 0.454
Other cardiovascular diseases 0.546 0.196
   Note: YLD/YLL ratio calculated using age-weighted DALYs, EME data from Murray and Lopez 1996a.
Injuries
The analysis of burden of injury is based on methods developed by Theo Vos for the
Mauritius Burden of Disease Study (Vos et al. 1995). These methods define an injury case as
an injury severe enough to warrant medical attention or that leads to death. They were also
adopted and applied by the Global Burden of Disease Study (Murray & Lopez 1996a).
We classified each injury according to cause using the list of causes specified in Annex
Table B. Within each cause group, each injury was classified according to type of injury
sequelae using the list of sequelae in Annex Table B. These were further classified by site
and extent of injury (where appropriate) and short- and long-term consequences. We then
applied the disability weights for each injury type and summed the resulting YLD for all
types of injury within each external cause group to produce age–sex-specific YLD estimates
for each external cause. The GBD disability weights and durations (Murray & Lopez 1996a,
page 214) were adopted with some minor modifications. There are short-term and long-term
sequelae weights for 18 types of injury.
We used two sources of injury incidence data—hospital inpatient data and hospital
emergency department data. In doing this we implicitly assumed that almost all injuries
with significant disability and long-term duration are hospitalised initially, so these two
sources cover all injuries associated with significant YLD. Most injuries in Australia which
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require medical care would receive that care. Further, examination of national survey data
on general practice activity (Britt et al. 1999) suggested that most injuries treated by GPs out
of hospitals were relatively minor.
The inpatient data were compiled from national hospital morbidity data for 1996–97
excluding transfers between hospitals and readmissions of the same person for the same
injury within 90 days. Hospital separations were allocated to each injury cause using the
principal injury cause code except for the adverse effects of medical treatment. A separation
was allocated to this group if there was any relevant external cause code on the hospital
record.
There are no national data for emergency presentations. Instead the incidence data were
based on data from the Victorian Emergency Minimum Dataset collection for the period July
1998 to February 1999. The ratio of emergency presentations (excluding those admitted) to
inpatient episodes was calculated for each age–sex–injury type group. This ratio was then
applied to the national inpatient data described above to give an estimate of national injury
emergency presentations by age, sex, external cause and type of injury.
Residual categories
A large number of diseases and injuries and their sequelae have been analysed in this study,
including all of those that make a large contribution to the total burden. However, there are
many others that have not been explicitly evaluated. Because YLL have been calculated for
all deaths, they are as complete as the death registration data allow. Because the YLL are
comprehensive, it is also necessary to estimate YLD for residual categories of disease and
injury to ensure a balanced picture of the total burden of disease.
For the main disease categories for which there were substantial numbers of deaths, YLD for
the residual category were estimated for each age–sex group. YLL for each age–sex group
were multiplied by the average YLD/YLL ratio for the combined set of disease categories
within that main disease category for which individual YLD analyses have been carried out.
For main disease categories where there was a very small mortality burden, explicit YLD
analyses were carried out for the residual category using available prevalence or incidence
data. For two such categories, mental disorders and oral health problems, YLD were not
estimated for the residual category. DALYs for these two residual categories include only
YLL due to mortality. The ‘Other’ categories for which explicit YLD analyses were carried
out are listed in Annex Table B.
4.3 Incidence, prevalence and duration of conditions
Although most results of the Australian Burden of Disease and Injury Study are reported
here in terms of YLL, YLD and DALYs, these are based on comprehensive estimates of the
incidence, prevalence and durations of a large number of disease and injuries and their
disabling sequelae. These estimates, the assumptions and models used, and the data
sources, are described in detail in the YLD worksheets. These worksheets are available from
AIHW (see Section 1.2). Two examples of worksheets are included here (Appendix B and
Appendix C). Annex Table D summarises total incidence and prevalence estimates across all
age groups in 1996 for males and females for all the diseases modelled in this study. For
some disease categories such as infectious diseases and cancers, detailed prevalence
estimates were not derived due to the complexity of the disease models. For a few others,
such as iron
50
Table 4.2: Estimated total incidence and prevalence of selected conditions, by sex, Australia, 1996
Incidence(a) Prevalence(b)
Disease category Male Female Persons Male Female Persons
HIV/AIDS 437 36 473 (c) (c) (c)
Diarrhoeal diseases 1,863,370 1,890,846 3,754,216 (d) (d) (d)
Colorectal cancer 6,005 5,198 11,203 (d) (d) (d)
Lung cancer 3,877 1,661 5,538 (d) (d) (d)
Non-melanoma skin cancers 167,751 115,074 282,825 (d) (d) (d)
Breast cancer — 8,630 8,630 (d) (d) (d)
Prostate cancer 10,444 — 10,444 (d) (d) (d)
Type 1 diabetes 926 915 1,841 36,000 37,580 73,590
Type 2 diabetes 21,006 14,497 35,503 247,490 221,890 469,380
Alcohol dependence/harmful use 120,162 41,320 161,482 538,520 189,310 727,820
Depression(e) 115,418 261,303 376,721 163,960 374,090 538,050
Dementia 9,529 14,305 23,834 48,160 76,130 124,290
Adult-onset hearing loss 70,212 41,272 111,484 2,245,780 842,540 3,088,320
Angina pectoris 28,468 16,080 44,548 90,550 77,600 168,150
Stroke 26,488 30,756 57,244 67,020 54,240 121,260
COPD 12,124 8,038 20,162 177,100 119,490 296,590
Asthma 32,048 37,386 69,434 533,910 672,220 1,206,140
Osteoarthritis 15,563 27,112 42,675 241,522 383,565 625,087
Road traffic accidents(f) 54,711 33,428 88,139 34,210 16,260 50,470
Suicide and self-inflicted injuries(f) 12,052 16,095 28,147 3,890 3,020 6,910
(a) Incident cases of disease or injury, except where otherwise specified.
(b) Prevalent cases of disease or injury, except where otherwise specified. All prevalence estimates over 1,000 cases have been rounded to the
nearest 10. Some prevalence estimates are derived from DISMOD modelling of incidence and duration and assume a stationary population
with no trends in incidence rates or average duration.
(c) YLD model gives prevalence of HIV infection based on estimated current average survival times. Actual prevalence in 1996 not estimated.
(d) Total prevalence not estimated.
(e) People with dysthymia or experiencing major depressive episode in 12-month period of 1996.
(f) Prevalence estimates include only people with long-term sequelae of injuries.
deficiency anaemia, the YLD estimates were based on prevalence data without derivation of
incidence and duration.
Table 4.2 contains estimates of the total number of incident and prevalent cases of selected
diseases and injuries in Australia for 1996. Refer to Annex Table D for similar information
on other conditions.
4.4 Leading causes of the disability burden
The ten leading causes of disease burden for Australia are shown in Table 4.3. Depression
leads the list for both males and females, causing 8% of the total non-fatal disease burden.
Hearing loss and alcohol dependence and harmful use are the second and third leading
contributors to non-fatal burden for males. Dementia and osteoarthritis are the second and
third leading contributors for females.
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Table 4.3: Top twenty causes of disability burden: YLD by sex, Australia, 1996
Males
YLD
(’000)
Per cent
of total Females
YLD
(’000)
Per cent
of total
1 Depression 35,816 6.2 1 Depression 56,979 9.8
2 Adult-onset hearing loss 33,012 5.7 2 Dementia 39,840 6.8
3 Alcohol dependence/abuse 28,163 4.9 3 Osteoarthritis 33,296 5.7
4 Dementia 25,251 4.4 4 Asthma 31,130 5.3
5 Asthma 24,661 4.3 5 Generalised anxiety disorder 20,488 3.5
6 COPD(a) 24,438 4.2 6 Diabetes mellitus(b) 20,404 3.5
7 Diabetes mellitus(b) 23,419 4.1 7 Vision disorders 16,700 2.9
8 Stroke 22,467 3.9 8 Stroke 15,588 2.7
9 Osteoarthritis 22,442 3.9 9 Adult-onset hearing loss 15,158 2.6
10 Ischaemic heart disease 22,252 3.9 10 COPD(a) 14,456 2.5
11 Benign prostatic hypertrophy 16,821 2.9 11 Breast cancer 13,424 2.3
12 Generalized anxiety disorder 11,342 2.0 12 Ischaemic heart disease 13,300 2.3
13 Borderline personality disorder 10,274 1.8 13 Alcohol dependence/abuse 12,901 2.2
14 Prostate cancer 9,974 1.7 14 Parkinson’s disease 12,210 2.1
15 Attention-deficit hyperactivity
disorder 9,369 1.6
15 Eating disorders 10,405 1.8
16 Schizophrenia 8,847 1.5 16 Social phobia 10,185 1.7
17 Bipolar affective disorder 8,797 1.5 17 Bipolar affective disorder 8,865 1.5
18 Parkinson’s disease 8,445 1.5 18 Schizophrenia 8,569 1.5
19 Social phobia 8,428 1.5 19 Rheumatoid arthritis 6,868 1.2
20 Peripheral arterial disease 7,895 1.4 20 Dental caries 6,807 1.2
Total 578,720 100.0 Total 583,321 100.0
(a) Chronic obstructive pulmonary disease (chronic bronchitis and emphysema).
(b) includes Type 1 and Type 2 diabetes.
The leading causes of non-fatal disease burden in Australia are broadly similar to those for
the Established Market Economies in the Global Burden of Disease Study (Figure 4.4). YLD
proportions for Australia are for non-age-weighted YLD whereas those for the EME are age-
weighted. They are thus not strictly comparable as the age weighting gives a somewhat
higher weight to mental disorders and conditions of younger ages, and a lower weighting to
conditions of older age such as senile dementias. However, we can draw some general
conclusions. Asthma appears in the top ten causes for Australia but not the EME, reflecting
the almost four times higher prevalence of asthma in Australia compared to the EME.
Hearing loss was not estimated in the Global Burden of Disease Study. Certain mental
disorders rank more highly in the EME than in Australia. This may reflect differences in the
methods and data used to estimate the burden of mental disorders in Australia (see
Section 4.2).
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Figure 4.4: Non-fatal burden of disease (YLD) for major disease groups, Australia, 1996
4.5 Disability burden—patterns by age and sex
The female YLD burden in Australia is 1% higher than the male YLD burden. In contrast,
the total YLL for males are 26% higher for males than females.
Table 4.4 shows the percentage distribution of YLD among the main disease and injury
groups for males and females, and for broad age groups. The non-fatal burden of nervous
system disorders, mental disorders and musculoskeletal disorders are all higher for females
than for males.
The male non-fatal burden is higher for cardiovascular disease, diabetes, chronic respiratory
diseases and cancers. The leading contributors to non-fatal burden in children are mental
disorders, chronic respiratory disease (asthma), and congenital abnormalities. The leading
causes of non-fatal burden among young adults (15–24 year olds) are mental disorders (60%
of total), followed by injuries. At ages 55 and over, mental disorders and injuries cease to be
major contributors to the non-fatal disease burden and are replaced by cardiovascular
disease, cancer, musculoskeletal disorders and nervous system and sense organ problems.
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Table 4.4: Percentage distribution of YLD by main disease category, sex and age group, Australia,
1996
Per cent of total YLD
Disease category Persons Male Female  0–14  15–34  35–54  55–74  75+
A. Infectious and parasitic diseases 1.5 1.4 1.6 3.1 2.1 1.6 0.6 0.3
B. Acute respiratory infections 1.2 1.2 1.2 4.2 1.1 0.8 0.5 0.6
C. Maternal conditions 0.3 0.0 0.5 0.0 1.0 0.1 0.0 0.0
D. Neonatal causes 0.8 0.8 0.7 6.2 0.0 0.0 0.0 0.0
E. Nutritional deficiencies 0.7 0.5 0.9 2.6 0.7 0.6 0.2 0.1
F. Malignant neoplasms 6.8 7.1 6.5 0.5 1.1 6.2 12.9 11.9
G. Other neoplasms 0.2 0.1 0.2 0.0 0.1 0.3 0.1 0.2
H. Diabetes mellitus 3.8 4.1 3.5 1.4 1.3 7.9 4.7 1.6
I. Endocrine and metabolic disorders 1.3 1.5 1.1 1.7 0.4 1.1 1.8 2.1
J. Mental disorders 27.0 25.9 28.0 23.4 59.9 33.5 6.8 0.5
K. Nervous system disorders 16.1 14.8 17.5 4.2 2.5 5.5 25.1 50.8
L. Cardiovascular disease 8.8 10.5 7.0 0.7 1.1 6.7 16.8 17.5
M. Chronic respiratory diseas 8.9 9.2 8.5 29.2 6.0 7.5 6.6 2.3
N. Diseases of the digestive system 2.1 1.9 2.2 0.9 2.8 2.4 1.9 1.4
O. Genitourinary diseases 4.1 4.9 3.3 0.3 4.8 4.3 5.2 3.7
P. Skin diseases 0.8 0.7 0.9 1.3 1.5 0.9 0.3 0.2
Q. Musculoskeletal diseases 7.1 5.6 8.6 1.6 3.0 11.3 11.8 3.8
R. Congenital abnormalities 1.2 1.3 1.0 9.4 0.0 0.0 0.0 0.0
S. Oral health 2.1 1.9 2.2 0.7 2.2 3.3 2.1 0.9
V. Ill-defined conditions 0.4 0.2 0.6 0.2 0.6 1.1 0.0 0.0
T. Unintentional injuries 4.7 5.8 3.5 8.3 6.7 4.5 2.5 2.2
U. Intentional injuries 0.3 0.5 0.1 0.1 0.9 0.3 0.0 0.0
Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
4.6 Prevalent burden of disability
Age–sex–specific estimates of the incidence and duration of diseases, injuries and their
sequelae were estimated for a total of 1260 categories. These categories are listed in Annex
Table B together with the disability weights used to calculate YLD for Australia. Adding
these YLD across all categories, including the residual categories for each major disease
group, gives us age–sex–specific estimates of the total years of life lost due to disability in
Australia.
Although the primary emphasis of this study is on incident years lost due to disability, we
have also calculated undiscounted prevalence-based YLD which reflect prevalent disability
at each age. Figure 4.5 compares the severity-weighted total prevalence of incident disability
and prevalent disability in Australia in 1996. Incident YLD for ages 0–4 include all disability
throughout life resulting from congenital and perinatal conditions and so are higher than
prevalent YLD for that age group, which include only disability experienced in that actual
age range. Incident YLD per capita are lower than prevalent YLD at older ages because
much of the disability experienced at older ages arises from chronic diseases and injuries
incident in middle age and earlier older ages.
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and prevalence of disability, 1996 short-term and long-term disability, by age, 1996
The total prevalent YLD per 100 population can be thought of as a severity-weighted
disability prevalence measured as a percentage of the population of that age. Figure 4.6
shows the contributions to the severity-weighted total prevalence of disability of chronic
mental conditions, chronic physical conditions and short-term conditions (lasting less than
6 months on average).
Mathers (1999a) estimated weighted disability prevalence rates (%) by age and sex for the
Australian population in 1993 using weights for disability and handicap severity levels
chosen to line up as closely as possible with appropriate preference weight ranges for the
Dutch weights. Results for males and females combined are shown in Figure 4.7 and
compared with the prevalence YLD (expressed as % for each age group) from the Australian
Burden of Disease study. YLD associated with short-term conditions lasting less than six
months (such as colds and flu) have been excluded, since the survey definition of disability
included only chronic disability lasting six months or more. YLD associated with anxiety
disorders and mild to moderate (but not severe) depression have also been excluded, since
the majority of disability associated with these conditions is unlikely to have been captured
by the ABS Disability Survey.
The YLD-based prevalence estimates correspond quite closely to the survey-based
prevalence estimate at younger and middle ages and at ages 75 and over. For ages in the
range 55–74 years, the YLD-based prevalence is significantly higher than the survey-based
prevalence. This may reflect the impact of chronic diseases prevalent at these ages that are
not being picked up by the Disability Survey screening questions.
The contribution of various groups of diseases and injury to the prevalent burden of
disability, measured in terms of prevalence YLD at various ages, is illustrated in Figure 4.8.
The prevalent burden of mental disorders is largest at young adult and middle ages. The
prevalent burden of chronic respiratory conditions has two peaks, one for asthma in
children, and the other for chronic obstructive pulmonary disease in older people. For most
other disease groups, the prevalent burden is concentrated at older ages.
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Figure 4.8: Causes of prevalent YLD, by age, 1996
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Table 4.5 summarises total prevalence YLD by main cause categories for males and females,
and for broad age groups.
Table 4.5: Total prevalence YLD by main disease category, sex and age group, Australia 1996
Prevalence YLD (’000) Prevalence YLD (’000) by age group
Disease category Persons Male Female  0–14  15–34  35–54  55–74  75+
A. Infectious and parasitic diseases 21.0 10.7 10.3 3.3 6.2 7.0 3.6 1.0
B. Acute respiratory infections 14.5 7.4 7.1 5.9 3.5 2.3 1.8 1.0
C. Maternal conditions 1.6 — 1.6 0.0 1.2 0.4 — —
D. Neonatal causes 19.9 10.0 9.9 5.1 5.7 5.5 3.6 0.0
E. Nutritional deficiencies 8.5 2.9 5.6 3.7 2.1 1.9 0.6 0.2
F. Malignant neoplasms 83.4 43.2 40.2 0.5 3.2 17.6 41.6 20.5
G. Other neoplasms 1.8 0.5 1.4 0.1 0.2 0.8 0.4 0.3
H. Diabetes mellitus 67.7 35.2 32.5 3.0 3.7 11.6 35.6 13.7
I. Endocrine and metabolic disorders 17.0 10.0 7.0 1.8 2.2 3.8 5.6 3.6
J. Mental disorders 315.7 151.2 164.5 33.9 170.9 89.7 20.4 0.8
K. Nervous system disorders 205.4 90.9 114.4 1.5 5.0 10.7 72.9 115.3
L. Cardiovascular disease 116.1 69.2 46.9 0.8 2.5 15.7 56.5 40.6
M. Chronic respiratory diseas 137.3 70.2 67.1 28.0 33.3 23.8 43.1 9.2
N. Diseases of the digestive system 35.7 16.3 19.4 1.2 6.6 9.2 13.1 5.7
O. Genitourinary diseases 58.1 33.4 24.7 0.6 11.2 12.0 20.0 14.3
P. Skin diseases 10.4 4.5 5.9 1.8 4.3 2.5 1.4 0.4
Q. Musculoskeletal diseases 104.7 41.3 63.4 1.5 6.6 21.1 54.2 21.3
R. Congenital abnormalities 29.8 16.2 13.6 7.4 9.4 8.9 3.8 0.1
S. Oral health 27.1 12.0 15.1 1.0 5.9 8.0 8.5 3.8
V. Ill-defined conditions 5.2 1.5 3.7 0.4 1.7 3.1 0.1 —
T. Unintentional injuries 92.8 59.2 33.6 5.2 15.6 25.5 33.8 12.7
U. Intentional injuries 6.4 4.9 1.5 0.1 1.3 2.2 2.3 0.5
Total 1,380.0 690.4 689.6 106.7 302.2 283.4 422.8 264.9
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4.7 Attributable burden of selected impairments and
disabilities
The total non-fatal burden of disease and injury is calculated for an exhaustive categorical
set of disease and injury categories, and the burden for specific impairments or functional
limitations is distributed across these categories. There are a number of impairments for
which epidemiological data at the population level has been used to attribute the associated
burden to a number of disease or injury categories. For example, lower limb amputation and
renal failure may both be due to a range of causes including infection, cancer, cardiovascular
disease, diabetes, congenital conditions and injuries. Cognitive impairment is a sequela for a
number of congenital, perinatal and early childhood conditions, some injuries, mental dis-
orders, neurological conditions and cardivascular disease.
This section provides estimates of the total YLD burden attributable to five selected
impairments (Table 4.6). For all of these except cognitive impairment, the total YLD burden
has been estimated from population data on the total prevalence or incidence of the
impairment and attributed back to disease and injury causes for the calculation of YLD by
cause.
In estimating the total burden for cognitive impairment, the total burden of some disease
categories such as mental retardation and senile dementias has been included. For other
diseases and injuries such as stroke, depression and brain injury, the EQ-5D+ descriptions
of the distribution of health states have been used to estimate the proportion of the burden
of these conditions that is attributable to cognitive impairment.
In a similar way, the EQ-5D+ descriptions for disease stages, severity levels and sequelae
can be used to estimate the proportion of YLD for each condition that is attributable to
functional limitations defined by the EQ-5D+ dimensions (see Section 2.5). This is illustrated
in Figure 4.9, which shows the total YLD associated with mobility limitations, self-care
limitations and cognitive disability by age for males and females. In estimating the YLD
Table 4.6: Total YLD for selected impairments, by sex and age group, Australia 1996
YLD (’000)
Impairment
As per cent
of total YLD Persons Male Female  0–14  15–34  35–54  55–74  75+
Cognitive impairment(a) 16.0 185,770 84,520 101,250 33,315 21,588 23,502 38,043 69,322
Lower limb amputation(b) 1.8 21,010 12,610 8,400 696 1,648 4,150 10,011 4,505
Urinary incontinence 1.1 13,072 5,095 7,977 368 2,985 4,530 3,704 1,485
End-stage renal failure(c) 0.3 3,025 1,686 1,339 61 514 953 1,203 294
Cerebral palsy(d) 0.3 3,441 1,708 1,733 3,441 — — — —
(a) Includes mental retardation due to congenital, perinatal and early childhood conditions, including cerebral palsy, as well as cognitive
impairments resulting from injury, mental disorders, senile dementia, Parkinson’s disease, stroke and acute myocardial infarction,
decompensated liver cirrhosis and injuries.
(b) Lower limb amputation is a consequence or sequela for a number of conditions including meningococcal infection, cancer, diabetes,
peripheral vascular disease and injuries.
(c) End-stage renal failure is a complication or sequela for a number of conditions including primary renal disease (nephritis and nephrosis),
infectious diseases, cancer, diabetes, congenital malformations and some injuries.
(d) All cerebral palsy including that resulting in intellectual disability (also counted in burden of cognitive impairment).
associated with these functional limitations, the disability weights were partitioned between
mobility, self-care, pain, anxiety and depression, and cognitive disability. The third
58
dimension, usual activities, was excluded on the basis that participation restrictions are a
consequence of the interaction between functional limitations and impairments (as
described by the other dimensions) and the physical and social environment. There are a
few conditions, such as hearing loss, in which the disability weight is entirely associated
with limitations of usual activities. The ‘Other’ category in Figure 4.9 thus includes the
burden associated with pain, anxiety and depression, and participation restrictions not
associated with mobility, self-care or cognitive limitations.
An estimated 10.5% of the overall non-fatal burden is attributable to mobility limitations for
both males and females. Self-care limitations are associated with 7% of the total male YLD
and 9% of the female YLD. Cognitive disability is associated with 11% of the total male YLD
and 12% of the female YLD.
With improvements in health data collections, it may become possible to ensure that YLD
estimates associated with disease sequelae are consistent with measured prevalences of
major impairments and the important domains of functional limitation.
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Figure 4.9: Non-fatal burden of disease and injury associated with mobility limitations,
self-care limitations and cognitive disability, Australia, 1996
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4.8 Socioeconomic disadvantage and disability
Inequality in disability burden was assessed for selected mental disorders among
Australians aged 18 years and over using data from the 1997 National Survey of Mental
Health and Wellbeing (see Section 2.8 for methods used). For the combined burden of
substance use disorders, affective disorders, anxiety disorders and borderline personality
disorder, there is a marked gradient in the YLD burden with socioeconomic disadvantage as
defined by a small area index of socioeconomic disadvantage (Figure 4.10 and Table 4.7).
The YLD burden in the bottom quintile (most disadvantaged) is 45% higher for males and
41% higher for females than the burden for males and females in the top quintile (least
disadvantaged). Inequalities in burden would be even greater for disadvantaged groups
defined in terms of individual circumstances rather than small area average disadvantage.
The ratio of the YLD rate per 1,000 population for the top and bottom quintiles is a measure
of the differential burden of mental disorders between the most disadvantaged and least
disadvantaged groups in Australia. Figure 4.10 illustrates the differential in YLD burden
due to selected mental disorders.
As described in Section 2.8, the Gini coefficient is a summary measure of the degree of
inequality across all quintiles of socioeconomic disadvantage. Table 4.7 gives Gini
coefficients for the male and female burden of mental disorders. This table also presents
estimates of the proportion of the burden that is attributable to variability in YLD rates
across the quintiles of socioeconomic disadvantage. The excess burden associated with
socioeconomic disadvantage is high for cannabis abuse and borderline personality disorder
(though these do not reach statistical significance). Among both males and females, the
over-all ‘excess’ burden of mental disorders associated with socioeconomic disadvantage is
around 20%, as are the excess burdens for anxiety disorders and affective disorders.
Table 4.7: Differentials and inequality in disability burden for selected mental disorders, by sex,
Australian aged 18 years and over, 1996
YLD ratio(a)
(bottom quintile/top quintile)      Gini coefficient                Excess burden(b)
Disease category Male Female Male Female Male Female
Substance use disorders 1.40* 1.40* 0.069* 0.064* 8.5* 9.6*
a. Alcohol dependence/harmful use 1.30* 1.34* 0.059* 0.060* 6.2* 8.6*
b. Heroin or polydrug dependence
and harmful use 1.26* 1.00* 0.054* –0.010* 3.0* –1.2*
c. Sedative dependence/abuse 1.97* 2.01* 0.165* 0.165* 15.1* 17.0*
d. Cannabis dependence/abuse 2.46* 2.63* 0.127* 0.135* 47.3* 53.0*
e. Other drug dependence/abuse 1.97* 2.01* 0.165* 0.165* 15.1* 17.0*
Affective disorders 1.33* 1.34* 0.055* 0.053* 18.6* 19.9*
Anxiety disorders 1.35* 1.36* 0.048* 0.046* 21.0* 22.2*
Borderline personality disorder 2.64* 2.71* 0.185* 0.186* 45.7* 48.4*
Total(c) 1.45* 1.41* 0.069* 0.058* 17.5* 20.0*
(a) Ratio of YLD per 1,000 population for bottom quintile of area index of socioeconomic disadvantage to YLD per 1,000 population for top
(least disadvantaged) quintile.
(b) Per cent of YLD burden that would be avoided if all quintiles had the same YLD rate as the least disadvantaged group.
(c) Total substance use disorders, affective disorders, anxiety disorders and borderline personality disorder.
* Asterisk indicates that rate ratio, Gini coefficient and excess burden differ significantly (p<0.05) from value for no difference (1, 0.0 and 0%
respectively).
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Figure 4.10: Differentials in YLD rates between top and bottom quintiles of socioeconomic
disadvantage, selected mental disorders, Australians aged 18 years and over, 1996
4.9 Disability-adjusted life expectancy
Health-adjusted life expectancies provide estimates of the average years of equivalent
“healthy” life that a person can expect to live at various ages (Wilkins 1994). Murray and
Lopez (1996a) published disability-adjusted life expectancy (DALE) estimates for the eight
regions of the world using prevalence YLDs as measures of severity-weighted disability
prevalence. For Established Market Economies in 1990, the estimated DALE at birth was
67.4 years for males and 73.9 years for females. These represent the average equivalent years
of good health that a newborn baby in the EME can expect to live. Approximately 8% of
total life expectancy at birth was lost due to disability for both males and females.
Table 4.8: Total life expectancy (LE), disability-adjusted life expectancy (DALE), and expected
years lost to disability (ELD) as a proportion of total life expectancy, by sex and age, Australia,
1996
Males Females
Age (years)
LE
(years)
DALE
(years)
ELD/LE
(per cent)
LE
(years)
DALE
(years)
ELD/LE
(per cent)
0 75.6 68.7 9.1 81.3 73.6 9.4
15 61.3 54.8 10.6 66.9 59.5 11.0
40 37.8 32.3 14.5 42.5 36.4 14.2
65 16.2 12.0 25.5 19.8 15.2 23.2
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Figure 4.11: Expected years of healthy life and expected years lost due to disability at birth,
15, 40 and 65 years of age, by sex, Australia, 1996
Australian prevalence YLD for 1996 have been used to calculate DALE for Australia using
Sullivan’s method (Table 4.8). Total DALE at birth are 68.7 years for males and 73.6 years for
females, similar to the values for the EME estimated in the GBD. Approximately 9% of total
life expectancy at birth is lost due to disability for both males and females in Australia.
Figure 4.11 shows DALE (years of healthy life) and years lost due to disability (total life
expectancy minus DALE) for males and females at ages 0, 15, 40 and 65 years.
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5 Burden of disease and injury
5.1 Overview
In this chapter, we present the results of the Australian Burden of Disease and Injury Study
for the total disease burden measured in DALYs by age, sex and cause for 1996. These
results quantify the combined burden of fatal and non-fatal health outcomes in a single
measure, the disability-adjusted life year or DALY. The DALY adds together: (a) the years
of life lost through all deaths in 1996, and (b) the years of healthy life lost through living
with disease, impairment and disability for all cases beginning in 1996.
Figure 5.1 shows the YLL and YLD contributions to total DALYs for the major disease
groups and injury. Inclusion of non-fatal health outcomes provides a substantially different
picture than that provided by traditional mortality statistics: mental disorders are now the
third leading cause of burden after cardiovascular diseases and cancers. Central nervous
system and chronic respiratory conditions are almost as large a contributor to total burden
as injuries.
Note that the burden of diabetes shown here does not include the burden of cardiovascular
disease attributable to diabetes as a risk factor. As discussed in Section 5.4, inclusion of the
attributable cardiovascular disease burden increases the total burden of diabetes from 3.0%
of total DALYs to 4.9%.
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Table 5.1: Total burden of disease for males and females in Australia, 1996
DALYs
Number Per 1,000 population
Age-standardised DALYs
per 1,000 population
Males 1,331,311 146.2 155.0
Females 1,178,963 128.1 121.0
Total 2,510,274 137.1 137.1
(a) Directly age-standardised using the 1996 total Australian population
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Figure 5.3: Comparison of total deaths and burden of disease (DALYs) for
main disease groups, Australia, 1996 (highest rank is the largest cause)
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The total burden of disease and injury in
Australia in 1996 is estimated to be 2.5 million
DALYs or 137 DALYs lost per 1,000 population.
In other words, among each 1,000 people in the
Australian population, during 1996 the lost years
of healthy life represented 13.7% of the total life
years lived. The male burden (in total DALYs) is
13% higher than the female burden (Figure 5.2).
When differences in the age-structure of the male
and female population are taken into account, the
male burden is 28% higher than the female
burden (Table 5.1). Non-fatal outcomes (YLD) are
responsible for 43% of the male burden and 49%
of the female burden.
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When causes of deaths are compared, in rank order, with the total disease burden in
DALYs, whether at individual condition level or main disease group level, there are
substantial differences (Figure 5.3). This reinforces the need to take non-fatal outcomes into
account as well as deaths when assessing the health of Australians. While a few leading
conditions—such as ischaemic heart disease, stroke, chronic obstructive pulmonary disease,
dementia and lung cancer—are at the top of both lists, there are 19 conditions in the top half
of the list for disease burden that are in the bottom half of the list for deaths. These include
most of the mental disorders, musculoskeletal disorders and sight and hearing loss.
5.2 Leading causes of disease burden
The ten leading causes of disease burden for Australia are shown in Table 5.2. Ischaemic
heart disease and stroke lead the list, together causing nearly 18% of the total disease
burden. Chronic obstructive pulmonary disease and lung cancer (also smoking-related
diseases) are the third and fifth leading cause of disease burden, accounting for another
7.3% of the total burden. Depression is the fourth leading cause of disease burden in
Australia, accounting for nearly 4% of the total burden.
The leading causes of disease burden in Australia are broadly similar to those for the
Established Market Economies (EME) in the Global Burden of Disease Study (Table 5.2).
However, asthma appears in the top ten causes for Australia but not the EME, reflecting the
almost four times higher prevalence of asthma in Australia compared to the EME. Road
traffic accidents appear in the top ten for the EME, but not for Australia, where they rank
twelth and cause 2.2% of the total disease burden (approximately half the proportion for the
EME). Alcohol dependence ranks more highly in the EME (4.7% of total burden) than in
Australia (1.8% of total burden). This may reflect differences in the methods and data used
to estimate the burden of mental disorders in Australia (see Section 4.2).
Table 5.2: The ten leading causes of disease burden (DALYs), Australia 1996 and Established
Market Economies 1990
   Australia 1996
Per cent of
total DALYs         Established Market Economies 1990(a)
Per cent of
total DALYs
1 Ischaemic heart disease 12.4 1 Ischaemic heart disease 9.0
2 Stroke 5.4 2 Depression 6.8
3 Chronic obstructive pulmonary disease 3.7 3 Stroke 5.0
4 Depression 3.7 4 Alcohol dependence and abuse 4.7
5 Lung cancer 3.6 5 Road traffic accidents 4.4
6 Dementia 3.5 6 Lung cancer 3.0
7 Diabetes mellitus 3.0 7 Dementia 2.9
8 Colorectal cancer 2.7 8 Osteoarthritis 2.7
9 Asthma 2.6 9 Diabetes mellitus 2.4
10 Osteoarthritis 2.2 10 Chronic obstructive pulmonary disease 2.3
  (a) Age-weighted DALYs for Established Market Economies from the Global Burden of Disease Study (Murray & Lopez 1996a). Non-age-
weighted DALYs for Australia.
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Table 5.3: Leading causes of disease burden: DALYs by sex, Australia, 1996
Males
DALY
(’000)
Per cent
of total Females
DALY
(’000)
Per cent
of total
1 Ischaemic heart disease 180,630 13.6 1 Ischaemic heart disease 130,700 11.1
2 Stroke 64,330 4.8 2 Stroke 72,248 6.1
3 Lung cancer 60,000 4.5 3 Depression 57,109 4.8
4 COPD 55,866 4.2 4 Dementia 55,510 4.7
5 Suicide and self-inflicted injuries 44,531 3.3 5 Breast cancer 54,109 4.6
6 Road traffic accidents 40,305 3.0 6 COPD 37,521 3.2
7 Diabetes mellitus 39,438 3.0 7 Asthma 36,242 3.1
8 Depression 35,907 2.7 8 Diabetes mellitus 35,493 3.0
9 Colorectal cancer 35,511 2.7 9 Osteoarthritis 33,695 2.9
10 Dementia 33,468 2.5 10 Colorectal cancer 31,440 2.7
11 Adult-onset hearing loss 33,012 2.5 11 Lung cancer 30,521 2.6
12 Prostate cancer 32,448 2.4 12 Generalised anxiety disorder 20,488 1.7
13 Alcohol dependence/abuse 31,553 2.4 13 Age-related vision disorders 16,700 1.4
14 Asthma 28,281 2.1 14 Road traffic accidents 15,403 1.3
15 Osteoarthritis 22,610 1.7 15 Adult-onset hearing loss 15,158 1.3
16 Benign prostatic hypertrophy 17,079 1.3 16 Parkinson's disease 14,312 1.2
17 Heroin dependence/abuse 16,319 1.2 17 Alcohol dependence/abuse 13,819 1.2
18 Inflammatory heart disease 14,544 1.1 18 Ovary cancer 12,623 1.1
19 HIV/AIDS 13,885 1.0 19 Lymphoma 11,487 1.0
20 Cirrhosis of the liver 13,500 1.0 20 Suicide and self-inflicted injuries 11,399 1.0
21 Falls 13,186 1.0 21 Lower respiratory tract infections 10,673 0.9
22 Lymphoma 11,964 0.9 22 Eating disorders 10,644 0.9
23 Melanoma 11,860 0.9 23 Falls 10,416 0.9
24 Generalised anxiety disorder 11,342 0.9 24 Social phobia 10,185 0.9
25 Parkinson's disease 11,264 0.8 25 Pancreas cancer 9,809 0.8
26 Leukemia 11,187 0.8 26 Bipolar affective disorder 8,902 0.8
27 Brain cancer 10,299 0.8 27 Schizophrenia 8,728 0.7
28 Borderline personality disorder 10,274 0.8 28 Rheumatoid arthritis 8,343 0.7
29 Mouth and oropharynx cancers 10,180 0.8 29 Leukemia 8,240 0.7
30 Peripheral arterial disease 10,152 0.8 30 Peripheral arterial disease 8,181 0.7
31 Lower respiratory tract
infections 9,844 0.7
31 Melanoma 8,150 0.7
32 Stomach cancer 9,753 0.7 32 Hypertensive heart disease 8,042 0.7
33 Attention-deficit hyperactivity
disorder 9,369 0.7
33 Inflammatory heart disease 7,855 0.7
34 Pancreas cancer 9,201 0.7 34 Brain cancer 7,474 0.6
35 Schizophrenia 8,960 0.7 35 Heroin dependence/abuse 6,856 0.6
36 Bipolar affective disorder 8,797 0.7 36 Dental caries 6,814 0.6
37 Social phobia 8,428 0.6 37 Nephritis and nephrosis 6,666 0.6
38 Aortic aneurysm 8,371 0.6 38 Skin diseases 6,343 0.5
39 Oesophagus cancer 7,694 0.6 39 Stomach cancer 6,289 0.5
40 Homicide and violence 7,608 0.6 40 Urinary incontinence 6,273 0.5
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Table 5.3: (continued): Leading causes of disease burden: DALYs by sex, Australia, 1996
Males
DALY
(’000)
Per cent
of total Females
DALY
(’000)
Per cent
of total
41 Low birthweight 6,892 0.5 41 Cirrhosis of the liver 6,101 0.5
42 Bladder cancer 6,883 0.5 42 Borderline personality disorder 6,097 0.5
43 Epilepsy 6,668 0.5 43 Low birthweight 6,075 0.5
44 Dental caries 6,649 0.5 44 Cervix cancer 6,045 0.5
45 Poisoning 6,505 0.5 45 Iron-deficiency anaemia 5,603 0.5
46 Kidney cancer 6,475 0.5 46 Kidney cancer 4,937 0.4
47 Other transport accidents 6,284 0.5 47 Uterus cancer 4,866 0.4
48 Nephritis and nephrosis 5,837 0.4 48 Epilepsy 4,851 0.4
49 Hypertensive heart disease 4,999 0.4 49 Inflammatory bowel disease 4,834 0.4
50 Congenital heart disease 4,830 0.4 50 Aortic aneurysm 4,716 0.4
51 Autism/Asperger's syndrome 4,749 0.4 51 Panic disorder 4,395 0.4
52 Drowning 4,641 0.3 52 Cataracts 4,341 0.4
53 Birth trauma & asphyxia 4,524 0.3 53 Non-rheumatic valvular disease 4,331 0.4
54 Inflammatory bowel disease 4,473 0.3 54 Peptic ulcer disease 4,313 0.4
55 Age-related vision disorders 4,356 0.3 55 Congenital heart disease 4,257 0.4
56 Non-rheumatic valvular disease 4,355 0.3 56 Mouth and oropharynx cancers 4,124 0.3
57 Other chromosomal anomalies 4,140 0.3 57 Oesophagus cancer 4,030 0.3
58 Multiple myeloma 4,085 0.3 58 Post-traumatic stress disorder 3,976 0.3
59 Machinery accidents 4,061 0.3 59 Periodontal disease 3,755 0.3
60 Sudden infant death syndrome 3,731 0.3 60 Birth trauma & asphyxia 3,635 0.3
61 Post-traumatic stress disorder 3,717 0.3 61 Multiple myeloma 3,598 0.3
62 Rheumatoid arthritis 3,646 0.3 62 Attention-deficit hyperactivity
disorder 3,590 0.3
63 Peptic ulcer disease 3,623 0.3 63 Chronic fatigue syndrome 3,505 0.3
64 Periodontal disease 3,495 0.3 64 Other chromosomal anomalies 3,418 0.3
65 Hepatitis 3,398 0.3 65 Agoraphobia 3,376 0.3
66 Liver cancer 3,431 0.3 66 Non-deficiency anaemia 3,351 0.3
67 Fires/burns/scalds 3,311 0.2 67 Occupational overuse syndrome 3,337 0.3
68 Bone/connective tissue cancers 3,279 0.2 68 Multiple sclerosis 3,184 0.3
69 Striking and crushing accidents 3,247 0.2 69 Homicide and violence 3,089 0.3
70 Cannabis dependence/abuse 3,092 0.2 70 Bone/connective tissue cancers 2,948 0.3
71 Non-melanoma skin cancers 3,017 0.2 71 Bladder cancer 2,939 0.2
72 Motor neurone disease 2,794 0.2 72 Gall bladder cancer 2,855 0.2
73 Septicaemia 2,763 0.2 73 Sudden infant death syndrome 2,819 0.2
74 Non-deficiency anaemia 2,706 0.2 74 Septicaemia 2,816 0.2
75 Iron-deficiency anaemia 2,676 0.2 75 Intestinal obstruction 2,776 0.2
Table 5.3 shows the 75 leading causes of burden of disease and injury in Australia for males
and females. Ischaemic heart disease, stroke and the smoking-related diseases lung cancer
and chronic obstructive lung disease (COPD) are the leading causes of burden for males,
followed by suicide and self-inflicted injury. Ischaemic heart disease and stroke are the
leading causes for females, followed by depression (including major depressive episodes
and dysthymia), breast cancer then dementia. Diabetes is ranked seventh for males and
eighth for females (this does not include the cardiovascular disease attributable to
diabetes—see Section 5.4).
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5.3 Age and sex patterns of disease burden
As noted in Section 5.1, the male disease burden in Australia is 13% higher than the female
disease burden. This difference is due to the sex difference in the mortality burden: YLLs for
males are 26% higher than those for females. In contrast, total YLD are 1% lower for males
than females. The main causes of disease burden for males and females are also contrasted
in Figure 5.4. Table 5.4 shows the distribution of total disease burden by age and sex for four
broad age groups, for which leading causes of burden are examined in more detail below.
Table 5.5 gives the percentage distribution of DALYs among the main disease and injury
groups for males and females, and for the four age groups.
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Figure 5.4: Burden of disease (DALYs) by sex and main disease groups, Australia, 1996
Table 5.4: Distribution of DALYs by life cycle stage and sex, Australia, 1996
Males DALY (’000)
Per cent
of total Females
DALY
(’000)
Per cent
of total
0–14 years 120,707 9.1 0–14 years 92,562 7.9
15–24 years 115,861 8.7 15–24 years 98,341 8.3
25–64 years 570,968 42.9 25–64 years 438,832 37.2
65 years and over 523,774 39.3 65 years and over 549,228 46.6
Total 1,331,311 100.0 Total 1,178,963 100.0
Males Females
Other
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Table 5.5: Percentage distribution of DALYs by main disease category, sex and age group,
Australia, 1996
Per cent of total DALYs
Disease category Persons Male Female  0–14  15–34  35–54  55–74  75+
A. Infectious and parasitic diseases 1.8 2.1 1.4 2.9 3.0 2.8 1.0 0.9
B. Acute respiratory infections 1.2 1.1 1.3 3.5 0.9 0.9 0.8 1.3
C. Maternal conditions 0.1 0.0 0.3 0.0 0.8 0.1 0.0 0.0
D. Neonatal causes 1.2 1.2 1.2 14.3 0.0 0.0 0.0 0.0
E. Nutritional deficiencies 0.4 0.2 0.5 1.7 0.5 0.4 0.1 0.1
F. Malignant neoplasms 19.1 19.0 19.3 2.3 3.9 20.2 30.6 18.8
G. Other neoplasms 0.3 0.2 0.3 0.2 0.2 0.3 0.3 0.4
H. Diabetes mellitus 3.0 3.0 3.0 1.0 1.0 5.1 3.6 2.4
I. Endocrine and metabolic disorders 1.2 1.2 1.2 1.8 0.7 1.2 1.3 1.2
J. Mental disorders 13.2 12.2 14.3 15.9 44.4 19.5 2.8 0.4
K. Nervous system disorders 9.4 8.1 10.9 4.3 2.8 4.0 10.8 18.1
L. Cardiovascular disease 21.9 22.5 21.2 1.1 2.4 13.1 27.7 41.4
M. Chronic respiratory diseases 7.1 7.1 7.1 20.2 4.6 5.1 7.0 6.0
N. Diseases of the digestive system 2.6 2.6 2.6 0.9 2.2 3.4 2.7 2.5
O. Genitourinary diseases 2.5 2.6 2.3 0.2 3.5 2.5 2.5 2.5
P. Skin diseases 0.4 0.3 0.5 0.9 1.1 0.5 0.2 0.2
Q. Musculoskeletal diseases 3.6 2.6 4.7 1.1 2.2 6.3 4.8 1.6
R. Congenital abnormalities 1.3 1.3 1.3 12.9 0.5 0.3 0.1 0.1
S. Oral health 1.0 0.8 1.1 0.5 1.6 1.8 0.8 0.3
V. Ill-defined conditions 0.5 0.4 0.5 3.2 0.4 0.6 0.0 0.0
T. Unintentional injuries 5.7 7.4 3.8 10.5 14.9 6.9 2.2 1.7
U. Intentional injuries 2.7 3.9 1.2 0.7 8.6 4.8 0.8 0.2
Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
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Children aged 0–14
Asthma is the leading cause of disease burden for Australian children, accounting for over
18% of their total disease burden. This is followed by low birthweight and attention-deficit
hyperactivity disorder (Table 5.6). Neonatal conditions and congenital anomalies together
account for 27% of the total disease burden in children.
Table 5.6: Leading causes of burden of disease and injury in children aged 0–14 years:
DALYs by sex, Australia, 1996
Boys DALYs
Per cent
of total Girls DALYs
Per cent
of total
1 Asthma 21,663 17.9 1 Asthma 17,219 18.6
2 Attention-deficit hyperactivity
disorder
3 Low birthweight
9,369
6,892
7.8
5.7
2 Low birthweight
3 Attention-deficit hyperactivity
disorder
6,075
3,590
6.6
3.9
4 Autism/Asperger’s syndrome 4,749 3.9 4 Birth trauma & asphyxia 3,589 3.9
5 Birth trauma and asphyxia 4,524 3.7 5 Other chromosomal anomalies 3,376 3.6
6 Other chromosomal anomalies 4,140 3.4 6 Depression 3,361 3.6
7 Congenital heart disease 3,911 3.2 7 Congenital heart disease 3,263 3.5
8 Road traffic accidents 3,911 3.2 8 Sudden infant death syndrome 2,819 3.0
9 Sudden infant death syndrome 3,731 3.1 9 Road traffic accidents 2,222 2.4
10 Depression 2,961 2.5 10 Eating disorders 1,861 2.0
Total 120,707 100.0 Total 92,562 100.0
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Figure 5.5: Main causes of disease burden (DALYs) in children aged 0–14 years,
Australia 1996
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Young adults aged 15–24
Alcohol dependence and harmful use and road traffic accidents are the leading causes of
disease burden for young Australians aged 15–24 years, each accounting for over 9% of their
total disease burden. These are followed by depression, bipolar affactive disorder and
suicide and self-inflicted injuries, which together account for 22% of the total disease burden
for this age group. Heroin dependence and harmful use is the fifth leading cause of burden
for 15–24 year olds, accounting for 6% of the total disease burden for this age group. In total,
mental disorders account for 55% of the total disease and injury burden for young adults.
Table 5.7: Leading causes of burden of disease and injury in young adults aged 15–24 years:
DALYs by sex, Australia, 1996
Males DALYs
Per cent
of total Females DALYs
Per cent
of total
Road traffic accidents 15,013 13.2 Depression 14,096 14.3
Alcohol dependence & harmful use 12,827 11.3 Bipolar affective disorder 7,054 7.2
Suicide and self-inflicted injuries 10,421 9.1 Alcohol dependence & harmful use 6,703 6.8
Bipolar affective disorder 7,076 6.2 Eating disorders 6,401 6.5
Heroin dependence & harmful use 8,411 7.3 Social phobia 5,886 6.0
Schizophrenia 5,291 4.6 Heroin dependence & harmful use 5,125 5.2
Depression 4,903 4.3 Asthma 5,057 5.1
Social phobia 4,674 4.1 Road traffic accidents 4,463 4.5
Borderline personality disorder 4,227 3.7 Schizophrenia 4,382 4.5
Generalised anxiety disorder 2,767 2.4 Generalised anxiety disorder 2,806 2.9
Total 115,861 100.0 Total 98,341 100.0
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Figure 5.6: Main causes of disease burden (DALYs) in young people aged 15–24 years,
Australia, 1996
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Adults aged 25–64 years
Although most deaths occur at ages 65 and over, the burden of disease arising at ages 25–64
is almost as large in absolute terms as that arising at ages 65 and over (Tables 5.8 and 5.9).
Ischaemic heart disease is the leading cause of disease burden in adults aged 25–64 years,
accounting for 8.5% of total DALYs (Table 5.8). Depression is the second leading cause, at
6.3% accounting for almost as much of the disease burden as ischaemic heart disease. These
are followed by chronic obstructive pulmonary disease (4.0%), suicide and self-inflicted
injuries (4.0%), and diabetes mellitus (3.9%). All cancers account for 20% of the total disease
burden in adults aged 25–64 years (Figure 5.7).
Table 5.8: Leading causes of burden of disease and injury in adults aged 25–64 years:
DALYs by sex, Australia, 1996
Males DALYs
Per cent
of total Females DALYs
Per cent
of total
Ischaemic heart disease 66,767 11.7 Depression 36,783 8.4
Suicide and self-inflicted injuries 31,630 5.5 Breast cancer 34,476 7.8
Depression 27,169 4.8 Osteoarthritis 21,354 4.9
COPD 25,428 4.5 Ischaemic heart disease 19,340 4.4
Lung cancer 23,792 4.2 Diabetes mellitus 17,993 4.1
Diabetes mellitus 21,612 3.8 Generalised anxiety disorder 16,690 3.8
Road traffic accidents 19,519 3.4 COPD 15,466 3.5
Stroke 18,423 3.2 Lung cancer 13,247 3.0
Alcohol dependence & harmful use 17,650 3.1 Stroke 12,737 2.9
Adult-onset hearing loss 17,300 3.0 Colorectal cancer 12,589 2.9
Total 570,968 100.0 438,832 100.0
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Figure 5.7: Main causes of disease burden (DALYs) in adults aged 25–64 years, Australia, 1996
73
Older Australians
Ischaemic heart disease and stroke are the leading causes of disease burden among older
Australians (aged 65 years and over), together accounting for 32% of the total disease
burden. These are followed by senile dementias (7.2%), lung cancer (5.0%) and chronic
obstructive pulmonary disease (4.9%). Hearing loss and benign prostate enlargement are
among the top 10 causes of disease burden for older men. Vision loss and osteoarthritis are
among the top 10 causes for older women. Cardiovascular diseases and cancers together
account for over 60% of the disease burden in older Australians, followed by disorders of
the nervous system (Figure 5.8).
Table 5.9: Leading causes of burden of disease and injury in adults aged 65 years and over, by sex,
Australia, 1996
Males DALYs
Per cent
of total Females DALYs
Per cent
of total
Ischaemic heart disease 113,681 21.7 Ischaemic heart disease 111,267 20.3
Stroke 45,111 8.6 Stroke 58,894 10.7
Lung cancer 36,206 6.9 Dementia 48,946 8.9
COPD 30,348 5.8 COPD 21,838 4.0
Dementia 27,804 5.3 Breast cancer 19,627 3.6
Prostate cancer 26,723 5.1 Colorectal cancer 18,812 3.4
Colorectal cancer 19,976 3.8 Lung cancer 17,273 3.1
Diabetes mellitus 15,958 3.0 Age-related vision disorders 15,591 2.8
Adult-onset hearing loss 15,404 2.9 Diabetes mellitus 15,232 2.8
Benign prostatic hypertrophy 9,902 1.9 Osteoarthritis 12,341 2.2
Total 523,774 100.0 Total 549,228 100.0
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Figure 5.8: Main causes of disease burden (DALYs) in older Australians, Australia, 1996
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5.4 Attributable burden: diabetes, depression,
osteoporosis, firearms and sporting injuries
The full contribution of some diseases and external causes of injury to the total disease
burden is poorly reflected in the cause groups used in this study. One example is diabetes
mellitus which, in addition to its direct sequelae, also contributes to increased risk of
ischaemic heart disease, stroke and peripheral vascular disease (DHAC & AIHW 1999c).
Attributable fractions methods analogous to those used for risk factors in Chapter 7 (see
Section 2.9) have been used to estimate the additional burden associated with diabetes,
depression and osteoporosis. Mortality and hospitalisation data have been used to estimate
the total burdens associated with firearms and sporting injuries, which are distributed
across the external cause of injury categories used in this report.
As well as contributing to the burden of disease in its own right, depression is a risk factor
for suicide and self-inflicted harm and for ischaemic heart disease (AIHW 1999c). We have
used estimates of the relative risk of suicide and ischaemic heart disease associated with
depression to estimate the total attributable burden of depression.
The burden of disease associated with osteoporosis (low bone mineral density) is largely
caused by fractures of the hip, vertebrae and wrist (Harris et al. 1998). Hip fracture in older
people is associated with long term disability and a decline in health status. Between 6%
and 40% will die within one year, while around half of the survivors will have long-term
disability. It is estimated that the proportion of women with osteoporosis increases from
15% in those aged 60–64 years up to 71% in those over 80 years of age. The DALYs
estimated for osteoporosis in Annex Table H include only the disability associated with low
bone mineral density per se. We have estimated the DALYs associated with osteoporotic
fractures using attributable fractions by age and sex for six fracture sites from Harris et al.
(1998).
Sporting activity is identified by the ICD-9 external cause codes as a cause of injury only for
falls and collisions. The sports injury category in this study thus provides only a partial
estimate of the burden of sports injuries. We have used information on place of occurrence
in the AIHW national hospital inpatient data to estimate the proportion of other external
causes of injury which are attributable to sports activity.
ICD-9 external cause codes identify firearm injuries within the ‘other unintentional injury’
category and each of the three intentional injury categories. We have added these comp-
onents together to estimate the total burden of firearm injuries in Australia. The majority
(82%) of this burden falls in the ‘Suicide and self-inflicted injury’ category.
Table 5.10: Attributable disease burden for selected diseases and injuries, by sex,
Australia, 1996
Males Females Persons
DALYs
Per cent of
total
DALYs DALYs
Per cent of
total
DALYs DALYs
Per cent of
total
DALYs
Diabetes mellitus 66,457 5.0 56,078 4.8 122,535 4.9
Depression 57,292 4.3 65,040 5.5 122,332 4.9
Osteoporosis 2,203 0.2 5,095 0.4 7,297 0.3
Firearm injuries 9,715 0.7 1,236 0.1 10,951 0.4
Sporting injuries     5,288 0.4     1,402 0.1      6,690 0.3
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Table 5.11: Attributable disease burden for selected diseases and injuries: deaths,
YLL, YLD and DALYs, Australia, 1996
Condition Attributable
deaths
Attributable
YLL
Attributable
YLD
Attributable
DALYs
Diabetes mellitus 8,373 69,534 53,001 122,535
Depression 1,365 28,531 93,801 122,332
Osteoporosis 586 4,282 3,016 7,297
Firearm injuries 523 10,881 70 10,951
Sporting injuries 73 1,814 5,639 6,690
Table 5.10 summarises the total attributable DALYs for these disease and injury categories
for males and females. Table 5.11 provides estimates of total attributable deaths, YLL, YLD
and DALYs for each of these disease and injury categories.
Inclusion of the attributable burden of cardiovascular disease due to diabetes increases the
burden of diabetes from 3% to 5% of total DALYs. The attributable burden of diabetes is
discussed in more detail in Section 6.5. Inclusion of the attributable burden of suicide and
ischaemic heart disease increases the total burden of depression also from 3% to 5% of total
DALYs. The inclusion of the attributable burden of sporting injuries increases the estimate
of sporting injury DALYs by 172%. The attributable deaths and YLL for sporting injuries
should be interpreted with caution as they have been derived using information on injury
hospitalisations which end in death.
5.5 The undiscounted burden of disease
As discussed in Sections 1.6 and 2.3, the Australian Burden of Disease Study has used a 3%
discount rate in calculating DALYs for each condition. Undiscounted DALYs (i.e. using a
zero discount rate) have also been calculated and totals for males and females are given in
Annex Table I. This section compares the discounted and undiscounted estimates of the
burden of disease in Australia. Table 5.12 shows the leading causes of disease burden in
Australia, when undiscounted DALYs are used. The leading causes of disease burden are
generally similar to those for discounted DALYs (see Table 5.3). However, depression has
Table 5.12: Leading causes of disease burden: undiscounted DALYs by sex, Australia, 1996
Males
DALY
(’000)
Per cent
of total Females
DALY
(’000)
Per cent
of total
1 Ischaemic heart disease 223,480 12.3 1 Ischaemic heart disease 156,297 10.0
2 Suicide and self-inflicted injuries 81,110 4.5 2 Stroke 86,573 2.6
3 Road traffic accidents 77,969 4.3 3 Breast cancer 74,041 2.2
4 Stroke 77,922 4.3 4 Dementia 63,400 1.9
5 Lung cancer 75,100 4.1 5 Depression 58,395 1.7
6 COPD 71,553 3.9 6 Diabetes mellitus 51,848 1.5
7 Diabetes mellitus 55,442 3.0 7 COPD 49,860 1.5
8 Adult-onset hearing loss 45,429 2.5 8 Asthma 49,549 1.5
9 Colorectal cancer 44,319 2.4 9 Osteoarthritis 43,450 1.3
10 Dementia 38,110 2.1 10 Colorectal cancer 40,574 1.2
76
0 50 100 150 200 250 300 350 400
Road traffic accidents
Suicide/self-inflicted injuries
Osteoarthritis
Asthma
Colorectal cancer
Diabetes mellitus
                                   Dementia
Lung cancer
Depression
COPD
Stroke
Ischaemic heart disease
DALYs (’000s)
Undiscounted
Discounted
Figure 5.9: Leading causes of disease burden (undiscounted DALYs), by sex, Australia, 1996
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moved from 3rd place for females to 5th place, and from 8th place for males to 13th. Road
traffic accidents, suicide and hearing loss have moved into the top ten causes for males.
Figure 5.9 compares the discounted and undiscounted DALYs for the top ten causes of
disease burden in Australia. Figure 5.10 compares the rank order of causes of disease
burden according to discounted and undiscounted DALYs. In general, the undiscounted
DALYs give greater relative weight to long-term conditions, particularly to those incident in
childhood, and to conditions with high levels of mortality at younger ages (e.g. road traffic
accidents and suicide).
Table 5.13 provides a summary of the percentage distribution of undiscounted DALYs for
the main disease and injury categories. The discounted DALY percentage distribution is in
Table 5.5. Total undiscounted DALYs for individual conditions are listed in Annex Table I.
Age–sex–specific undiscounted estimates for individual conditions are available from
AIHW.
Table 5.13: Percentage distribution of undiscounted DALYs by main disease category, sex and age
group, Australia, 1996
Per cent of total undiscounted DALYs
Disease category Persons Male Female  0–14  15–34  35–54  55–74  75+
A. Infectious and parasitic diseases 2.0 2.4 1.5 2.6 3.3 3.1 1.0 0.9
B. Acute respiratory infections 1.1 1.0 1.2 2.6 0.7 0.8 0.8 1.3
C. Maternal conditions 0.1 0.0 0.3 0.0 0.6 0.1 0.0 0.0
D. Neonatal causes 2.3 2.3 2.3 19.4 0.0 0.0 0.0 0.0
E. Nutritional deficiencies 0.3 0.2 0.4 1.0 0.4 0.3 0.1 0.1
F. Malignant neoplasms 18.5 17.7 19.6 2.9 4.8 21.9 30.9 18.6
G. Other neoplasms 0.3 0.2 0.3 0.3 0.2 0.3 0.3 0.4
H. Diabetes mellitus 3.2 3.0 3.3 1.4 1.2 4.7 4.1 3.1
I. Endocrine and metabolic disorders 1.2 1.1 1.2 1.8 0.7 1.2 1.2 1.1
J. Mental disorders 12.0 11.2 12.9 11.6 36.1 15.9 2.5 0.4
K. Nervous system disorders 8.6 7.5 9.9 3.6 2.9 4.2 10.6 18.4
L. Cardiovascular disease 19.8 20.3 19.3 1.1 2.8 13.7 27.7 41.0
M. Chronic respiratory diseases 6.9 6.7 7.1 13.7 4.8 5.4 7.0 5.9
N. Diseases of the digestive system 2.7 2.6 2.7 1.0 2.7 3.7 2.8 2.5
O. Genitourinary diseases 2.3 2.3 2.3 0.3 3.0 2.4 2.4 2.5
P. Skin diseases 0.4 0.3 0.4 0.5 0.7 0.4 0.2 0.2
Q. Musculoskeletal diseases 3.4 2.4 4.5 0.8 1.9 6.1 4.7 1.5
R. Congenital abnormalities 2.2 2.2 2.2 16.6 0.7 0.3 0.2 0.1
S. Oral health 0.8 0.6 0.9 0.2 1.1 1.5 0.7 0.2
V. Ill-defined conditions 0.7 0.6 0.7 4.5 0.3 0.4 0.0 0.0
T. Unintentional injuries 7.7 10.0 5.0 13.1 19.6 7.9 2.2 1.7
U. Intentional injuries 3.6 5.2 1.8 0.9 11.5 5.7 0.8 0.2
Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
78
5.6 Socioeconomic disadvantage and the burden of
disease
It has not been possible to complete comprehensive analyses of total burden of disease by
quintile of socioeconomic disadvantage for all disease and injury categories for this first
report on the burden of disease and injury in Australia. Provisional estimates of differentials
in burden of disease measured in DALYs for the main disease and injury groups are
presented here. These are based on YLD estimates for mental disorders by quintile of
disadvantage (see Section 4.8) and provisional YLD estimates for other main disease groups
derived as described in Section 2.8.
There is a marked gradient in the total burden of disease with socioeconomic disadvantage
as defined by a small area index of socioeconomic disadvantage at SLA (local government)
area level (Table 5.14). The ratio of the age-standardised DALY rate per 1,000 population for
the top and bottom quintiles of disadvantage is a measure of the differential mortality
burden between the most disadvantaged and least disadvantaged groups in Australia. This
takes into account differences in the age structure of the population across quintiles of
socioeconomic disadvantage.
The burden per 1,000 population in the bottom quintile (most disadvantaged) is 37% higher
for males and 27% higher for females than the burden for males and females in the top
quintile (least disadvantaged). The estimated differentials in the non-fatal burden of YLD
are somewhat smaller than for the mortality burden for males, and slightly larger for
females.
Table 5.14: Differentials in the burden of disease and injury between top and bottom quintiles of
socioeconomic disadvantage, age-standardised YLL, YLD and DALYs per 1,000 population,
Australia, 1996
Males Females Persons
YLL ratio(a) 1.41  (1.38–1.45) 1.26  (1.22–1.29) 1.35  (1.32–1.37)
YLD ratio(a) 1.32  (1.13–1.46) 1.29  (1.05–1.53) 1.30  (1.09–1.44)
DALY ratio(a) 1.37  (1.28–1.43) 1.27  (1.14–1.41) 1.32  (1.22–1.39)
Excess burden (per cent) (b) 18.7  (15.1–21.5) 15.4    (9.3–19.6) 17.1  (13.7–19.4)
(a) Ratio of age-standardised rate per 1,000 population for botton (5th) quintile of area index of socioeconomic disadvantage to the
age-standardised rate per 1,000 population for the top (1st) quintile. Range given is brackets is the estimated 95% confidence or
uncertainty interval (see Section 2.8).
(b) Per cent of total burden (DALYs) that would be avoided if all quintiles had the same age-standardised DALY rate as the least
disadvantaged (1st) quintile. Range given is brackets is the estimated 95% confidence or uncertainty interval (see Section 2.8).
Table 5.14 also presents estimates of the proportion of the total disease burden that is
attributable to variability in DALYs across the quintiles of socioeconomic disadvantage.
Interpretation of these estimates is straightforward. The excess disease burden associated
with socioeconomic disadvantage is almost 20% of total male burden and around 15% of
total female burden. If it were possible to reduce disease and injury incidence and mortality
in all areas to a level equivalent to that of the least disadvantaged quintile, the potential
savings in lost years of ‘healthy’ life would be 17% of the total disease burden. These are
larger than the attributable burden for risk factors such as tobacco smoking, hypertension or
physical inactivity estimated in Chapter 7, although some of the effects of socioeconomic
disadvantage are mediated by these traditional risk factors (Mathers 1994a). Part of the
excess burden estimated here is associated with higher levels of smoking and other risk
factors in the more disadvantaged quintiles.
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Figure 5.11: Estimated burden of disease and injury (age-standardised DALYs per 1,000 
population) by quintile of area socioeconomic disadvantage, by sex, 1996
Figure 5.11 illustrates the differentials in disease burden across the five quintiles of
socioeconomic disadvantage. There is an increase in the burden of disease with each
increasing level of socioeconomic disadvantage for both males and females. As noted
previously (see Section 3.5), these differentials relate to quintiles defined using a small area
based index of socioeconomic disadvantage. The differentials reported here will thus almost
certainly understate the true differentials in mortality burden by level of socioeconomic
disadvantage at the individual level in Australia.
Table 5.15 summarises the differentials in disease burden between the top and bottom
quintiles for selected main cause groups (those responsible for significant shares of the total
burden).
These differentials are largest for intentional injuries and unintentional injuries, diabetes,
digestive system disorders (in males) and mental disorders. They are smallest for cancers
and for nervous system and sense organ disorders in women (where there is actually a
higher burden among the least disadvantaged women). This may reflect higher survival
rates in the least disadvantaged women, resulting in higher non-fatal burden due to senile
dementias and sense organ disorders. It may also reflect limitations in self-reported
prevalence data on sense disorders.
It must be emphasised that the non-fatal contributions to socioeconomic differentials in
burden of disease described here are provisional. More detailed analysis of YLD differentials
by socioeconomic status for individual conditions using available Australian data are
required in order to better estimate the impact of socioeconomic conditions on the burden of
disease and injury in Australia.
Males Females
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Table 5.15: Differentials in the burden of disease and injury between top and bottom quintiles
of socioeconomic disadvantage, by selected main disease categories and sex, Australia, 1996
                             DALY ratio(a)
                              (bottom quintile/top quintile)
Disease category Male Female
A. Infectious and parasitic diseases and acute
respiratory infections        1.30*        1.43*
D. Neonatal causes 1.34* 1.32*
F. Malignant neoplasms 1.19* 1.11*
H. Diabetes mellitus 1.64* 2.26*
I. Endocrine and metabolic disorders 1.21* 1.37*
J. Mental disorders 1.43* 1.53*
K. Nervous system disorders 1.32* 0.84*
L. Cardiovascular disease 1.30* 1.22*
M. Chronic respiratory diseases 1.48* 1.34*
N. Diseases of the digestive system 2.11* 1.54*
O. Genitourinary diseases 1.16* 1.23*
Q. Musculoskeletal diseases 1.44* 1.44*
T. Unintentional injuries 1.79* 1.39*
U. Intentional injuries 1.76* 1.54*
Other causes 1.17* 1.20*
All causes 1.37* 1.27*
(a) Ratio of age-standardised DALYs per 1,000 population for most disadvantaged (5th) quintile of area index of socioeconomic
disadvantage to age-standardised DALYs per 1,000 population for least disadvantaged (1st) quintile.
* Asterisk indicates that rate ratio differs significantly (p<0.05) from 1.0 (no differential between top and bottom quintiles).
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6 National Health Priority Areas
The National Health Priority Areas (NHPA) initiative is a collaborative effort involving
Commonwealth, State and Territory governments. It seeks to focus public attention and
health policy on those areas that are considered to contribute significantly to the burden of
disease in Australia, and for which there is potential for health gain. The NHPAs agreed by
Australian Health Ministers are cardiovascular health, cancer control, injury prevention and
control, mental health, diabetes mellitus and asthma. The NHPA initiative recognises that in
order to reduce the burden of disease, strategies should be holistic, encompassing the
continuum of care from prevention through to treatment and management (AIHW & DHFS
1997).
This chapter provides an overview of the burden of disease associated with the six NHPAs.
The burden of cardiovascular disease and renal failure attributable to diabetes has been
included with the diabetes burden in this chapter. The six NHPAs account for 70% of the
total burden of disease and injury in Australia, comprising 81% of the YLL and 57% of the
YLD (Figure 6.1).
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Figure 6.1: Contribution of NHPAs to total burden of disease and injury in Australia, 1996
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6.1 Cardiovascular disease
Cardiovascular health can be seen as a test case for Australia’s future well-being. In recent
years we have made major advances in preventing heart stroke and vascular disease and
treating it once it occurs. Despite this, cardiovascular diseases are leading causes of
mortality and morbidity in Australia (DHAC & AIHW 1999a). Most of the premature deaths
and much of the morbidity caused by cardiovascular diseases are preventable. Further, since
these diseases share risk factors with several other conditions including diabetes and some
major types of cancer, addressing these risk factors will produce wider health gains than
just those flowing directly from a reduction in cardiovascular diseases.
Table 6.1: The burden of disease attributable to cardiovascular disease, Australia, 1996
Males Females Persons
Number Per cent Number Per cent Number Per cent
Deaths 26,456 38.8 27,335 45.2 53,791 41.8
YLL 237,844 31.6 208,912 35.1 446,756 33.1
YLD 60,823 10.5 41,006 7.0 101,829 8.8
DALYs 298,667 22.5 249,918 21.2 548,584 21.9
Cardiovascular disease is responsible for 21.9% of total DALYs in 1996 (Table 6.1). This
represents 41.8% of all deaths, 33.1% of YLL and 8.8% of YLD. The cardiovascular disease
burden is dominated by ischaemic heart disease and stroke, which account for almost 57%
and 25% of the cardiovascular DALYs respectively (Figure 6.2). The burden of ischaemic
heart disease is 38% higher for men than women while the burden of stroke is 12% higher
for women than men (Figure 6.3). The rates of DALYs per 1,000 population rise with age
and are higher for men than women at all ages (Figure 6.4).
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Figure 6.2: The burden of cardiovascular disease by type and condition, 1996
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Figure 6.3: The burden of cardiovascular disease by sex and condition, 1996
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Figure 6.4: The burden of cardiovascular disease by sex, age and condition, 1996
Mathers and Penm (1999a) estimated the direct costs to the health system of cardiovascular
disease for Australia in 1993–94 (Table 6.2). These cost estimates cannot be directly related to
the DALY estimates because, to the extent that health expenditures for prevention and
treatment are effective at reducing the burden of disease, they relate to the burden currently
averted by the health system. The burden estimates given above, on the other hand, relate to
the current incident burden that is not averted at present by health interventions.
However, the cost estimates do give an indication of the size of the financial burden of
cardiovascular disease on the Australian health system. In 1993–94 the total health system
costs of cardiovascular disease was estimated at $3.9 billion or 12.5% of total health
expenditure.
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Table 6.2: Cardiovascular disease: health system costs ($ million) by health sector, Australia,
1993–94
Hospital(a) Medical(b)
Pharma-
ceuticals Other All sectors
Per cent of
total
Rheumatic heart disease 19 2 1 2 24 0.6
Ischaemic heart disease 574 88 105 127 894 22.8
Stroke 283 31 13 303 630 16.1
Inflammatory heart disease(c) 29 4 2 5 40 1.0
Hypertension(d) 55 217 476 84 831 21.2
Non-rheumatic valvular disease 52 7 3 5 67 1.7
Aortic aneurysm 46 5 2 7 60 1.5
Peripheral arterial disease 134 17 9 49 209 5.3
Cardiac dysrhythmias(e) 114 36 31 43 224 5.7
Heart failure(f) 157 47 45 162 411 10.5
Other cardiovascular disease(g) 179 48 25 57 309 7.9
High serum cholesterol 6 42 135 16 199 5.1
Unspecified treatment and aftercare 6 1 1 1 9 0.2
Prevention and screening 9 1 1 1 12 0.3
Total cardiovascular disease 1,663 546 849 861 3,919 100.0
Notes:
(a) Public and private acute hospitals, repatriation hospitals and psychiatric hospitals. Includes public hospital non-admitted services.
(b) Medical services for private patients in hospitals are included under Hospitals.
(c) Inflammatory heart disease comprises cardiomyopathy, myocarditis, endocarditis, pericarditis and other diseases of the pericardium and
endocardium.
(d) Hypertension comprises high blood pressure and hypertensive heart and renal disease.
(e) For the burden of disease estimates, this category has been distributed between ischaemic heart disease and other cardiovascular
diseases.
(f) For the burden of disease estimates, this category has been distributed between ischaemic heart disease, cardiomyopathy, hypertensive
heart disease and other cardiovascular diseases.
(g) This category includes chronic pulmonary heart disease.
Source: Mathers & Penm 1999a, Table 1.
6.2 Cancer
Cancer has a major impact on the Australian community in terms of morbidity, mortality
and costs. On average, one in three men and one in four women are likely to develop cancer
before the age of 75. The number of new cases has been steadily rising, though much of this
rise is due to population growth, the aging of the population and increased rates of
detection for some cancers. Mortality from cancer is decreasing, reflecting changes in
patterns of exposure to risk factors, changes in treatment and early detection techniques and
the use of medical services (DHAC & AIHW 1998a).
Cancer was responsible for 19.1% of total DALYs in 1996 (Table 6.3). This represents 26.8%
of all deaths, 29.7% of YLL and 6.8% of YLD. Seven cancers have been identified as the focus
of the cancer priority area—lung cancer, skin cancer, cancer of the cervix, breast cancer
(among women), colorectal cancer, prostate cancer and non-Hodgkin’s lymphoma (NHL).
These cancers together account for around 61% of the burden of cancer (DALYs) for men
and 63% for women.
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Table 6.3: The burden of disease attributable to cancer, Australia, 1996
Males Females Persons
Number Per cent Number Per cent Number Per cent
Deaths 19,496 28.6 15,030 24.8 34,526 26.8
YLL 211,001 28.0 188,862 31.7 399,863 29.7
YLD 41,117 7.1 37,599 6.5 78,716 6.8
DALYs 252,118 19.0 226,461 19.2 478,579 19.1
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Figure 6.5: The burden of cancer by site for males, 1996
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Figure 6.6: The burden of cancer by site for females, 1996
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Figure 6.7: The burden of cancer by site, all persons, 1996
The cancer burden for men is dominated by lung, colorectal and prostate cancers, which
together account for around 51% of the male cancer DALYs (Figure 6.5). The cancer burden
for women is dominated by breast, colorectal and lung cancers, which together account for
around 50% of the female cancer DALYs (Figure 6.6). There are considerably more YLL lost
for all cancers than YLD, reflecting the fact that the burden of cancer is dominated by
mortality rather than lengthy periods of disability (Figure 6.7). The DALY rate per 1,000
pop- ulation peaks in the age range 55 to 74 for both men and women, with the rate for
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smaller at all ages than that for men. (Figure 6.8). NHL constitutes 93% of the YLL and 89%
of the YLD for lymphoma, which together make up 93% of the lymphoma DALYs.
Although cancer of the cervix has been identified as one focus of the cancer priority area, it
does not appear in the top ten cancers for women listed in Figure 6.6. In fact it contributes
the twelfth highest number of DALYs. This is an illustration of the fact that the size of a
health problem is not the only determinant of whether or not it should be a priority. Cancer
of the cervix is a priority cancer because it is one of the few cancers where precancerous
lesions are cost-effectively detectable and treatable. Hence, mortality from this cancer can be
largely prevented with current screening and treatment methods.
The estimated financial burden of cancer to the Australian health system is shown in
Table 6.4. In 1993–94, the total health system costs of cancer were estimated at $1.9 billion or
6% of total health expenditure. This expenditure partly relates to burden currently averted
by screening and treatment (which is not included in the DALY estimates above) and partly
to burden either not successfully treated or arising from the impact of treatment on patients’
quality of life.
We can derive a rough estimate of the average cost per DALY currently averted by
modelling the progress of the cancer under the hypothetical scenario of no diagnostic or
treatment services. The resulting DALY estimate represents the total burden including the
burden currently averted by treatment. A very simple model was used which assumed that
all cancers surface in the disseminated phase (bypassing the diagnostic and treatment
phases) and proceed to the terminal phase and death. The resulting estimates should be
regarded as only indicative, but they do provide a guide to the average cost per DALY
currently averted.
The model was applied to lung cancer, as an example of a cancer with low cure rates and
short survival times, and breast cancer in women, as an example of a cancer with moderate
to high cure rates and long survival times. The hypothetical total DALYs for lung cancer
with no diagnosis or treatment is 94,615, which is 4.5% higher than the observed DALYs.
This corresponds to an average cost of $26,200 per DALY averted. The hypothetical total
DALYs for breast cancer is 112,255 which is a little more than twice the observed DALYs
and represents a cost of $3,145 per DALY averted.
Table 6.4: Cancer: health system costs by health sector, Australia, 1993–94 ($ million)
Hospital(a) Medical(b)
Pharma-
ceuticals Other All sectors
Per cent of
total
Skin 141 112 5 41 298 15.6
Colorectal 171 11 3 19 205 10.8
Breast 80 11 16 77 184 9.7
Lung 81 7 3 17 107 5.6
Prostate 66 14 8 13 101 5.3
Cervix 22 46 1 17 86 4.5
Other cancers 767 61 17 79 923 48.5
Total 1,327 261 53 263 1,904 100.0
Notes:
(a) Public and private acute hospitals, repatriation hospitals and psychiatric hospitals. Includes public hospital non-admitted services.
(b) Medical services for private patients in hospitals are included under Hospitals.
Source: Mathers et al. 1998, Table C2
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6.3 Mental health
The remarkable progress in physical and material wellbeing for most Australians over the
twentieth century has not necessarily been matched by gains in mental and subjective
wellbeing. Based on the 1995 National Health Survey more than one million Australians are
estimated to suffer from a mental disorder, with almost half of these affected long-term.
Mental disorders form a substantial part of the burden of disease in Australia, accounting
for nearly 30% of the non-fatal burden in 1996. Depression is the most common mental
disorder reported, both recent and long-term (ABS 1998b) and has been identified as the
major focus of the mental health priority area (DHAC & AIHW 1999c).
The burden of mental disorders is dominated by years lost due to disability and
considerable effort was put into modelling the impact of mental disorders, drawing on
epidemiological data and data from the 1997 National Mental Health Survey carried out by
the Australian Bureau of Statistics (ABS 1998b). YLD estimates have been made for 22
specific mental disorders (not including senile dementias which are included among the
central nervous system conditions).
Mental illness was responsible for 13.3% of total DALYs in 1996 (Table 6.5). This represents
0.8% of all deaths, 1.4% of YLL and 27.2% of YLD—reflecting the fact mental illness is not a
major direct cause of death but it is a major cause of chronic disability. Figure 6.9 shows the
distribution of YLL and YLD by main category of mental disorder. Affective disorders
account for 33% of the burden of mental disorders, followed by substance use disorders
(24%)
Table 6.5: The burden of disease attributable to mental illness, Australia, 1996
Males Females Persons
Number Per cent Number Per cent Number Per cent
Deaths 630 0.9 381 0.6 1,012 0.8
YLL 13,014 1.7 5,202 0.9 18,216 1.4
YLD 151,216 26.2 164,469 28.2 315,685 27.2
DALYs 164,230 12.4 169,671 14.4 333,901 13.3
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Figure 6.9: The burden of mental illness by major category of mental disorder, 1996
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Figure 6.10: The burden of mental illness by sex and major category of mental disorder, 1996
and then anxiety disorders (23%). Alcohol abuse accounts for 56% of the burden of
substance abuse in Australia. Substance abuse is the only category with a substantial YLL
component.
Figure 6.10 shows the distribution of mental health DALYs by sex and by main category of
mental disorder. While the same three conditions dominate for both males and females, the
major cause of mental disorder for males is substance use disorders, accounting for 33% of
their mental health DALYs. Alcohol abuse accounts for 59% of male substance use
disorders. The major cause of mental disorder for women is affective disorders, accounting
for 39% of women’s mental health DALYs. This is almost entirely depression (87%).
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Figure 6.11: The burden of mental illness by age and sex, 1996
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Figure 6.11 shows the distribution by age and sex of DALYs per 1,000 population due to
depression and to other mental disorders. The rate peaks in the age range 15 to 24 for both
males and females. For males, this is dominated by substance use disorders (43%). For
females it is mainly affective disorders (34%) and anxiety disorders (22%). The proportion of
the burden attributable to depression peaks at 50% in the 45 to 54 year age group for men
and at 64% in the 55 to 64 year age group for women.
Estimated health system expenditure for mental disorders in 1993–94 is shown in Table 6.6.
Including specialised community mental health services and drug and alcohol residential
centres, the total health system costs of mental disorders are estimated at $3.0 billion or 9.6%
of total health expenditure.
Table 6.6: Mental health: health system costs by health sector, Australia, 1993–94 ($ million)
Hospital(a) Medical(b)
Pharma--
ceuticals
Other
health
services(c Other(d
All
sectors
Per cent
of total
Dementia 110 11 2 9 582 714 23.6
Substance abuse disorders 136 46 12 18 136 348 11.5
Schizophrenia 275 26 8 106 40 454 15.0
Other non-drug psychosis 63 5 1 6 53 128 4.2
Affective disorders 217 141 68 70 148 644 21.3
Anxiety disorders 24 102 51 25 37 239 7.9
Personality disorders 24 7 1 12 9 53 1.8
Stress and adjustment disorders 28 27 7 31 19 112 3.7
Mental retardation 16 1 0 3 5 26 0.9
Disorders of psychological
development 2 2 0 3 10 16 0.5
Eating disorders 14 3 0 1 4 22 0.7
Disorders of childhood and
adolescence 10 9 1 19 16 55 1.8
Behavioural syndromes and other
mental disorders 17 53 45 9 50 174 5.8
Unspecified mental disorders,
prevention and screening 5 6 2 23 1 37 1.2
Total 941 438 199 334 1,110 3,022 100.0
Notes:
(a) Public and private acute hospitals, repatriation hospitals and psychiatric hospitals. Excludes public hospital non-admitted services.
(b) Medical services for private patients in hospitals are included under Hospitals.
(c) Includes hospital non-inpatient services, specialised community mental health services, residential and non-residential treatment services
run by non-government organisations, and allied health services.
(d) Includes National Drug Strategy funding for prevention, research expenditure and other institutional, non-institutional and administration
expenditure. Does not include expenditure for other public health services, non-specialised community health services, ambulances, or
medical aids and appliances.
Source: AIHW analysis of health expenditure data.
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6.4 Injury
Injury is the principal cause of death in people under 45 years of age, a leading cause of
mortality, morbidity and permanent disability in Australia, and a major source of health
care costs. Injuries cause a range of physical, cognitive and psychological disabilities that
seriously affect the quality of life of injured people and their families. According to the 1993
ABS disability survey, approximately 15% of people with a disability in Australia attribute
their disabling condition to an injury or accident. However, the majority of injury is
preventable and there are significant opportunities for reducing the burden of injury by
implementing effective prevention strategies (DHAC & AIHW 1998b).
Injury was responsible for 8.4% of total DALYs in 1996 (Table 6.7). This represents 5.9% of
all deaths, 11.3% of YLL and 5.0% of YLD. Figure 6.12 shows the distribution of injury YLL
and YLD by cause of injury. The burden of injury is dominated by suicide and self-inflicted
injuries and road traffic accidents, which together comprise 53% of injury DALYs.
Table 6.7: The burden of disease attributable to injury, Australia, 1996
Males Females Persons
Number Per cent Number Per cent Number Per cent
Deaths 5,422 8.0 2,123 3.5 7,545 5.9
YLL 114,696 15.2 37,587 6.3 152,283 11.3
YLD 36,429 6.3 21,197 3.6 57,627 5.0
DALYs 151,126 11.4 58,784 5.0 209,910 8.4
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Figure 6.12: The burden of injury by external cause of injury, 1996
92
0 10 20 30 40 50
Legal intervention and war
Natural and environmental factors
Adverse effects of medical treatment
Sports injuries
Suffocation and foreign bodies
Machinery accidents
Fires/burns/scalds
Drowning
Other transport accidents
Poisoning
Homicide and violence
Other unintentional injuries
Falls
Road traffic accidents
Suicide and self-inflicted injuries
DALYs (’000)
Males
Females
Figure 6.13: The burden of injury by sex and external cause, 1996
DALYs for suicide and self-inflicted injuries mostly comprise YLL (99%) while road traffic
accidents have a substantial YLD component (18%). Figure 6.13 shows the distribution of
injury DALYs by sex and by cause of injury. While the same two causes dominate for both
males and females, the major cause of injury for men is suicide and self-inflicted injury,
accounting for 30% of men’s injury DALYs. The major cause of injury for women is road
traffic accidents, accounting for 26% of women’s injury DALYs.
Figure 6.14 shows the distribution by age and sex of DALYs per 1,000 population due to
injury, grouped into the three major causes and an ‘other injuries’ group. The total rate
peaks in the age range 15 to 24 for both males and females and then falls with age before
rising again for men over 75 and women over 65. The major cause of DALYs in the 15 to 24
year age group is road traffic accidents (39% for males and 46% for females). The major
cause at ages 75 and over is falls (69% for men and 45% for women).
Table 6.8 gives estimated direct health system costs of injuries for Australia in 1993–94. The
total health system costs of injuries was estimated at $2.6 billion or 8.3% of total health
expenditure. This expenditure partly relates to the injury burden currently averted by
treatment (which is not included in the DALY estimates above) and partly to the injury
burden remaining after treatment.
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Figure 6. 14: The burden of injury by age, sex and leading cause, 1996
Table 6.8: Injury: health system costs by health sector, Australia, 1993–94 ($ million)
Hospital(a) Medical(b)
Pharma-
ceuticals Other(c) All sectors
Per cent of
total
Unintentional injuries(d)
   Road traffic accidents 232 56 16 68 372 14.3
   Other transport accidents 37 10 3 7 58 2.2
   Poisoning 20 1 1 3 26 1.0
   Accidental falls 501 112 32 166 810 31.1
   Fire, burns or scalds 41 8 3 4 55 2.1
   Accidental drowning 3 1 0 1 6 0.2
   Machine injuries 27 8 2 7 44 1.7
   Adverse effects of medical
   treatment(e) 300 38 23 43 403 15.5
   Other unintentional injuries 381 124 36 87 630 24.2
Intentional injuries
   Suicide and self-inflicted injury 48 11 4 11 72 2.8
   Homicide and violence 72 24 7 20 125 4.8
Total injury and poisoning 1,663 393 127 418 2,601 100.0%
 Notes:
(a) Public and private acute hospitals, repatriation hospitals and psychiatric hospitals. Includes public hospital non-admitted services.
(b) Medical services for private patients in hospitals are included under Hospitals.
(c) Includes research expenditure and other institutional, non-institutional and administration expenditure. Does not include public health
services, community health services, ambulances, or medical aids and appliances.
(d) Expenditure for injuries unspecified whether intentional or unintentional has been distributed pro rata between unintentional and intentional
injuries.
(d) Includes surgical and medical misadventure, and adverse effects of drugs in therapeutic use.
Source: Mathers & Penm 1999b.
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6.5 Diabetes
Diabetes mellitus is a chronic disease, characterised by hyperglycaemia or high levels of
blood glucose, which is caused by deficient insulin production and/or resistance to its
action. Complications of diabetes include retinopathy, cataract, glaucoma, neuropathy,
nephropathy, diabetic foot ulcers and amputations. The prevalence of diabetes is rising,
with the estimated number of Australians with diagnosed or undiagnosed diabetes almost
doubling since the early 1980s (DHAC & AIHW 1999b).
There are two major types of diabetes: Type 1 diabetes (also referred to as IDDM or insulin-
dependent diabetes) and Type 2 diabetes (also referred to as NIDDM or non-insulin-
dependent diabetes). Around one-half of Type 1 diabetes is incident in childhood and it is
one of the most common serious childhood conditions in Australia, whereas Type 2 diabetes
occurs in adults and is usually not diagnosed until after the age of 40 years.
In addition to its direct sequelae, diabetes also contributes to increased risk of ischaemic
heart disease, stroke and peripheral vascular disease (AIHW 1999c). Attributable fractions
methods were used in Section 5.4 to estimate the total burden associated with diabetes,
including the attributable burden of cardiovascular diseases.
Diabetes was responsible for 4.9% of total DALYs in 1996 (Table 6.9). This represents 6.5% of
all deaths, 5.2% of YLL and 4.6% of YLD—reflecting the fact diabetes is a major cause of
chronic disability as well as premature death. Figure 6.15 shows the total YLL and YLD
resulting from  Type 1 and Type 2 diabetes directly,  as well as the attributable YLL and
YLD
Table 6.9: The burden of disease attributable to diabetes, Australia, 1996
Males Females Persons
Number Per cent Number Per cent Number Per cent
Deaths          4,369 6.4        4,004 6.6          8,373 6.5
YLL        37,233 4.9       32,301 5.4        69,534 5.2
YLD        29,224 5.1       23,778 4.1        53,001 4.6
DALYs        66,457 5.0       56,078 4.8       122,535 4.9
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Figure 6.15: The total attributable burden of diabetes by type and condition, 1996
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Figure 6.16: The attributable burden of diabetes per 1,000 population
by type of disease, age and sex, 1996
from ischaemic heart disease, stroke and peripheral vascular disease. Overall, diabetes
causes almost as much disability burden (43% of total DALYs) as mortality burden. The
burden is relatively evenly shared between males and females, with males responsible for
54% of the burden of diabetes. The burden of diabetes, together with attributable heart
disease and peripheral vascular disease, is greater for males than females. The attributable
burden for stroke is shared equally by males and females.
Figure 6.16 shows the total attributable DALYs per 1,000 population for diabetes by age and
sex. The rates for men and women are both small at ages below 35. At ages over 35, the rates
are higher for men than women. Between ages 35 and 54 the burden is mainly due to
diabetes and its complications. For ages 55 and over, the proportion of burden due to
ischaemic heart disease (IHD), stroke and peripheral vascular disease (PVD) rises to 64% for
men and 63% for women at ages over 75.
As shown in Table 6.10, the total health system costs attributable to diabetes were estimated
to be $681 million in 1993–94 or 2.2% of total health expenditure for that year. This
expenditure partly relates to the potential burden of diabetes averted by treatment,which is
not included in the DALY estimates above.
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Table 6.10: Diabetes and its sequelae: health system costs by health sector, Australia, 1993–94
($ million)
Hospital(a) Medical(b)
Pharma-
ceuticals Other All sectors
Per cent of
total
Type 1 diabetes 31 28 41 55 155 22.8
Type 2 diabetes(c) 41 40 59 93 233 34.1
Blindness 1 0 0 3 4 0.6
Glaucoma 2 1 0 1 4 0.6
Cataract 12 1 0 7 20 2.9
Nephropathy 9 1 0 5 15 2.2
Chronic skin ulcer 13 4 2 7 25 3.7
Absence of extremities 1 0 0 1 3 0.4
Ischaemic heart disease(d) 54 11 13 28 105 15.4
Stroke 31 4 1 39 75 11.0
Peripheral vascular disease(e) 6 0 0 4 10 1.6
Hypertension 1 8 19 4 32 4.7
Total 201 98 136 247 681 100.0
Notes:
(a) Public and private acute hospitals, repatriation hospitals and psychiatric hospitals. Includes public hospital non-admitted services.
(b) Medical services for private patients in hospitals are included under Hospitals.
(c) A significant proportion of older people admitted to nursing homes from hospital have principal diagnosis of hypoglycemia or
hyperinsulinism and it is likely that many of these older people had Type 2 diabetes. The Type 2 diabetes costs shown here include $15.9
million for hypoglycemia and hyperinsulinism.
(d) Includes heart failure due to complications of diabetes.
(e) Includes atherosclerosis.
Source: Mathers & Penm 1999a, Table 6.
6.6 Asthma
Asthma is the most recently declared national health priority area. Most cases are diagnosed
before the age of 15 and it is a leading cause of disability in children. According to the 1995
ABS National Health Survey, around 11% of Australians reported asthma as a recent or
long-term condition. Asthma was responsible for 2.6% of total DALYs in 1996 (Table 6.11).
This represents 0.6% of all deaths and YLL, and 4.8% of YLD—reflecting the fact asthma is a
major cause of chronic disability rather than death.
Seventy per cent of the total burden of asthma is incident in childhood (ages 0–14). The
average duration of asthma incident in childhood is estimated to be around 17 years, and for
asthma incident in adulthood to be around 30 years. As a result, a larger proportion of the
prevalent burden of asthma falls in adulthood: around 67% of prevalent YLD for asthma
Table 6.11: The burden of disease attributable to asthma, Australia, 1996
Males Females Persons
Number Per cent Number Per cent Number Per cent
Deaths 300 0.4 433 0.7 733 0.6
YLL 3,620 0.5 5,112 0.9 8,732 0.6
YLD 24,661 4.3 31,130 5.3 55,791 4.8
DALYs 28,281 2.1 36,242 3.1 64,523 2.6
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Figure 6.17: Prevalent YLD due to asthma and to all other causes by age, 1996
relate to ages 15 and over, and 34% to ages 25 and over. Figure 6.17 shows the prevalent
YLD due to asthma and to all other causes by age. The proportion of prevalent YLD due to
asthma peaks in the 5–14 year age group, where it represents 24% of all prevalent YLD. In
contrast, the absolute burden of prevalent YLD for asthma peaks in the 15–24 year age
group, where it represents 12% of prevalent YLD.
Figure 6.18 shows the total YLL and YLD due to asthma compared with other chronic
respiratory diseases. Asthma together with chronic obstructive pulmonary disease (COPD)
account for the majority of the burden of chronic respiratory diseases. Asthma is responsible
for 36% of chronic respiratory disease DALYs while COPD is responsible for 52%. The
asthma DALYs are dominated by YLD (87%) while the burden for COPD have a larger
mortality component (YLL account for 61% of total DALYs for COPD).
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Figure 6.18: The burden of chronic respiratory disease by disease type, 1996
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Figure 6.19: The burden of chronic respiratory disease by disease type and sex,
1996
Figure 6.19 shows the DALYs due to asthma compared with other chronic respiratory
diseases by sex. Women have a higher proportion of asthma DALYs than men (56%) while
men have a higher proportion of COPD DALYs (60%).
Figure 6.20 shows DALYs per 1000 population due to asthma compared with other chronic
respiratory diseases by age and sex. Asthma dominates at ages under 15 and reduces with
age while the rate for COPD increases with age to peak in the 55 to 74 year age group for
men and the 75 and over age group for women.
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Figure 6.20: The burden of chronic respiratory disease per 1,000 population by
disease type, age and sex, 1996
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Table 6.12 shows estimated direct costs to the health system of chronic respiratory diseases
for Australia in 1993–94. Although asthma accounts for fewer DALYs than COPD, it
accounts for more expenditure. In 1993–94 the total health system costs of asthma was
estimated at  $478 million, which was 40% of the total expenditure on chronic respiratory
diseases, compared with COPD which accounted for 35% of this expenditure. To the extent
that current interventions are effective in reducing the severity of symptoms or curing
disease, these expenditures relate to the burden of chronic respiratory diseases currently
averted by treatment,which is not included in the DALY estimates above.
Table 6.12: Chronic respiratory diseases: health system costs by health sector, Australia, 1993–94
($ million)
Expenditure type Hospital(a) Medical(b)
Pharma-
ceuticals Other All sectors
Per cent of
total
Asthma 94 102 199 82 478 40.1
COPD(c) 112 61 66 61 300 25.2
Other chronic respiratory diseases(d) 205 60 87 62 413 34.7
Total 411 223 352 205 1,191 100.0
Notes:
(a) Public and private acute hospitals, repatriation hospitals and psychiatric hospitals. Includes public hospital non-admitted services.
(b) Medical services for private patients in hospitals are included under Hospitals.
(c) Excludes extrinsic allergic alveolitis (ICD-9 code 495) and chronic pulmonary heart disease (ICD-9 codes 416.0, 416.8 and 416.9).
(d) Includes extrinsic allergic alveolitis (ICD-9 code 495) but excludes chronic sinusitis (ICD-9 code 473) and peritonsillar abscess (ICD-9 code
475).
Source: AIHW unpublished analysis of health expenditure data.
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7 Attributable burden for ten
major risk factors
7.1 Overview
This Chapter shifts the focus from the proximate disease and injury causes of the burden of
disease in Australia to health risks and determinants. It aims to identify modifiable risk
factors and the scope for health gain possible from further reductions in the exposure of the
population to these hazards. The burden of disease and injury attributable to various health
risks can be estimated if we know the prevalence of exposure to the risk factor in the
community and the relative risk of each causally associated disease or injury for those
exposed to the risk factor (see Section 2.9). For some conditions, direct estimates for
attributable fractions are directly available from surveillance systems or epidemiological
studies.
The attributable fractions estimated below are interpreted as the proportions of current
disease burden attributable to current and past exposure to the risk factors concerned.
Another form of attributable fraction would estimate the proportion of current disease
burden that would be prevented in the future if exposure to the risk factor were eliminated.
This form of attributable fraction is relevant to analysis of potential public health
interventions but requires a model that predicts the disease burden under an alternative
hypothetical or ‘counterfactual’ scenario.33
Most of the estimates of attributable burden are based on one or more categories of risk
exposure compared with an ‘unexposed’ group. In reality, many risks tend to be continuous
and may not display clear thresholds. Recognising only one to four risk categories may
result in some underestimation of the complete attributable burden but makes it easier to
align categories used in prevalence and relative risk studies.
The models implicit in the use of attributable fractions are relatively simplistic. While each
of these risk factors has been associated with disease or injury in its own right, two or more
factors often occur together and may interact to produce higher or lower risks. To the extent
possible, estimates are based on relative risks derived from studies which control for the
effects of other risk factors, so that they capture the independent contribution of the risk
factor. However, it is unlikely that these studies can control for all of the complexities of the
interaction between risk factors. The total burden attributable to all risk factors analyzed
here is unlikely to be exactly equal to the sum of the burdens attributable to each risk factor
separately. Similarly, we can not necessarily conclude that complete elimination of any one
risk factor would necessarily reduce the burden of disease by the whole of the
corresponding attributable burden. Despite these limitations, the attributable DALY
estimates represent a useful measure of the size of the health problem presented by these
risk factors.
Although attributable risks are analysed separately for each risk factor, in reality risks are
embedded within a social, cultural and environmental context. Public health policies aimed
at modifying lifestyle risk factors and structural determinants of health could actually
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worsen health inequality unless they are designed to be sensitive to different sociocultural
contexts and other underlying contributory determinants.
Three criteria were used to select risk factors for inclusion in this study:
· there is good evidence that the risk factor is causally associated with at least one major
category of diseases or injuries;
· relative risk estimates are available from recent high-quality epidemiological studies;
and
· nationally representative estimates of prevalence of the risk factor are available for
Australia.
Tobacco, alcohol consumption, illicit drugs, obesity, hypertension, high blood cholesterol,
physical inactivity, unsafe sex, occupational exposures and risks, and inadequate fruit and
vegetable consumption were selected for analysis in this first report. The total burden in
DALYs associated with these risk factors is summarised in Figure 7.1. Alcohol harm refers
to the excess mortality caused by moderate, harmful and hazardous drinking levels. Alcohol
benefit refers to the burden (primarily from cardiovascular disease) averted by alcohol
consumption in the Australian population.
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Figure 7.1: Proportion of total burden attributed to selected risk factors, by sex, Australia, 1996
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Tobacco smoking is the risk factor responsible for the greatest burden of disease in
Australia, responsible for the loss of around 227,000 DALYs in 1996 (about 12% of the total
burden of disease and injury in males and 7% in females). This is followed by physical
inactivity, responsible for about 7% of the total burden. While the risk factor estimates for
physical inactivity are based, to the extent possible, on studies which controlled for the
effects of overweight and obesity, it is possible that there is some overlap in the obesity and
physical inactivity burdens, and possibly also with those for hypertension and high blood
cholesterol. Notwithstanding this, the combination of the ten risk factors considered in this
chapter may account for somewhere between one-third and one-half of the burden of
disease and injury in Australia in 1996.
Hypertension causes over 5% of the total burden of disease and injury, and high blood
cholesterol nearly 3%. It is likely that the total burden attributable to blood cholesterol is
higher than this, since there is evidence that there is a continuous gradient of risk associated
with increasing blood cholesterol levels, not just for ‘high’ blood cholesterol (Stamler et al.
1986, Verschuren et al. 1995). Overweight and obesity cause an estimated 4% of the total
burden of disease and injury. This estimate is less certain than those for other risk factors
since few of the obesity studies have properly controlled for physical inactivity and other
cardiovascular risk factors.
The overall burden of disease associated with diet is difficult to assess from available
evidence (Crowley et al. 1992). Total energy balance is associated with the prevalence of
physical inactivity and obesity, and fat intake is partially reflected in the prevalence of high
blood cholesterol. Similarly, salt intake is partly reflected in the prevalence of hypertension.
Inadequate fruit and vegetable consumption is the only dietary factor for which the
attributable burden is directly estimated here. Inadequate consumption is characterised as
consumption of less than five servings of fresh fruit and vegetables per day, in line with
current dietary recommendations. This has been causally linked to cancer and
cardiovascular disease and accounts for nearly 3% of the total burden of disease.
The net harm associated with alcohol consumption is around 2.2% of total burden, as the
injury and chronic disease burden associated with harmful and hazardous levels of alcohol
consumption are offset by the burden of cardiovascular disease prevented by alcohol
consumption.
Illicit drugs are responsible for a similar level of harm to alcohol for males, at 2.2% of total
male burden. Just over half this burden is due to premature mortality, the other half to YLD
resulting from drug dependence or harmful use (Figure 7.2). In contrast, 75% of the burden
resulting from tobacco smoking is due to premature mortality, whereas only 15% of the net
alcohol burden is due to premature mortality.
Although this report is not the place to review the evidence on the cost-effectiveness and
acceptability of known interventions to reduce exposure to the risk factors analysed here,
much is known about what works and what does not. In particular, physical inactivity is
emerging as worthy of a similar level of societal concern as that given to tobacco smoking
and illicit drugs (United States Department of Health and Human Services 1996, DHFS
1998). Obesity is likely to prove a more difficult target, but will benefit from improvement in
physical activity levels (DHFS 1997).
Overviews of some of the major findings for each risk factor, together with more detailed
summary results and methods, are given in the following sections.
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Figure 7.2: Proportion of total burden attributed to selected risk factors, YLL and YLD
contributions, Australia, 1996
7.2 Tobacco
Tobacco is the risk factor associated with the greatest disease burden, being responsible for
around 9.7% of all DALYs in 1996. It increases the risk of coronary heart disease, stroke and
peripheral vascular disease as well as a range of cancers and other diseases and conditions.
In 1995, almost 3.2 million adult Australians (around 23.5% of the adult population) were at
risk of developing heart disease and other chronic conditions from smoking tobacco
products (AIHW 1999c).
Smoking rates have been declining since the early 1970s and this trend has continued into
the 1990s (see Figure 7.3). The Anti-Cancer Council of Victoria surveys show that the rate of
decline in current smoking has slowed in more recent years. Smoking among 15 year old
school students has stayed relatively constant over the past 10 years (AIHW 1999c).
In 1995, about 27% of men and 23% of women over 16 years of age smoked tobacco. Men
and women aged 25 to 29 years have the highest proportion of smokers at around 35%.
After 30 years of age, the rate of smoking declines with increasing age and is lowest among
men and women over 70 years of age (14% for men and 8% for women). In 1995, the
proportion of ex-smokers in Australia was 32% for men and 22% for women. The
proportion of people claiming to have never smoked was 39% for men and 53% for women.
The proportion of men who smoke is higher than that for women at all ages except 16–19
and 20–24 (Hill et al. 1998). In 1996, 24% of 15 year old school boys and 29% of 15 year old
school girls smoked tobacco (D. Hill, personal communication as reported in AIHW 1999c).
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Figure 7.3: Proportion of persons who are current smokers, 1974 to
1995
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Figure 7.4: Proportion of Australians who were smokers in 1995, by sex and age
Because of the long timelag between exposure to tobacco smoke and some of its associated
ill-effects (which may be many decades in the case of cancers) the current prevalence of
smoking is not helpful in understanding the current associated disease burden. The method
proposed by Peto and Lopez (1993) describes an artificial compound prevalence measure of
tobacco exposure derived from a comparison between lung cancer rates in the country of
interest and lung cancer rates among non-smokers observed in a large long-term follow-up
study in the USA. We used this method to determine exposure to tobacco for the cancers on
our risk factor list and for chronic obstructive pulmonary disease (COPD). The mean time
between exposure to tobacco and the other diseases on our list is considerably shorter than
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that for cancer and COPD, so we used the 1995 Australian smoking prevalence figures for
these attributable fractions (Hill et al. 1998).
The study by English et al. (1995) identified a list of conditions for which there was evidence
of causation by tobacco smoking. We derived attributable fractions for a subset of these
conditions using the risk ratios identified in that study. Of the conditions identified by
English et al., we excluded peptic ulcer disease because subsequent studies have shown that
smoking plays a much smaller part in its aetiology than previously believed. We also
excluded heart failure (except where it is associated with ischaemic heart disease), ectopic
pregnancy, spontaneous abortion, antepartum haemorrhage, hypertension in pregnancy,
premature rupture of membranes and a number of low-prevalence cancers because they
were associated with a very small number of DALYs. We added a number of conditions to
the list—asthma and lower respiratory tract infections in children, which are associated with
passive smoking (NMHRC 1997), otitis media, which is also associated with passive
smoking (Stenstrom et al. 1993) and age-related vision loss (Mitchell et al. 1999). We used
the attributable fractions identified in these studies for these extra conditions.
Table 7.1: The attributable burden of tobacco smoking by condition, Australia, 1996
Condition
Attributable
deaths
Attributable
YLL
Attributable
YLD
Attributable
DALYs
Attributable
DALYs as a
proportion of
total DALYs
Lung cancer 6,262 69,662 6,267 75,929 3.0
COPD 4,645 40,464 19,322 59,786 2.4
Ischaemic heart disease 2,507 32,317 6,254 38,571 1.5
Stroke 740 8,788 5,302 14,090 0.6
Mouth and oropharynx cancers 423 5,204 2,135 7,340 0.3
Age-related vision disorders 0 0 6,626 6,626 0.3
Oesophagus cancer 519 5,478 436 5,914 0.2
Kidney cancer 432 4,622 691 5,313 0.2
Pancreas cancer 387 3,977 148 4,125 0.2
Bladder cancer 327 2,848 854 3,702 0.1
Peripheral vascular disease 65 582 2,572 3,153 0.1
Larynx cancer 175 1,946 1,190 3,136 0.1
Asthma 1 31 3,079 3,111 0.1
Low birthweight 64 1,951 1,031 2,982 0.1
SIDS 73 2,227 0 2,227 0.1
Inflammatory bowel disease 9 94 1,982 2,076 0.1
Stomach cancer 163 1,697 201 1,898 0.1
Lower respiratory infections 70 912 483 1,395 0.1
Fire injuries 34 644 438 1,083 < 0.1
Otitis media 1 42 738 780 < 0.1
Cervix cancer 44 559 98 658 < 0.1
Uterus cancer  –45  –487  –190  –677 < 0.1
Parkinson’s disease  –22  –180  –901  –1,080 < 0.1
Total 16,875 183,380 58,759 242,138 9.7
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Table 7.2: The burden of disease attributable to tobacco, Australia, 1996
Males Females Persons
Number Per cent Number Per cent Number Per cent
Deaths 11,694 17.1 5,181 8.6 16,875 13.1
YLL 124,769 16.6 58,611 9.8 183,380 13.6
YLD 36,731 6.4 22,027 3.8 58,759 5.1
DALYs 161,500 12.1 80,638 6.8 242,138 9.7
Table 7.1 lists the conditions we associated with tobacco smoking, along with the associated
deaths, YLL, YLD and DALYs. Table 7.2 lists the total attributable YLL, YLD and DALYs as
a proportion of the total disease burden.
Most of the burden of tobacco is due to lung cancer, COPD and ischaemic heart disease.
These three together comprise almost 72% of the attributable burden of tobacco smoking
and account for almost 7% of all DALYs. The remaining attributable burden is mainly due
to various other forms of cancer, circulatory diseases and respiratory diseases. There are a
small number of DALYs among children under 14 attributable to smoking. These mainly
represent the effect of passive smoking. The majority of the tobacco disease burden starts at
around ages 35–44 and rises with age. For men this peaks at ages 65–74 but for women it is
highest in the oldest age group (Figure 7.5).
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Figure 7.5: The attributable burden of tobacco smoking, by age and sex, 1996
7.3 Alcohol
There is growing evidence that regular intake of alcohol protects against cardiovascular
disease, but that alcohol consumption at all levels above abstinence increases the risk of
various other diseases and injuries (Roche 1997). The burden of disease and injury currently
averted by alcohol consumption is 2.8% of the total disease burden, around one-half of the
disease burden (4.9% of total) that is currently caused by alcohol consumption.
Apparent consumption data show that average per capita alcohol consumption has
dropped steadily over the last decade, although the rate of decline has slowed in recent
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years (Figure 7.6). There are a number of recent sources of data on the prevalence of alcohol
consumption in the Australian population, including the 1997 National Mental Health
Survey, the 1995 National Health Survey and the 1999 National Drug Strategy Household
Survey. Of these, only the National Health Survey collected information on the type of
alcoholic drinks consumed as well as the number. We used the National Health Survey data
to estimate the prevalence of alcohol consumption at various levels by age and sex. Because
the National Health Survey collected information relating to the last three days on which
alcohol was consumed, we have reweighted the National Health Survey data to give equal
weight to the samples interviewed on each of the seven days of the week.
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Figure 7.6: Trends in the apparent consumption of alcohol
per capita, Australia, 1940–1996
According to these reweighted data, the average annual consumption of alcohol was
7.5 litres per person aged 15 years and over (9.7 litres for males and 4.3 litres for females).
This is extremely close to the apparent consumption per capita for 1995 of 7.7 litres alcohol
(ABS 1996a). The prevalence of alcohol consumption was categorised into four levels as
shown in Table 7.3. These levels are consistent with those used by English et al. (1995) for
the analysis of risks of alcohol consumption and with the National Health and Medical
Research Council’s recommendations on alcohol consumption (NHMRC 1992). The
prevalence of each level of alcohol intake was estimated by age group and sex using the
average weekly consumption of alcohol estimated for National Health Survey respondents
and converting this to standard drinks per day (10 ml alcohol = 7.9 g alcohol).
The proportion of men and women who are abstainers has increased from 1989–90 to 1995
and the proportion of men who drink at hazardous and harmful levels has also decreased
(Figure 7.7). This reflects the decline in apparent per capita consumption over this period
(Figure 7.6). However, the proportion of women who drink at hazardous levels has
increased from 8.5% to 10.5%, while the proportion of women who drink a harmful levels
has remained constant at around 2%.
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Table 7.3: Classification and prevalence of alcohol intake levels used in this report
Average number of standard drinks per day
(1 standard drink = 10 g alcohol) Prevalence (%) in 1995
Alcohol intake Male Female Male Female
Abstinence 0 –0.25 0 –0.25 17.6 31.0
Low 0.26 –4.00 0.26 –2.00 67.9 56.2
Hazardous 4.01 –6.00 2.01 –4.00 8.3 10.5
Harmful >6 >4 6.3 2.2
Source: English et al. (1995), ABS National Health Survey 1995.
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Figure 7.7: Prevalence of abstinence, low risk, harmful and hazardous alcohol consumption,
comparison of recent surveys, Australia
We have estimated the attributable burden of alcohol consumption using the prevalence
data for 1995 together with relative risks or population attributable fractions estimated for
20 conditions by English et al. (1995) for which there was evidence of causation by alcohol
consumption. Of the conditions identified by English et al., we excluded epilepsy because of
possible problems with misdiagnosis (epileptic fits coupled with hypoglycaemia are
common during withdrawal from acute alcohol intoxication). A current AIHW project is
reviewing more recent epidemiological studies and revising relative risk and attributable
fractions for alcohol in Australia. We used results from this project to update the relative
risks for breast cancer and stroke to include latest findings. We also updated the population
attributable fractions for falls to take into account differences for younger and older people.
Low and moderate risk (‘hazardous’) levels of consumption of alcohol protect against
hypertension, ischaemic heart disease, stroke and gallstones. The attributable burden of
disease averted by current levels of alcohol consumption is estimated by comparison with a
counterfactual scenario in which all people are abstainers. This ‘currently averted’ burden is
referred to below as ‘alcohol benefit’. It is estimated separately to ‘alcohol harm’ since the
benefits and harm are differently distributed. As shown in Figure 7.8, the harmful effects of
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Figure 7.8: The burden of disease and injury attributable to the harmful and beneficial effects
of alcohol, by age and sex, Australia, 1996
alcohol are distributed relatively evenly across all age groups, whereas almost all the
benefits from alcohol are found in ages over 45 and particularly in older people. This
suggests that different public health advice may be appropriate for younger and older
people. Moderate alcohol use is beneficial at middle and older ages, while excessive alcohol
use is harmful at all ages.
Table 7.4 lists the conditions causally associated with alcohol use, along with the associated
deaths, YLL, YLD and DALYs. Table 7.5 lists the total attributable YLL, YLD and DALYs as
a proportion of the total disease burden.
Road traffic accidents and liver cirrhosis are the leading causes of death contributing to the
mortality burden of alcohol in Australia (Table 7.4). Alcohol dependence and harmful use is
by far the leading cause of years lost due to disability among conditions caused by alcohol.
Deaths from cardiovascular disease averted by alcohol consumption outweigh the deaths
due to injuries, cancers and other chronic diseases in Australia. However, the burden of
disease and injury averted by alcohol consumption is substantially lower than that caused
by alcohol consumption for men. For women, the harm and benefit are almost equally
balanced (Table 7.5).
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Table 7.4: The attributable burden of alcohol consumption by condition, Australia, 1996
Cause Deaths YLL YLD DALYs
As per cent of
total DALYs
Alcohol benefit
Hypertension  –130  –876  –287  –1,162 0.0
Ischaemic heart disease  –4,480  –38,994  –5,211  –44,205  –1.8
Stroke  –2,509  –18,652  –5,380  –24,032  –1.0
Gallstones  –39  –322  –231  –554 0.0
Total  –7,157  –58,844  –11,108  –69,953  –2.8
Alcohol harm
Alcohol dependence/abuse 406 4,308 41,065 45,372 1.8
Road traffic accidents 510 12,647 2,715 15,363 0.6
Cirrhosis of the liver 710 10,525 415 10,940 0.4
Stroke 639 6,466 3,670 10,136 0.4
Breast cancer 289 4,374 1,441 5,815 0.2
Suicide and self-inflicted injury 228 5,128 42 5,170 0.2
Cancer of mouth and pharynx 267 3,480 1,505 4,986 0.2
Colorectal cancer 417 4,545 356 4,901 0.2
Homicide and violence 139 3,173 1,382 4,555 0.2
Accidental falls 223 2,986 1,259 4,246 0.2
Larynx cancer 120 1,372 864 2,236 0.1
Fires 64 1,232 838 2,071 0.1
Inflammatory heart disease 86 1,231 643 1,874 0.1
Liver cancer 133 1,600 60 1,660 0.1
Drowning 69 1,485 25 1,510 0.1
Hypertension 136 1,022 359 1,381 0.1
Poisoning 41 1,013 17 1,030 < 0.1
Pancreatitis 42 441 55 495 < 0.1
Occupational injury 4 78 204 282 < 0.1
Suffocation and inhalation 9 173 6 179 < 0.1
Total 4,492 67,005 56,881 123,885 4.9
Net burden of alcohol consumption  –2,631 8,395 45,787 54,182 2.2
Table 7.5: The burden of disease attributable to alcohol consumption, Australia, 1996
Alcohol harm
 as % of total
Alcohol benefit
 as % of total
Net attributable
burden as % of total
Males Females Males Females Males Females
Deaths 4.7 2.1  –4.5  –6.7 0.3  –4.6
YLL 6.4 3.1  –3.7  –5.2 2.7  –2.1
YLD 6.8 3.1  –0.8  –1.1 6.0 1.9
DALYs 6.6 3.1  –2.4  –3.2 4.2  –0.1
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7.4 Illicit drugs
Illicit drugs are a direct cause of death as well as being risk factors for conditions such as
HIV/AIDS, hepatitis, low birthweight, inflammatory heart disease, poisoning and suicide
and self-inflicted injuries. They account for nearly 2% of all DALYs.
It is extremely difficult to obtain accurate prevalence data on the use of illicit drugs. Their
illegality and their low prevalence makes them difficult to address with population surveys
while data from use of health systems or interaction with the criminal justice system tends
to identify mainly heavy users and those who succumb to the drug’s effects. However, the
evidence suggests that the majority of illicit drug users use drugs infrequently without
becoming addicted (Makkai & McAllister 1998).
The best source of data on the population prevalence of illicit drug use in Australia comes
from a series of surveys carried out as part of the Commonwealth Government’s National
Drug Strategy between 1985 and 1998 (Makkai & McAllister 1998, AIHW 1999a). These
surveys aimed to monitor patterns of drug use, both licit and illicit, in the general Australian
community. The results of these surveys give a reasonably accurate picture of overall drug
use in the Australian community, though with the exception of cannabis the prevalence
rates are so low that detailed stratified analyses are statistically unreliable.
Figure 7.9 shows the prevalence of cannabis use by age and sex for 1995. The rates for both
men and women peak in the 20–29 year age group and reduce with age thereafter. The rates
for men are higher than those for women at all ages.
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Figure 7.9: Proportion of people who have used cannabis in the past year by
      age and sex, Australia, 1995
Successive surveys used different methods so comparisons between them must be treated
with caution. However, they do provide an indication of trends over time in drug use.
Figure 7.10 shows recent trends in the prevalence of cannabis use by age. These show
evidence of an increase in prevalence for the age groups 14–19 and 20–29 but not for the
older age groups.
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One indicator of trends in the size of the illicit drug use problem is the number of people
who die from illicit drug abuse or dependence. The main direct causes of death from illicit
drug use are opiates, with only 23 of the 4,658 deaths from illicit drug dependence, abuse or
poisoning in the 11 years from 1986 to 1996 not related to opiates. Figure 7.11 shows the
trends in deaths from opiate abuse, dependence or poisoning between 1986 and 1996. The
highest death rates are in the age groups 20–29 and 30–39. While the rates for all age groups
except the oldest increased over this period, the biggest increases have been in the 30–39
year age group.
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Figure 7.10: Trends in the prevalence of cannabis use by age, Australia, 1988–95
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Figure 7.11: Death rates from opiate abuse, dependence or poisoning by age,
     Australia, 1986–96
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All these indicators suggest an increasing trend in illicit drug use. The most recent data
show that this increase has continued since 1995, with the proportion of people using any
illicit drug rising from 17.8% in 1995 to 22.0 in 1998 (AIHW 1999a).
We used the attributable fractions for illicit drugs developed by English et al. (1995). These
fractions reflect the incidence of illicit drug use in 1992 but since most of the conditions are
directly drug-related (i.e. the attributable fraction is 1) the changes since then will only have
a small effect. We combined all poisoning into one group then calculated the fraction from
the ratio of cases or deaths coded to illicit drugs and all cases or deaths.
Table 7.6 lists the conditions associated with illicit drug use, along with the associated
deaths, YLL, YLD and DALYs. Table 7.7 lists the total attributable YLL, YLD and DALYs as
a proportion of the total disease burden. The biggest burden comes from heroin dependence
and harmful use, which accounts for around half the burden. This is not the full burden of
heroin use, since it also contributes to other conditions such as HIV/AIDS, hepatitis and
suicide. The proportion of total deaths accounted for by illicit drugs is around half the
proportion of years of life lost, reflecting the fact that the burden of illicit drugs is mainly
among young people.
Table 7.6: The attributable burden of illicit drugs by condition, Australia, 1996
Condition
Attributable
deaths
Attributable
YLL
Attributable
YLD
Attributable
DALYs
Attributable
DALYs as a
proportion of
total DALYs
Heroin dependence and harmful
use 406 10,457 14,005 24,462 1.0
Cannabis dependence and harmful
use 0 0 4,416 4,416 0.2
Poisoning 159 4,023 33 4,055 0.2
Other drug dependence and
harmful use 217 2,149 1,319 3,468 0.1
Suicide and self-inflicted injuries 118 3,104 35 3,138 0.1
Sedative dependence and harmful
use 7 143 2,968 3,111 0.1
Hepatitis C 106 1,264 151 1,415 0.1
Hepatitis B 31 501 9 510 0.0
HIV/AIDS 9 203 61 264 0.0
Low birthweight 6 170 90 259 0.0
Inflammatory heart disease 1 19 6 25 0.0
Total 1,060 22,031 23,093 45,124 1.8
Table 7.7: The burden of disease attributable to illicit drugs, Australia, 1996
Males Females Persons
Number Per cent Number Per cent Number Per cent
Deaths 702 1.0 358 0.6 1,060 0.8
YLL 16,437 2.2 5,594 0.9 22,031 1.6
YLD 13,273 2.3 9,820 1.7 23,093 2.0
DALYs 29,710 2.2 15,414 1.3 45,124 1.8
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Figure 7.12: The attributable burden of illicit drugs by age and sex, 1996
The DALYs for illicit drugs and the YLD both peak in the 15–24 year age group while the
YLL peaks in the 25–34 year age group for both men and women (Figure 7.12). The burden
is higher for men than women at younger ages, but higher for women at ages above 55
years. Sedative abuse and analgesic abuse are the major causes of the illicit drug burden at
older ages.
7.5 Obesity
People who are overweight or obese have a higher risk of ill health including coronary heart
disease, stroke, congestive heart failure, and Type 2 diabetes. Overweight and obesity is also
associated with hypertension and high blood cholesterol. Obesity accounts for an estimated
4.3% of all DALYs. Life expectancy is reduced by obesity, mainly through the effects of
increased body fat on related conditions. Evidence that reducing weight reduces ill health
and death from cardiovascular disease is inconclusive. However, among the overweight,
weight loss reduces the incidence and severity of high blood pressure, high blood
cholesterol and diabetes.
To assess the numbers of people that are overweight and/or obese in the population, the
Body Mass Index (BMI) is used. BMI is calculated as weight (kg) divided by height squared
(m2). A BMI of 25 or greater usually indicates overweight, and 30 or greater indicates
obesity. In 1995, just over 7.3 million adult Australians (around 56% of the adult population)
were overweight. Over 2.4 million (or 18% of the adult population) of those were obese
(AIHW 1999c).
There have been significant increases in the proportions of overweight and obese
Australians over the last 15 years (Figure 7.13). Trend data (from Australian capital cities
only) indicate that the proportion of overweight women aged between 25 and 64 years has
increased from 26.7% in 1980 to 43.0% in 1995. The proportion of overweight men in that
age group increased from 47.6% to 62.8% over the same period. The proportion of obese
men in that age group has increased dramatically from 7.8% in 1980 to 17.6% in 1995 and,
for women, from 6.9% to 16.1% (AIHW 1999c).
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Figure 7.13: Prevalence of overweight and obesity, by sex, 
Australians aged 25–64, 1980–95
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Figure 7.14: Prevalence of overweight and obesity, by age and
      sex, Australia, 1995
In 1995, 64% of men and 49% of women over 18 years of age were overweight or obese
while 14% of both men and women were obese. Levels of overweight and obesity increase
with age until around age 60 and then decline slightly (Figure 7.14). Men were more likely
to be overweight or obese than women at all ages but while more men than women were
obese at younger ages, more women than men were obese at older ages.
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Table 7.8: Relative risks associated with overweight and obesity
Overweight (BMI 25–29) Obese (BMI 30 and over)
Males Females Males Females
Condition and sources <65 65+ <65 65+ <65 65+ <65 65+
Ischaemic heart disease (Harris et al. 1993, Harris
et al. 1997, Mansonet al. 1990, Rimm et al. 1995) 1.35 1.00 1.40 1.00 1.80 1.20 2.00 1.25
Ischaemic stroke (Rexrode et al. 1997) 1.35 1.00 1.35 1.00 1.50 1.15 1.60 1.20
Bowel cancer (Lee & Paffenbarger 1992) 1.20 1.20 1.20 1.20 1.40 1.40 1.40 1.40
Gall bladder disease (Sahi et al. 1998, Stampfer et
al. 1992) 1.50 1.50 1.50 1.50 2.25     2.25      2.25     2.25
Hypertension (Sjostrom et al. 1992, Ascherio et al.
1992, Wittemann et al. 1989) 1.40 1.40 1.40 1.40 2.35 2.35 2.35 2.35
Adult-onset diabetes (Carey et al. 1997, Colditz et
al. 1990, Colditz et al. 1995, Njolstad et al. 1998) 1.80 1.80 1.80 1.80 3.20 3.20 3.20 3.20
Osteoarthritis (Anderson & Felson 1988) 1.35 1.35 1.35 1.35 2.40 2.40 2.40 2.40
Back problems (Tsai et al. 1992, Rissanen et al.
1990) 1.21 1.21 1.10 1.10 1.50 1.50 1.25 1.25
Cancer of endometrium (Armstrong B personal
communication 1999) — — 1.00 1.00 — — 1.75 1.75
Cancer of kidney (Moller et al 1994, Tavani & La
Vecchia 1997) 1.00 1.00 1.00 1.00 1.00 1.00 1.50 1.50
<45 45+ <45 45+
Post-menopausal breast cancer (Huang et al. 1997,
Sellers et al. 1992, Tretlie 1989, Yong et al. 1996,
Lubin et al. 1985, Mayberry 1994) — — 1.00 1.00 — — 1.30 1.30
A number of epidemiological studies have shown that there is an overall increased risk of
all-cause mortality among people who are obese (Seidell et al. 1996, Bender et al. 1998). A
systematic review of studies of the relationships between overweight and obesity and
specific diseases is currently being undertaken for the International Obesity Taskforce
(IOTF) under the direction of Professor Ian Caterson. We use studies identified in this
review, and in a review of cancer risk factors (Professor Bruce Armstrong, personal
communication 1999), to estimate relative risks for a number of diseases where there is good
evidence of a causal association with overweight and obesity (Table 7.8). The interpretation
of results from these studies is not straightforward because they often used different cut-off
points in BMI and control for a few other risk factors only. Firstly, we extrapolated from the
published relative risks to estimate relative risks for overweight and obesity defined
according to the BMI ranges used here. Secondly, we halved the excess relative risks to
allow for confounding by other risk factors such as physical inactivity, not often controlled
for in the studies. The attributable burden estimates for obesity are thus more uncertain than
those for other risk factors.
We used the 1995 National Nutrition Survey as the source of obesity prevalence estimates.
The attributable fractions were assumed to apply to both YLL and YLD. Table 7.9 lists the
conditions associated with overweight and obesity, along with the attributable deaths, YLL,
YLD and DALYs. Cardiovascular diseases and hypertension account for 40% of the total
burden of obesity, followed by diabetes (28%), musculoskeletal problems (17%), then
cancers (14%).
Table 7.10 lists the total attributable YLL, YLD and DALYs as a proportion of the total
disease burden. Overweight and oebsity are responsible for about the same proportion of
the disease burden (4.3%) in both males and females.
The burden of disease associated with obesity starts for both men and women in the 15–24
year age group and rises with age  (Figure 7.15).  The burden for men peaks in the 65–75 age
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Table 7.9: The attributable burden of overweight and obesity by condition, Australia, 1996
Condition
Attributable
deaths
Attributable
YLL
Attributable
YLD
Attributable
DALYs
Attributable
DALYs as a
proportion of
total DALYs
Ischaemic heart disease      2,302      28,135     5,323       33,458 1.3
Ischaemic stroke         427        3,842     1,902         5,743 0.2
Colorectal cancer         748        8,460     1,761       10,221 0.4
Gall bladder disease           76           615        408         1,023 0.0
Hypertension         500        3,519        525         4,044 0.2
Type 2 diabetes mellitus      1,388      13,105   17,624       30,729 1.2
Osteoarthritis           28           169   17,869       18,038 0.7
Back problems(a)            1             11        970            981 0.0
Uterus cancer(b)           45           527        215            742 0.0
Kidney cancer           37           449          62            511 0.0
Post-menopausal breast cancer         182        2,664        886         3,550 0.1
Total      5,735      61,496   47,544 109,040 4.3
Notes:
(a) Back problems comprise chronic back pain and slipped disc.
(b) Cancer of the endometrium represents 98% of uterus cancer.
Table 7.10: The burden of disease attributable to overweight and obesity, Australia, 1996
Males Females Persons
Number Per cent Number Per cent Number Per cent
Deaths      2,921 4.3     2,813 4.6 5,735 4.5
YLL    33,718 4.5   27,778 4.7 61,496 4.6
YLD    24,129 4.2   23,415 4.0 47,544 4.1
DALYs    57,847 4.3   51,193 4.3 109,040 4.3
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Figure 7.15: The attributable burden of overweight and obesity by age and sex, 1996
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group and declines in the 75 and over age group. The burden for women is highest in the
oldest age group. The burden is higher for men across all ages groups except ages 70 and
over, where it is much higher for women.
7.6 Hypertension
Hypertension is a major risk factor for coronary heart disease, stroke, peripheral vascular
disease and renal failure, accounting for 5.4% of all DALYs. The term ‘hypertension’ refers
to those people with high blood pressure and/or receiving treatment for high blood
pressure. High blood pressure is defined as systolic blood pressure ³ 160 mmHg and/or
diastolic blood pressure ³ 95mmHg. The risk of disease increases as the level of blood
pressure increases. When high blood pressure is controlled by medication the risk of
cardiovascular disease is reduced, but not to the levels of non-affected people. Research has
shown that high blood pressure is associated with other cardiovascular risk factors,
including high cholesterol levels, obesity and diabetes (AIHW 1999c).
In 1995, around 2.2 million adult Australians (17% of men and 15% of women over 18 years
of age) had high blood pressure and/or were on treatment for the condition. The proportion
of men and women with high blood pressure increases with age. Among people aged 65–69
years, about 41% of men and women had high blood pressure and/or were on treatment for
the condition. (AIHW 1999c)
The prevalence of hypertension has declined significantly since the early 1980s (Figure 7.16).
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Figure 7.16: Rates of hypertension by sex, Australia, 1980–95
120
0%
10%
20%
30%
40%
50%
60%
70%
15–24 25–34 35–44 45–54 55–64 65–74 75+
Age
Per cent
Males
Females
Source: AIHW 1999c.
Figure 7.17: Rates of hypertension by age and sex, Australia, 1995
There has also been a significant decline in mean blood pressure levels during the same
period. This decline occurred equally among those not on anti-high blood pressure medic-
ation as among those on treatment (AIHW 1999c).
Kannel (1995) used the Framingham study data to identify a list of conditions associated
with hypertension. We used this list of treatments and the associated estimated risk ratios,
along with prevalence data from the 1995 National Nutrition Survey and the estimated fall
in risk due to treatment derived by Collins et al. (1990), to calculate attributable fractions for
hypertension. Kannel included heart failure as a separate condition but we have attributed it
to other categories of heart disease. Hence rather than being included as a separate
condition attributable to hypertension, it has been included as part of ischaemic heart
disease and hypertensive heart disease. In addition we have included renal failure, with an
attributable fraction equal to the proportion of renal deaths in 1996 classified to hypertensive
renal disease (ICD-9 code 403).
Table 7.11 lists the conditions we associated with hypertension, along with the associated
deaths, YLL, YLD and DALYs. Table 7.12 lists the total attributable YLL, YLD and DALYs
as a proportion of the total disease burden.
Table 7.11: The attributable burden of hypertension by condition, Australia, 1996
Condition
Attributable
deaths
Attributable
YLL
Attributable
YLD
Attributable
DALYs
Attributable
DALYs as a
proportion of
total DALYs
Ischaemic heart disease 7,948 64,217 7,706 71,923 2.9
Stroke 4,327 31,714 12,016 43,730 1.7
Hypertensive heart disease 1,643 11,310 1,731 13,041 0.5
Nephritis and nephrosis 263 1,826 3,820 5,646 0.2
Peripheral arterial disease 188 1,456 273 1,730 0.1
Total 14,369 110,524 25,547 136,070 5.4
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Table 7.12: The burden of disease attributable to hypertension, Australia, 1996
Males Females Persons
Number Per cent Number Per cent Number Per cent
Deaths 6,335 9.3 8,034 13.3 14,369 11.2
YLL 53,420 7.1 57,103 9.6 110,524 8.2
YLD 14,826 2.6 10,721 1.8 25,547 2.2
DALYs 68,247 5.1 67,824 5.8 136,070 5.4
Most of the burden of hypertension is due to ischaemic heart disease and stroke, which
together comprise almost 85% of the attributable burden of hypertension and account for
more than 4.6% of all DALYs.
The burden of disease associated with hypertension starts for men in the 15–24 year age
group and rises steadily with age. The burden for women starts in the 25–34 year age group
and also rises steadily with age. The burden is higher for men across all ages groups except
ages 70 and over, where it is much higher for women.
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Figure 7.18: The attributable burden of hypertension by age and sex, 1996
7.7 High blood cholesterol
High blood cholesterol levels are a major risk factor for coronary heart disease and
peripheral vascular disease, accounting for 2.6% of all DALYs. This may also be a risk factor
for stroke but the evidence is less clear, so stroke has been excluded from this analysis
(Bucher et al. 1998). High blood cholesterol is the main cause of the process by which the
blood vessels that supply the heart and other parts of the body become clogged. Risk of
heart disease increases with increasing blood cholesterol levels (AIHW 1999c).
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Total blood cholesterol levels above 5.5 mmol/l are an indication of increased risk of
developing coronary heart disease. Levels above 6.5 mmol/l are considered to indicate very
high risk. High levels of low-density lipoprotein (LDL) cholesterol and low levels of high-
density lipoprotein (HDL) cholesterol, especially in the presence of high levels of
triglycerides, are indicative of risk of heart disease. (AIHW 1999c)
Average blood cholesterol levels appear to have remained relatively unchanged during the
1980s and there are no later data on trends during the 1990s (Table 7.13). In 1989, over 47%
of men and 39% of women aged 20–69 years had blood cholesterol levels above 5.5mmol/l.
There were a total of 4.5 million Australian adults aged 20–69 years with higher than
desirable cholesterol levels. In terms of those at very high risk of cardiovascular disease,
over 15% of men and women (aged 20–69) had blood cholesterol levels of 6.5 mmol/l or
more.
Table 7.13: Average blood cholesterol levels for persons aged 25–64 by sex, 1980–1989
Sex 1980 1983 1989
                             mmol/L
Men 5.72 5.67 5.66
Women 5.68 5.63 5.55
Note: Estimates adjusted for age.
Source: Bennett and Magnus 1994.
We used the prevalence data from the 1989 Risk Factor Prevalence Survey as a proxy for the
1996 prevalence of high cholesterol levels. The mortality risk from high blood cholesterol,
controlling for other major risk factors, was estimated at 31% per 40mg/dl increase in blood
cholesterol in a meta-analysis of the Seven Country Study (Menotti et al. 1996). We assumed
a 31% higher risk in males with blood cholesterol between 5.5 and 6.49 mmol/l and a relative
risk of 1.72 (or 1.31 times 1.31) in males with higher levels. There is evidence that relative
risks are lower for females than males, being less than half the male rate at any given age
(Preventive Services Taskforce 1996, page 16). For females, we assumed a 16% higher
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Figure 7.19: Rates of high blood cholesterol by age and sex, Australia, 1989
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risk for blood cholesterol between 5.5 and 6.49 mmol/l and a 36% higher risk for blood chol-
esterol levels of 6.5 mmol/l.
The prevalence of high cholesterol is lower for women than men at all ages except for the
two oldest age groups (Figure 7.19). The prevalence among women for the oldest group is
very high, but this estimate is based on a small sample size and so should be treated with
caution. Consequently the high attributable DALYs estimate for women in the oldest age
group should also be treated with caution.
Table 7.14 lists the conditions we associated with high cholesterol, along with the associated
deaths, YLL, YLD and DALYs. Table 7.15 lists the total attributable YLL, YLD and DALYs
as a proportion of the total disease burden.
Table 7.14: The attributable burden of high cholesterol by condition, Australia, 1996
Condition
Attributable
deaths
Attributable
YLL
Attributable
YLD
Attributable
DALYs
Attributable
DALYs as a
proportion of
total DALYs
Ischaemic heart disease 6,419 54,172 6,977 61,150 2.4
Peripheral arterial disease 133 948 2,524 3,472 0.1
Total 6,552 55,120 9,502 64,622 2.6
Table 7.15: The burden of disease attributable to high cholesterol, Australia, 1996
Males Females Persons
Number Per cent Number Per cent Number Per cent
Deaths 3,923 5.8 2,629 4.3 6,552 5.1
YLL 35,788 4.8 19,332 3.2 55,120 4.1
YLD 6,741 1.2 2,760 0.5 9,502 0.8
DALYs 42,529 3.2 22,093 1.9 64,622 2.6
Most of the burden of high cholesterol is due to ischaemic heart, which comprises almost
95% of the attributable DALYs and accounts for more than 2.4% of all DALYs.
The burden of disease associated with high cholesterol starts for men in the 25–34 year age
group and rises steadily with age. The burden for women starts in the 35–44 year age group
and also rises steadily with age. The burden is higher for men across all age groups except
ages 70 and over, where it is much higher for women. It is likely that the total burden
attributable to blood cholesterol is higher than these estimates, since there is evidence that
there is a continuous gradient of risk associated with increasing blood cholesterol levels, not
just for ‘high’ blood cholesterol (Stamler et al. 1986, Verschuren et al. 1995).
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Figure 7.20: The attributable burden of high cholesterol by age and sex, 1996
7.8 Physical inactivity
There is strong epidemiological evidence that physical inactivity is causally associated with
increased risk of mortality and incidence for a number of diseases and injury. Physical
activity reduces risk of coronary heart disease. People who do not participate in regular
physical activity are almost twice as likely to die from coronary heart disease as those who
participate. The evidence also suggests that physical activity may also play a protective role
against stroke as leisure-time physical activity and vigorous work-related physical activity
have been shown to lower the incidence of stroke.
Insufficient physical activity tends to occur with other risk factors for cardiovascular disease
such as obesity, high blood pressure, high blood cholesterol and HDL cholesterol. There is
also evidence that people who increase their level of physical activity will reduce their levels
of these risk factors.
Bauman et al. (1999) have reviewed and analysed the population attributable risk of disease
and injury due to physical inactivity, using a standard attributable risk approach. They
reviewed epidemiological studies to estimate relative risks for coronary heart disease,
stroke, Type 2 diabetes, hypertension, colorectal cancer, breast cancer, depression and falls.
These relative risks were used together with prevalence data on levels of physical activity
among Australians to estimate the attributable burden of physical inactivity for these
diseases. Muscular weakness has been estimated as a contributing cause in as much as 80%
of low back pain (DASETT 1988). In the absence of firm epidemiological evidence, 50% of
the burden of chronic back pain has been attributed to physical inactivity.
Many of the studies of the association between physical inactivity and cardiovascular
disease relate to occupational cohorts or people aged under 65 years. There is some evidence
that cardiovascular disease relative risks are lower for older people (Gillum et al. 1996,
Naidoo et al. 1997). To avoid overestimating the impact of physical inactivity, we halved the
excess relative risks for cardiovascular conditions and diabetes in people aged 65 years and
over.
125
0
10
20
30
40
50
60
70
80
90
100
<30 30-44 45-59 60+
Age (years)
Prevalence (%)
Vigorous
Moderate
Low
Sedentary
0
10
20
30
40
50
60
70
80
90
100
<30 30-44 45-59 60+
Age (years)
Prevalence (%)
Source: Bauman et al. 1999.
Figure 7.21: Physical activity levels of Australian adults aged 18–75, by sex and age group, 1997
In 1995, over 4.5 million adult Australians (or over one-third of the adult population)
reported doing no leisure-time physical activity. There has been little change in physical
activity patterns during the 1980s and little change since. The proportions of people who are
physically inactive decreased slightly between 1989–90 and 1995 from 36% to 34% in men,
and from 36% to 34% in women. This fall was mainly due to an increase in physical activity
among people aged 35–54 years (Armstrong 1998). Walking for physical activity increased
in popularity during the 1990s with 45% of men and 53% of women walking for recreation
or exercise in 1995 compared with 41% and 49% respectively in 1989–90 (Armstrong 1998).
National prevalence data on levels of physical activity among Australian adults were
derived from the Active Australia 1997 National Physical Activity Survey (Bauman 1999,
Bauman et al. 1999). Figure 7.21 shows the prevalence among Australia adults of four levels
of physical activity: sedentary, low, moderate and vigorous. These levels were defined by an
estimation of the daily energy expenditure based on the frequency and duration of reported
physical activity. Based on the literature review carried out by Bauman et al. (1999), we
estimated the attributable burden of physical inactivity using the relative risks for moderate,
low and sedentary levels in comparison with vigorous activity shown in Table 7.16.
Table 7.16: Relative risks for diseases and injuries associated with physical inactivity
Cause Relative risk at ages under 65 Relative risk at ages 65 and over
Sedentary Low Moderate Vigorous Sedentary Low Moderate Vigorous
Colorectal cancer 1.70 1.70 1.21 1.00 1.70 1.70 1.21 1.00
Breast cancer 1.40 1.40 1.27 1.00 1.40 1.40 1.27 1.00
Hypertension 1.50 1.50 1.00 1.00 1.25 1.25 1.00 1.00
Ischaemic heart disease—mortality 1.90 1.50 1.36 1.00 1.45 1.25 1.18 1.00
Ischaemic heart disease—incidence 1.50 1.50 1.00 1.00 1.25 1.25 1.00 1.00
Stroke 2.00 2.00 1.00 1.00 1.50 1.50 1.00 1.00
Type 2 diabetes mellitus 1.30 1.30 1.00 1.00 1.15 1.15 1.00 1.00
Falls 2.50 2.50 1.79 1.00 2.50 2.50 1.79 1.00
Depression 1.30 1.30 1.00 1.00 1.30 1.30 1.00 1.00
Males Females
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Table 7.17: The attributable burden of physical inactivity by condition, Australia, 1996
Cause Deaths YLL YLD DALYs
As per cent of
total DALYs
Colorectal cancer          1,543       17,091        3,580        20,671 0.8
Breast cancer             691        9,855        3,257        13,112 0.5
Hypertension             207        1,499           225          1,724 0.1
Ischaemic heart disease          6,853       61,882        5,439        67,321 2.7
Stroke          2,872       23,231        9,541        32,772 1.3
Type 2 diabetes mellitus             256        2,607        4,423          7,030 0.3
Falls             591        5,111        6,219        11,330 0.5
Depression                0             37       12,013        12,050 0.5
Chronic back pain                5             43        2,127          2,171 0.1
Total        13,019     121,356       46,825       168,181 6.7
Table 7.17 shows the contribution of these diseases to the estimated total attributable burden
of physical inactivity in Australia in 1996. Ischaemic heart disease and stroke account for
60% of the total, followed by colorectal cancer (12%), breast cancer (8%) and depression
(7%). Of the total disease and injury burden in Australia, 6.0% and 7.5% is attributed to
physical inactivity for males and females respectively (Table 7.18).
Table 7.18: The burden of disease attributable to physical inactivity, Australia, 1996
Males Females Persons
Number Per cent Number Per cent Number Per cent
Deaths          5,924 8.7          7,095 11.7     13,019 10.1
YLL        58,520 7.8        62,836 10.5   121,356 9.0
YLD        21,183 3.7        25,642 4.4     46,825 4.0
DALYs        79,703 6.0        88,478 7.5   168,181 6.7
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Figure 7.22: Attributable burden of physical inactivity: YLL, YLD and DALYs, by age
and sex, Australia, 1996
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7.9 Unsafe sex
Berkley (1998) has estimated the global burden of disease attributable to unsafe sex by using
an attributable fractions approach for selected causes. We follow a similar approach to
estimate the burden of disease in Australia that is attributable to unsafe sex. One hundred
per cent of the burden of sexually transmitted diseases is attributed to unsafe sex, as well as
97% of male burden and 71% of female burden for HIV/AIDS (based on the 1996 proportion
of incident cases due to sexual transmission). Fractions of hepatitis B and hepatitis C burden
that are attributed to sexual transmission are derived from surveillance reports of the
National Centre for HIV Epidemiology and Clinical Research and the Australian Hepatitis C
Surveillance Strategy.
Berkley (1998) chose to estimate the burden of maternal conditions attributable to unsafe sex
by estimating the proportion of terminations due to unwanted pregnancy and the
proportion of births that were ‘unwanted’. We assume 93% of terminations in Australia are
for unwanted pregnancies (Adelson et al. 1995) and use Berkley’s estimate for Established
Market Economies of 80% unmet contraceptive need in 15–19 year olds and 15% overall in
15–44 year olds. We use Berkley’s estimate that 90% of cervix cancer is attributable to sexual
transmission of the human papilloma virus.
Table 7.19 shows the contribution of these diseases to the estimated total attributable burden
of unsafe sex in Australia in 1996. HIV/AIDs accounts for 61% of the total, followed by
cervix cancer (24%) and other sexually transmitted diseases (8%). Table 7.20 shows the
proportion of the total burden of disease that is attributable to unsafe sex for males (1.1%)
and females (0.7%).
Table 7.19: The attributable burden of unsafe sex by condition, Australia 1996
Cause Deaths YLL YLD DALYs
As per cent of
total DALYs
HIV/AIDS 506 11,541 2,361 13,901 0.55
Other sexually transmitted diseases(a) 5 82 1,823 1,904 0.08
Hepatitis B 51 820 143 964 0.03
Hepatitis C 19 226 27 253 0.01
Abortion                1             22           299             321 0.01
Other maternal conditions                1             37           223             260 0.01
Cervix cancer             292        4,533           907          5,441 0.22
Total
            875       17,261        5,698        22,959 0.91
(a) Gonorrhea, syphilis, chlamydia and pelvic inflammatory disease attributable to sexually transmitted diseases.
Table 7.20: Total burden of disease attributable to unsafe sex, Australia, 1996
Males Females Persons
Number Per cent Number Per cent Number Per cent
Deaths 539 0.8 337 0.6 875 0.7
YLL 11,903 1.6 5,359 0.9 17,261 1.3
YLD 2,308 0.4 3,390 0.6 5,698 0.5
DALYs 14,210 1.1 8,749 0.7 22,959 0.9
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7.10 Occupational exposures and risks
The burden of disease and injury attributable to occupational exposures has been estimated
for Australia using three principal sources to estimate population attributable fractions.
The proportions of injury deaths for each age-sex-external cause group attributable to
occupational exposures were estimated from a recent Australian study of work-related
fatalities carried out by the National Occupational Health and Safety Commission (NOHSC
1998). The data for this study were obtained primarily from coroner’s files. The study
included all people who died as a result of work-related trauma in Australia in the four-year
period 1989 to 1992. This includes people who were injured while working, where the death
would not have occurred in the absence of the occupational factors, and people who were
not working but killed directly as a result of someone else’s work activity. The study
excluded persons who committed suicide and persons who died from diseases, even if there
appeared to be some connection to work.
The attributable fractions for non-fatal injuries were derived from an analysis of the AIHW
national hospital morbidity database. For each age–sex–external cause group, the
attributable fraction for occupational injuries was estimated as the ratio of hospital episodes
where ‘workplace’ was specified as the place where the injury occurred to the total hospital
episodes where a place of occurrence was specified.
For each cancer category in the Australian Burden of Disease Study, the proportion
attributable to occupational exposures to hazardous substances was estimated using results
from an earlier study carried out for NOHSC (Kerr et al. 1996). This study also provided
attributable fractions for a number of other chronic diseases, including neurological
disorders, cardiovascular disease, chronic respiratory diseases and renal disease.
Approximate attributable fractions for osteoarthritis and back problems were derived
separately from the research literature.
There were an estimated total of 2,005 deaths in Australia in 1996 attributed to occupational
exposures—1.6% of total deaths (see Tables 7.21 and 7.22). Because many of these deaths
occur at younger ages, the mortality burden is a somewhat higher proportion (2.0%) of the
total mortality burden. The attributable burden of occupational exposures is nearly 44,000
DALYs—1.7% of the total burden of disease and injury in 1996. Cancers are responsible for
41% of the attributable burden, followed by injuries (33%) and other chronic diseases (25%).
Table 7.21: The attributable burden of occupational exposures by condition, Australia, 1996
Cause Deaths YLL YLD DALYs
As per cent of
total DALYs
Cancers 1,409 15,687 2,331 18,018 0.7
Other chronic diseases 227 2,509 8,543 11,052 0.4
Injuries 369 8,335 6,191 14,526 0.6
Total 2,005 26,531 17,065 43,596 1.7
Table 7.22: The burden of disease attributable to occupational exposures, Australia, 1996
Males Females Persons
Number Per cent Number Per cent Number Per cent
Deaths 1,638 2.4 367 0.6 2,005 1.6
YLL 21,973 2.9 4,557 0.8 26,530 2.0
YLD 9,748 1.7 7,318 1.3 17,065 1.5
DALYs 31,721 2.4 11,875 1.0 43,596 1.7
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Figure 7.23 illustrates the age distribution of the occupational burden of disease and injury
for males and females. The overall attributable burden for males is nearly 3 times higher
than that for females. The mortality burden for females is one-fifth that for males, but the
non-fatal burden is almost as large as that for males.
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Figure 7.23: Attributable burden of occupational exposures: YLL, YLD and DALYs, by age
and sex, Australia, 1996
7.11 Inadequate fruit and vegetable consumption
There is increasing evidence that fresh fruit and vegetable consumption offers protection
against cancer at many sites, and diets high in fruit and vegetables are protective against
coronary heart disease (Ziegler 1991, Block et al. 1992, Tavani & La Vecchia 1995, Rimm et
al. 1996, Steinmetz & Potter 1996, Miller et al. 1997, NZMOH 1999). The New Zealand
Ministry of Health has reviewed relevant epidemiological studies and estimated relative
risks associated with inadequate fruit and vegatable consumption, for all cancers, ischaemic
heart disease and stroke (see Table 7.23). Inadequate consumption was defined as less than
5 servings of fruit or vegetables per day, in line with dietary recommendations (NZMOH
1999). We used these relative risks together with prevalence estimates of inadequate fruit
and vegetable consumption based on the 1995 National Nutrition Survey (ABS, unpublished
tabulations) to derive attributable fractions for these conditions.
Table 7.23: Relative risks associated with inadequate fruit and vegetable consumption
Age group All cancers Ischaemic heart disease Stroke
25–44 1.40 1.18 1.14
45–64 1.30 1.18 1.13
65–74 1.20 1.11 1.10
75 and over 1.10 1.00 1.05
Source: New Zealand Ministry of Health 1999.
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Figure 7.24: The proportion of people aged 25
and over who consume less than five servings of
fruit or vegetables per day by age and sex, 1995
The proportion of people aged 25 and over who consume less than five servings of fruit or
vegetables per day varies from a low of 46%, for women aged 55 to 64, to a high of 70% for
men aged 35 to 44. The proportion for men is higher than that for women at all ages over 25
(Figure 7.24).
The attributable burden of inadequate fruit and vegetable consumption was 68,077
DALYs—2.7% of total DALYs (Table 7.24). These DALYs comprised mainly YLL, with the
attributable YLL accounting for 4.2% of total YLL while attributable YLD accounted for 1.0%
of total YLD.
Table 7.24: The burden of disease attributable to inadequate fruit and vegetable
consumption, Australia, 1996
Males Females Persons
Number Per cent Number Per cent Number Per cent
Deaths 2,541 3.7 1,516 2.5 4,057 3.2
YLL 33,082 4.4 22,881 3.8 55,963 4.2
YLD 7,044 1.2 5,071 0.9 12,114 1.0
DALYs 40,126 3.0 27,951 2.4 68,077 2.7
Table 7.25: The attributable burden of inadequate fruit and vegetable consumption
by condition, Australia 1996
Cause Deaths YLL YLD DALYs
As per cent of
total DALYs
Cancers 3,143 42,854 8,467 51,321 2.0
Ischaemic heart disease 734 10,592 2,063 12,655 0.5
Stroke 180 2,517 1,584 4,101 0.2
Total 4,057 55,963 12,114 68,077 2.7
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Although some of the attributable mortality and disability relate to heart disease and stroke,
most is attributable to cancer—75% of attributable DALYs relate to cancer, which accounts
for 2.0% of total DALYs (Table 7.25). In fact around 11% of all cancer DALYs are attributable
to inadequate fruit and vegetable consumption. The overall attributable burden is higher for
men than women at all ages and is highest for both men and women between the ages of 55
and 74 (Figure 7.25).
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Figure 7.25: YLL and YLD attributable to inadequate fruit and vegetable consumption,
by age and sex, Australia, 1996
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8 Discussion and conclusions
8.1 Key findings
This study has provided the first comprehensive assessment of the health status of the
Australian population. Mortality, disability, impairment, illness and injury arising from 176
diseases, injuries and risk factors were measured using a common metric, the disability-
adjusted life year or DALY. As discussed in the first chapter, one DALY is a lost year of
‘healthy’ life. This report provides estimates of the contribution of fatal and non-fatal health
outcomes to the total burden of disease and injury measured in DALYs in Australia in 1996.
The study uses the methods developed for the Global Burden of Disease Study, adapted to
the Australian context and drawing extensively on Australian sources of population health
data. These methods are described in some detail in Chapter 2.
Key findings—mortality
Life expectancy at birth in 1996 was 75.6 years for Australian males and 81.3 years for
Australian females. Male life expectancy is six years shorter than female life expectancy.
Australia ranks around 10th in the world in terms of total life expectancy at birth. Australia
ranks fifth lowest in the world, behind Japan, Greece, Sweden and Italy, in terms of the
probability of dying between ages 15 and 59.
As discussed in Chapter 3, premature mortality was responsible for 1.35 million years of life
lost (discounted at 3% per annum) in Australia in 1996. Males lost 26% more years of life
than females. Cardiovascular disease, cancers and injury were responsible for 72% of the
total mortality burden in both males and females. In people aged 75 years and over,
cardiovascular diseases account for more than half the years of life lost, whereas cancers are
a more important cause than CVD for all ages below 75. Injuries are the main cause of lost
years of life in young adults and children aged 5–14 years, and neonatal conditions the main
cause in children aged under five.
Overall, the age-adjusted mortality burden in Australia has declined by 44% in the 15 years
between 1981 and 1996. There have been substantial declines in the mortality burden of
cardiovascular diseases, road traffic accidents, low birthweight, and stomach cancer for both
males and females. The burden of smoking-related diseases (lung cancer, COPD) has
decreased in males but increased substantially in females. The largest increases in mortality
burden have occurred for HIV/AIDS, suicide and prostate cancer in males, for senile
dementias and heroin dependence and abuse in both sexes, and for lung cancer and chronic
obstructive pulmonary disease in women.
Socioeconomic disadvantage is an important predictor of premature mortality. The most
disadvantaged quintile of the Australian population lost 35% more years of life than the
least disadvantaged quintile in 1996. Among Australians aged less than 65, the differential
burden between lowest and highest quintile is even greater, at 60% excess burden in the
most disadvantaged group. The overall inequality in mortality burden is 50% larger for
males than females in Australia. The inequality in mortality burden is greatest for maternal
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mortality, followed by ill-defined conditions (sudden infant death syndrome) in both sexes,
followed by digestive system diseases and injuries in males.
Men in the bottom quintile of socioeconomic disadvantage have a 40% higher chance of
dying between ages 25 and 64 than men in the top quintile. There is a 3.6-year gap in life
expectancy at birth for males between the bottom and top quintiles, and a 1.9-year gap for
females. Between 1986 and 1996, these socioeconomic differentials have remained similar for
females and for adult and older males, but have widened for boys and young men aged
15–24 years, particularly for motor vehicle accidents and suicide. They have narrowed for
drug overdose deaths (rates have increased faster in the top quintile than the bottom
between 1986 and 1996).
Key findings—disability
As discussed in Chapter 4, mental disorders are the leading cause of years of life lost due to
disability, accounting for nearly 30% of the non-fatal burden (YLD) in Australia. The next
leading main cause group is nervous system and sense organ disorders, responsible for 16%
of the disability burden.
In terms of specific conditions, depression is the leading cause of non-fatal disease burden in
Australia, causing 8% of the total YLD in 1996. Hearing loss and alcohol dependence and
harmful use are the second and third leading contributors to non-fatal burden for males.
Dementia and osteoarthritis are the second and third leading contributors for females.
In contrast, to the mortality burden, the disability burden is almost identical for males and
females. The non-fatal burden of nervous system disorders, mental disorders and
musculoskeletal disorders are all higher for females than for males. The male burden is
higher for cardiovascular disease, diabetes, chronic respiratory diseases and cancers. This
confirms previous conclusions based on health survey data that females have greater
incidence and prevalence of the more common non-fatal health problems, whereas males
have greater incidence of the major diseases and injuries associated with high case fatality
(such as cardiovascular diseases, cancers, chronic respiratory conditions and injuries).
As well as estimating the burden of non-fatal conditions using the standard DALY
incidence-based approach (with 3% discounting), this study also produced undiscounted
YLL, YLD and DALYs and prevalence-based YLD. The latter counts each lost year of good
health at the age it is lived, rather than discounting it back to the time of incidence and
counting it as an incident loss of health at that age. As expected, the prevalence-based YLD
are lower in childhood and higher at older ages than the incidence-based YLD. The overall
prevalence of ‘disability’ measured in terms of the prevalence YLD rate is reasonably
consistent with the prevalence of disability as measured in the 1998 Survey of Disability,
Ageing and Carers (ABS 1999a).
Section 4.7 illustrated the potential of the burden of disease methods to estimate the total
burden attributable to impairments such as amputation or cognitive impairment. Cognitive
impairment (including congenital and childhood-acquired impairment) is responsible for an
estimated 16% of the non-fatal disease burden in Australia. If the disability weights are
defined in terms of a multi-attribute health state descriptor such as the EuroQol (see Section
2.5, Box 2.1), there is also the potential to apportion the burden of disease across the single
attributes. This is also illustrated in Section 4.8, which presented provisional estimates of the
non-fatal burden attributable to several types of disability.
Inequality in disability burden was assessed for selected mental disorders among
Australians aged 18 years and over. These included substance abuse disorders, affective
disorders, anxiety disorders and borderline personality disorder. Overall, for these
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conditions, the most disadvantaged quintile of the Australian population lost 45% (males)
and 41% (females) more years of ‘healthy’ life than the least disadvantaged quintile.
Australian males born in 1996 can expect to live the equivalent of 68.7 years of good health,
compared to 73.6 years for females. Approximately 9% of total life expectancy at birth is
‘lost’ due to disability for both males and females in Australia.
Key findings—burden of disease and injury
Inclusion of non-fatal health outcomes provides a substantially different picture from that
provided by traditional mortality statistics: mental disorders are now the third leading cause
of burden after cardiovascular diseases and cancers (see Chapter 5). Central nervous system
and chronic respiratory conditions are almost as large a contributor to total burden as
injuries. The leading main disease groups contributing to the burden of disease were
cardiovascular disease (22%), followed by cancer (19%) and then mental disorders (14%).
The total burden of disease and injury in Australia in 1996 was estimated to be 2.5 million
DALYs or 137 DALYs lost per 1,000 population. In other words, among each 1,000 people in
the Australian population, during 1996 the lost years of healthy life represented 13.7% of the
total life years lived. The male burden (in total DALYs) is 13% higher than the female
burden.
In terms of specific conditions, ischaemic heart disease and stroke lead the list, together
causing nearly 18% of the total disease burden. Chronic obstructive pulmonary disease and
lung cancer (also smoking-related diseases) are the third and fifth leading cause of disease
burden, accounting for another 7.3% of the total burden. Depression is the fourth leading
cause of disease burden in Australia, accounting for 3.7% of the total burden. If the
attributable burden of suicide and self-inflicted injury is included, then depression accounts
for an overall 5% of the total burden of disease and injury in Australia.
Diabetes is the sixth leading cause of disease burden in Australia, accounting for more
DALYs lost than colorectal cancer. Inclusion of the attributable burden of cardiovascular
disease due to diabetes increases the burden of diabetes from 3% to 5% of total DALYs.
Depression and diabetes then share equal third place as leading cause of disease burden,
after ischaemic heart disease and stroke.
The six National Health Priority Areas account for 70% of the total burden of disease and
injury in Australia, comprising 81% of the YLL and 57% of the YLD (Chapter 6).
The burden per 1,000 population in the most disadvantaged quintile of the population is
37% higher for males and 27% higher for females than the burden for males and females in
the least disadvantaged quintile. The excess mortality burden associated with socioeconomic
disadvantage is almost 20% of total male burden and around 15% of total female burden.
Key findings—attributable burden of risk factors
Risk factors, including lifestyle behaviours (such as tobacco smoking, physical inactivity,
alcohol consumption, diet, unsafe sex), physiological states (such as obesity, high blood
pressure, high cholesterol) and societal conditions (such as occupational exposures and
socioeconomic disadvantage) are responsible for a sizable proportion of the total burden of
disease in Australia—and for much of the inequality in the burden falling on different
population groups. Chapter 7 provides estimates of the attributable burden for ten risk
factors for which prevalence and relative risk data were available. The combination of these
ten risk factors may account for between one-third and one-half of the burden of disease and
injury in Australia in 1996.
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Tobacco smoking is the risk factor responsible for the greatest burden of disease in
Australia: about 12% of the total burden of disease in males and 7% in females. Physical
inactivity is responsible for about 8% of the total burden of disease, and obesity a somewhat
lower proportion at around 4.4%.
Hypertension causes over 5% of the total burden of disease and injury, and high blood
cholesterol nearly 3%. Inadequate fruit and vegetable intake is also responsible for around
3% of the total disease burden.
The net harm associated with alcohol consumption is around 2.2% of the total burden, as the
injury and chronic disease burden associated with harmful and hazardous levels of alcohol
consumption are offset by the burden of cardiovascular disease prevented by alcohol
consumption. The protective effect is only relevant after age forty-five, whereas the harmful
effects of alcohol are apparent at all ages.
Illicit drugs are responsible for a level of harm similar to that of alcohol for males, at 2.1% of
total male burden. Just over half this burden is due to premature mortality, the other half to
YLD resulting from drug dependence or harmful use. Illicit drugs account for about 1% of
the total female burden.
Unsafe sex is responsible for around 1% of the total burden of disease in Australia in 1996.
HIV/AIDs accounts for 61% of the total burden of disease that is attributable to unsafe sex,
followed by cervix cancer (24%) and other sexually transmitted diseases (8%).
Occupational exposures to toxic chemicals and injury risks were responsible for an
estimated total of 2,005 deaths in Australia in 1996—1.6% of total deaths. Because many of
these deaths occur at younger ages, the mortality burden is a somewhat higher proportion
(2.0%) of the total mortality burden. The total attributable burden of occupational exposures
is 1.7% of total DALYs lost in 1996. Cancers are responsible for 41% of this attributable
burden, followed by injuries (33%) and other chronic diseases (25%).
8.2 Precision of estimates
The calculation of YLL is straightforward, and the precision of the estimates is almost
entirely dependent on the quality of the data on underlying cause of death. As discussed in
Section 3.1, there are several ICD-9 categories (‘garbage’ codes, and ill-defined or unknown
categories) for which deaths have been redistributed to disease and injury causes based on
disease registry data and expert opinion. These redistributions do not involve large
numbers of deaths and have little effect on the precision of the YLL estimates.
Extensive epidemiological modelling drawing on a very wide range of data sources,
research findings and expert opinion was required to estimate YLD. Thus the precision of
the YLD estimates is not really quantifiable in the usual statistical sense of deriving a
confidence interval. The precision varies between diseases and depends on the specific
disease model applied and the source and nature of the data underlying the disease model.
Furthermore, the disease weights have not been derived in the Australian context and so
may not completely reflect Australian societal preferences for disease states. This is
discussed further in Section 8.4. For both these reasons, the YLD estimates (and hence the
DALY estimates) should be regarded as provisional and developmental. The analyses
carried out for this study will provide a framework for more detailed analysis of particular
conditions and guidance in identifying data gaps and deficiencies. It is hoped that further
improvements over time in methods, models and data will result in step by step
improvements in the accuracy and certainty in estimates of burden of disease in Australia.
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It has not been possible in the timeframe of this first report to carry out full sensitivity
analyses for each disease and injury category. This has been done for YLL, but only for a
few diseases for YLD. Using simulation methods (Section 2.10), it is possible to quantify the
uncertainty interval for each YLD estimate to take into account the confidence intervals
around incidence or prevalence data, and the uncertainties associated with the various
assumptions and estimates also used. The example worksheet for dementia in Appendix B
includes an uncertainty analysis for dementia YLD.
Among major causes of disease burden, the uncertainty is probably highest for YLD
estimates for hearing loss, osteoarthritis, and alcohol dependence and harmful use.
Although population data on measured hearing loss thresholds were used to estimate YLD
for hearing loss, there was considerable uncertainty associated with the modelling of the
effects of hearing aids in reducing disability and in the average durations associated with
progression through mild to moderate to severe hearing loss. Additionally, the large burden
for hearing loss is the product of high prevalence with low disability weights. Trade-off
methods generally produce greater degrees of uncertainty for very mild conditions and
uncertainty in the hearing loss weights will contribute to greater uncertainty in the YLD
estimates. YLD for osteoarthritis are based on overseas studies which measured incidence
and severity of osteoarthritis. These estimates are lower than would be suggested by the
Australian self-report population data on osteoarthritis. The uncertainty in YLD for alcohol
dependence and harmful use relates mainly to assessing levels of disability for younger
people classified in the National Mental Health Survey as having an alcohol problem.
Broader sensitivity analyses suggest, however, that the uncertainty in the estimates of
disease burden for many conditions may not be excessive. Overall, about half the burden is
contributed by YLL, where estimates are generally fairly precise. Around 40% of the YLD
burden is contributed by a small number of diseases (including ischaemic heart disease,
cancers, stroke, diabetes, and affective and anxiety disorders) for which reasonably good
Australian data were available. This leaves around 30% of the total disease burden with
varying higher levels of uncertainty.
It should also be noted that precise values of the DALY burden for many of the conditions
lower down in the overall rankings of causes will fluctuate from year to year due to
variations in the incidence and mortality of such conditions. In particular, the estimates for
many of the infectious diseases will vary from year to year depending on whether the year
is an epidemic year or not. For this reason, precise ordering of the smaller causes of burden
is not very useful.
8.3 Data gaps and deficiencies
The extensive epidemiological modelling carried out in this study for over 1200 disease and
sequelae categories has enabled us to identify many data gaps and deficiencies in Australian
population health data (even given the high quality and extensive availability of such data
in Australia compared to many other countries). Some of the major gaps and deficiencies are
listed below:
• Incidence or prevalence data for some diseases (e.g. cancer, some infectious diseases) is
relatively complete but data for many others is unavailable or has severe limitations.
The most important of these in terms of their contribution to YLD are:
Osteoarthritis and rheumatoid arthritis: The only population-level data we are aware of for
Australia is self-reported data from the National Health Surveys. The self-
reported prevalence of both types of arthritis is considerably higher than the best
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estimates from epidemiological studies. YLD estimates for this study were thus
based on overseas population-based epidemiological studies using clinical
criteria to define incident cases.
Asthma: Self-reported asthma prevalence from the National Health Surveys is two to
three times higher than the prevalence of asthma measured in population
samples based on a history of wheezing in the last 12 months and a positive
airway hyperresponsiveness test. These samples are only available for a
restricted set of age groups.
Diabetes: There is no recent Australian population data on the ratio of undiagnosed to
diagnosed Type 2 diabetes (see Section 4.2). YLD estimates in this report assume
the ratio is 0.5:1 based on a recent US study.
Vision disorders: The prevalence of vision impairment is derived from the Blue
Mountains Eye Study (see Section 4.2). It is not known how representative this
for all Australians.
Hearing loss: The prevalence of hearing impairment with use of usual aids (if any) is not
known in Australia. YLD estimates for adult-onset hearing loss are based on a
recent population survey of measured hearing loss (Wilson et al. 1998, 1999)
together with assumptions about the effectiveness of hearing aids.
Chronic obstructive pulmonary disease: Prevalence and severity estimates are based on the
Busselton Study. It is not known how representative these are of the Australian
population.
Ischaemic heart disease: The only available prevalence data for angina in Australia is self-
report data on treated angina from the 1989 National Heart Foundation Risk
Factor Survey. Information on the prevalence and severity of heart failure is not
available.
Other heart diseases: No population-level data is available on the incidence or prevalence
of rheumatic heart disease, hypertensive heart disease or inflammatory heart
diseases such as cardiomyopathy.
Stroke: No recent population-level studies of stroke incidence or prevalence have been
carried out in Australia.
· Information on the distribution of severity of disease is inadequate or lacking for many
important conditions. These include asthma, angina, heart failure, stroke, peripheral
arterial disease, osteoarthritis and dementia.
· Case fatality rates are not available for the vast majority of conditions. Improvements in
record linkage and retention of identifiers in population surveys should allow this to be
addressed at relatively low cost using the AIHW National Death Index.
• There is a need for data which will allow monitoring of the course of a disease (e.g.
ability to identify different hospital records relating to a single person and ability to
track disease outcomes and relate disease/injury to subsequent disability). Information
is available on the average progression times through severity levels for vision and
hearing loss, or the average time for development of complications for diseases such as
diabetes.
· There are inconsistencies between commonly quoted incidence, prevalence and
mortality estimates for a number of important diseases such as Type 1 diabetes and
dementia.
· There are inconsistencies between self-reported health data from population surveys
and best estimates from epidemiological studies for a number of important diseases (e.g.
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arthritis, asthma, upper and lower respiratory conditions). The major limitations of self-
reported data on health conditions relate to:
– under-reporting of undiagnosed conditions (e.g. many mental health problems,
diabetes);
– over-reporting of some conditions (e.g. where symptoms such as joint pain are
incorrectly labelled as osteoarthritis, or occasional wheezing as asthma); and
– lack of information on condition severity (resulting in high prevalences due to
inclusion of very minor conditions or minor symptoms).
· This study made some attempts to harmonise impairment, disability and
epidemiological data for a few conditions (e.g. intellectual disability, cerebral palsy,
stroke). There are severe limitations in the available Australian population survey data
relating disability to underlying disease and injury causes due to the limitations of self-
report data on causes, and the mixing of impairments, diseases, and risk factors in the
reporting categories for main causes of disability. There is a need for population
epidemiological studies of the causes of disability that use consistent and well-defined
criteria for identifying diseases, injuries and risk factors.
8.4 Methodological issues and developments
In the course of undertaking this study, it has become apparent that there are a number of
methodological issues which require further thinking and development in order to improve
the validity and applicability of the DALY metric. Efforts are already underway
internationally in some of these areas. We briefly summarise the major areas where methods
need to be improved. A more detailed paper on these issues is planned.
Comorbidities—the Australian studies have made the first attempts to take comorbidities into
account in estimating the total burden of disease. This was done for
comorbidities between congenital malformations, between mental disorders
and between physical disorders at older ages. We did not attempt to adjust for
cormorbidities between mental and physical disorders—although Australian
data is available that would allow analyses of mental–physical comorbidities to
be undertaken. There are a number of issues which need to be addressed,
including how to model the effect of comorbidities on combined disability
weights, how to deal with comorbidities that arise from common causes, and
how to manage the potentially large number of comorbidity combinations.
Discounting—this makes YLD analysis very complex for diseases with long-term sequelae as
we then need to get precise estimates of progression times. Also, discounting is
not currently carried out entirely consistently, e.g. YLL are not discounted back
to the point of disease incidence. The latter would require complex and
uncertain modelling for many conditions at present.
DISMOD—the first version of DISMOD uses cross-sectional mortality rates to model
duration of diseases. This means that estimation of disease duration takes into
account only the current period life expectancy of the population, whereas the
YLL take into account either cohort life expectancies or use an ideal standard
life table with greater life expectancies than currently observed. It is not
possibly to simply insert cohort projected mortality rates into the DISMOD
data files. Version 2 of DISMOD is currently under development and will
incorporate a number of methodological improvements.
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Numerical valuation of health states—a substantial program of research and development is
required to address the following issues:
· what are the key domains to include in summary health state instruments
for use to obtain population data on health outcomes and for use in val-
uation exercises;
· obtaining disability weights using more panels which are more repres-
entative of the general population;
· inclusion of the experience of people with particular conditions in
valuation exercises;
· comparability of weights across cultures and between socioeconomic
groups; and
· the need for development of Australian-specific weights.
On the one hand, Australian specific weights would lead to estimates which
may best suit the needs of Australian health policy development. On the other
hand, an international standard may provide weights which are close enough
to Australian preferences so that the differences from Australian specific
weights are negligible in terms of policy development while allowing direct
international comparisons. Internationally derived weights would also mean
the weights could be based on more and more extensive studies without
requiring large resource input from the Australian health budget.
Population disability data—This study has taken some steps towards developing consistency
between DALY estimates and population data on impairments and functional
limitations. The development of standard validated summary health state
measures for inclusion in population surveys and for use in longitudinal
epidemiological studies will be an important step.
Microsimulation methods—data analysis requirements for a complex burden of disease study
with many disease categories and population subgroups can rapidly exceed
the capabilities of spreadsheet or database software. Microsimulation methods
potentially allow a very flexible approach to dealing with many disease and
population categories and with the interactions between them (e.g. differing
incidence rates for different groups, and comorbidities and interactions
between conditions).
Cost-effectiveness analysis—there are a number of issues in using DALYs as health outcome
measures in cost-effectiveness analyses which need to be addressed.
8.5 Future directions
The initial analyses carried out for this study will provide a framework for more detailed
analysis of particular conditions, for burden of disease estimates for priority subpopulations
and for analysis of the impact of risk factors and health determinants to inform health policy
making and priority setting. Further improvements over time in methods, models and data
will result in step-by-step improvements in accuracy and certainty in estimates of burden of
disease in Australia. The Australian Institute of Health and Welfare is continuing work in
this area.
Some of the potential priorities for future work in Australia may include:
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1. Analysis of the Indigenous burden of disease and injury in Australia as a first step
towards assessing Indigenous needs for health service provision and as a tool to monitor
national progress in this important area. A recent report on Indigenous health
expenditure (Deeble et al. 1998) outlined the potential to use burden of disease analysis
in addressing questions of Indigenous need for health services and equity of health
funding. The National Indigenous Health Information Plan has also identified
Indigenous burden of disease analysis as a priority.
2. More detailed modelling of incidence, prevalence, mortality and burden of disease for
specific diseases and injuries to support planning and evaluation for National Health
Priority Areas and national strategies for specific conditions or health determinants.
3. A full analysis of the attributable burden of socioeconomic disadvantage in Australia to
support national public health planning and monitoring of inequality in health status
4. State-level analyses of burden of disease, building on the Victorian and national studies
but using state-specific population and health data. Local area analyses and
urban/rural/remote analyses may also be of interest.
5. Estimation of Australian social preferences for a comprehensive set of conditions and
sequelae. Two Australian research groups have already commenced work in this area.
6. Linkage of burden of disease analysis and marginal cost-effectiveness analysis of
potential interventions. Estimation of the potential for cost-effective reduction of disease
burden at the population level could be carried out for a number of case studies in order
to inform priority setting processes for health policy and research.
7. More broadly, the usefulness of burden of disease analyses for policy makers and health
planners remains to be fully evaluated. It is hoped that this initial report will provide
useful information that may allow such applications to be explored.
8.6 Conclusions
This report has addressed the need for comprehensive and comparable information on the
causes of loss of health in the Australian population. This study provides the first detailed
and internally consistent estimates for Australia of the incidence, prevalence, duration,
mortality and disease burden for an exhaustive and mutually exclusive set of disease and
injury categories. It has also taken first steps towards quantifying the burden associated
with a range of risk factors and health determinants, including socioeconomic disadvantage.
While every attempt has been made to identify the best available information in relation to
each disease, injury and risk factor category, and to consult as widely as possible, it must be
emphasised that the estimates published here should be seen as provisional and
developmental. It is hoped that others will contribute to future improvements in data,
disease models and disability weights.
One fundamental goal in constructing summary measures is to identify the relative
magnitude of different health problems, including diseases, injuries and risk factors. There
are two dominant traditions in widespread use for causal attribution: categorical attribution
and counterfactual analysis. Burden of disease analysis uses categorical attribution to
attribute the fatal and non-fatal burden of diseases and injuries to an exhaustive and
mutually exclusive set of disease and injury categories. It generally uses counterfactual
analysis to attribute the burden of disease to health determinants and risk factors. The
DALY methodology provides a conceptual framework linking determinants to disease and
injury, through to impairments, disability and other health outcomes. It brings together a
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range of concepts and data sources to present internally consistent information on the
origins, patterns, nature and consequences of disability and related health conditions.
The DALY methodology also provides a way to link information on disease causes and
occurrence to information on both short-term and long-term health outcomes, including
impairments, functional limitations (disability) and, potentially, restrictions in participation
in usual roles (handicap). The burden of disease methodology is designed to inform health
policy in relation to the prevention and treatment (cure or reduction in severity) of these
health outcomes. In principle, consistent use of measurement instruments and classification
categories for impairments and functional limitations in epidemiological studies of the
sequelae of diseases and injuries and in population disability surveys should enable burden
of disease analysis to provide DALY estimates consistent with the overall prevalence of
impairments and disabilities in the population.
It would then be possible to measure and monitor the health of Australians within a
coherent and integrated statistical framework, with a summary measure of population
health status at the apex of a hierarchy of related measures, rather than a piecemeal set of
unconnected measures. The macro measures at the apex of the system, such as health-
adjusted life expectancies, would provide a broad population-based overview of trends and
patterns. At the next level, health gap measures such as the DALY would provide cause-
specific summary measures of burden for use in quantifying the causes of health losses, in
identifying the potential for health gain and in linking health interventions to changes in
population health. At a lower level again would be the component parts of the picture:
incidence rates, prevalence rates, severity distributions, case fatality rates, etc. The two
families of summary health measures—health gaps (DALYs) and health expectancies—
could be measured in such a way as to make them not only conceptually but also
quantitatively complementary. This would require using consistent health state descriptors
and valuations for both indicators.34
This coherent system of health statistics would represent a major advance in our ability to
monitor population health (both levels and distributions), and to accumulate knowledge
about causal factors. The use of a common metric such as the DALY for burden of disease
analysis, measurement of clinical outcomes, and cost-effectiveness analyses would allow
existing or prospective interventions to be judged both in terms of cost-effectiveness, and
their relative impacts in reducing the burden of disease and ill-health. This study, together
with the parallel Victorian study (Department of Human Services 1999a, 1999b) are a first
step towards exploring the usefulness of these methods to provide information to assist in
health planning and priority setting.
In summary, burden of disease analysis provides a unique perspective on health—one that
integrates fatal and non-fatal outcomes, yet allows the two classes of outcomes to be
examined separately as well. Additionally, the burden can be readily disaggregated by
cause for analysis at the level of diseases and risk factors, and can be estimated for any
subgroup of the population for which data are available. Causal analysis needs to be
extended from the proximal biological and behavioural factors to more distal social,
economic and cultural determinants of health, including health care and welfare support
services. Perhaps also the outcome measure may need to be expanded to include wider
aspects of disease burden such as non-health domains of wellbeing and the impact on
family and society. Until these analyses can be done, however, the results reported here
may provide a valuable insight into the scope for further health gain in Australia.
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Appendix A Technical notes
These numbered additional explanatory and technical notes refer to superscript references in the text
of the main body of the report. References in these notes are included in the main reference list
above.
Chapter 1
1. The second type of information is addressed through a range of statistical activity to monitor
health expenditure, workforce numbers and infrastructure (AIHW 1998a, 1999b, 1999d); the third is
still largely unexplored territory, although there are increasing numbers of cost-effectiveness studies
for particular health interventions (Salkeld et al. 1994, Lave & Joshi 1996).
2. Different countries may have different values and wish to include different importance weights in
the calculation of the burden of disease. It is nevertheless desirable to conduct cross-national
comparisons and this requires the adoption of common criteria. Those incorporated in the WHO
analysis would be widely regarded as reasonable and representative of a wide range of values.
3. When descriptive DALYs (describing current burden) are used in an evaluation setting (e.g. if
disease incidence is decreased through an intervention or survival prospects improve), there is the
issue that the YLL have been estimated against a standard ideal life expectancy rather than the actual
health-adjusted life expectancy of the population group concerned. An example would be improved
survival after breast cancer screening or mastectomy, where a QALY adjustment is required to the
YLL recovered- life after mastectomy probably will not be valued at equivalent to full health. A
simple pro-ration of the DALY might be the starting point for macro evaluation work (i.e. 10%
reduction in incidence generates 10% reduction in the DALYs), but there will probably be a need to
develop more sophisticated models for specific policy analyses. There may also be an equity
argument to use the same ideal life expectancy for everyone—to avoid the situation where an
intervention is less cost-effective for disadvantaged groups with lower current life expectancies.
4. Examples of health state profiles intended for use with health state valuations include the EuroQol
with three levels on each of five dimensions (Dolan et al. 1996, Dolan 1997), the Health Utilities Index
with 5 or 6 levels on eight dimensions (Torrance et al 1995, Furlong et al. 1998) and the AQOL with
4 levels on fifteen dimensions (Hawthorne & Richardson 1995).
5. The original 1992 version of DALYs asked public health practitioners to use a rating scale method
to map disease sequelae into six disability classes, defined using word definitions related to activities
of daily living and instrumental activities of daily living (Murray 1994). The final version of the
Global Burden of Disease 1990 study (Murray & Lopez 1996a) used disability weights for disease
sequelae derived directly using a deliberative approach with multiple person trade-off methods.
Participants were instructed to evaluate the average individual with the (disease or injury) condition
described, taking into account the average social response or milieu. The resulting preferences are
probably influenced by perceptions of the average handicap (participation restriction) stemming
from each condition.
6. The current revision process for the ICIDH has emphasised that participation restriction (formerly
referred to as handicap), results from the interaction of impairments, functional limitations (formerly
referred to as disability), individual and cultural beliefs and expectations, and the physical and social
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environment (WHO 1999b). Murray (1996, page 33) argued that the DALY should attempt to capture
the impact of disability rather than handicap on equity grounds. The disadvantage resulting from
disability may be smaller in already disadvantaged population groups, since they have less
advantage to lose, and so allocating resources to avert handicap rather than disability could
exacerbate inequalities.
Mathers (1997c), Nord (1997) and Wolfson (1998) have argued that summary population health
measures should relate to dimensions of health, such as impairments and activity limitations, that
are intrinsic to the person or ‘within the skin’, rather than dimensions of health or broader wellbeing
that are determined by the interaction between the individual and the social and environmental
contexts. Here, ‘within the skin’ includes mental health and function as well as physical health and
refers to functioning at the level of the body and individual (in the terms used by the draft ICIDH
revision).
7. Aspects of the standard gamble, time trade-off and person trade-off methods approximate
situations that frequently arise in health services. The standard gamble is similar to the choice faced
by a patient with a serious condition for which the treatment could result in death, but if successful
would leave the patient much better off. The time trade-off is similar to a patient having a chronic
condition where the treatment is likely to improve but shorten life. The person trade-off is similar to
the situation faced by a health planner allocating scarce resources between treatments for different
conditions.
All these methods capture something more than pure health state preference or utility (Nord 1992,
Nord et al. 1993). Ratings scales approaches tend to give preferences for mild health states that are
too low (for example, the Quality of Wellbeing Scale values 50 dental pulp extractions as equivalent
to saving a year of life). The standard gamble approach is affected by aversion to risk: some people
are less willing to gamble with life than others. Time trade-off is influenced by the length of time
being traded, as most people value years of life further into the future less than years closer to the
present. Current person trade-off approaches are influenced by equity considerations (willingness to
trade health in one group of people against that in another).
The majority of economists have argued that preferences should be obtained using a trade-off
instrument which requires respondents to consider the ‘cost’ of good health in terms of what they are
trading it off for. In particular, if we are to accept that the final metric gives us a trade-off between
life and quality of life, then the trade-off should involve life. This narrows the options for the
standard gamble, PTO and TTO (Richardson & Nord 1997, Brazier et al. 1999).
8. Nord (1994) and Murray and Lopez (1996a) have argued that for evaluation of health programs at
the societal level and for assessment of burden of disease or health benefits at the population level,
the person trade-off (PTO) is to be preferred to the standard gamble or time trade-off. This is because
the PTO method measures preferences in terms closest to the uses to which the weights are to be put.
These authors have argued that the PTO more directly attempts to measure social preferences for
health states, rather than the average of individual preferences for health states. The two are not
necessary identical. For example, a majority of individuals may have little individual preference for
being fertile because they are past the reproductive stage or do not plan to have children. But they
may place a greater social value on fertility because they value fertility for those who are of
reproductive age and desire to have children.
9. The deliberative approach ensures that people understand the task they are being asked to
perform, by asking the group to discuss and defend differences in the weights chosen by members. It
does not require members of the group to reach consensus on the weights, but to ensure they have
thought through the reasons for their choices and understood the questions posed to them (Murray
and Lopez 1996a). In contrast, most studies by health economists have used an individual
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questionnaire format that does not require explicit conceptualisation or group deliberation. A
number of focus group studies, including some carried out by AIHW in 1991, have shown that many
people do not understand the trade-off exercises correctly.
10. If the purpose is to obtain comparable values across a wide range of conditions for use in health
policy applications, there are practical and theoretical problems in using groups of health
professionals or people with particular health problems or disabilities. Each individual in a
deliberative group is required to elicit preferences for a number of health states to ensure consistency
and comparability of preferences across a range of health states. Individuals from either of these two
groups do not have a comprehensive understanding of health states outside their own experience
and so are not better placed than a general population to quantify social health state preferences:
· Health professionals may have a better understanding of health states in their area of expertise,
but are no better placed than anyone else to evaluate disability states outside their professional
fields.
· People with a particular health problem or in a particular disability state may be the best persons
to understand that state but are no better placed than others to evaluate other disability states.
Additionally, there is evidence that people with experience of a health problem tend to rate it
less severely than do people who have not experienced the problem. This may reflect adaptation
or more accurate knowledge.
The ethical and equity issues relating to the use of disability weights derived by people who have
adapted to long-term health problems or disabilities has been discussed in detail by Murray (1996:
29–32). Additionally, some health economists have argued that we should generally use the
‘insurance principle’ according to which we make policy on the basis of before-the-facts assessments.
Otherwise policy may be determined by people speaking too narrowly from their vested interest in a
particular health problem. Given the opposite dangers of discrimination and ignorance of the states
being assessed, however, it will be important to develop techniques to better describe health states
for weighting exercises. This will provide a greater role for those who have directly experienced
illness, impairment and disability by allowing their experiences to inform the weighting process. To
date, the majority of writers have argued for the inclusion of a personal perspective (Brazier et al.
1999, Richardson et al. 1999).
11. This may reflect insufficient sample sizes to detect these differences or the general lack of
comparable data on health state preferences. However, it is possible that there is reasonable cross-
cultural agreement on what constitutes a severe or less severe health state, and on the contributions
of different domains of health to the overall preference for the health state, if the health is defined in
terms of ‘within-the-skin’ domains.
12. The use of health state preferences and summary measures for policy making, priority setting or
resource allocation, e.g. in allocation based on marginal cost-effectiveness criteria, does not require
us to maximise health outcomes. This is one option, but there are other options which society may
prefer:
· We might give priority to the worst-off (Nord 1996).
· We could attach greater priority to large benefits than to the sum of many small ones, with life-
saving counting the most of all. Thus an intervention which gave 40 DALYs to one individual
might be preferred to an intervention which gave 1 DALY to 40 individuals.
· We could attach greater importance to giving everyone some benefits as opposed to larger
benefits for a few. Richardson and Nord (1997) present some empirical evidence that Australians
prefer more equally distributed benefits to less equally distributed benefits.
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· Or we might attach less importance to life extension past a normal lifespan, thus attaching
greater moral weight to achieving a ‘fair innings’ (Williams 1999).
It is useful to apply Rawls’ principle of a veil of ignorance (Rawls 1971) in considering these options.
An individual behind a veil of ignorance does not know who he or she is in a population and must
choose one of the above approaches, or a combination, keeping in mind that he or she could be any
member of the population, and experience any health problem. Wolfson (1998) has argued that
summary measures assist us in making explicit these trade-offs between efficiency (maximising
health outcomes) and equity (providing health benefits to all groups and reducing inequalities in
health outcomes). They allow us not only to measure the burden of a health problem and the
potential for health gain, but also to generate measures of the distributional impacts of health-related
interventions. Equity concerns could then be addressed explicitly in any priority setting or resource
allocation process, along with the potential to reduce the overall burden.
13. For ease of calculation, the DALY formulae use a continuous discounting function of the form e-rt
where r is the discount rate and t is time. The rate (3% in this study) is not precisely the same as the
annual discount rate used in the discrete form of the discount function (1+r)-t. With a continuous
discount rate of 3%, the corrresponding annual discount rate is 2.96%.
14. A number of arguments have been advanced to support discounting in economic analyses (see
Goodin 1982, Murray & Lopez 1996a). These include:
· pure time preference (impatience, moral urgency ‘the currently sick deserve help’ and moral
myopia ‘I want my cake now’);
· uncertainty and risk (‘I might be dead next year so I discount its value’—the world average
death rate is about 1% per annum);
· diminishing marginal utility coupled with historical rising levels of consumption (‘I will be better
off next year and so will value marginal benefits less’); and
· opportunity cost of capital (without discounting society could always buy more benefit in the
future by investing the money rather than spending it now).
15. The excessive sacrifice argument is that if there is a greater payoff through future investment than
present (say, because technology is improving), then with zero discounting we would postpone all
current spending resulting in an excessive sacrifice by the current generation for future generations.
16. Arguments against discounting future health gains (or losses) include:
· life does not lose value (to society) if it is in the future rather than the present (Goodin 1982);
· life cannot be valued in monetary terms so the usual opportunity cost arguments do not apply
(Anand & Hanson 1997);
· if we are concerned about excessive sacrifice, we should build this in to our thinking as an equity
principle directly, rather than discount (Parfit 1984); and
· the social discount rate may very well not be constant for every year into the future (Murray &
Acharya 1997).
17. There are good arguments to use a ‘social discount rate’ rather than an opportunity cost of capital
rate or an average of individual discount rates (which empirical studies show can vary from 0% to
10% or more). Individuals may have different concerns for public issues (including the future of their
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children and descendents) than for private issues. It can also be argued that the time preferences of
individuals are not relevant to the time preferences for a stable society.
18. This is a low positive rate that is probably at the lower limit of acceptability for those economists
who are persuaded by the opportunity cost argument and at the upper end of acceptability for those
wanting to avoid the excessive sacrifice problem (Murray & Acharya 1997).
19. The GBD incorporated age-weighting into the DALY using an integrable mathematical function
that rises rapidly from zero at birth to a peak in the early twenties after which it steadily declines.
This function has three parameters specifying its maximum amplitude, peak age, and the proportion
of the age weight that is applied (so that the value for a year at birth can be set anywhere from zero
(full age weighting) to one (uniform age weights). The amplitude was chosen so that total global
DALYs were the same with and without age weights.
Chapter 2
20. The use of a standard life table to calculate the years of life lost due to a death at a given age
achieves three objectives:
· deaths at the same age in any population subgroup contribute equally to the burden of disease;
· deaths at all ages contribute to the burden of disease (unlike the usual methods for calculating
potential years of life lost to age 75); and
· deaths at a given age in different years result in the same years of life lost, so that changes in the
burden over time are not confounded by changes in expected years of life lost.
Table A.1: Comparison of disability weights for GBD indicator conditions with Dutch weights
Global Burden of Disease Study Dutch study
Indicator condition Weight Comparable condition Weight
Angina pectoris(a) 0.18 Angina 0.22
Late complications after STD infection 0.11 Infertility 0.19
Rheumatoid arthritis 0.21 Mild rheumatoid arthritis 0.21
Mild mental retardation 0.36 Mild mental handicap 0.21
Deafness 0.33 Severe hearing loss 0.37
Blindness 0.62 Severe vision loss 0.43
Down syndrome without cardiac malformation 0.41 Down syndrome without comorbid conditions 0.51
Paraplegia 0.67 Paraplegia 0.57
Unipolar major depression 0.62 Severe depression 0.76
Quadriplegia 0.90 Quadriplegia 0.86
Dementia 0.76 Moderate or severe dementia(b) 0.73
Active psychosis 0.72 Schizophrenia, several psychotic episodes
Alcoholic psychosis
0.71
0.83
(a) Average of weights for mild stable angina and severe stable angina, assuming relative prevalences as modelled for Australia in this study.
(b) Average weight derived assuming relative prevalences of moderate and severe dementia as described in Appendix B.
Sources: Stouthard et al. 1997, Murray and Lopez 1996a.
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21. For younger ages, it is necessary to project mortality rates beyond 2051. Gompertz curves were
fitted to the observed and projected life expectancies at birth for males and females from 1966 to 2051
using the method of Rowland (1994) in order to project period life expectancies up to 2095. The
asymptotic life expectancies at birth for Australian males and females are 84.7 and 87.4 years for
males and females respectively. The asymptotic male/female difference is 2.7 years, very close to the
2.5 year difference used for the GBD standard life tables.
22. Twelve of the 22 indicator conditions used in the development of the GBD weights had
comparable counterparts in the Dutch study. Table A.1 lists these conditions and the weights derived
by each of the two studies.
23. Multiplicative multi-attribute functions provide much better fit to observed preference data than
additive models (Furlong et al. 1998). A multiplicative model of the following form was fitted to the
Dutch weights for 153 disease sequelae or stages:
p   s    d   d   d  d   d   d   d   d   d   d   d   d  = log(w) 636253524342333223221312 +++++++++++++
where
dij  = 1  if EQ-5D+ state is  j on dimension i, 0 otherwise.
s   = 1  if EQ-5D+ is 111111 but there is a disease present
p   = 1  if the prognosis for the disease is uncertain (0 otherwise).
Annualised weights associated with a short duration disease in an annual profile were excluded. A
small number of outliers were also eliminated from analysis. Nearly all of these were states described
by a distribution of EQ-5D+ states for which the overall weight was not consistent with the mix of
states.
The fitted regression model resulted in a single attribute weight slightly greater than 1 (on a scale
where 1= good health) for the second level (some problems) in the third dimension (usual activities—
work, family leisure). A final regression model was fitted in which this attribute weight was
constrained to be equal to 1.
24. HUI3 levels have been mapped to EQ-5D+ levels through examining and matching as closely as
possible the attribute-level definitions. There is no self-care dimension in the HUI3; the dexterity
dimension in HUI3 has been mapped (approximately) to the self-care dimension. The HUI3 contains
dimensions for vision and hearing loss whereas the EQ-5D+ does not. However, Dutch weights are
available for 3 levels of hearing loss and 3 levels of vision loss and these have been used to include a
comparison of the vision and hearing loss dimensions in Figure 2.4. The attribute levels are matched
as shown in Table A.2.
25. The apparent close correspondence for vision and hearing loss weights is misleading. The vision
and hearing dimensions of HUI3 have single attribute weights very consistent with the Dutch
weights for mild, moderate and severe vision and hearing loss. However, HUI3 weights for mild
hearing loss and vision loss are for conditions that are fully corrected by aids (spectacles, hearing
aid). The Dutch weights are for the net impairment after correction.
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Table A.2: Mapping of HUI3 levels to EQ-5D+ levels for Figure 2.5
Dimension EQ-5D+ states Comment
Mobility No problems walking around
Some problems walking about Average of ambulation states 3 and 4 (requires walking aids)
Confined to bed Average of ambulation states 5 and 6 (unable to walk alone even
with aids + cannot walk at all)
Self-care No problems washing or dressing
Some problems wash/dress HUI3 dexterity level 2–4 (problems with fingers or hands)
Unable to wash or dress HUI3 dexterity level 5–6 (need help or unable to do most tasks)
Usual activities No problems (work, family, leisure) No comparable scale in HUI3
Some problems
Unable to perform
Pain/discomfort No pain or discomfort
Moderate pain or discomfort Average of pain states 2 and 3 (mild to moderate and moderate
pain preventing activity)
Extreme pain or discomfort Average of pain states 4 and 5 (moderate to severe pain preventing
activity and severe pain preventing activity)
Anxiety/
depression
Not anxious or depressed Happy and interested in life
Moderately anxious or depressed Average of somewhat unhappy and very unhappy
Extremely anxious or depressed So unhappy that life is not worthwhile
Cognition No problems cognitive function
Some cognitive problems Somewhat forgetful, some problems with thinking and solving day
to day problems
Extreme problems Average of states 5 and 6 (very forgetful, great difficulty or unable
to solve day to day problems)
The following HUI3 dimensions are not in EQ-5D+ but Dutch weights for these states have been measured
Vision No problems with vision
Mild vision loss Some difficulty reading newspaper, no difficulty recognising faces
at 4m
Moderate vision loss Great difficulty reading newspaper, some difficulty recognising
faces at 4 m
Severe vision loss Unable to read newspaper or recognise faces at 4m
Hearing No problems with hearing
Mild hearing loss Some difficulty in group conversation
Moderate hearing loss Great difficulty in group conversation, some difficulty one on one
(average of HUI3 states 3,4)
Severe hearing loss Great difficulty one on one and unable to participate in group
discussions (average of HUI3 states 5,6).
26. DISMOD© is a software program developed by the Burden of Disease Unit at the Centre for
Health and Population Studies, Harvard, to assist disease experts to arrive at internally consistent
estimates of incidence, duration and case fatality rates for the Global Burden of Disease Study. The
program is based on a multi-state life table and uses various input parameters to derive consistent
epidemiological estimates of disease incidence, duration and case fatality. Some of the input
parameters are general (such as the age composition of the male or female population and the
general mortality risk at each age) and others specific to the disease under consideration (such as
instantaneous incidence and remission rates and cause-specific mortality risk). Outputs from the
program include estimates of prevalence, average duration (before remission or death) and cause-
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specific mortality by age. Because data on the prevalence of most conditions is easier to obtain than
incidence rates, DISMOD is often used iteratively to find a set of incidence rates by age that match
the observed prevalences, given estimates of remission rates and cause-specific mortality risk
derived from population data or epidemiological studies.
27. For 2 conditions with weights w1 and w2, the weight for the comorbid state with both conditions
is assumed to be
  ) w- (1 ) w- (1 - 1 =  w 2112 ´
This is equivalent to assuming that the weights in QALY form (0=dead, 1=good health) are mult-
iplicative. The combined weight is apportioned between the two conditions as follows:
a. Rank the conditions so that w1 is the larger weight (more severe condition). The weight for this
condition is taken to be w1.
b. The comorbid weight attributed to the second condition is then the balance of the comorbid
weight:
 ) w- (1   w=    w-   w= w 12112
adj
2 ´
Example 1: if a person has ischaemic heart disease (weight 0.2) and diabetes (weight 0.07), then
the adjusted weight for both conditions is 0.256 and the adjusted weight for diabetes 0.056.
Example 2: if a person has dementia (weight 0.44) and mild vision loss (weight 0.02), then the
adjusted weight for both conditions is 0.45 and the adjusted weight for the vision loss is 0.01.
c. For 3 comorbid conditions, follow a similar procedure and sequentially attribute the additional
weight to the second and third conditions (ranked in descending order of severity.
Example 3: if a person has dementia (weight 0.44), ischaemic heart disease (weight 0.2) and
mild vision loss (weight 0.02), then the adjusted weight for all 3 conditions is 0.577 and the
adjusted weights for the ischaemic heart disease and vision loss are 0.128 and 0.009
respectively.
28. Conditions for which comorbidity adjustments have been made at older ages are shown in
Table A.3 below.
29. The IRSD is compiled initially at the Collector’s District (CD) level, a census collection unit
broadly equivalent in urban areas to a small group of suburban blocks, comprising approximately
250 dwellings (CDs in rural regions usually contain fewer dwellings). Lower IRSD scores are
indicative of greater socioeconomic disadvantage. This study uses IRSD scores for Statistical Local
Areas (SLAs), which in most cases correspond to council boundaries defined by Local Government
Areas. IRSD scores for each SLA are constructed by taking the weighted average, using population
counts from the 1986 and 1996 census, across all CDs comprising the SLA. In aggregate, SLAs cover
the whole of Australia without gaps or overlaps.
30. The Gini coefficient is based on the Lorenz curve, and is widely used to measure income
inequality in populations (Creedy 1996). The Lorenz curve can be used to examine the inequality in
distribution of health outcome measures. In Figure 2.6, for example, the x and y ordinates could
represent the cumulative proportion of people across small areas ranked in terms of decreasing
mortality burden per capita and the cumulative total mortality burden respectively. If no inequality
exists, the Lorenz curve corresponds to the diagonal line of equality. As the extent of inequality
increases, so does the area between the line of equality and the Lorenz Curve. The Gini coefficient is
defined as the area enclosed by the line of equality and the Lorenz Curve expressed as a proportion
of the area below the diagonal and is bounded to range from zero (complete equality) to one
(complete inequality).
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Table A.3: Comorbidity adjustments for diseases with low disability weights and high prevalence
at older ages
Comorbidity adjustment
to weight
Category Code
Prevalence
at ages 65+
Disability
weight Age 65–74 Age 75+
Edentulism S3 40.6% 0.004 0.946 0.872
Iron deficiency/mild anaemia E2 2.7% 0.005 0.947 0.872
Osteoarthritis grade 2 (asympt.) Q2 7.9% 0.010 0.953 0.873
Moderate anaemia E2 0.6% 0.011 0.952 0.873
Vision loss—mild K8c 7.1% 0.020 0.952 0.869
Hearing loss—mild 25–34 dB K8d 24.7% 0.020 0.951 0.907
Urinary incontinence O3 8.1% 0.025 0.955 0.915
Hearing loss—mild 35–44 dB K8d 13.5% 0.028 0.937 0.898
Skin problems P1, P2 1.6% 0.056 0.938 0.900
Non-melanoma skin cancer F11 0.1% 0.058 0.938 0.900
Diabetes mellitus—cases Ha 12.5% 0.070 0.951 0.918
Asthma M2 5.6% 0.076 0.959 0.927
Hearing loss—moderate K8d 13.4% 0.080 0.946 0.886
Angina L2 5.1% 0.080 0.951 0.898
Osteoarthritis grade 2 (sympt.) Q2 1.6% 0.140 0.942 0.889
Osteoarthritis grade 3 (asympt.) Q2 6.1% 0.140 0.943 0.891
Melanoma F10 0.5% 0.145 0.943 0.891
Hearing loss—severe K8d 2.7% 0.153 0.976 0.864
Vision loss—moderate K8c 2.2% 0.170 0.927 0.857
COPD M1 6.9% 0.170 0.958 0.894
Peripheral arterial disease L8 1.5% 0.243 0.977 0.888
Cancer—medium average weight F14–16,19,22,24 2.3% 0.255 (a) (a)
Heart failure L2 0.3% 0.353 (a) (a)
Cancer—high average weight F3,4,7,8,12 2.5% 0385 (a) (a)
Osteoarthritis grade 3 (sympt.) Q2 2.4% 0.420 (a) (a)
Vision loss—severe K8c 2.1% 0.430 (a) (a)
Dementia K1 5.6% 0.440 (a) (a)
Stroke L3 1.9% 0.540 (a) (a)
(a) Comorbidity adjustments not made for these conditions, although they are taken into account as comorbid conditions in calculating the
comorbidity adjustments for lower severity conditions
31. There is extensive epidemiological evidence that socioeconomic disadvantage is causally related
to higher mortality levels (Mathers 1994a, Wilkinson and Marmot 1998). Some but not all of the
mortality differentials are mediated by differences in the prevalence of lifestyle risk factors such as
tobacco smoking, physical inactivity, alcohol consumption, overweight and dietary risk factors.
Chapter 3
32. If male YLL are calculated using the cohort life expectancies for females, then the male excess
mortality burden rises from 26%to 43%The latter figure includes the years of life lost due to the male-
female gap in projected life expectancies in Australia. If YLL are not discounted, then the male excess
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mortality burden is  31% based on  projected cohort life expectancies for males and females and 53%
if female life expectancies are used for both males and females.
Chapter 7
33. Estimation of the proportion of current disease burden that would be prevented in the future if
exposure to the risk factor were eliminated requires answers to ‘what if’ questions. The contribution
of the risk factor can be estimated by comparing the current level and projected future levels of a
summary measure of population health with the levels that would be expected for some hypothetical
or ‘counterfactual’ distribution of risk factor exposure. Counterfactual analysis requires a model that
predicts the levels of a summary measure under an alternative hypothetical scenario. Sometimes
these models are extremely simple but in the case of risk factors, which can have complex time and
distributional characteristics, the models can be quite complex. The validity of the estimate depends
on the validity of the model used to predict the counterfactual scenarios (Murray et al. 1999).
Counterfactual analysis of summary measures has a potentially wide spectrum of uses from the
assessment of specific policies or actions to more general assessments of the contribution of diseases,
injuries or risk factors. Murray et al. (1999) identified four major types of counterfactual scenario that
may be used for this type of assessment:
· The effect of small changes in the disease, injury or risk factor can be assessed and the results
expressed as the elasticity of the summary measure with respect to changes in the disease, injury
or risk factor.
· The change in a summary measure expected with complete elimination of a risk factor can be
assessed for some risk factors such as tobacco or alcohol use, but not for others such as blood
pressure.
· The changes in future levels of a summary measure could be assessed for elimination of the risk
for one year, followed by a return to the status quo at the end of the year. The health effects that
are due to one year of risk exposure would then be traced out in terms of changes in future
health expectancies or future burden.
· The change in a summary measure from the appplication of an intervention can be assessed.
More generally, Murray and Lopez (1999) have developed a classification of various counterfactual
risk distributions that can be used for these purposes, including the theoretical minimum risk, the
plausible minimum risk, the feasible minimum risk and the cost-effective minimum risk. They used
the examples of tobacco and alcohol to explore the implications of using these different types of
counterfactual distributions to define attributable burden and avoidable burden.
Chapter 8
34. Wolfson (1998) has outlined a vision of a coherent and integrated statistical framework, with
summary measures of population health status at the apex of a hierarchy of related measures. Such a
system should include the capability to ‘drill down’ below the summary measure to component parts
such as incidence rates, prevalence rates, severity distributions, case fatality rates, etc. It should also
allow us to ‘drill down’ below whole of population level to examine inequalities in health and to
estimate the impacts of a given intervention on various sub-groups.
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Appendix B YLD worksheet example:
Dementia
Appendices B and C give two examples of YLD worksheets. This appendix contains the worksheet
for dementia. Appendix C contains the woksheet for stroke. These worksheets are provided to give
the reader a better understanding of the data and methods used to estimate YLD for each disease
and injury. Readers interested in obtaining other worksheets should contact the Australian Institute
of Health and Welfare (contact details on page iv).
YLD worksheet: Dementia
REGION: Australia
Code: K1
1. Case definition and sequelae
Disease category Sequelae Definition
Dementia Mild Significant impairment of daily activities only
Moderate Independent living is not possible without limited supervision
Severe Permanent supervision required
2. Disease weights
Sequelae Weight Comment
Mild 0.270 Dutch weight
Moderate 0.630 Dutch weight
Severe 0.940 Dutch weight
3. Mortality data for Alzheimer’s disease and other dementias
0–4 5–14 15–24 25–34 35–44 45–54 55–64 65–74 75+ Total
Number of deaths
   Males 5 4 0 1 0 2 20 158 1,114 1,305
   Females 3 2 1 2 1 3 22 142 2,416 2,593
Deaths per 100,000
   Males 0.8 0.3 0.0 0.1 0.0 0.2 2.6 25.8 322.3 14.3
   Females 0.5 0.2 0.1 0.1 0.1 0.3 2.9 20.8 430.0 28.3
4. Over 100 studies have been reported from throughout the world to estimate the prevalence of
dementia in general population samples, including Australian studies (see Henderson & Jorm 1998).
There have now been three age-specific prevalence meta-analyses. Jorm et al. (1987) used data from
22 studies from throughout the world and found a consistent trend for prevalence to double with
every 5.1 years of age. The exponential rise was somewhat steeper for Alzheimer’s disease (doubling
every 4.5 years of age) than for vascular dementia (doubling every 5.3 years of age). Hofman et al.
(1991) pooled data from 12 European studies carried out between 1980 and 1990. This meta-analysis
differed from the one by Jorm et al. (1987) in that it excluded non-European and older studies.
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Nevertheless, as shown in Table 1, the estimated prevalence rates are strikingly similar to the ones
derived from the earlier meta-analysis.
The third meta-analysis, Ritchie et al. (1992), used data from the 3 studies which had been carried out
since 1980 and which used DSM-III diagnostic criteria for dementia. By restricting the studies to
those that used the same diagnostic criteria, the authors found much less variability in the prevalence
rates in the upper age ranges than had the other two meta-analyses. However, the number of studies
included was only small. The estimated prevalence rates from Ritchie et. al. (1992) are also shown in
the following table.
Prevalence rates of dementia from age-specific prevalence meta-analyses
Age groups
Prevalence rates from
Jorm et al. (1987)
Prevalence rates from
Hofman et al. (1991)
Prevalence rates from
Ritchie et al. (1992)
60–65 0.7 1 0.9
65–69 1.4 1.4 1.6
70–74 2.8 4.1 2.8
75–79 5.6 5.7 4.9
80–84 11.1 13 8.7
85+ 23.6 24.5 16.4
Source: Henderson & Jorm 1998
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(Schoenberg et al. 1981 quoted in Henderson & Jorm 1998). This study found that people with
dementia had a poorer survival rate than others of the same age and sex and that the relative risk of
mortality is greater for earlier onset cases. From the survival data quoted in Henderson and Jorm
(1998), we estimate that the mortality relative risk (RR) is 1.6 for 5-year mortality after medical
diagnosis and 1.8 for 10-year mortality after medical diagnosis. We use RR of 1.8 for ages up to 75
and 1.6 for ages 75+ in DISMOD to estimate incidence and duration of dementia.
7. Dementia is rare below the age of 60. Nevertheless, this younger group is an important one to
consider because they have somewhat different service needs. While the prevalence of dementia in
older people is best estimated by community surveys, this method is not suitable for rare disorders
because of the very large sample that would be required. For younger people, we must rely on
counting cases which have come to medical attention. No studies of the prevalence of dementia in
5. We will use the Jorm et al. (1987)
prevalence rates to estimate the
prevalence and incidence of dementia
cases in Australia. These rates have
been used to produce previous Aust-
ralian estimates (Jorm & Henderson
1990, 1993) and are very close to those
of Hofman et al. (1991). DISMOD is
used to estimate incidence rates
consistent with these prevalence rates.
6. Rather than use case fatality rates
chosen to match observed dementia
deaths (because dementia cases may
have higher relative risk of mortality
from general causes), we have used
survival data from a medical case
register for the US city of Rochester
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younger persons have been carried out in Australia, so we must rely on overseas data. Henderson
and Jorm (1998) quote prevalence rates for dementia below age 60 from a medical case register in
Rochester in the United States (Kokmen et al. 1989). These are used to estimate approximate
incidence rates in DISMOD assuming mortality RR 1.6.
8. Disability weights are derived from two Dutch studies; Barendregt and Bonneux (1998) give the
prevalence of minimal (13.8%), mild (41.3%), moderate (30.0%) and severe dementia (15.0%) based
on the Clinical Dementia Rating scores amongst people over 55 in a community-based, prospective
study of degenerative diseases. At the Erasmus University in Rotterdam, new disability weights
were generated using the person trade-off method of the Global Burden of Disease study with a
description in EuroQol terms of each disability (Stouthard et al. 1997). Separate disability weights are
given for mild dementia (only significant impairment of daily activities): 0.27; moderate dementia
(independent living is not possible without limited supervision): 0.63; and severe dementia
(permanent supervision required): 0.94. Because the prevalence meta-analysis did not include
‘minimal severity’ dementia, we use the relative prevalence of mild, moderate and severe dementia
from Barendregt and Bonneux (1998) to calculate an ‘average’ disability weight.
9. Combining the prevalence figures with the above disability weights gives an average disability
weight of:
0.479 * 0.27 + 0.348 * 0.63 + 0.174 * 0.94 = 0.512
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Jorm and Jolley included studies with a variety of diagnostic criteria in their analysis. Those that
used DSM-III criteria had somewhat lower incidence rates, but Jorm and Jolley did not give separate
incidence estimates based on these in their paper. We base the YLD estimates below on the incidence
rates derived from the prevalence meta-analysis of Jorm et al. (1987).
10. Jorm and Jolley (1998) have carried out
a meta-analysis of incidence of dementia.
These are based on much fewer studies
than the prevalence meta-analyses.
Estimated incidence rates for mild+
dementia in Europe are substantially
higher than those estimated here from the
prevalence studies. If the same mortality
RR is assumed in DISMOD as above, the
prevalence rates resulting from the Eur-
opean incidence rates for mild+ dementia
reach 505 at age 85+. If the mortality RR is
varied to achieve consistency between the
incidence and prevalence rates from meta-
analyses, the average survival with
dementia has to drop to under 2 years.
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Calculation of YLD for Australia 1996
Undiscounted
Australia
Population
(’00,000) Incidence
Incidence
per
100,000
Age at
onset Duration
Disability
weight YLDs
YLD per
100,000 YLDs
YLD per
100,000
Males
0 –4 6.66 0 0 2.5 0.0 0.512 0 0 0
5 –14 13.39 0 0 10 0.0 0.512 0 0 0
15 –24 13.64 0 0 20 0.0 0.512 0 0 0
25 –34 14.31 0 0 30 0.0 0.512 0 0 0
35 –44 14.03 0 0 40 0.0 0.512 0 0 0
45 –54 11.72 117 10 50 23.7 0.512 1,017 87 1,421
55 –64 7.74 665 86 59.9 14.5 0.512 4,002 517 4,936
65 –74 6.14 1,828 298 69.8 9.2 0.512 7,520 1,226 8,606
75+ 3.46 6,918 2,001 80.7 3.8 0.512 12,712 3,677 13,450
All ages 91.08 9,529 105 76.8 5.8 0.51 25,251 277 28,412 311.9
Females
0 –4 6.31 0 0 2.5 0.0 0.512 0 0 0
5 –14 12.75 0 0 10 0.0 0.512 0 0 0
15 –24 13.12 0 0 20 0.0 0.512 0 0 0
25 –34 14.31 0 0 30 0.0 0.512 0 0 0
35 –44 14.08 0 0 40 0.0 0.512 0 0 0
45 –54 11.37 114 10 50 28.3 0.512 1,109 98 1,646
55 –64 7.64 657 86 60 18.4 0.512 4,754 622 6,187
65 –74 6.82 2,052 301 69.9 11.9 0.512 10,506 1,541 12,493
75+ 5.62 11,482 2,043 81.3 4.3 0.512 23,470 4,176 25,000
All ages 92.03 14,305 155 78.4 6.2 0.51 39,840 433 45,326 492.5
Comparison with the Global Burden of Disease estimates
Incidence per 100,000 Average duration
GBD Australia GBD Australia
Males
0 –4 5.5 0 29.5 0.0
5 –14 0.9 0 40.1 0.0
15 –44 0.9 0 31.7 0.0
45 –59 40.6 29 18.4 14.5
60+ 553.5 674 6.4 9.3
All ages 93.6 105 7.5 5.8
Females
0 –4 5.5 0 31 0.0
5 –14 0.9 0 42.5 0.0
15 –44 0.9 0 34.4 0.0
45 –59 40.6 29 21.3 18.4
60+ 665.2 853 7.3 10.8
All ages 120.2 155 8.1 6.2
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Comparison with EME and Mauritius
YLD* per 100,000 Males Females Persons YLD/DALY (%) DALY/100,000
Australia 166.6 244.2 Australia 73 485.9
Mauritius 64.0 93.1 Mauritius 96 81.4
EME 236.9 370.0 EME 85 359.6
*Age-weighted and discounted YLD and DALYs.
Uncertainty analysis
The main sources of uncertainty in YLD estimates for dementia arise from uncertainties in the
prevalence rates, the disability weights and the severity distribution of dementia. Although there are
uncertainties in the mortality relative risk assumptions used to derive incidence rates from
prevalence rates using DISMOD, the YLD uncertainty is essentially dependent on the prevalence
uncertainty and we based the combined uncertainty of incidence and duration on the relative
uncertainty in prevalence rates.
Although Jorm et al. (1987) derived confidence intervals for their prevalence meta-analysis estimates,
we have compared their prevalence estimates with those of Hofman et al. (1991), which are around
15–20% higher at some ages,  and those of Ritchie et al. (1992), which are around 20% lower at most
ages. We modelled the uncertainty in the prevalence rates at each age using a triangular distribution
with most probably value centred on the prevalence rate estimates of Jorm et al. and upper and
lower limits 30% greater and lower respectively.
Stouthard et al. (1997) provided 95% confidence intervals for the disability weights for mild
moderate and severe dementia. We assume that the uncertainty in these weights is normally
distributed with means and standard deviations as follows:
Dementia severity Disability weight
95% confidence
interval
Estimated standard
error
Mild 0.270 (0.129; 0.418) 0.0737
Moderate 0.630 (0.414; 0.856) 0.1128
Severe 0.940 (0.927; 0.954) 0.0069
There is also uncertainty in the assumed distribution of mild, moderate and severe dementia. This is
based on the  Clinical Dementia Rating scores amongst people over 55 in a community-based,
prospective Dutch study (Barendregt & Bonneux 1998). We assume that the severity distribution in
Australia is similar to that in the Netherlands and do not model further uncertainty in severity
beyond that resulting from the uncertainty in the disability weights above.
Using these assumed distributions of uncertainty in prevalence rates and disability weights, we used
@RISK (see Section 2.10) to carry out Latin hypercube sampling using 2000 iterations to estimate the
uncertainty in the YLD estimates for males and females. Results are shown in the following Table.
The relative standard errors of the YLD estimates for dementia are 13% for males and for females,
and 12% for both sexes combined.
Sex Total YLD
95% confidence
interval
Estimated relative
standard error (%)
Males 25,251 (20,190; 30,870) 13
Females 39,840 (31,550; 48,730) 13
Total 65,091 (52,760; 77,830) 12
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Appendix C YLD worksheet example:
Stroke
YLD worksheet: Stroke
REGION: Australia
Code: L3
1. Case definition and sequlae
Disease category Sequelae Definition
First-ever stroke with full
recovery
First-ever stroke, no long-term disability after 6 months
Mild permanent impairments No mobility or self-care problems, some problems usual
activities, pain, anxiety/depression.
Moderate permanent
impairments
Some mobility and self-care problems, some problems usual
activities, pain, anxiety/depression.
Stroke
Severe permanent
impairments
Some problems walking about, severe problems self-care,
usual activities, pain, anxiety/depression.
2. Disease weights
Sequelae Weight Comment
First-ever stroke with full recovery 0.000
Mild permanent impairments 0.360 Dutch weight
Moderate permanent impairments 0.630 Dutch weight
Severe permanent impairments 0.920 Dutch weight
3. Incidence of first-ever stroke is derived from public and private hospital data for Australia 1996 on
hospitalised cases of stroke (ICD-9 codes 430–434, 436–437 in principal diagnosis field). The ad-
missions data excludes people who died during the hospital episode. Admission data are based on
counting people rather than admission episodes—we assume readmissions of the same person with a
stroke diagnosis within the year refer to the same stroke.
About one-quarter—22% (Perth); 28% (Auckland)—of non fatal strokes are managed outside the
hospital system. (Bonita et al. 1994). It is likely that more strokes in those aged 75 years and over are
cared for outside hospitals (particularly in nursing homes). Assuming that an arbitrary 44% of
strokes in the 75+ age group did not come to hospital, the 75+ rate has been increased by a factor of
44%. Stroke incidence in other age groups has been increased by 17% in males and 9% in females to
maintain an aggregate of 22% of strokes in all ages cared for outside hospitals.
Nearly three-quarters—69% (Perth); 73%(Auckland)—of recorded strokes are first ever strokes.
(Bonita et al. 1994). Estimated first-ever non-fatal strokes in 1996 are calculated by applying the
inflation factors for strokes managed outside hospitals, then taking 69% of these (proportion first-
ever). Rates are shown in the fifth and sixth columns in the next table. These are first-ever strokes not
resulting in death prior to or during hospitalisation.
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Estimated incidence of non-fatal first-ever stroke in Australia 1996 based on admissions data
Admissions Admissions/100,000       Incidence stroke/100,000
1996–97 1996–97 1996–97 1996–97       First-ever non-fatal
Male Female Male Female Male Female
0–4 32 23 5 4 4 3
5–14 28 24 2 2 2 1
15–24 74 59 5 4 4 3
25–34 155 150 11 10 9 8
35–44 336 340 24 24 19 18
45–54 971 655 83 58 67 43
55–64 2,177 1,249 281 163 227 123
65–74 4,859 2,954 792 433 639 326
75+ 5,069 6,101 1,466 1,086 1,457 1,079
Total 13,701 11,555
Of incident stroke cases, 4. 24% die within 28 days (Anderson et al. 1994, Bonita et al. 1994). Higher
case fatality rates were reported at 29% in cases >75years compared to 18% in cases <75 years.
(Bonita et al. 1994). Stroke mortality rates during the 1990s in Australia have been declining at
around 5% per annum below age 75 and around 2-3% per annum for ages 75 and over (Mathur &
Gajanayake 1998). It is estimated that around 50% of this decline is attributable to declining incidence
and around 50% to decreasing case fatality. Assuming fatality rates in Australia in 1990 were similar
to those in Perth, we reduce the Perth case fatality rates to reflect half the declines in Australian
stroke mortality between 1990 and 1996. Case fatality rates were reported at 22% in males and 26%
females. (Bonita et al. 1994).
The relative gender differences have been retained in both age groups:
Case fatality rates Under 75 Over 75 Total
Perth 1989–90 18% 29% 24%
% decline between 1990 and 1996 14% 9%
Extrapolated 1996 15% 27%
Perth 1989–90 All ages Extrapolated 1996 Under 75 Over 75
Male 22% Male 14% 24%
Female 26% Female 17% 29%
Total 24% Total 15% 27%
5. The hospital inpatient figures exclude those dying during admission. The Perth figures relate to all
strokes. Assuming that most deaths in the first 28 days occur while hospitalised, the number of
deaths in the first 28 days can be extrapolated from the recorded survivors of first stroke, for
instance, in the <75 age group, where the case fatality rate = 15%, we equate hospital episodes to 85%
of incident strokes. Thus the adjusted number of early deaths = 100/85*15% of recorded survivors of
first strokes. The proportional factors for each age and sex group have been determined as follows:
Proportional factor Under 75 Over 75
Male 17% 32%
Female 20% 40%
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Method 1: Total incidence/100,000 of first-ever stroke 1996
Age group Factor Males Factor Females
0–4 17% 5 20% 3
5–14 17% 2 20% 2
15–24 17% 5 20% 4
25–34 17% 10 20% 9
35–44 17% 23 20% 22
45–54 17% 78 20% 52
55–64 17% 265 20% 148
65–74 17% 745 20% 392
75+ 32% 1,924 40% 1,513
Total 162 146
6. As a check on these estimates, a second approach has also been used. This starts with estimates of
incidence from the only comprehensive population-based Australian study of stroke incidence
(Anderson et al 1993) for a part of North and East Perth in 1989–90. A recent paper (Simons et al.
1998) gives estimates of stroke incidence in the Dubbo population. However, the initial study
population excluded institutionalised older people, so the rates are not representative of the entire
population. Incidence rates in the Table below are for the Perth study population. These have been
adjusted downwards by half the average annual decline in mortality rates to estimate incidence rates
for 1996.
Annual incidence first-ever stroke, Perth WA, 1989–90 (Anderson et al. 1993)
  Incidence/100,000 Annual decline Total decline 1990–1996 Incidence/100,000
Male Female Male Female Male Female Male Female
0–14 0 6 –0.075 –0.041 0.20 0.12 0 5
15–24 11 10 –0.075 –0.041 0.20 0.12 9 9
25–34 5 17 –0.044 –0.069 0.12 0.19 4 14
35–44 45 22 –0.032 –0.060 0.09 0.17 41 18
45–54 110 77 –0.057 –0.056 0.16 0.16 92 65
55–64 351 98 –0.055 –0.070 0.15 0.19 297 79
65–74 807 447 –0.050 –0.055 0.14 0.15 693 378
75–84 1,905 1,244 –0.027 –0.034 0.08 0.10 1,756 1,122
85+ 3,010 2,161 –0.017 –0.023 0.05 0.07 2,860 2,016
The following table and figure compare the incidence estimates based on hospital data for 1996 with
the estimates based directly on the Perth incidence data.
Annual incidence rate, first ever stroke Australia, 1996
Method 1 Method 2
Age Group Male Female Male Female
0–4 5 3 0 5
5–14 2 2 0 5
15–24 5 4 9 9
25–34 10 9 4 14
35–44 23 22 41 18
45–54 78 52 92 65
55–64 265 148 297 79
65–74 745 392 693 378
75+ 1,924 1,513 1,948 1,348
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7. The graph below compares incidence rates for first-ever stroke calculated from the 1996
hospitalisation data (series 1) with the incidence rates calculated by direct extrapolation of those
observed in Perth in 1990 (series 2). The two sets of rates are almost identical for males (the inflation
factor of 44% at step 3 above was chosen to give a good match for all ages). Use of the same factor for
females gives a slightly higher incidence rate in age group 75+ based on the hospitalisation data (but
it was decided to keep the same factor for both sexes).
The resulting incidence rates for stroke 28-day survivors is shown on the right-hand side:
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8. For modelling of stroke survivors past the first 28 days we need to know the number of deaths. As
only 58% of deaths in stroke cases are attributed to stroke (Anderson et al. 1994), we have multiplied
recorded stroke deaths by 100/58. Next we deducted the modelled 28-day deaths (Note 5) from the
extrapolated ABS deaths to obtain number of deaths in the stroke survivors. DISMOD was then used
to model duration of survival for stroke survivors who did not die in the first 28 days (from
estimated incidence rate and death rate). DISMOD only models up to age 90 and therefore we have
included only deaths deaths between 75 and 89 in the 75+ age group.
Recorded deaths
stroke
Total deaths—in
people with stroke
Deaths from
stroke in 28
days
Deaths in 28-day
survivors
Probability of dying—
general population
Expected deaths
stroke survivors(a)
Male Female Male Female Male Female Male Female Male Female Male Female
0–4 1 0 2 0 4 3 0 0 0.0013 0.0010 0 0
5–14 2 3 3 5 4 4 0 2 0.0002 0.0001 0 0
15–24 8 5 14 9 10 9 4 0 0.0009 0.0003 0 0
25–34 20 14 34 25 21 23 13 2 0.0011 0.0004 0 0
35–44 64 42 110 73 45 52 65 21 0.0016 0.0008 0 0
45–54 158 119 272 206 130 99 142 106 0.0030 0.0020 2 1
55–64 323 215 557 371 291 189 266 182 0.0097 0.0054 17 5
65–74 1,113 863 1,919 1,487 649 448 1,270 1,039 0.0280 0.0148 110 33
75–89 3,022 4,627 5,210 7,978 1,616 2,442 3,594 5,536 0.0940 0.0729 474 442
Total 5,216 7,623 8,993 13,144 2,770 3,269 5,354 6,888 603 481
(a) Excluding stroke attributable deaths
Incidence survivors/100,000
Final estimate
Age
group Male Female
0-4 4 3
5–14 2 1
15–24 4 3
25–34 9 8
35–44 19 18
45–54 67 43
55–64 227 123
65–74 639 326
75+ 1,457 1,079
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DISMOD estimates of prevalence and duration for 28-day stroke survivors
Incidence/100,000
Stroke attributable
deaths/100,000 Prevalence/100,000 Duration (years) Prevalent cases
Age
group Male Female Male Female Male Female Male Female Male Female
0–4 4 3 0.0 0.0 10 7 53.2 60.8 67 44
5–14 2 1 0.0 0.1 30 20 46.1 53.8 402 255
15–24 4 3 0.3 0.0 58 40 37.5 43.9 791 525
25–34 9 8 0.9 0.1 117 94 30.3 34.4 1,674 1,345
35–44 19 18 4.6 1.5 231 216 24.4 25.9 3,240 3,042
45–54 67 43 11.9 9.3 587 472 19.3 19.0 6,878 5,367
55–64 227 123 32.1 23.1 1,831 1,156 13.5 12.7 14,166 8,834
65–74 639 326 189.0 147.6 5,079 2,625 8.3 6.8 31,162 17,896
75+ 1,457 1,100 902.5 906.4 11,128 4,712 4.4 3.2 38,475 26,481
Total 96,856 63,790
These durations are reasonably consistent with observed 1-year case fatality rates—38% for Perth in
1990 (Anderson et al. 1993). As 23% died within one month, the average case fatality rate for the next
11 months was 16%. Assuming that the instantaneous case fatality rates decline further in following
years, this average is reasonably consistent with the average case fatality rates derived using
DISMOD (around 10% for 65–74 years and 20% for 75 years and over).
9. The 1995 ABS National Health Survey provides self-report data on the prevalence (chronic or
recent) of stroke including stroke after-effects (condition code 119). The reported prevalence per
1,000 is shown at the top of the next page (left). There were 110,507 persons with prevalent stroke or
stroke-after effects in 1995 according to this survey. The prevalence of 28-day stroke survivors
estimated at Step 8 corresponds to a total of 121,000 persons in 1996, quite consistent with the self-
report data.
The 1993 Disability Survey gives an estimate of 39,200 people where stroke was the main cause of
their disability (see table at the top of the next page to right). This is reasonably consistent with the
NHS estimate, since many old people with mild disability resulting from stroke and with
comorbidities will not report stroke as their main cause of disability. Of these, 21,000 have profound
handicap (always requiring assistance for mobility, self-care or communication tasks), and 9,300 have
severe or moderate handicap (sometimes requiring assistance or problems with self-care but not
requiring assistance). There are three disease weights corresponding to different levels of permanent
impairment (mild, moderate, severe) developed in the Netherlands study (Stouthard et al. 1997).
Assuming that profound handicap corresponds to severe permanent impairments, and severe or
moderate handicap corresponds to moderate permanent impairments, mild impairment prevalence
can be calculated by subtracting the severe and moderate estimates from the total prevalence of
survivors with permanent impairments.
Men are more likely to make a complete recovery from stroke (50%) than women (37%) (Bonita et al.
Stroke 1997). Among stroke survivors, more women are dependent (27%) than men (16%) on others
for self-care. We assumed that half the male incident cases and 37% of women experience mild
disability for 6 months and the other half experience permanent impairments. The prevalence of
survivors with permanent impairments was calculated from the total DISMOD prevalence of
survivors by multiplying it by 50% for men and 63% for women.
An average disability weight for the permanently impaired survivors is calculated as the prevalence-
weighted sum of the three disability weights for mild, moderate and severe impairments.
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1995 National Health Survey 1993 Disability Survey: prevalence per 1,000
     Prevalence per 1,000 Profound h'cap Sev/mod h'cap Total disabled
Male Female Male Female Male Female Male Female
0–4 0 0
5–14 0 0 0–54 0.0 0.0 0.0 0.1 0.2 0.2
15–24 0 0 55–64 1.4 1.2 2.0 0.0 3.7 1.2
25–34 0 0 65–74 2.8 5.2 5.8 1.5 13.4 8.8
35–44 0 0 75+ 15.1 18.9 3.6 3.7 22.5 23.9
45–54 1 2 Total 0.9 1.6 0.7 0.4 2.1 2.3
55–64 17 7
65–74 35 12
75+ 52 50
Total 4.5 4.6
DISMOD estimates of total stroke survivor
prevalence per 1,000
Mild balance (DISMOD
prev- prof/sev/mod)
Average
disability weights
Age group Male Female Male Female Male Female
0–4 0.1 0.1 0.0 0.0 0.360 0.360
5–14 0.3 0.2 0.1 0.0 0.360 0.360
15–24 0.5 0.3 0.2 0.1 0.360 0.360
25–34 1.0 0.8 0.5 0.4 0.360 0.360
35–44 1.9 1.8 0.9 1.0 0.360 0.360
45–54 4.9 3.7 2.4 2.2 0.366 0.373
55–64 15.4 9.1 7.7 5.6 0.481 0.455
65–74 41.7 17.1 20.8 10.7 0.467 0.551
75+ 53.6 48.1 26.8 30.2 0.567 0.579
Total number 67,021 54,243
10. YLD for those who die within 28 days
Use average length of stay for those who die in hospital as estimate of duration. Use disability
weight for severe permanent impairments.
Population
(’00,000) Incidence
Incidence
per 100,000
Age at
onset Duration
Disability
weight YLDs
YLD per
100,000
Undiscounted
YLDs  (r=0)
Males
0–4 6.66 28 4 2.5 0.00 0.920 0.0 0.0 0.0
5–14 13.39 50 4 10.0 0.00 0.920 0.0 0.0 0.0
15–24 13.64 135 10 20.0 0.00 0.920 0.4 0.0 0.4
25–34 14.31 296 21 30.0 0.01 0.920 1.5 0.1 1.5
35–44 14.03 630 45 40.0 0.01 0.920 5.3 0.4 5.3
45–54 11.72 1,520 130 50.0 0.01 0.920 14.8 1.3 14.8
55–64 7.74 2,251 291 59.9 0.02 0.920 31.6 4.1 31.7
65–74 6.14 3,984 649 69.8 0.02 0.920 62.4 10.2 62.5
75+ 3.46 5,588 1616 80.7 0.02 0.920 110.1 31.8 110.2
All ages 91.08 14,483 159 67.5 0.02 0.920 226.3 2.5 226.3
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10. YLD for those who die within 28 days (continued)
Population
(’00,000) Incidence
Incidence
per 100,000
Age at
onset Duration
Disability
weight YLDs
YLD per
100,000
Undiscounted
YLDs  (r=0)
Females
0–4 6.31 22 3 2.5 0.00 0.920 0.0 0.0 0.0
5–14 12.75 46 4 10.0 0.00 0.920 0.1 0.0 0.1
15–24 13.12 117 9 20.0 0.00 0.920 0.0 0.0 0.0
25–34 14.31 326 23 30.0 0.00 0.920 0.8 0.1 0.8
35–44 14.08 726 52 40.0 0.01 0.920 5.2 0.4 5.2
45–54 11.37 1,130 99 50.0 0.01 0.920 14.4 1.3 14.4
55–64 7.64 1,448 189 60.0 0.02 0.920 20.7 2.7 20.7
65–74 6.82 3,055 448 69.9 0.01 0.920 40.7 6.0 40.7
75+ 5.62 13,722 2442 81.3 0.02 0.920 234.1 41.7 234.1
All ages 92.03 20,592 224 73.5 0.02 0.920 316.1 3.4 316.2
11. YLD for survivors who recover completely
Men are more likely to make a complete recovery from stroke (50%) than women(37%). (Bonita in
Stroke 1997). Among stroke survivors, more women are dependent (27%) than men (16%), on others
for self care. We assumed that half the male incident cases and 37% of women, experience mild
disability for 6 months.
Population
(’00,000) Incidence
Incidence
per 100,000
Age at
onset Duration
Disability
weight YLDs
YLD per
100,000
Undiscounted
YLDs  (r=0)
Males
0–4 6.66 13 2 2.5 0.50 0.360 2.3 0.3 2.3
5–14 13.39 11 1 10.0 0.50 0.360 2.0 0.2 2.0
15–24 13.64 30 2 20.0 0.50 0.360 5.3 0.4 5.4
25–34 14.31 63 4 30.0 0.50 0.360 11.2 0.8 11.3
35–44 14.03 136 10 40.0 0.50 0.360 24.2 1.7 24.4
45–54 11.72 392 33 50.0 0.50 0.360 70.0 6.0 70.5
55–64 7.74 879 114 59.9 0.50 0.360 157.0 20.3 158.2
65–74 6.14 1,961 320 69.8 0.50 0.360 350.4 57.1 353.0
75+ 3.46 2,518 728 80.7 0.50 0.360 449.9 130.1 453.3
All ages 91.08 6,003 66 70.0 0.5 0.360 1072 11.8 1,080.5
Females
0–4 6.31 9 1 2.5 0.50 0.360 1.5 0.2 1.6
5–14 12.75 9 1 10.0 0.50 0.360 1.6 0.1 1.6
15–24 13.12 22 2 20.0 0.50 0.360 4.0 0.3 4.0
25–34 14.31 56 4 30.0 0.50 0.360 10.1 0.7 10.2
35–44 14.08 128 9 40.0 0.50 0.360 22.8 1.6 23.0
45–54 11.37 246 22 50.0 0.50 0.360 44.0 3.9 44.3
55–64 7.64 470 61 60.0 0.50 0.360 83.9 11.0 84.5
65–74 6.82 1,111 163 69.9 0.50 0.360 198.5 29.1 200.0
75+ 5.62 3,031 539 81.3 0.50 0.360 541.5 96.4 545.6
All ages 92.03 5,082 55 73.2 0.5 0.360 907.9 9.9 914.8
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12. YLD for those who survive 28 days and have permanent disability
Use duration modelled with DISMOD at step 8 above (assuming average duration same for those
who remit and those who have permanent disability).
Population
(’00,000) Incidence
Incidence
per 100,000
Age at
onset Duration
Disability
weight YLDs
YLD per
100,000
Undiscounted
YLDs  (r=0)
Males
0–4 6.66 13 2 2.5 53.2 0.360 123 18.6 247
5–14 13.39 11 1 10.0 46.1 0.360 101 7.6 188
15–24 13.64 30 2 20.0 37.5 0.360 242 17.7 403
25–34 14.31 63 4 30.0 30.3 0.360 448 31.3 682
35–44 14.03 136 10 40.0 24.4 0.360 844 60.2 1,191
45–54 11.72 392 33 50.0 19.3 0.366 2,104 179.6 2,772
55–64 7.74 879 114 59.9 13.5 0.481 4,689 606.1 5,703
65–74 6.14 1,961 320 69.8 8.3 0.467 6,726 1,096.2 7,598
75+ 3.46 2,518 728 80.7 4.4 0.567 5,888 1,703.1 6,286
All ages 91.08 6,003 66 70.0 9.0 0.500 21,169 232.4 25,071
Females
0–4 6.31 9 1 2.5 60.8 0.360 87 13.8 189
5–14 12.75 9 1 10.0 53.8 0.360 86 6.8 175
15–24 13.12 22 2 20.0 43.9 0.360 194 14.9 351
25–34 14.31 56 4 30.0 34.4 0.360 435 30.4 699
35–44 14.08 128 9 40.0 25.9 0.360 829 58.9 1,192
45–54 11.37 246 22 50.0 19.0 0.373 1,329 116.9 1,743
55–64 7.64 470 61 60.0 12.7 0.455 2,257 295.3 2,714
65–74 6.82 1,111 163 69.9 6.8 0.551 3,788 555.7 4,190
75+ 5.62 3,031 539 81.3 3.2 0.579 5,357 953.2 5,618
All ages 92.03 5,082 55 73.2 6.9 0.540 14,364 156.1 16,871
14. Total YLD for Stroke
Population
(’00,000) Incidence
Incidence
per 100,000
Age at
onset Duration
Disability
weight YLDs
YLD per
100,000
Undiscounted
YLDs  (r=0)
Males
0–4 6.66 54 8 2.5 — 0.171 126 0.3 250
5–14 13.39 73 5 10.0 — 0.112 104 0.2 190
15–24 13.64 195 14 20.0 — 0.110 248 0.6 409
25–34 14.31 422 29 30.0 — 0.107 461 0.8 695
35–44 14.03 901 64 40.0 — 0.108 874 63.6 1,221
45–54 11.72 2,304 197 50.0 — 0.124 2,189 207.8 2,858
55–64 7.74 4,008 518 59.9 — 0.184 4,878 689.8 5,893
65–74 6.14 7,906 1,289 69.8 — 0.205 7,139 1328.8 8,014
75+ 3.46 10,625 3,073 80.7 — 0.220 6,449 2100.9 6,849
All ages 91.08 26,488 291 68.6 — 0.190 22,467 271.3 26,378
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Population
(’00,000) Incidence
Incidence
per 100,000
Age at
onset Duration
Disability
weight YLDs
YLD per
100,000
Undiscounted
YLDs  (r=0)
Females
0–4 6.31 39 6 2.5 — 0.158 89 0.0 191
5–14 12.75 64 5 10.0 — 0.101 88 0.1 177
15–24 13.12 162 12 20.0 — 0.099 199 0.2 355
25–34 14.31 438 31 30.0 — 0.093 447 43.8 710
35–44 14.08 982 70 40.0 — 0.094 857 90.9 1,220
45–54 11.37 1,622 143 50.0 — 0.111 1,387 180.4 1,802
55–64 7.64 2,387 312 60.0 — 0.160 2,362 430.5 2,819
65–74 6.82 5,277 774 69.9 — 0.192 4,027 970.1 4,431
75+ 5.62 19,784 3,520 81.3 — 0.144 6,132 2,120.0 6,398
All ages 92.03 30,756 334 73.4 — 0.150 15588 288.9 18,102
Comparison with the Global Burden of Disease estimates for EME: stroke
         Incidence per 100,000 Average duration
GBD Australia GBD Australia
Males
0 –4 1.1 8 0 26.9
5 –14 0.3 5 0.0 23.3
15 –44 20 36 27.5 15.7
45 –59 119 276 14.5 9.3
60+ 767 859 5.6 4.9
All ages 149 291 8.2 5.7
Females
0 –4 0.8 6 0 30.7
5 –14 0.2 5 0 27.2
15 –44 16 38 31.5 17.6
45 –59 102 185 17.3 9.1
60+ 712 530 5.1 4.4
All ages 172 334 7.4 4.2
Comparison with EME and Mauritius
YLD* per 100,000 Males Females Persons YLD/DALY (%) DALY/100,000
Australia 174.7 118.1 Australia 34% 435
Mauritius 134.4 98.4 Mauritius 14% 857
EME 199.5 190.7 EME 31% 624
*Age-weighted and discounted YLD and DALYs.
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Annex Table A: Disease and injury categories and ICD-9 codes
Code      Disease category ICD-9 codes
I  Communicable diseases, maternal and neonatal
conditions
001–139, 260–269, 280–281, 320–322, 381–382,
460–466, 480–487, 614–616, 630–676, 760–779
A. Infectious & parasitic diseases 001–139, 320–322, 323.1, 614–616, 771.0, 771.3
 1. Tuberculosis 010–018, 137
2. Sexually transmitted diseases
(apart from HIV/AIDS) 090–099, 614–616
a. Syphilis 090–097
b. Chlamydia 614–616
(a)
c. Gonorrhoea 098
d. Other STDs
(a)
3. HIV/AIDS 042–044, 875+AIDS flag
(b)
4. Intestinal infectious diseases 001–009
5. Childhood immunisable diseases 032, 033, 037, 045, 055, 056, 138, 771.0, 771.3
a. Diphtheria 032
b. Whooping cough 033
c. Tetanus 037, 771.3
d. Polio 045, 138
e. Measles 046.2, 055, 323.1
f. Rubella 056, 771.0
g. Haemophilus influenzae type b (Hib)
(c)
6. Meningitis 036, 320–322
7. Septicaemia 038
8. Arbovirus infection 66.3
9. Hepatitis 070
a. Hepatitis A 070.0–.1
b. Hepatitis B 070.2–.3, 070.6–.9
c. Hepatitis C 070.4–.5
10. Malaria 084
11. Trachoma 076, 139.1
12. Other infectious and parasitic Balance of Category A
B. Acute respiratory infections 460–466, 480–487, 381–382
1. Lower respiratory tract infections(d) 466, 480–487
2. Upper respiratory tract infections(e) 460–465
3. Otitis media 381–382
C. Maternal conditions 630–676
1. Maternal haemorrhage 640–641, 666
2. Maternal septis 670
3. Hypertension in pregnancy 642
4. Obstructed labour 660
5. Abortion 630–639
6. Other maternal conditions Balance of Category C
D. Neonatal causes 760–779 (excluding 771.0 and 771.3)
1. Birth trauma & asphyxia 767–768, 770.1–770.9
2. Low birth weight 764–765, 769
3. Neonatal infections 770.0, 771.1, 771.2, 771.4–.8
4. Other neonatal causes Balance of Category D
E. Nutritional deficiencies 260–269, 280–281
1. Protein-energy malnutrition 260–263
2. Iron-deficiency anaemia 280, 281
3. Other nutritional deficiencies Balance of Category E
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Annex Table A (continued): Disease and injury categories and ICD-9 codes
Code      Disease category ICD-9 codes
I  Non-communicable diseases, maternal and neonatal
conditions
140–259, 270–279, 282–319, 323–380, 383–459, 467–
479, 488–613, 617–629, 680–759
F. Malignant neoplasms 140–209
1. Mouth and oropharynx cancers 140–149
2. Oesophagus cancer 150
3. Stomach cancer 151
4. Colorectal cancer 153–154
5. Liver cancer 155
6. Gall bladder cancer 156
7. Pancreas cancer 157
8. Lung cancer 162
9. Bone and connective tissue cancers 170–171
10. Melanoma 172
11. Non-melanoma skin cancers 173
12. Breast cancer 174
13. Cervix cancer 180
14. Uterus cancer 179, 181–182
15. Ovary cancer 183
16. Prostate cancer 185
17. Testicular cancer 186
18. Bladder cancer 188
19. Kidney cancer(f) 189
20. Brain cancer 191
21. Thyroid cancer 193
22. Lymphoma 200–202
22a. Non-Hodgkin’s lymphoma 200, 202
22b. Hodgkin’s disease 201
23. Multiple myeloma 203
24. Leukemia 204–208
25. Other malignant neoplasms(g) Balance of Category F
G. Other neoplasms 210–239
1. Uterine myomas 218
2. Benign brain tumour 225
3. Other  benign neoplasms Balance of category G
H. Diabetes mellitus 250
1. Type 1 diabetes 250._1
2. Type 2 diabetes 250._0
I. Endocrine and metabolic disorders 240–249, 251–259, 270–279, 282–289
1. Non-deficiency anaemia 282–285
a. Thalassaemia 282.4
b. Other non-deficiency anaemia 282.0–282.3, 282.5–285
2. Cystic  fibrosis 277.0
3. Haemophilia 286.0–286.2
4. Other endocrine and metabolic Balance of Category I
J. Mental disorders 291–319
1. Substance use disorders
a. Alcohol dependence and harmful use 291, 303, 305.0
b. Heroin or polydrug dependence and harmful use 304.0, 304.7, 305.5
c. Benzodiazepine dependence and harmful use 304.1, 305.4
d. Cannabis dependence and harmful use 304.3, 305.2
e. Other drug dependence and harmful use 304.2, 304.4–304.6, 304.8, 304.9, 305.1, 305.3, 305.4,
305.6–305.9
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Annex Table A (continued): Disease and injury categories and ICD-9 codes
Code      Disease category ICD-9 codes
J. Mental disorders (continued)
2. Schizophrenia 295
3. Affective disorders 296, 300.4, 311
a. Depression 296.2, 296.3, 296.9, 300.4, 311
b. Bipolar affective disorder 296.0, 296.1, 296.4–296.8
4. Anxiety disorders
a. Panic disorder 300.01
b. Agoraphobia 300.20–300.22
c. Social phobia 300.23
d. Generalised anxiety disorder 300.02
e. Obsessive-compulsive disorder 300.3
f. Post-traumatic stress disorder 309.81
g. Separation anxiety disorder 309.2
5. Borderline personality disorder 301.83
6. Eating disorders 307.1, 307.5
a. Anorexia nervosa 307.1
b. Bulimia nervosa 307.5
7. Childhood conditions 314.0, 299.0
a. Attention-deficit hyperactivity disorder 314.0
b. Autism and Asperger’s syndrome 299.0
 8. Mental retardation (no defined aetiology) (h) 317–319
9. Other mental disorders Balance of Category J
K. Nervous system and sense organ disorders 290, 323.0, 323.2–380, 383–389
1. Dementia(i) 290, 330–331
2. Epilepsy 345
3. Parkinson’s disease 332
4. Multiple sclerosis 340
5. Motor neuron disease 335.2
6. Huntington’s chorea 333.4
7. Muscular dystrophy 359.1
 8. Sense organ disorders 360–380, 383–389
a. Glaucoma(j) 365
b. Cataracts(j) 366
c. Age-related vision disorders(k) 367
d. Adult-onset hearing loss(l) 389
9. Other nervous system disorders Balance of Category K
L. Cardiovascular disease 390–402, 404–415, 416.1, 417–459
1. Rheumatic heart disease 390–398
2. Ischaemic heart disease(m) 410–414, proportion 427.1+.4+.5, 440.9, 429.0+.2+9, 428
3. Stroke 430–438
4. Inflammatory heart disease(n) 420–422, 425, proportion of 428
5. Hypertensive heart disease 401–402, proportion of 428
6. Non-rheumatic valvular disease 424
7. Aortic aneurysm 441
8. Peripheral arterial disease 440.0–440.8, 442–444
9. Other cardiovascular disease Balance of Category L
M. Chronic respiratory disease 416.0, 416.8+9, 470–478, 490–519
1. Chronic obstructive pulmonary disease(o) 416.0, 416.8+9, 490–492, 495–496
2. Asthma 493
3. Other chronic respiratory diseases Balance of Category M
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Code      Disease category ICD-9 codes
N. Diseases of the digestive system 456, 530–579
1. Peptic ulcer disease 531–533, plus 50% of 578
2. Cirrhosis of the liver 456, 571, 572.2–572.8, plus 50% of 578
3. Appendicitis 540–543
4. Intestinal obstruction 560, 550.0+1,551–552
5. Diverticulitis 562
6. Gall bladder and bile duct disease 574–576
7. Pancreatitis 577
8. Inflammatory bowel disease(p) 555–556
9. Vascular insufficiency of intestine 557
10. Other digestive system diseases Balance of Category N
O. Genitourinary diseases(q) 403, 580–611, 617–629
1. Nephritis and nephrosis(r) 403, 580–586
2. Benign prostatic hypertrophy 600
3. Urinary incontinence(s) 625.6
4. Other genitourinary diseases Balance of Category O
P. Skin diseases 680–709
1. Eczema 691–693
2. Other skin diseases Balance of Category P
Q. Musculoskeletal diseases 710–739
1. Rheumatoid arthritis 714
2. Osteoarthritis 715
3. Chronic back pain 720–721, 724.5–724.9
4. Slipped disc 722,724.3–724.4
5. Occupational overuse syndrome(t) —
6. Osteoporosis(u) 733.0
7. Other musculoskeletal disorders Balance of Category Q
R. Congenital anomalies 740–759
1. Anencephaly 740
2. Spina bifida 741
3. Congenital heart disease 745–747
4. Cleft lip and/or palate 749
5. Digestive system malformations 750–751
a. Anorectal atresia 751.2
b. Oesophageal atresia 750.3
c. Other digestive system malformations Balance of Category R5
6. Urogenital tract malformations 752–753
a. Renal agenesis 753.0
b. Other urogenital tract malformations 752, 753.1–753.9
7. Abdominal wall defect 756.7
8. Down syndrome 758.0
9. Other chromosomal anomalies 758.1–758.9
10. Other congenital anomalies Balance of Category R
S. Oral health 520–529
1. Dental caries 521
2. Periodontal disease 523
3. Edentulism 520, 525.1
4. Other oral health problems
V. Ill-defined conditions(v)
1. Sudden infant death syndrome 798.0
2. Chronic fatigue syndrome 780.7
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Code      Disease category ICD-9 codes
III. Injuries(w) E800–999
T. Unintentional injuries E800–949
1. Road traffic accidents E810–819, 826–829, 929.0
2. Other transport accidents(x) E800–807,820–825,830–848,929.1
3. Poisoning E850–869, 929.2
4. Falls E880–885, 886.9, 887–888, 929.3
5. Fires/burns/scalds E890–899, 924.0, 924.8, 924.9, 929.4
6. Drowning E910
7. Sports injuries(y) E886.0, 917.0, 927
8. Natural and environmental factors E900–909, 929.5
9. Machinery accidents E919, 920.0, 920.1, 920.4
10. Suffocation and foreign bodies E911–915
11. Adverse effects of medical treatment E870–876, E930–949
a. Surgical/medical misadventure E870–876
b. Adverse effects of drugs in therapeutic use E930–949
12. Other unintentional injuries E878–879, 916, 917.1–917.9, 918, 920.2, 920.3, 920.5–
920.9, 921–923, 924.1, 925–926, 928.0–928.8, 929.8
a. Cutting and piercing accidents 920.2–920.3, 920.5–920.9
b. Striking and crushing accidents 916–918 excluding 917.0
c. Other unintentional injuries (z) Balance of category T12.
U. Intentional Injuries 950–979, E990–999
1. Suicide and self-inflicted injuries E950–959
2. Homicide and violence E960–969
3. Legal intervention and war E970–979, 990–999
(a) ICD-9 code not available for chlamydia. Pelvic Inflammatory disease (614–616) is main sequela. 60% of PID attributed to
chlamydia, balance to A2d. Other STDs.
(b) In 1996, for the first time, ABS coded most AIDS deaths to codes 042-044 (HIV infection).  Nine deaths due to ‘contaminated
blood’ (ICD 875) where HIV/AIDS was mentioned on death certificate were also included.  Two additional female deaths with
HIV/AIDS mentioned on death certificate also included for consistency with notified AIDS death.
(c) Hib not specifically identified in ICD-9, but included in codes 320.0 and 464.3.
(d) Includes pneumonia, acute bronchitis, influenza.
(e) Includes common cold, infectious sinusitis, pharyngitis.
(f) Includes non-kidney urinary organs (ICD 189.2–189.9).
(g) In 1996 6.6% of all deaths due to malignant neoplasms were coded to ICD-9 195–199, (malignant neoplasm of other and
unspecified sites including those whose point of origin cannot be determined, secondary and unspecified neoplasm). These have
been distributed pro-rata across all malignant neoplasm categories within each age–sex group, so that category F25 includes
only malignant neoplasms of other specified sites.
(h) Excludes congenital, infectious and injury cases; mental retardation due to these causes are included as sequelae there.
(i) Includes Alzheimer’s disease, senile dementias and other dementia.
(j) Excludes glaucoma and cataracts due to diabetes mellitus (included as sequelae there).
(k) Age-related myopia, presbyopia etc. Excludes congenital vision loss and vision loss sequelae to other diseases or injuries.
(l) Age-related presbyacusis, conduction deafness. Excludes congenital deafness and deafness following otitis media.
(m) The Global Burden of Disease project identified differential coding between ischaemic heart disease (410–414) and these ill-
defined cardiovascular codes.  See page 30 for description of attribution methods.
(n) Cardiomyopathy, myocarditis, endocarditis, pericarditis.
(o) Includes chronic bronchitis and emphysema.
(p) Includes ulcerative colitis and Crohn’s disease.
(q) Excludes acute urinary tract infections.
(r) Excludes diabetic nephropathy and nephropathy resulting from congenital, injury, cancer and infectious causes.
(s) Urinary incontinence not due to neurological disorders, stroke, prostate problems or other diseases or injury. Includes stress
incontinence following childbirth.
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(t) Relevant ICD codes for occupational overuse syndrome or repetition strain injury (RSI) are in musculoskeletal and nervous
system chapters, but are not specific.
(u) Does not include the attributable burden of fractures.
(v) The balance of ICD-9 Chapter XVI ‘Symptoms, signs and ill-defined conditions’, apart from SIDS and chronic fatigue syndrome
(780.7) is distributed pro rata across Groups I and II within each age–sex group. Note that this differs from the GBD which
distributed it pro-rata across Group I only for ages 0–4 and Group II only for ages 5 and over.  There were 327 deaths in this
category in Australia in 1996, of which 13 were aged 0–4.
(w) There were 139 injury deaths in Australia in 1996 where it was not determined whether the injury was accidental or intentional
(E980–989).  The GBD allocated these deaths pro-rata to intentional and unintentional injury. Because unintentional injuries are
dominated by motor vehicle accidents and falls, this has the effect of reallocating the majority of undetermined deaths to
accidental deaths.  However, very few of the undetermined deaths are falls or road traffic accidents, and most are thought to be
intentional deaths where the coroner did not have sufficient evidence to make that finding.  These deaths have thus been re-
allocated, 10% to the unintentional injury category and 90% to the intentional injury category (to suicide for ages 15+ and to
violence for ages 0–14).
(x) Railway, water, air transport and non-road vehicles.
(y) Only includes sports injuries identifiable from four digit ICD-9 codes.
(z) Unspecified unintentional injuries (E928.9, E929.9) redistributed among unintentional injuries categories.
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Annex Table B: Disease categories and disability weights
Disease category, subcategory, or sequelae
Disability
weight Comments
Communicable diseases, maternal and neonatal
conditions
A.  Infectious & parasitic diseases
  1. Tuberculosis
Pulmonary tuberculosis 0.295 GBD weight
Extra-pulmonary tuberculosis 0.300 GBD weight
  2.  Sexually transmitted diseases (not HIV/AIDS)
a.  Syphilis
Primary syphilis 0.148 GBD weight
Secondary syphilis 0.048 GBD weight
Tertiary syphilis (cardiovascular) 0.196 GBD weight
Tertiary syphilis (gummas) 0.102 GBD weight
Tertiary syphilis (neurologic) 0.283 GBD weight
Syphilis (congenital) 0.315 GBD weight
b.  Chlamydia
Conjunctivitis 0.180 GBD weight
Urethritis 0.067 GBD weight
Cervicitis 0.049 GBD weight
Pelvic inflammatory disease 0.420 GBD weight
Ectopic pregnancy 0.549 GBD weight
Chronic pelvic pain 0.122 GBD weight
Infertility 0.180 GBD weight
Tubo-ovarian abscess 0.549 GBD weight
c.  Gonorrhoea
Urethritis 0.067 GBD weight
Cervicitis 0.049 GBD weight
Pelvic inflammatory disease 0.420 GBD weight
Ectopic pregnancy 0.549 GBD weight
Chronic pelvic pain 0.122 GBD weight
Infertility 0.180 GBD weight
Tubo-ovarian abscess 0.549 GBD weight
d.  Other sexually transmitted disease
Pelvic inflammatory disease 0.420 GBD weight
Ectopic pregnancy 0.549 GBD weight
Chronic pelvic pain 0.122 GBD weight
Infertility 0.180 GBD weight
Tubo-ovarian abscess 0.549 GBD weight
  3.  HIV/AIDS
Diagnosed asymptomatic HIV 0.200 Dutch weight
Symptomatic HIV 0.310 Dutch weight
AIDS 0.560 Dutch weight
AIDS—terminal phase 0.950 Dutch weight
  4.  Diarrhoeal diseases and gastroenteritis
Uncomplicated episode 0.093 GBD age-specific weights. Average shown here
Complicated episode 0.420 Dutch weight for complicated episode (50%) plus
GBD weight for uncomplicated episode (50%)
  5.  Childhood immunisable diseases
a.  Diphtheria
Cases 0.230 GBD weight
Neurological complications 0.078 GBD weight
Myocarditis 0.323 GBD weight
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Disease category, subcategory, or sequelae
Disability
weight Comments
b.  Whooping cough
Pertussis episode 0.178 GBD weight
Mental retardation (treated) 0.420 GBD weight (0.394  0–4 years, 0.420  5–14 years)
Mental retardation (untreated) 0.483 GBD weight (0.469  0–4 years, 0.483  5–14 years)
c.  Tetanus
Cases 0.612 GBD weight
d.  Poliomyelitis
Poliomyelitis 0.369 GBD weight
e.  Measles
Episodes 0.152 GBD weight
Measles encephalitis 0.338 GBD weight for neurological sequelae of encephalitis
Sub-acute sclerosing panencephalitis 0.930 Dutch weight for end-stage disease
f.  Rubella
Episodes 0.152 GBD weight for measles episode
Congenital cataract 0.430 Dutch weight for severe vision loss
Congenital heart disease 0.350 Dutch weight for heart failure
Congenital deafness 0.230 Dutch weight
g.  Haemophilus influenzae type b (Hib)
Epiglottitis 0.152 GBD weight for haemophilus influenzae episode
Meningitis 0.430 Average of weights for meningitis manifestations
Septicaemia 0.350 GBD weight
Pneumonia 0.230 Estimated using EQ5D + regression model
  6.  Meningitis
Acute episode 0.913 Estimated using EQ-5D+ regression model
After effects up to 6 months 0.226 Estimated using EQ-5D+ regression model
VP shunt 0.170 Dutch weight for motor deficit
Hearing loss 0.234 Average of Dutch weights for mild, moderate, and
severe loss
Seizure disorder 0.110 Dutch weight
Less severe developmental problems 0.100 Average of Dutch weights for developmental
problems
Mental retardation 0.250 Dutch weight
Motor deficit + mental retardation 0.760 Dutch weight
Less severe developmental problems 0.100 Based on Dutch weights for developmental problems
Scarring/deformity 0.133 Based on GBD amputation weights
  7.  Septicaemia
Cases 0.613 GBD age-specific weights (average shown here)
  8.  Arbovirus infection (incl. Ross River fever)
a.  Ross River virus Infection
Acute phase 0.258 Dutch weight for moderate rheumatoid arthritis
Chronic phase 0.140 Dutch weight for mild rheumatoid arthritis
b.  Barmah Forest virus
Acute phase 0.258 Dutch weight for moderate rheumatoid arthritis
Chronic phase 0.140 Dutch weight for mild rheumatoid arthritis
c.  Other arbovirus infection
Australian encephalitis 0.613 GBD weight for Japanese encephalitis
Japanese encephalitis 0.613 GBD weight
Kunjun 0.613 GBD weight for Japanese encephalitis
Cognitive impairment 0.451 GBD weight
Neurological sequelae 0.334 GBD weight
d.  Dengue fever
Dengue haemorrhagic fever 0.172 GBD age-specific weights (average shown here)
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Disease category, subcategory, or sequelae
Disability
weight Comments
  9.  Hepatitis
a.  Hepatitis A
Uncomplicated episode 0.093 GBD age-specific weights. Average shown here
Complicated episode 0.420 Dutch weight for complicated episode (50%) plus
GBD weight for uncomplicated episode (50%)
Prolonged or relapsing episode 0.140 Dutch weight for mild depression.
b.  Hepatitis B
Cases 0.000 Asymptomatic cases only
Acute symptomatic episode 0.210 Dutch weight
Chronic symptomatic carrier 0.360 Dutch weight
Compensated liver cirrhosis 0.310 Dutch weight
Decompensated liver cirrhosis 0.840 Dutch weight
Hepato-cellular cancer — See sequelae and weights for F5. Liver cancer
c.  Hepatitis C
Cases 0.000 Asymptomatic cases only
Acute symptomatic episode 0.210 Dutch weight for Hepatitis B
Chronic symptomatic carrier 0.360 Dutch weight for Hepatitis B
Compensated liver cirrhosis 0.310 Dutch weight
Decompensated liver cirrhosis 0.840 Dutch weight
Hepato-cellular cancer — See sequelae and weights for F5. Liver cancer
  10.  Malaria
Episodes 0.175 GBD age-specific weights (average shown here)
Neurological sequelae (treated) 0.436 GBD weight for 0–4 years.
Anaemia 0.012 GBD age-specific weights (average shown here)
  11.  Trachoma
Moderate vision loss 0.170 Dutch weight
Severe vision loss 0.430 Dutch weight
B.  Acute respiratory infections
  1.  Lower respiratory tract infections
Influenza episode 0.047 Estimated using EQ-5D + regression model
Acute bronchitis episode 0.132 Estimated using EQ-5D + regression model
Pneumonia episode 0.373 Estimated using EQ-5D + regression model
  2.  Upper respiratory tract infections
Acute nasopharyngitis 0.014 Estimated using EQ-5D + regression model
Acute sinusitis 0.061 Estimated using EQ-5D + regression model
Pharyngitis/tonsillitis 0.061 Estimated using EQ-5D + regression model
  3.  Otitis media
Acute episodes 0.090 Dutch weight for 1 day severe pain plus 4 days
moderate pain
Chronic otitis media 0.110 Dutch weight for early acquired mild to moderate
hearing loss
Deafness 0.233 Dutch weight for early acquired severe hearing loss
C.  Maternal conditions
  1.  Maternal haemorrhage
Cases 0.011 GBD weight for moderate anaemia
Severe anaemia 0.093 GBD weight
  2.  Maternal septis
Episodes 0.000 GBD weight
Infertility 0.180 GBD weight
  3.  Hypertension in pregnancy
Episodes 0.117 Estimated using EQ-5D+ regression model
Neurological sequelae 0.388 GBD weight
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Disease category, subcategory, or sequelae
Disability
weight Comments
  4.  Obstructed labour
Episodes 0.349 Estimated using EQ-5D+ regression model
  5.  Abortion
Episodes spontaneous abortion 0.000 GBD weight
Episodes induced abortion 0.000 GBD weight
Infertility 0.180 GBD weight
D.  Neonatal causes
  1.  Birth trauma & asphyxia
Deafness 0.230 Dutch weight
Seizure 0.110 Dutch weight
Cerebral palsy without intellectual disability 0.170 Dutch weight
Mild intellectual disability 0.290 Dutch weight
Moderate intellectual disability 0.430 Dutch weight
Severe intellectual disability 0.820 Dutch weight
Profound intellectual disability 0.760 Dutch weight
  2.  Low birth weight
Mild permanent disability 0.110 Dutch weight for mild to moderate early acquired
hearing loss
Severe hearing loss 0.370 Dutch weight
Vision loss 0.170 Dutch weight for moderate vision loss
Epilepsy 0.110 Dutch weight
Cerebral palsy without intellectual disability 0.170 Dutch weight
Mild intellectual disability 0.290 Dutch weight
Moderate intellectual disability 0.430 Dutch weight
Severe intellectual disability 0.820 Dutch weight
Profound intellectual disability 0.760 Dutch weight
  3.  Neonatal infections
Acute neonatal episode 0.894 Dutch weight for acute meningitis episode
Deafness 0.370 Dutch weight
Motor deficit 0.170 Dutch weight
Mild intellectual disability 0.290 Dutch weight
Moderate intellectual disability 0.430 Dutch weight
Severe intellectual disability 0.820 Dutch weight
Profound intellectual disability 0.760 Dutch weight
  4.  Other neonatal causes
Mild intellectual disability 0.290 Dutch weight
Moderate intellectual disability 0.430 Dutch weight
Severe intellectual disability 0.820 Dutch weight
Profound intellectual disability 0.760 Dutch weight
Cerebral palsy without intellectual disability 0.170 Dutch weight for motor deficit
E.  Nutritional deficiencies
  1.  Protein-energy malnutrition
Stunting 0.002 GBD Weight
Wasting 0.053 GBD Weight
Developmental disability 0.024 GBD Weight
  2.  Iron-deficiency anaemia
Non-anaemic iron deficiency 0.005 Estimated using EQ-5D+ regression model
Mild anaemia 0.005 GBD weight
Moderate anaemia 0.011 GBD weight
Severe anaemia 0.090 GBD weight
Very severe anaemia 0.250 GBD weight
Cognitive impairment 0.024 GBD weight
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Disease category, subcategory, or sequelae
Disability
weight Comments
  3.  Other nutritional deficiencies
Iodine deficiency goitre 0.026 GBD weight for Grade 2 Goitre
F.  Malignant neoplasms
  1.  Mouth and oropharynx cancers
Diagnosis and primary therapy 0.560 Dutch weight for oesophageal cancer
State after intentionally curative primary therapy 0.370 Dutch weight for oesophageal cancer
In remission 0.370 Dutch weight for oesophageal cancer
Disseminated cancer 0.900 Dutch weight for oesophageal cancer
Terminal stage 0.930 Dutch weight for end-stage disease
  2.  Oesophagus cancer
Diagnosis and primary therapy 0.560 Dutch weight
State after intentionally curative primary therapy 0.370 Dutch weight
Irradically removed or disseminated carcinoma 0.900 Dutch weight
Preterminal  and terminal stages 0.930 Dutch weight for end-stage disease
  3.  Stomach cancer
Diagnosis and primary therapy 0.530 Dutch weight
State after intentionally curative primary therapy 0.380 Dutch weight
Irradically removed or disseminated carcinoma 0.730 Dutch weight
Preterminal  and terminal stages 0.930 Dutch weight for end-stage disease
  4.  Colorectal cancer
Diagnosis and primary therapy 0.430 Dutch weight
State after intentionally curative primary therapy 0.200 Dutch weight
In remission 0.430 Dutch weight
Irradically removed or disseminated carcinoma 0.830 Dutch weight
Terminal stage 0.930 Dutch weight for end-stage disease
  5.  Liver cancer
Diagnosis and initial treatment 0.430 Dutch weight for colorectal cancer
State after intionally curative primary therapy 0.200 Dutch weight for colorectal cancer
Clinically disease free 0.200 Dutch weight for colorectal cancer
Irradically removed/disseminated/preterminal 0.830 Dutch weight for colorectal cancer
Terminal phase 0.930 Dutch weight for end-stage disease
  6.  Gall bladder cancer
Diagnosis and initial treatment 0.430 Dutch weight for colorectal cancer
State after intionally curative primary therapy 0.200 Dutch weight for colorectal cancer
Clinically disease free 0.200 Dutch weight for colorectal cancer
Irradically removed/disseminated/preterminal 0.830 Dutch weight for colorectal cancer
Terminal phase 0.930 Dutch weight for end-stage disease
  7.  Pancreas cancer
Diagnosis and initial treatment 0.430 Dutch weight for colorectal cancer
State after intionally curative primary therapy 0.200 Dutch weight for colorectal cancer
Disseminated 0.830 Dutch weight for colorectal cancer
Terminal phase 0.930 Dutch weight for end-stage disease
191
Annex Table B (continued): Disease categories and disability weights
Disease category, subcategory, or sequelae
Disability
weight Comments
  8.  Lung cancer
Diagnosis and primary therapy for operable
non-small cell cancer
0.440 Dutch weight
Disease free after primary therapy for
non small cell cancer
0.470 Dutch weight
Diagnosis and primary therapy for non operable
 non-small cell cancer
0.760 Dutch weight
Disseminated non-small cancer 0.910 Dutch weight
Terminal stage non small cell cancer 0.930 Dutch weight for end-stage disease
Diagnosis and chemotherapy small cell cancer 0.680 Dutch weight
Disease free after primary therapy for
 small cell cancer
0.470 Dutch weight
Small cell cancer in remission 0.540 Dutch weight
Relapse/terminal stage small cell cancer 0.930 Dutch weight for end-stage disease
  9.  Bone and connective tissue  cancers
Diagnosis and primary therapy 0.350 Provisional weight based on Dutch weights
State after intentionally curative primary therapy 0.300 Provisional weight based on Dutch weights
In remission 0.300 Provisional weight based on Dutch weights
Disseminated carcinoma 0.750 Provisional weight based on Dutch weights
Terminal stage 0.930 Dutch weight for end-stage disease
  10.  Melanoma
Primary treatment, no evidence dissemination 0.190 Dutch weight
No evidence of dissemination after initial
treatment
0.190 Dutch weight
Primary treatment, lymph node but no distant
dissemination
0.430 Dutch weight
In remission 0.190 Dutch weight
Disseminated melanoma 0.810 Dutch weight
Terminal phase 0.930 Dutch weight for end-stage disease
  11.  Non-melanoma skin cancers
Basal cell carcinoma 0.050 Dutch weight
Squamous cell carcinoma undisseminated 0.070 Dutch weight
Squamous cell carcinoma with dissemination 0.400 Dutch weight
Squamous cell carcinoma–local recurrence 0.500 Dutch weight
Terminal phase 0.930 Dutch weight for end-stage disease
  12.  Breast cancer
Diagnostic, primary therapy, non-invasive
tumour <2 cm
0.260 Dutch weight
Diagnostic, primary therapy, tumour 2–5 cm or
lymph node dissemination
0.690 Dutch weight
Diagnostic, primary therapy, tumour >5 cm 0.810 Dutch weight
Disease free after initial treatment 0.260 Dutch weight
In remission 0.260 Dutch weight
Disseminated cancer 0.790 Dutch weight
Terminal phase 0.930 Dutch weight for end-stage disease
  13.  Cervix cancer
Diagnosis and primary therapy 0.430 Provisional weight based on Dutch weights
State after intentionally curative primary therapy 0.200 Provisional weight based on Dutch weights
In remission 0.200 Provisional weight based on Dutch weights
Disseminated carcinoma 0.750 Provisional weight based on Dutch weights
Terminal stage 0.930 Dutch weight for end-stage disease
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Disease category, subcategory, or sequelae
Disability
weight Comments
  14.  Uterus cancer
Diagnosis and primary therapy 0.430 Provisional weight based on Dutch weights
State after intentionally curative primary therapy 0.200 Provisional weight based on Dutch weights
In remission 0.200 Provisional weight based on Dutch weights
Disseminated carcinoma 0.750 Provisional weight based on Dutch weights
Terminal stage 0.930 Dutch weight for end-stage disease
  15.  Ovary cancer
Diagnosis and primary therapy 0.430 Provisional weight based on Dutch weights
State after intentionally curative primary therapy 0.200 Provisional weight based on Dutch weights
In remission 0.200 Provisional weight based on Dutch weights
Disseminated carcinoma 0.750 Provisional weight based on Dutch weights
Terminal stage 0.930 Dutch weight for end-stage disease
  16.  Prostate cancer
Diagnostic, primary therapy, localised cancer 0.270 Dutch weight
Follow-up without active therapy (watchful
waiting)
0.270 Dutch weight
In remission 0.200 Dutch weight
Clinically disease-ree after primary therapy 0.180 Dutch weight
Hormone refractory cancer 0.640 Dutch weight
Terminal stage 0.930 Dutch weight end-stage disease
  17.  Testicular cancer
Diagnosis and primary therapy 0.270 Provisional weight based on Dutch weights
State after intentionally curative primary therapy 0.180 Provisional weight based on Dutch weights
In remission 0.180 Provisional weight based on Dutch weights
Disseminated carcinoma 0.640 Provisional weight based on Dutch weights
Terminal stage 0.930 Dutch weight for end-stage disease
  18.  Bladder cancer
Diagnosis and primary therapy 0.270 Provisional weight based on Dutch weights
State after intentionally curative primary therapy 0.180 Provisional weight based on Dutch weights
In remission 0.180 Provisional weight based on Dutch weights
Disseminated carcinoma 0.640 Provisional weight based on Dutch weights
Terminal stage 0.930 Dutch weight for end-stage disease
  19.  Kidney cancer
Diagnosis and primary therapy 0.270 Provisional weight based on Dutch weights
State after intentionally curative primary therapy 0.180 Provisional weight based on Dutch weights
In remission 0.180 Provisional weight based on Dutch weights
Disseminated carcinoma 0.640 Provisional weight based on Dutch weights
Terminal stage 0.930 Dutch weight for end-stage disease
  20.  Brain cancer
Diagnosis and primary therapy 0.680 Provisional weight based on Dutch weights
State after intentionally curative primary therapy 0.180 Provisional weight based on Dutch weights
Disseminated carcinoma 0.750 Provisional weight based on Dutch weights
Terminal stage 0.930 Dutch weight for end-stage disease
  21.  Thyroid cancer
Diagnosis and primary therapy 0.270 Provisional weight based on Dutch weights
State after intentionally curative primary therapy 0.180 Provisional weight based on Dutch weights
In remission 0.180 Provisional weight based on Dutch weights
Disseminated carcinoma 0.640 Provisional weight based on Dutch weights
Terminal stage 0.930 Dutch weight for end-stage disease
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Disease category, subcategory, or sequelae
Disability
weight Comments
  22a.  Non-Hodgkin’s lymphoma
Low grade, dissemination stage I and II 0.190 Dutch weight
Low grade, dissemination stage III and IV 0.610 Dutch weight
Intermediate/high grade, dissemination stage I 0.550 Dutch weight
Intermediate/high grade, dissemination
stage II, III or IV
0.750 Dutch weight
Temporary remission after treatment 0.190 Dutch weight
Preterminal phase 0.750 Dutch weight
Terminal phase 0.930 Dutch weight for end-stage disease
Complete remission 0.190 Dutch weight
  22b. Hodgkin’s disease
Low grade, dissemination stage I and II 0.190 Dutch weight
Low grade, dissemination stage III and IV 0.610 Dutch weight
Intermediate/high grade, dissemination stage I 0.550 Dutch weight
Intermediate/high grade, dissemination
stage II, III or IV
0.750 Dutch weight
Temporary remission after treatment 0.190 Dutch weight
Preterminal phase 0.750 Dutch weight
Terminal phase 0.930 Dutch weight for end-stage disease
Complete remission 0.190 Dutch weight
  23.  Multiple myeloma
Diagnosis and primary therapy 0.190 Provisional weight based on Dutch weights
State after intentionally curative primary therapy 0.190 Provisional weight based on Dutch weights
In remission 0.190 Provisional weight based on Dutch weights
Disseminated carcinoma 0.750 Provisional weight based on Dutch weights
Terminal stage 0.930 Dutch weight for end-stage disease
  24a.  Acute myeloid leukemia 
Diagnosis and primary therapy 0.550 Provisional weight based on Dutch weights
State after intentionally curative primary therapy 0.190 Provisional weight based on Dutch weights
Preterminal stage 0.750 Provisional weight based on Dutch weights
Terminal stage 0.930 Dutch weight for end-stage disease
  24b. Chronic myeloid leukemia 
Diagnosis and primary therapy 0.550 Provisional weight based on Dutch weights
State after intentionally curative primary therapy 0.190 Provisional weight based on Dutch weights
In remission 0.190 Provisional weight based on Dutch weights
Preterminal stage 0.750 Provisional weight based on Dutch weights
Terminal stage 0.930 Dutch weight for end-stage disease
  24c.  Acute lymphoid leukemia
Diagnosis and primary therapy 0.550 Provisional weight based on Dutch weights
State after intentionally curative primary therapy 0.190 Provisional weight based on Dutch weights
In remission 0.190 Provisional weight based on Dutch weights
Preterminal stage 0.750 Provisional weight based on Dutch weights
Terminal stage 0.930 Dutch weight for end-stage disease
  24d. Chronic lymphoid leukemia
Diagnosis and primary therapy 0.550 Provisional weight based on Dutch weights
State after intentionally curative primary therapy 0.190 Provisional weight based on Dutch weights
In remission 0.190 Provisional weight based on Dutch weights
Preterminal stage 0.750 Provisional weight based on Dutch weights
Terminal stage 0.930 Dutch weight for end-stage disease
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Annex Table B (continued): Disease categories and disability weights
Disease category, subcategory, or sequelae
Disability
weight Comments
G.  Other neoplasms
  1.  Uterine myomas
Symptomatic cases 0.066 Estimated using EQ-5D+ regression model
Hysterectomy or myomectomy 0.349 Estimated using EQ-5D+ regression model
Reproductive disability 0.180 GBD weight for infertility
  2.  Benign brain tumour
Diagnosis and primary therapy 0.680 Provisional weight based on Dutch weights
State after intentionally curative primary 0.180 Provisional weight based on Dutch weights
Pre-terminal stage 0.750 Provisional weight based on Dutch weights
Terminal stage 0.930 Dutch weight for end-stage disease
H.  Diabetes mellitus
  1.  Type 1 diabetes
Cases 0.070 Dutch weight
Retinopathy—moderate vision loss 0.170 Dutch weight
Retinopathy—severe vision loss 0.430 Dutch weight
Cataract—mild vision loss 0.020 Dutch weight
Cataract—moderate vision loss 0.170 Dutch weight
Cataract—severe vision loss 0.430 Dutch weight
Glaucoma—mild vision loss 0.020 Dutch weight
Glaucoma—moderate vision loss 0.170 Dutch weight
Glaucoma—severe vision loss 0.430 Dutch weight
Neuropathy 0.190 Dutch weight
Nephropathy 0.290 Dutch weight
Diabetic foot 0.220 GBD weight
Amputation—toe 0.064 GBD weight
Amputation—foot or leg 0.300 GBD weight
  2.  Type 2 diabetes
Cases 0.070 Dutch weight
Retinopathy—moderate vision loss 0.170 Dutch weight
Retinopathy—severe vision loss 0.430 Dutch weight
Cataract—mild vision loss 0.020 Dutch weight
Cataract—moderate vision loss 0.170 Dutch weight
Cataract—severe vision loss 0.430 Dutch weight
Glaucoma—mild vision loss 0.020 Dutch weight
Glaucoma—moderate vision loss 0.170 Dutch weight
Glaucoma—severe vision loss 0.430 Dutch weight
Neuropathy 0.190 Dutch weight
Nephropathy 0.290 Dutch weight
Diabetic foot 0.220 GBD weight
Amputation—toe 0.064 GBD weight
Amputation—foot or leg 0.300 GBD weight
I.  Endocrine and metabolic disorders
  1.  Non-deficiency anaemia
a.  Thalassaemia
Very severe anaemia 0.250 GBD weight
b.  Other non-deficiency anaemia
Genetically inherited anaemias 0.090 GBD weight
Severe anaemia 0.090 GBD weight
Very severe anaemia 0.250 GBD weight
  2.  Cystic  fibrosis
Cases 0.530 Dutch weight for severe COPD
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Annex Table B (continued): Disease categories and disability weights
Disease category, subcategory, or sequelae
Disability
weight Comments
  3.  Haemophilia
Severe cases 0.270 Weight based on QALY measurements
Moderate cases 0.050 Weight based on QALY measurements
J.  Mental disorders
  1.  Substance use disorders
a.  Alcohol dependence and harmful use
Harmful use 0.110 Dutch weight for problem drinking
Moderate dependence 0.330 Average of Dutch weights for problem drinking and
manifest alcoholism
Manifest alcoholism 0.550 Dutch weight
b.  Heroin or polydrug dependence and harmful use
Cases 0.270 Locally derived weight, slightly higher than GBD
weight 0.252
c.  Benzodiazepine dependence and harmful use
Cases 0.184 Extrapolation by Australian mental health experts
d.  Cannabis dependence and harmful use
Cases 0.113 Extrapolation by Australian mental health experts
e.  Other drug dependence and harmful use
Stimulant dependence and harmful use 0.110 Dutch weight for problem drinking
Other drug dependence 0.113 Dutch weight for cannabis dependence
Analgesic nephropathy 0.290 Dutch weight for diabetic nephropathy
  2.  Schizophrenia
Cases 0.434 Composite GBD weight—psychosis (30%), treated
schizophrenia (70%).
  3.  Affective disorders
a.  Major depression
Dysthymia cases 0.140 Dutch weight for mild depression
Major depressive episode—mild 0.140 Dutch weight
Major depressive episode—moderate 0.350 Dutch weight
Major depressive episode—severe 0.760 Dutch weight
b.  Bipolar affective disorder
Cases 0.176 Composite Dutch weight - mild depression (50%) non
episodes; 25% moderate depression, 25% local
extrapolated weight for episodic manic phase
  4.  Anxiety disorders
a.  Panic disorder
Mild to moderate panic disorder 0.160 Dutch weight
Severe panic disorder 0.690 Dutch weight
b.  Agoraphobia
Mild to moderate agoraphobia   0.110 Dutch weight
Severe agoraphobia 0.550 Dutch weight
c.  Social phobia
Mild to moderate social phobia 0.170 Dutch weight
Severe social phobia 0.590 Dutch weight
d.  Generalized anxiety disorder (GAD)
Mild to moderate GAD 0.170 Dutch weight
Severe GAD 0.600 Dutch weight
e.  Obsessive-compulsive disorder (OCD)
Mild to moderate OCD 0.170 Dutch weight
Severe OCD 0.600 Dutch weight
f.  Post-traumatic stress disorder (PTSD)
Mild to moderate PTSD 0.130 Dutch weight
Severe PTSD 0.510 Dutch weight
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Annex Table B (continued): Disease categories and disability weights
Disease category, subcategory, or sequelae
Disability
weight Comments
g.  Separation anxiety disorder
Mild to moderate separation anxiety disorder 0.110 Dutch weight for mild to moderate agoraphobia
Severe separation anxiety disorder 0.550 Dutch weight for severe agoraphobia
  5.  Borderline personality disorder
Symptomatic cases 0.540 Extrapolation by Australian mental health experts
  6.  Eating disorders
a.  Anorexia nervosa
Cases 0.280 Dutch weight
b.  Bulimia nervosa
Cases 0.280 Dutch weight
  7.  Childhood conditions
a.  Attention-deficit hyperactivity disorder
Mild 0.020 Dutch weight.
Moderate to severe 0.150 Dutch weight.
b.  Autism and Asperger’s syndrome
Autism cases 0.550 Dutch weight
Asperger’s syndrome cases 0.250 Average of Dutch weights for moderate/severe ADHD
and for autism
  8.  Mental retardation (no defined aetiology)
Mild intellectual disability 0.290 Dutch weight
Moderate intellectual disability 0.430 Dutch weight
Severe intellectual disability 0.820 Dutch weight
Profound intellectual disability 0.760 Dutch weight
K.  Nervous system and sense organ disorder
  1.  Dementia
Mild 0.270 Dutch  weight
Moderate 0.630 Dutch weight
Severe 0.940 Dutch weight
  2.  Epilepsy
Epilepsy 0.110 Dutch  weight
  3.  Parkinsons’s disease
Initial stage 0.480 Dutch weight
Intermediate stage 0.790 Dutch weight
End-stage 0.920 Dutch weight
  4.  Multiple sclerosis
Relapsing-remitting phase 0.330 Dutch weight
Progressive phase 0.670 Dutch weight
Progressive from onset 0.670 Dutch weight
  5.  Motor neuron disease
Cases 0.670 Dutch weight for progressive phase of multiple
sclerosis.
  6.  Huntington’s chorea
Initial stage 0.480 Dutch weight for initial stage Parkinson’s disease
Intermediate stage 0.790 Dutch weight for intermediate stage Parkinson’s
disease
End-stage 0.920 Dutch weight for end-stage Parkinson’s disease
  7.  Muscular dystrophy
Initial stage   0.480 Dutch weight for initial stage Parkinson’s disease
Paraplegia 0.570 Dutch weight
Quadriplegia 0.840 Dutch weight
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Disease category, subcategory, or sequelae
Disability
weight Comments
  8.  Sense organ disorders
a.  Glaucoma
Cases 0.000 GBD and Dutch weights
Mild vision loss 0.020 Dutch weight
Moderate vision loss 0.170 Dutch weight
Severe vision loss 0.430 Dutch weight
b.  Cataracts
Cases 0.000 GBD and Dutch weights
Mild vision loss 0.020 Dutch weight
Moderate vision loss 0.170 Dutch weight
Severe vision loss 0.430 Dutch weight
c.  Age-related vision disorders
Mild vision loss 0.020 Dutch weight
Moderate vision loss 0.170 Dutch weight
Severe vision loss 0.430 Dutch weight
d.  Adult-onset hearing loss
Mild hearing loss (25–34 dBHTL) 0.020 One half of Dutch weight for mild hearing loss
Mild hearing loss (35–44 dBHTL) 0.040 Dutch weight
Moderate hearing loss 0.120 Dutch weight
Severe hearing loss 0.370 Dutch weight
L.  Cardiovascular disease
  1.  Rheumatic heart disease
Rheumatic fever 0.047 Regression weight for influenza
Rheumatic heart disease
   Untreated 0.323 GBD weight
   Treated 0.171 GBD weight
  2.  Ischaemic heart disease
Angina pectoris 0.178 Dutch weight
Acute myocardial infarction 0.395 GBD (treated) age-specific weights (average shown
here)
Heart failure 0.353 Dutch weight
  3.  Stroke
First- ever stroke with full recovery 0.000
Mild permanent impairments 0.360 Dutch weight
Moderate permanent impairments 0.630 Dutch weight
Severe permanent impairments 0.920 Dutch weight
  4.  Inflammatory heart disease
Cardiomyopathy cases 0.353 Dutch weight for heart failure
Endocarditis cases 0.353 Dutch weight for heart failure
Myocarditis cases 0.353 Dutch weight for heart failure
Pericarditis cases 0.353 Dutch weight for heart failure
  5.  Hypertensive heart disease
Cases 0.352 Based on Dutch weight for heart failure
  6.  Non-rheumatic valvular disease
cases 0.060 Dutch weight for mild heart failure
  7.  Aortic aneurysm
Cases 0.430 Dutch weight for early colorectal cancer
  8.  Peripheral arterial disease
Cases 0.248 Estimated using EQ-5D+ regression model
Amputation 0.209 GBD weight
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Disease category, subcategory, or sequelae
Disability
weight Comments
M.  Chronic respiratory disease
  1.  Chronic obstructive pulmonary disease
Mild to moderate COPD 0.170 Dutch weight
Severe COPD 0.530 Dutch weight
  2.  Asthma
Mild asthma 0.030 Dutch weight
Severe asthma 0.230 Estimated using EQ-5D+ regression model and
Australian data on severity distribution of disability
  3.  Other chronic respiratory diseases 0.164 Provisional weight—average weight for COPD
N.  Diseases of the digestive system
  1.  Peptic ulcer disease 0.066 Dutch weight
  2.  Cirrhosis of the liver 0.339 GBD weight
  3.  Appendicitis 0.463 GBD weight
  4.  Intestinal obstruction
Cases   0.463 Dutch weight for appendicitis
Stoma closed 0.211 Estimated using EQ-5D+ regression model
Stoma continuing 0.211 Estimated using EQ-5D+ regression model
  5.  Diverticulitis
Cases 0.400 Dutch weight for inflammatory bowel disease
—active exacerbation
Stoma closed 0.211 Estimated using EQ-5D+ regression model
Stoma continuing 0.211 Estimated using EQ-5D+ regression model
  6.  Gall bladder and bile duct disease
Cases 0.349 Estimated using EQ-5D+ regression model
  7.  Pancreatitis
Cases 0.349 Estimated using EQ-5D+ regression model
  8.  Inflammatory bowel disease
Crohn’s disease 0.224 Dutch weight
Ulcerative colitis 0.224 Dutch weight
Stoma closed 0.211 Estimated using EQ-5D+ regression model
Stoma continuing 0.211 Estimated using EQ-5D+ regression model
9.  Vascular insufficiency of intestine
Cases 0.400 Dutch weight for inflammatory bowel disease—active
exacerbation
Stoma closed 0.211 Estimated using EQ-5D+ regression model
Stoma continuing 0.211 Estimated using EQ-5D+ regression model
O.  Genitourinary diseases
  1.  Nephritis and nephrosis
End-stage renal failure with dialysis 0.290 Dutch weight for diabetic nephropathy
End-stage renal failure with transplant 0.290 Dutch weight for diabetic nephropathy
Transplanted patient 0.110 GBD weight for treated renal failure, Dutch weight for
uncertain prognosis
Untreated end-stage renal failure 0.104 GBD weight
  2.  Benign prostatic hypertrophy
Symptomatic case 0.038 GBD weight
Prostatectomy 0.349 Estimated using EQ-5D+ regression model
Urethral stricture 0.151 GBD weight
Impotence 0.195 GBD weight
Severe urinary incontinence   0.157 Estimated using EQ-5D+ regression model
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Disease category, subcategory, or sequelae
Disability
weight Comments
  3.  Urinary incontinence
Occasional urine leakage 0.000 No weight for occasional urine leakage
Moderate incontinence 0.025 GBD weight for stress incontinence (0.033 for 60+)
Severe incontinence 0.157 Estimated using EQ-5D+ regression model
  4.  Other genitourinary diseases
Menstrual disorders 0.033 Estimated from EQ-5D+ regression model
Hysterectomy 0.349 Estimated from EQ-5D+ regression model
Reproductive disability following hysterectomy
for menorrhagia 0.180 Estimated from EQ-5D+ regression model
for genital prolapse 0.180 Estimated from EQ-5D+ regression model
for endometriosis 0.180 Estimated from EQ-5D+ regression model
Other short-term reproductive disability 0.180 GBD weight
Other long-term reproductive disability 0.180 GBD weight
P.  Skin diseases
  1.  Eczema 0.056 Estimated from EQ-5D+ regression model
  2.  Other skin diseases 0.056 Estimated from EQ-5D+ regression model
Q.  Musculoskeletal diseases
  1.  Rheumatoid arthritis
Mild 0.210 Dutch weight
Moderate 0.370 Dutch weight
Severe 0.940 Dutch weight
  2.  Osteoarthritis
Grade 2 (radiological) hip or knee (asympt.) 0.010 Dutch weight
Grade 2 symptomatic 0.140 Dutch weight
Grade 3–4 (radiological) hip or knee (asympt.) 0.140 Dutch weight
Grade 3–4 symptomatic 0.420 Dutch weight
  3.  Chronic back pain
Episodes 0.060 Dutch weight
  4.  Slipped disc
Episodes 0.060 Dutch weight for back problems
Excision or destruction of disc 0.060 Dutch weight for back problems
Chronic pain 0.125 Estimated using EQ-5D+ regression model
  5.  Occupational overuse syndrome
Mild handicap or disability 0.056 Estimated using EQ-5D+ regression model
Moderate handicap 0.293 Estimated using EQ-5D+ regression model
Severe or profound handicap 0.516 Estimated using EQ-5D+ regression model
  6.  Osteoporosis
Diagnosed cases 0.009 Estimated using EQ-5D+ regression model
  7.  Other musculoskeletal disorders
Recent non-chronic episodes 0.060 Dutch weight for low back pain
Chronic conditions 0.060 Dutch weight for low back pain
R.  Congenital anomalies
  1.  Anencephaly
Liveborn cases 1.000
  2.  Spina bifida
Low-level spina bifida aperta 0.160 Dutch weight
Medium-level spina bifida aperta 0.500 Dutch weight
High-level spina bifida aperta 0.680 Dutch weight
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Disease category, subcategory, or sequelae
Disability
weight Comments
  3.  Congenital heart disease
Surgically treated congenital atrial or
ventricular septal defect
0.030 Dutch weight
Child/adolescent in permanent stage after
surgical treatment for Fallot's tetralogy
or transposition of great arteries
0.200 Dutch weight
Young adult in permanent stage after surgical
treatment for Fallot's tetralogy or
transposition of great arteries
0.110 Dutch weight
Child/adolescent in permanent stage after
surgical treatment for pulmonary
stenosis
0.020 Dutch weight
Young adult in permanent stage after surgical
treatment for pulmonary stenosis
0.160 Dutch weight
Complex not curatively operable congenital
heart disease
0.720 Dutch weight
  4.  Cleft lip and/or palate
Cleft palate—untreated 0.231 GBD weight
Cleft palate—treated 0.015 GBD weight
Cleft lip—untreated 0.098 GBD weight
Cleft lip—treated 0.016 GBD weight
  5.  Digestive system malformations
a.  Anorectal atresia
Cases 0.850 GBD weight for anorectal atresia
Longterm disability 0.037 GBD weight for symptomatic urethritis
b.  Oesophageal atresia
Cases 0.850 GBD weight for anorectal atresia
Longterm disability 0.037 GBD weight for symptomatic urethritis
c.  Other digestive system malformations
Small intestine atresia 0.850 GBD weight for digestive system atresias
Other 0.850 GBD weight for digestive system atresias
  6.  Urogenital tract malformations
a.  Renal agenesis
Bilateral renal agenesis or dysgenesis 0.850 GBD weight for renal agenesis
Unilateral renal agenesis or dysgenesis 0.037 GBD weight for symptomatic urethritis
End-stage renal failure 0.294 Dutch weight
b.  Other urogenital tract malformations
Hypospadias 0.000 Assumed negligible ongoing disability
Cystic kidney disease 0.037 GBD weight for acute urethritis
Obstructive defects of renal pelvis and ureter 0.037 GBD weight for renal diseases
Other urinary tract malformations 0.290 Dutch weight for renal failure
  7.  Abdominal wall defect
Cases 0.850 GBD weight for abdominal wall defect
Long-term disability 0.200 Dutch weight for permanent stage treated CVD
malformation
  8.  Down syndrome
Child aged 0–9 with other malformations 0.690 Dutch weight
Child aged 0–9 without other malformations 0.510 Dutch weight
Person aged 10–39 years 0.350 Dutch weight
Adult 40 years of age and over 0.650 Dutch weight
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Disease category, subcategory, or sequelae
Disability
weight Comments
  9.  Other chromosomal conditions
Mild intellectual disability 0.290 Dutch weight
Moderate intellectual disability 0.430 Dutch weight
Severe intellectual disability 0.820 Dutch weight
Profound intellectual disability 0.760 Dutch weight
S.  Oral health
  1.  Dental caries
Episode resulting in filling 0.005 Dutch weight
Episode resulting in tooth loss 0.014 Estimated using EQ-5D+ regression model
  2.  Periodontal disease
Gingivitis 0.000 Dutch weight
Pockets 6 mm or more deep 0.001 Dutch weight
  3.  Edentulism
Cases 0.004 Estimated using EQ-5D+ regression model
V.  Ill-defined conditions
  1.  Sudden infant death syndrome 0.000.
  2.  Chronic fatigue syndrome
Mild handicap 0.137 Estimated using EQ-5D+ regression model
Moderate handicap 0.449 Estimated using EQ-5D+ regression model
Severe or profound handicap 0.760 Estimated using EQ-5D+ regression model
III. Injuries - type of injury sequelae
  1.  Fractures
Skull—short-term 0.431 GBD weight
Skull—long- term 0.350 GBD weights (0.404 for ages 65+)
 Face bones 0.223 GBD weight
Vertebral column 0.266 GBD weight
Rib or sternum 0.199 GBD weight
Pelvis 0.247 GBD weight
Clavicle, scapula or humerus 0.153 GBD weight
Radius or ulna 0.180 GBD weight
Hand bones 0.100 GBD weight
Femur—short-term 0.372 GBD weight
Femur—long-term 0.272 GBD weight
Patella, tibia or fibula 0.271 GBD weight
Ankle 0.196 GBD weight
Foot bones 0.077 GBD weight
  2.  Injured spinal cord 0.725 GBD weight
  3.  Dislocations
Shoulder, elbow or hip 0.074 GBD weight
Other dislocation 0.074 GBD weight for shoulder, elbow or hip dislocation
  4.  Sprains 0.064 GBD weight
  5.  Intracranial injuries
Short-term 0.359 GBD weight
Long-term 0.350 GBD weight
  6.  Internal injuries 0.208 GBD weight
  7.  Open wound 0.108 GBD weight
  8.  Injury to eyes
Short-term 0.108 GBD weight for open wound
Long-term 0.298 GBD weight (0.301 for ages 0–14)
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Disease category, subcategory, or sequelae
Disability
weight Comments
  9.  Amputations
Thumb 0.165 GBD weight
Finger 0.102 GBD weight
Arm 0.257 GBD weight
Toe 0.102 GBD weight
Foot 0.300 GBD weight
Leg 0.300 GBD weight
  10.  Crushing 0.218 GBD weight
  11.  Burns
Less than 20%—short-term 0.158 GBD weight
Less than 20%—long- term 0.001 GBD weight
20 to 60%—short-term 0.441 GBD weight
20 to 60%—long-term 0.255 GBD weight
Greater than 60%—short-term 0.441 GBD weight
Greater than 60%—long- term 0.255 GBD weight
  12.  Injured nerves
Short-term 0.064 GBD weight
Long-term 0.064 GBD weight
  13.  Poisoning 0.608 GBD weight (0.611 for ages 0–14)
T.  Unintentional injuries
  1.  Road traffic accidents 0.149 Average weight across all injury sequelae
  2.  Other transport accidents 0.142 Average weight across all injury sequelae
  3.  Poisoning 0.593 Average weight across all injury sequelae
  4.  Falls 0.141 Average weight across all injury sequelae
  5.  Fires/burns/scalds 0.172 Average weight across all injury sequelae
  6.  Drowning 0.211 Average weight across all injury sequelae
  7.  Sports injuries 0.118 Average weight across all injury sequelae
  8.  Natural and environmental factors 0.158 Average weight across all injury sequelae
  9.  Machinery accidents 0.112 Average weight across all injury sequelae
  10.  Suffocation and foreign bodies 0.162 Average weight across all injury sequelae
  11.  Adverse effects of medical treatment 0.433 Average weight across all injury sequelae
  a.  Surgical and medical misadventure 0.380 Average weight across all injury sequelae
  b.  Adverse effects of drugs in therapeutic use 0.453 Average weight across all injury sequelae
  12.  Other unintentional injuries 0.112 Average weight across all injury sequelae
  a.  Cutting and piercing accidents 0.104 Average weight across all injury sequelae
  b.  Striking and crushing accidents 0.157 Average weight across all injury sequelae
  c.  Other other unintentional injuries 0.111 Average weight across all injury sequelae
U.  Intentional injuries
  1.  Suicide and self-inflicted injuries 0.447 Average weight across all injury sequelae
  2.  Homicide and violence 0.166 Average weight across all injury sequelae
  3   Legal intervention and war 0.120 Average weight across all injury sequelae
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Annex Table C: Principal data sources for estimation of YLD
Primary data source(a) Disease and injury categories
A. Disease registers, surveillance and notification systems
1. National Notifiable Diseases Surveillance System,
National Centre for Disease Control within the
Commonwealth Department of Health and Aged
Care (see Communicable Diseases Intelligence
bulletin).
A1 Tuberculosis
A2 STDs (apart from HIV/AIDS)
A5 Childhood immunisable diseases
A8 Arbovirus infection
A9 Hepatitis
A10 Malaria
2. HIV/AIDS National Registry, National Centre in HIV 
Epidemiology and Clinical Research
(NCHECR 1998)
A3 HIV/AIDS
3. National Cancer Statistics Clearinghouse, AIHW
(AIHW & AACR 1998)
F Malignant neoplasms (except NMSC)
4. National perinatal dataset, AIHW National Perinatal 
Statistics Unit (Day et al. 1999)
D2 Low birth weight
5. Tasmanian Insulin-Treated Diabetes Register H1 Type 1 Diabetes
6. Australian and New Zealand Register of Dialysis and
Transplant Patients (ANZDATA)
O1 Nephritis and nephrosis
7. Victorian Huntington’s Chorea Register K6 Huntington's chorea
8. National Congenital Malformations Monitoring
System, AIHW National Perinatal Statistics Unit 
(Day et al. 1999)
R Congenital anomalies (apart from R9 Other
chromosomal anomalies)
9. Australian Sentinel Practice Research Network
(ASPREN)
B1 Lower respiratory tract infections (influenza)
B. Health service utilisation data
10 National Hospital Morbidity Database, AIHW
(AIHW 1999b)
A2d Other STDs (pelvic inflammatory disease)
A4 Intestinal infectious diseases
A6 Meningitis
A7 Septicaemia
C Maternal conditions
D1 Birth trauma & asphyxia
D3 Neonatal infections
E3 Other nutritional deficiencies
G Benign neoplasms
I1b Other non-deficiency anaemia
L2 Ischaemic heart disease (AMI)
L4 Inflammatory heart disease
L6 Non-rheumatic valvular disease
L7 Aortic aneurysm
N3. Appendicitis
N4 Intestinal obstruction
N5 Diverticulitis
N6 Gall bladder and bile duct disease
N7 Pancreatitis
N9 Vascular insufficiency of intestine
O2 Benign prostatic hypertrophy
O4 Other genitourinary diseases
Q4 Slipped disc
T Unintentional injuries (hospitalised)
U Intentional injuries (hospitalised)
11. Victorian Emergency Minimum Dataset, T Unintentional injuries (non-hospitalised)
U Intentional injuries (non-hospitalised)
12. Medicare claims database, Health Insurance 
Commission
C5 Abortion
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Annex Table C (continued): Principal data sources for estimation of YLD
Primary data source(a) Disease and injury categories
13. National survey of general practice (BEACH)
AIHW General Practice Statistics and 
Classification Unit (Britt et al. 1999)
B Acute respiratory infections
N1 Peptic ulcer disease
14. Nutrition Information System, Northern Territory
Health Department
E1 Protein-energy malnutrition (Indigenous)
C. Australian population health surveys
15. National Drug Strategy Household Survey 1998, 
AIHW (AIHW 1999a)
J1b Heroin/polydrug dependence & harmful use
X6 Alcohol (consumption prevalences)
16. Survey of Disability, Ageing and Carers 1998, ABS
(ABS 1999a)
O3 Urinary incontinence (severe)
17. National Mental Health Survey 1997, ABS
(ABS 1999b)
J1 Substance use disorders (except heroin)
J3 Affective disorders (check bipolar)
J4 Anxiety disorders (except J4g Separation
anxiety disorder)
J5 Borderline personality disorder
18. Active Australia Baseline Survey 1997
(Bauman 1999)
X3 Physical inactivity (prevalence)
19. National Women’s Longitudinal Health Survey
(Brown et al. 1996)
O3 Urinary incontinence
20. Child Dental Health Survey 1996, AIHW Dental 
Statistics Research Unit (AIHW DSRU 1998)
S1 Dental caries
21. National Oral Health Survey 1988-89 , AIHW Dental 
Statistics Research Unit (AIHW DSRU 1998)
S1 Dental caries
S2 Periodontal disease
S3 Edentulism
22 South Australian Dental Surveys 1988 to 1996, 
AIHW Dental Statistics Research Unit
(AIHW DSRU 1998)
S1 Dental caries
S3 Edentulism
23. National Health Survey 1995, ABS
(ABS 1996a)
B2 Upper respiratory tract infections (colds)
B3 Otitis media
H2 Type 2 diabetes (diagnosed)
M3 Other chronic respiratory diseases
O4 Other genitourinary diseases (menstrual)
P2 Other skin diseases
Q3 Chronic back pain
Q6 Osteoporosis
Q7 Other musculoskeletal disorders
X1 Tobacco smoking (prevalence)
24. National Nutrition Survey 1995, ABS
(ABS 1996b)
X4 High blood pressure (prevalence)
25. Survey of Disability, Ageing and Carers 1993, ABS
(ABS 1993)
L8 Peripheral arterial disease
Q5 Occupational overuse syndrome
26. Risk Factor Prevalence Study 1989, National Heart 
Foundation of Australia (Risk Factor Study 
Management Committee 1990)
L1 Ischaemic heart disease (angina)
X5 High blood cholesterol (prevalence)
27. National Oral Health Survey 1987-88, AIHW Dental 
Statistics Research Unit (AIHW DSRU 1998)
S1 Caries
S3 Edentulism
D. Epidemiological studies
28. Meta-analyses of epidemiological studies K1 Dementia
X1 Tobacco smoking (relative risks)
X2 Alcohol (relative risks)
X3 Illicit drugs (relative risks)
X3 Physical inactivity (relative risks)
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Primary data source(a) Disease and injury categories
29. Australian epidemiological studies A11 Trachoma
B3 Otitis media (Indigenous)
D4 Other neonatal causes
E2 Iron-deficiency anaemia
F11 Non-melanoma skin cancers
I1a Thalassaemia
I2 Cystic  fibrosis
I3 Haemophilia
J6 Eating disorders
J8 Mental retardation
K4 Multiple sclerosis
K8 Sense organ disorders
L3 Stroke
M1 Chronic obstructive pulmonary disease
M2 Asthma
N2. Cirrhosis of the liver
P1 Eczema
R9 Other chromosomal anomalies
V2 Chronic fatigue syndrome
X8 Unsafe sex (attributable fractions)
X9 Occupation (attributable fractions)
30. Overseas  epidemiological studies H2 Type 2 diabetes (undiagnosed)
J2 Schizophrenia
J7b Autism and Asperger’s syndrome
K2 Epilepsy
K3 Parkinson's disease
K5 Motor neuron disease
K7 Muscular dystrophy
L5 Hypertensive heart disease
N8 Inflammatory bowel disease
Q1 Rheumatoid arthritis
Q2 Osteoarthritis
X2 Obesity (relative risks)
X4 High blood pressure (risks)
X5 High blood cholesterol (risks)
E. Estimates
31. Derived from Global Burden of Disease Study L1. Rheumatic heart disease
S2 Periodontal disease
32. Expert estimates J4g Separation anxiety disorder
J7a Attention-deficit hyperactivity disorder
33. Extrapolation from Australian mortality data(b) A12 Other infectious and parasitic diseases
C6 Other maternal conditions
I4 Other endocrine and metabolic disorders
K9 Other nervous system disorders
L9 Other cardiovascular disease
M3 Other chronic respiratory disease
N10 Other digestive system diseases
R10 Other congenital anomalies
(a) Primary source for estimates of incidence or prevalence. For many disease categories, multiple sources were used and
estimates
cross checked for consistency and validity. Detailed descriptions of analyses for specific disease and injury categories are in the
YLD worksheets, which are available on request.
(b) YLD for most ‘Other’ categories have been estimated from YLL by applying the average YLD/YLL ratio for other conditions in the
same disease group.
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Annex Table D: Incidence and prevalence of disease and injury, by sex and cause, Australia,
1996
Incidence per 1,000(a)
   Prevalence per
   1,000(b)    Total
Disease category Male Female Male Female Incidence Prevalence
A. Infectious & parasitic diseases(c)
 1. Tuberculosis 0.1 0.1 — — 1,067 —-
2. Sexually transmitted diseases
(apart from HIV/AIDS)
a. Syphilis 0.1 0.1 — — 1,749 —
b. Chlamydia 1.1 0.6 — — 15,291 —
c. Gonorrhoea 0.2 0.1 — — 2,594 —
d. Other STDs(d) 0.0 1.0 — — 9,225 —
3. HIV/AIDS(e) 0.0 0.0 0.9 0.1 473 9,110
4. Diarrhoeal diseases 204.6 205.5 1.7 1.7 3,754,216 30,860
5. Childhood immunisable diseases
a. Diphtheria 0.0 0.0 — — 0 —
b. Whooping cough 0.2 0.3 — — 5,052 —
c. Tetanus 0.0 0.0 — — 2 —
d. Polio 0.0 0.0 — — 0 —
e. Measles 0.0 0.0 — — 249 —
f. Rubella 0.2 0.1 — — 2,862 —
g. Hib 0.0 0.0 — — 150 —
6. Meningitis 0.1 0.1 — — 1,169 —
7. Septicaemia 0.9 0.7 — — 14,618 —
8. Arbovirus infection —
a. Roos River virus infection 0.8 0.9 — — 15,614 —
b. Barmah Forest virus infection 0.1 0.1 — — 1,662 —
c. Dengue and other arbovirus 0.0 0.0 — — 119 —
9. Hepatitis(f)
a. Hepatitis A 0.8 0.4 — — 10,762 —
b. Hepatitis B 0.0 0.0 — — 322 —
c. Hepatitis C 0.8 0.4 — — 11,000 —
10. Malaria 0.1 0.0 — — 847 —
B. Acute respiratory infections
1. Lower respiratory tract infections 174.5 205.5 — — 3,480,150 —
2. Upper respiratory tract infections 2,283.1 2,456.3 — — 43,399,250 —
3. Otitis media 52.5 58.7 2.3 2.3 1,018,490 41,420
C. Maternal conditions
1. Maternal haemorrhage 0.0 3.5 — — 32,406 —
2. Maternal sepsis 0.0 0.2 — — 2,109 —
3. Hypertension in pregnancy 0.0 3.1 — — 28,799 —
4. Obstructed labour 0.0 1.4 — — 12,524 —
5. Abortion(g) 0.0 13.7 — — 125,700 —
D. Neonatal causes
1. Birth trauma and asphyxia 4.8
(h) 3.5(h) 1.1(i) 0.8(i) 1,074 17,510
2. Low birth weight 59.9
(h) 68.8(h) 3.9(i) 4.4(i) 16,502 76,070
3. Neonatal infections 47.2
(h) 38.0(h) 0.0(i) 0.0(i) 10,992 315
4. Other neonatal causes (j) 0.4(h) 0.3(h) 0.3(i) 0.2(i) 99 5,180
E. Nutritional deficiencies
1. Protein-energy malnutrition 0.1 0.1 1.2 1.1 1,400 21,130
2. Iron deficiency (with or without
anaemia) — — 33.6 67.0 — 769,400
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Incidence per 1,000(a)
   Prevalence per
   1,000(b)    Total
Disease category Male Female Male Female Incidence Prevalence
II. Non-communicable diseases
F. Malignant neoplasms(k)
1. Mouth and oropharynx cancers 0.2 0.1 — — 2,666 —
2. Oesophagus cancer 0.1 0.0 — — 1,044 —
3. Stomach cancer 0.1 0.1 — — 1,937 —
4. Colorectal cancer 0.7 0.6 — — 11,203 —
5. Liver cancer 0.0 0.0 — — 623 —
6. Gall bladder cancer 0.0 0.0 — — 549 —
7. Pancreas cancer 0.1 0.1 — — 1,698 —
8. Lung cancer 0.4 0.2 — — 5,538 —
9. Bone and connective tissue cancers 0.0 0.0 — — 764 —
10. Melanoma 0.5 0.4 — — 7,797 —
11. Non-melanoma skin cancers 18.4 12.5 — — 282,825 —
12. Breast cancer 0.0 0.9 — — 8,630 —
13. Cervix cancer 0.0 0.1 — — 1,117 —
14. Uterus cancer 0.0 0.2 — — 1,508 —
15. Ovary cancer 0.0 0.1 — — 1,168 —
16. Prostate cancer 1.1 0.0 — — 10,444 —
17. Testicular cancer 0.1 0.0 — — 572 —
18. Bladder cancer 0.2 0.1 — — 2,648 —
19. Kidney cancer 0.1 0.1 — — 1,921 —
20. Brain cancer 0.2 0.1 — — 2,288 —
21. Thyroid cancer 0.0 0.1 — — 812 —
22. Lymphoma 0.2 0.2 — — 3,508 —
23. Multiple myeloma 0.1 0.0 — — 806 —
24. Leukemia 0.1 0.1 — — 2,041 —
G. Other neoplasms
1. Uterine myomas 0.0 2.2 0.0 3.5 20,307 31,860
2. Benign brain tumour 0.0 0.1 0.1 0.1 1,017 1,970
H. Diabetes mellitus
1. Type 1 diabetes 0.1 0.1 0.4 0.4 1,841 73,590
2. Type 2 diabetes 2.3 1.6 2.7 2.4 35,503 469,380
I. Endocrine and metabolic disorders
1. Non-deficiency anaemia 0.5 0.5 0.5 0.4 8,417 8,370
2. Cystic  fibrosis 0.5(h) 0.5(h) 0.3 0.2 127 4,010
3. Haemophilia 0.1
(h) 0.0(h) 0.1 0.0 9 522
J. Mental disorders
1. Substance use disorders
a. Alcohol dependence/harmful use 13.2 4.5 5.9 2.1 161,482 727,820
b. Heroin or polydrug dependence
and harmful use 0.3 0.2 0.3 0.2 4,284 41,790
c. Sedative dependence/abuse 0.3 0.3 1.1 1.0 5,253 19,230
d. Cannabis dependence/abuse 3.6 1.1 14.1 4.6 42,935 170,960
e. Other drug dependence/abuse 4.0 1.2 3.2 0.9 47,961 38,130
2. Schizophrenia 0.1 0.1 0.4 0.3 1,611 64,800
3. Affective disorders
a. Depression(l) 12.7 28.4 1.8 4.1 376,721 538,050
b. Bipolar affective disorder 0.3 0.3 0.7 0.7 6,062 133,360
208
Annex Table D (continued): Incidence and prevalence of disease and injury, by sex and
cause, Australia 1996
Incidence per 1,000(a)
   Prevalence per
   1,000(b)    Total
Disease category Male Female Male Female Incidence Prevalence
4. Anxiety disorders(m)
a. Panic disorder 0.3 0.8 3.1 11.0 10,173 128,740
b. Agoraphobia 0.2 0.4 1.8 6.0 5,124 71,390
c. Social phobia 1.1 1.2 14.3 17.5 20,998 291,070
d. Generalised anxiety disorder 0.9 1.5 11.6 19.5 21,998 285,560
e. Obsessive-compulsive disorder 0.2 0.3 1.4 1.8 4,511 29,090
f. Post-traumatic stress disorder 0.4 0.6 4.1 5.6 9,091 88,360
g. Separation anxiety disorder 4.1 3.9 5.8 5.4 73,199 102,480
5. Borderline personality disorder 0.9 0.6 3.9 2.9 13,790 61,900
6. Eating disorders 0.0 0.7 0.2 4.4 7,031 42,940
7. Childhood conditions
a. Attention-deficit disorder 1.6 0.6 13.8 5.2 20,138 173,250
b. Autism and Asperger’s syndrome 0.0 0.0 2.7 0.6 528 29,730
 8. Mental retardation 0.0 0.0 1.4 1.0 333 21,840
K. Nervous system and sense organ
 disorders
1. Dementia 1.0 1.6 5.3 8.3 23,834 124,290
2. Epilepsy 0.3 0.3 0.4 0.3 5,258 6,280
3. Parkinson’s disease 0.3 0.5 1.3 2.6 7,730 36,430
4. Multiple sclerosis 0.0 0.0 0.0 0.1 394 767
5. Motor neuron disease 0.0 0.0 0.0 0.0 348 594
6. Huntington’s chorea 0.0 0.0 0.1 0.1 104 1,560
7. Muscular dystrophy 0.0 0.0 0.1 0.0 40 732
 8. Sense organ disorders
a. Glaucoma(n) 0.7 0.9 7.5 10.4 14,230 164,040
b. Cataracts 0.6 1.5 5.3 13.1 19,252 168,830
c. Age-related vision disorders 0.4 1.3 2.5 8.1 16,001 97,770
d. Adult-onset hearing loss 7.7 4.5 246.6 91.6 111,484 3,088,320
L. Cardiovascular disease
1. Rheumatic heart disease 0.0 0.1 0.1 0.3 766 3,780
2. Ischaemic heart disease(o)
Angina pectoris 3.1 1.7 9.9 8.4 44,548 168,150
Acute myocardial infarction 2.4 1.5 1.3 0.4 35,566 14,930
3. Stroke 2.9 3.3 7.4 5.9 57,244 121,260
4. Inflammatory heart disease 0.5 0.3 1.6 0.8 7,602 21,750
5. Hypertensive heart disease 0.1 0.2 0.1 0.4 2,131 5,100
6. Non-rheumatic valvular disease 0.2 0.2 0.6 0.5 3,580 10,200
7. Aortic aneurysm 0.8 0.3 0.1 0.0 10,223 818
8. Peripheral arterial disease 0.7 0.4 4.3 2.8 10,170 65,030
M. Chronic respiratory disease
1. COPD 1.3 0.9 19.4 13.0 20,162 296,590
2. Asthma 3.5 4.1 58.6 73.0 69,434 1,206,140
3. Other chronic respiratory diseases 0.7 0.5 2.9 2.8 11,136 51,870
N. Diseases of the digestive system
1. Peptic ulcer disease 8.0 9.0 8.6 10.4 156,045 174,070
2. Cirrhosis of the liver 0.1 0.0 0.7 0.5 1,017 10,670
3. Appendicitis(p) 1.4 1.2 0.1 0.0 23,896 960
4. Intestinal obstruction(p) 1.5 1.6 0.7 0.8 27,923 13,980
5. Diverticulitis(p) 3.8 4.6 0.6 0.7 77,117 11,890
6. Gall bladder and bile duct disease(p) 2.3 4.9 0.1 0.3 66,132 3,820
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Incidence per 1,000(a)
   Prevalence per
   1,000(b)    Total
Disease category Male Female Male Female Incidence Prevalence
7. Pancreatitis(p) 0.7 0.5 0.0 0.0 11,303 652
8. Inflammatory bowel disease 0.1 0.1 3.3 3.9 1,491 66,470
9. Vascular insufficiency of intestine(p) 0.1 0.1 0.2 0.2 2,356 3,070
O. Genitourinary diseases
1. Nephritis and nephrosis(q) 0.2 0.2 0.6 0.4 3,283 9,360
2. Benign prostatic hypertrophy(r) 5.9 0.0 21.5 0.0 53,752 195,440
3. Urinary incontinence(s) 0.4 1.0 5.5 27.9 12,985 307,210
4a. Menstrual disorders(t) 0.0 11.6 0.0 2.9 106,952 26,740
4b. Infertility(u) 1.4 2.1 4.4 7.2 32,248 105,540
P. Skin diseases
1. Eczema 1.6 3.1 2.1 4.0 42,306 55,710
2. Other skin diseases 4.8 5.0 6.6 7.2 89,708 125,940
Q. Musculoskeletal diseases
1. Rheumatoid arthritis 0.1 0.3 1.9 4.1 3,799 55,090
2. Osteoarthritis 1.7 2.9 26.5 41.7 42,675 625,090
3. Chronic back pain(v) 344.9 314.5 33.0 31.0 6,035,367 585,850
4. Slipped disc(w) 9.2 6.5 23.5 13.7 143,489 340,120
5. Occupational overuse syndrome 0.1 0.6 0.2 1.9 6,618 19,850
6. Osteoporosis 0.2 1.4 3.2 13.7 14,358 155,220
7. Other musculoskeletal disorders(x) 140.1 138.5 37.0 30.6 2,551,313 618,600
R. Congenital anomalies(h)
1. Anencephaly 0.0 0.0 — — 10 —
2. Spina bifida 0.2 0.2 — — 42 —
3. Congenital heart disease 2.9 3.2 — — 774 —
4. Cleft lip and/or palate 1.4 1.2 — — 324 —
5. Digestive system malformations 0.9 0.5 — — 170 —
6. Urogenital tract malformations 8.6 3.6 — — 1,578 —
7. Abdominal wall defect 0.3 0.4 — — 84 —
8. Down syndrome 1.0 0.9 — — 252 —
9. Other chromosomal anomalies 1.3 1.0 — — 291 —
S. Oral health
1. Dental caries(y) 596.4 591.7 1,050.4 1,026.6 10,877,803 19,014,040
2. Periodontal disease(z) 21.4 22.2 54.3 57.9 399,688 1,027,180
3. Edentulism 1.5 3.5 43.1 109.1 45,212 1,396,740
V. Ill-defined conditions
1. Sudden infant death syndrome 0.0 0.0 — —- 215 —
2. Chronic fatigue syndrome 0.2 0.4 0.4 1.0 5,508 13,340
III. Injuries(#)
T. Unintentional injuries
1. Road traffic accidents 6.0 3.6 3.8 1.8 88,139 50,470
2. Other transport accidents 2.5 0.6 1.1 0.3 28,012 12,650
3. Poisoning 1.3 1.3 0.4 0.2 23,969 5,150
4. Falls 19.2 20.0 3.3 2.4 359,141 51,460
5. Fires/burns/scalds 1.8 1.1 16.9 8.4 25,901 231,240
6. Drowning 0.0 0.0 0.1 0.0 502 1,060
7. Sports injuries 5.7 2.0 0.9 0.2 70,732 9,800
8. Natural and environmental factors 2.7 1.1 0.4 0.3 35,217 6,330
9. Machinery accidents 2.3 0.2 4.8 0.6 22,861 49,340
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Incidence per 1,000(a)
   Prevalence per
   1,000(b)    Total
Disease category Male Female Male Female Incidence Prevalence
10. Suffocation and foreign bodies 0.0 0.0 0.1 0.0 377 1,170
11. Adverse effects of medical treatment 0.6 0.8 0.9 1.3 12,571 19,830
a. Surgical/medical misadventure 0.1 0.2 0.3 0.6 3,403 7,800
b. Adverse effects of drugs in
therapeutic use
0.4 0.6 0.6 0.7 9,168 12,040
12. Other unintentional injuries 49.8 48.6 23.9 17.1 900,052 375,710
U. Intentional Injuries
1. Suicide and self-inflicted injuries 1.3 1.7 0.4 0.3 28,147 6,910
2. Homicide and violence 4.0 1.2 1.6 0.5 47,585 19,000
3. Legal intervention and war 0.0 0.0 0.0 0.0 455 82
(a) Incident cases of disease or injury per 1,000 total male and female population, except where otherwise specified.
(b) Prevalent cases of disease or injury per 1,000 total male and female population, except where otherwise specified. All
prevalence estimates over 1,000 cases have been rounded to the nearest 10. Some prevalence estimates are derived from
DISMOD modelling of incidence and duration and assume a stationary population with no trends in incidence rates or average
duration.
(c) Apart from HIV/AIDS and diarrhoeal diseases, prevalences of infectious and parasitic diseases have not been estimated.
(d) Hospitalised pelvic inflammatory disease, excluding proportion attributed to chlamydia or gonorrhea.
(e) Estimated prevalence of HIV/AIDS based on 1996 incidence rates assuming that current average survival times have held in
the past. The actual prevalence of HIV/AIDS will be lower due to lower survival times in earlier years than at present.
(f) Acute symptomatic infections.
(g) Includes an estimated 35,000 spontaneous abortions and 90,700 terminations of pregnancy.
(h) Incident cases per 1,000 livebirths.
(i) Prevalent cases with long-term disability resulting from the condition.
(j) Incidence of intellectual disability due to other perinatal causes.
(k) Prevalences of cancer cases have not yet been estimated, although this could be done using the cancer YLD models.
(l) People with dysthymia or experiencing major depressive episode in 12-month period of 1996.
(m) People experiencing symptomatic episodes in 12-month period of 1996.
(n) Glaucoma estimates relate to primary open angle glaucoma (whether or not causing sight impairment) and include diabetes
related glaucoma.
(o) Incidence refers to total AMI events, prevalence to post-AMI heart failure.
(p) Incident cases estimated from hospitalisation data.
(q) All end-stage renal failure including renal failure due to infections, cancer, diabetes, congenital and injury cases (these
excluded from DALY estimates for nephritis and nephrosis).
(r) Symptomatic benign prostate enlargement resulting in treatment.
(s) Moderate and severe urinary incontinence (leaking urine occurring ‘often’) not due to neurological disorders, stroke, prostate
problems or other diseases or injury.
(t) Based on self-reported episodes of menstrual problems in 1995 National Health Survey.
(u) Incidence and prevalence of persons with infertility resulting in inability to achieve desired reproductive outcomes over a period
of 12 months or longer. Excludes infertility due to other diseases and infertility resulting from surgery
(v) Incidence refers to episodes of backpain resulting in activity limitations.
(w) Incidence refers to total episodes of intervertebral disc disorders in 1996, prevalence refers to number of people with chronic
conditions.
(x) Incident episodes of other musculoskeletal disorders, prevalence to number of people with chronic musculoskeletal conditions.
(y) Prevalence estimates relate to total decayed teeth (excluding missing and filled teeth), not to people with decayed teeth.
(z) Periodontal disease with pockets 6 mm or more deep.
(#) Prevalence estimates are for long-term sequelae of injuries only.
Annex Table E: Deaths by age, sex and cause, Australia, 1996
Male Female
Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
All causes 128,711 68,201 60,510 1,310 3,298 6,486 25,023 32,084 942 1,072 3,708 14,665 40,123
I   Communicable diseases, maternal
and neonatal conditions
4,719 2,531 2,187 452 207 428 551 894 348 50 107 326 1,356
A. Infectious & parasitic diseases 1,960 1,271 689 36 193 371 311 359 18 29 58 163 421
 1. Tuberculosis 77 49 28 1 — 1 18 29 — 1 — 12 15
2. Sexually transmitted diseases
(apart from HIV/AIDS)
5 3 2 — 2 — — 1 — — — 1 1
a. Syphilis 3 3 — — 2 — — 1 — — — — —
b. Chlamydia 2 — 2 — — — — — — — — 1 1
c. Gonorrhoea — — — — — — — — — — — — —
d. Other STDs — — — — — — — — — — — — —
3. HIV/AIDS 526 509 17 — 165 294 49 1 — 8 7 2 —
4. Diarrhoeal diseases 82 27 55 3 — 1 3 20 — 1 1 8 45
5. Childhood immunisable diseases 16 11 5 3 1 — 4 3 — 1 2 1 1
a. Diphtheria — — — — — — — — — — — — —
b. Whooping cough 2 2 — 2 — — — — — — — — —
c. Tetanus — — — — — — — — — — — — —
d. Polio 11 7 4 — — — 4 3 — — 2 1 1
e. Measles 2 1 1 — 1 — — — — 1 — — —
f.  Rubella 1 1 — 1 — — — — — — — — —
g. Haemophilus influenzae type b — — — — — — — — — — — — —
6. Meningitis 71 38 32 20 4 8 3 3 8 7 3 5 9
7. Septicaemia 595 280 315 4 2 10 74 189 3 2 8 41 261
8. Arbovirus infection (Ross River etc.) — — — — — — — — — — — — —
9. Hepatitis 362 233 129 — 9 39 113 72 — 3 26 54 46
a. Hepatitis A 3 2 1 — — 1 — 1 — — — 1 —
b. Hepatitis B 107 62 45 — 6 18 27 11 — 1 19 15 9
c. Hepatitis C 253 169 84 — 2 21 87 59 — 2 7 38 37
10. Malaria 2 2 — — 1 — 1 — — — — — —
11. Trachoma — — — — — — — — — — — — —
12. Other infectious and parasitic 223 119 105 5 9 18 45 41 7 5 11 39 42
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Male Female
Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
B. Acute respiratory infections 1,912 817 1,095 24 13 56 228 494 21 10 40 154 869
1. Lower respiratory tract infections 1,875 805 1,071 20 13 55 226 489 18 9 38 152 853
2. Upper respiratory tract infections 27 7 20 1 — 1 2 3 2 — 2 1 15
3. Otitis media 9 5 4 3 — — — 2 1 1 — 1 1
C. Maternal conditions 12 — 12 — — — — — — 7 5 — —
1. Maternal haemorrhage 2 — 2 — — — — — — 1 1 — —
2. Maternal sepsis 2 — 2 — — — — — — 1 1 — —
3. Hypertension in pregnancy 2 — 2 — — — — — — 2 — — —
4. Obstructed labour — — — — — — — — — — — — —
5. Abortion 1 — 1 — — — — — — — 1 — —
6. Other maternal conditions 5 — 5 — — — — — — 3 2 — —
D. Neonatal causes 703 392 311 392 — — — — 309 — 2 — —
1. Birth trauma and asphyxia 209 116 94 116 — — — — 92 — 2 — —
2. Low birthweight 277 155 123 155 — — — — 123 — — — —
3. Neonatal infections 72 40 32 40 — — — — 32 — — — —
4. Other neonatal causes 144 81 62 81 — — — — 62 — — — —
E. Nutritional deficiencies 132 52 80 — — — 12 40 — 3 2 9 66
1. Protein-energy malnutrition 71 34 37 — — — 8 26 — 1 2 5 29
2. Iron-deficiency anaemia 56 16 40 — — — 3 13 — 2 — 3 35
3. Other nutritional deficiencies 5 2 3 — — — 1 1 — — — 1 2
II. Non—communicable diseases 116,447 60,248 56,200 606 913 4,527 23,622 30,579 459 537 3,140 13,989 38,075
F. Malignant neoplasms 34,526 19,496 15,030 82 243 1,804 9,681 7,685 61 223 2,011 6,252 6,482
1. Mouth and oropharynx cancers 780 552 228 — 3 83 366 100 — 1 28 98 101
2. Oesophagus cancer 1,011 657 354 — — 69 350 238 — — 21 135 197
3. Stomach cancer 1,321 799 521 — 8 90 379 323 — 3 45 202 271
4. Colorectal cancer 4,973 2,674 2,299 — 10 241 1,493 930 — 17 208 934 1,140
5. Liver cancer 384 275 108 2 — 37 175 61 1 1 3 61 42
6. Gall bladder cancer 353 114 239 — — 12 53 49 — — 20 96 124
7. Pancreas cancer 1,738 828 910 — 3 74 431 319 — 3 50 326 531
8. Lung cancer 7,307 5,090 2,217 — 2 397 2,953 1,738 — 5 242 1,138 832
9. Bone and connective tissue cancers 308 160 148 7 26 16 62 49 3 19 24 44 58
10. Melanoma 978 626 352 — 32 134 254 206 1 13 90 111 138
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Male Female
Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
11. Non-melanoma skin cancers 398 269 129 — — 16 96 158 — — 6 34 88
12. Breast cancer 2,823 — 2,823 — — — — — — 41 689 1,184 909
13. Cervix cancer 325 — 325 — — — — — — 16 92 123 94
14. Uterus cancer 306 — 306 — — — — — — — 21 141 144
15. Ovary cancer 878 — 878 — — — — — 1 13 135 409 321
16. Prostate cancer 2,846 2,846 — — — 31 979 1,836 — — — — —
17. Testicular cancer 32 32 — — 15 11 4 2 — — — — —
18. Bladder cancer 851 588 262 1 3 23 221 339 — 1 9 73 179
19. Kidney cancer 881 510 371 2 — 51 262 196 2 2 32 155 180
20. Brain cancer 1,068 637 430 18 50 157 290 122 22 29 90 191 99
21. Thyroid cancer 77 32 45 — 1 5 14 12 — — 5 10 30
22. Lymphoma 1,595 810 785 6 27 126 372 279 1 19 87 325 352
23. Multiple myeloma 640 350 290 — — 36 166 148 — 1 21 132 136
24. Leukemia 1,401 818 583 31 48 93 327 320 25 30 50 181 297
25. Other malignant neoplasms 1,253 827 426 15 14 102 435 260 5 10 43 150 218
G. Other neoplasms 583 304 279 7 8 18 84 186 5 7 19 53 195
1. Uterine myomas 4 — 4 — — — — — — — 4 — —
2. Benign brain tumour 64 31 33 — — 5 13 13 — 2 6 10 15
3. Other benign neoplasms 515 273 242 7 8 13 71 173 5 5 9 43 179
H. Diabetes mellitus 3,269 1,694 1,575 — 9 108 694 883 2 7 74 464 1,028
1. Type 1 diabetes 174 78 96 — 8 20 26 25 2 4 17 27 45
2. Type 2 diabetes 3,095 1,616 1,479 — 2 89 667 858 — 3 57 437 983
I. Endocrine and metabolic disorders 1,205 595 610 20 29 86 237 223 25 31 56 163 334
1. Non-deficiency anaemia 154 60 93 3 4 2 18 33 1 4 7 19 62
2. Cystic fibrosis 39 17 22 3 12 2 — — 6 14 2 — —
3. Haemophilia 35 17 18 1 — 4 6 6 — — 4 5 9
4. Other endocrine and metabolic 977 501 477 13 12 78 213 184 18 13 43 139 263
J. Mental disorders 1,012 630 381 2 265 182 103 78 — 60 54 80 187
1. Substance use disorders 900 590 310 1 264 178 95 52 — 55 46 71 138
a. Alcohol dependence/harmful use 270 215 54 — 20 70 90 36 — 4 19 21 10
b. Heroin or polydrug dependence
and harmful use
406 335 72 — 231 102 2 — — 49 23 — —
c. Sedative dependence/abuse 7 4 3 — 1 2 1 — — — 2 — 1
d. Cannabis dependence/abuse — — — — — — — — — — — — —
e. Other drug dependence/abuse 217 36 181 1 12 5 2 16 — 2 2 50 127
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Male Female
Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
2. Schizophrenia 22 8 14 — 1 2 2 3 — — 2 4 8
3. Affective disorders 41 15 26 — — — 1 14 — — — 1 25
a. Depression 36 15 21 — — — 1 14 — — — — 21
b. Bipolar affective disorder 5 — 5 — — — — — — — — 1 4
4. Anxiety disorders 1 — 1 — — — — — — — — — 1
a. Panic disorder 1 — 1 — — — — — — — — — 1
b. Agoraphobia — — — — — — — — — — — — —
c. Social phobia — — — — — — — — — — — — —
d. Generalised anxiety disorder — — — — — — — — — — — — —
e. Obsessive-compulsive disorder — — — — — — — — — — — — —
f.  Post-traumatic stress disorder — — — — — — — — — — — — —
g. Separation anxiety disorder — — — — — — — — — — — — —
5. Borderline personality disorder — — — — — — — — — — — — —
6. Eating disorders 16 3 13 — — — — 3 — 4 4 1 4
7. Childhood conditions — — — — — — — — — — — — —
a. Attention-deficit disorder — — — — — — — — — — — — —
b. Autism and Asperger’s syndrome — — — — — — — — — — — — —
 8. Mental retardation 4 1 3 — — — — 1 — 1 1 1 —
9. Other mental disorders 27 13 14 1 — 2 5 5 — — 1 2 11
K. Nervous system and sense organ
 disorders
5,812 2,402 3,409 67 98 134 514 1,589 35 53 84 400 2,837
1. Dementia 3,897 1,305 2,593 9 1 2 178 1,114 5 3 4 164 2,416
2. Epilepsy 260 161 99 14 45 52 32 18 4 30 18 23 24
3. Parkinsons’s disease 685 403 283 — — 1 97 305 — — 1 36 246
4. Multiple sclerosis 102 27 75 — — 10 12 5 — 2 26 33 14
5. Motor neuron disease 342 212 130 — 2 32 117 60 — 1 11 73 45
6. Huntington’s chorea 40 24 16 — — 9 9 6 — — 2 8 6
7. Muscular dystrophy 44 37 7 6 21 6 2 2 — 2 2 2 1
 8. Sense organ disorders — — — — — — — — — — — — —
a. Glaucoma — — — — — — — — — — — — —
b. Cataracts — — — — — — — — — — — — —
c. Age-related vision disorders — — — — — — — — — — — — —
d. Adult-onset hearing loss — — — — — — — — — — — — —
9. Other nervous system, sense organ 441 234 206 38 29 22 66 79 25 14 20 61 85
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Male Female
Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
L. Cardiovascular disease 53,791 26,456 27,335 23 164 1,673 9,345 15,251 17 72 519 4,613 22,115
1. Rheumatic heart disease 347 125 221 1 7 11 51 55 1 2 15 91 112
2. Ischaemic heart disease 32,681 17,263 15,418 — 66 1,168 6,524 9,505 — 20 233 2,738 12,427
3. Stroke 12,839 5,216 7,623 3 28 222 1,436 3,528 3 20 162 1,078 6,361
4. Inflammatory heart disease 1,265 759 506 14 28 141 324 251 8 18 47 129 304
5. Hypertensive heart disease 1,643 618 1,025 — 3 21 148 446 — 0 6 110 908
6. Non-rheumatic valvular disease 933 433 500 — 3 24 143 262 1 1 13 76 409
7. Aortic aneurysm 1,438 909 529 — 4 33 378 494 — 1 5 140 383
8. Peripheral arterial disease 693 302 391 — — 3 89 209 — — 5 51 335
9. Other cardiovascular disease 1,952 831 1,121 5 24 50 252 500 4 11 33 199 874
M. Chronic respiratory disease 8,469 4,951 3,519 15 26 116 1,812 2,982 14 23 121 1,163 2,197
1. COPD 6,163 3,822 2,342 2 2 56 1,461 2,301 6 4 55 892 1,384
2. Asthma 733 300 433 9 19 32 120 120 4 16 50 133 230
3. Other chronic respiratory diseases 1,573 829 744 4 5 27 231 561 4 3 16 138 583
N. Diseases of the digestive system 3,904 2,030 1,873 12 25 343 816 835 3 13 128 429 1,299
1. Peptic ulcer disease 654 288 366 — — 13 93 183 — — 6 57 303
2. Cirrhosis of the liver (non-hepatitis) 1,318 888 430 1 15 280 448 144 — 6 86 165 172
3. Appendicitis 27 16 11 1 — 2 5 8 — 1 2 2 6
4. Intestinal obstruction 357 139 218 4 1 2 31 101 1 1 6 12 198
5. Diverticulitis 187 73 113 — 1 5 25 42 — — 3 23 87
6. Gall bladder and bile duct disease 237 116 120 — 2 3 35 76 — 1 3 24 92
7. Pancreatitis 174 96 78 1 1 13 42 39 — — 4 24 50
8. Inflammatory bowel disease 37 19 18 — — 4 6 9 — — 2 7 9
9. Vascular insufficiency of intestine 356 141 214 — 1 3 59 78 — 1 3 53 157
10. Other digestive system diseases 558 253 305 5 3 18 72 154 2 3 13 63 224
O. Genitourinary diseases 1,945 873 1,072 1 8 22 174 667 2 1 19 178 872
1. Nephritis and nephrosis 1,441 651 790 1 7 15 102 526 1 1 10 98 679
2. Benign prostatic hypertrophy 38 38 — — — — 9 29 — — — — —
3. Urinary incontinence — — — — — — — — — — — — —
4. Other genitourinary diseases 466 183 283 — 1 7 63 112 1 — 8 80 194
P. Skin diseases 176 58 117 — — 3 12 43 — 1 1 12 103
1. Eczema 2 1 1 — — — — 1 — — — — 1
2. Other skin diseases 174 57 116 — — 3 12 42 — 1 1 12 102
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Annex Table E (continued): Deaths by age, sex and cause, Australia, 1996
Male Female
Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
Q. Musculoskeletal diseases 796 236 561 — 1 11 104 119 3 12 17 139 389
1. Rheumatoid arthritis 209 55 154 — — 1 30 24 — 2 3 50 99
2. Osteoarthritis 96 25 71 — — 1 6 18 — — — 2 69
3. Chronic back pain 6 3 3 — — — 2 1 — — — 1 2
4. Slipped disc 4 2 2 — — — 1 1 — — — 1 1
5. Occupational overuse syndrome — — — — — — — — — — — — —
6. Osteoporosis 86 12 74 — — — 3 9 — — — 8 66
7. Other musculoskeletal disorders 394 138 256 — 1 9 62 66 3 10 14 77 152
R. Congenital anomalies 737 398 339 253 37 26 44 37 199 33 36 41 30
1. Anencephaly 12 6 6 6 — — — — 6 — — — —
2. Spina bifida 15 8 7 5 2 — 1 — 6 1 — — —
3. Congenital heart disease 249 136 113 92 18 14 9 3 70 20 13 8 3
4. Cleft lip and/or palate — — — — — — — — — — — — —
5. Digestive system malformations 23 10 13 5 1 — 1 3 9 1 1 2 —
6. Urogenital tract malformations 129 75 54 19 3 2 22 28 9 0 3 18 23
7. Abdominal wall defect 2 2 — 2 — — — — — — — — —
8. Down syndrome 48 24 24 7 2 4 10 1 6 — 8 9 1
9. Other chromosomal disorders 46 18 28 18 — — — — 26 — 1 1 —
10. Other congenital anomalies 212 119 93 98 11 6 1 2 67 11 9 3 3
S. Oral health 9 2 7 — — — 1 1 — — — 1 6
1. Dental caries 1 — 1 — — — — — — — — — 1
2. Periodontal disease — — — — — — — — — — — — —
3. Edentulism — — — — — — — — — — — — —
4. Other oral health problems 8 2 6 — — — 1 1 — — — 1 5
V. Ill—defined conditions 214 123 92 123 — — — — 92 — — — —
1. Sudden infant death syndrome 214 123 92 123 — — — — 92 — — — —
2. Chronic fatigue syndrome — — — — — — — — — — — — —
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Annex Table E (continued): Deaths by age, sex and cause, Australia, 1996
Male Female
Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
III. Injuries 7,545 5,422 2,123 252 2,178 1,531 850 611 135 485 461 350 692
T. Unintentional injuries 4,701 3,175 1,526 229 1,198 761 494 493 115 281 216 254 660
1. Road traffic accidents 2,050 1,481 570 94 740 346 183 118 53 197 120 111 89
2. Other transport accidents 235 207 29 19 87 59 34 8 6 9 7 5 1
3. Poisoning 370 267 102 5 146 96 11 9 1 38 43 13 7
4. Falls 1,139 546 594 7 43 72 122 301 1 7 10 68 507
5. Fires/burns/scalds 146 99 48 17 22 26 19 15 7 7 8 8 17
6. Drowning 255 194 61 48 58 52 28 9 29 9 9 10 3
7. Sports injuries 5 5 — — 5 — — — — — — — —
8. Natural and environmental factors 56 33 23 2 7 11 7 5 2 4 5 4 8
9. Machinery accidents 59 58 1 3 13 21 17 2 1 — — — —
10. Suffocation and foreign bodies 154 112 43 23 25 31 24 9 8 4 4 16 10
11. Adverse effects of medical treatment 55 27 28 1 2 5 12 6 — 1 5 13 9
a. Surgical/medical misadventure 36 16 19 — 1 3 9 3 — — 3 10 6
b. Adverse effects of drugs in
therapeutic use
19 10 9 1 1 2 3 3 — 1 2 3 3
12. Other unintentional injuries 175 148 27 10 51 42 36 9 6 3 5 5 8
U. Intentional injuries 2,844 2,247 597 23 980 770 356 118 20 205 245 96 32
1. Suicide and self-inflicted injuries 2,515 2,021 494 8 873 704 323 113 7 166 211 83 28
2. Homicide and violence 323 221 102 15 103 65 33 5 13 38 34 13 4
3. Legal intervention and war 6 5 1 — 4 1 — — — 1 — — —
Australian population (’000) 18,272 9,106 9,165 2,005 2,795 2,574 1,387 346 1,906 2,707 2,545 1,446 562
Deaths per 1,000 population 7.04 7.49 6.60 0.65 1.18 2.52 18.04 92.80 0.49 0.40 1.46 10.14 71.39
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Annex Table F: YLL by age, sex and cause, Australia, 1996
Male Female
Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
All causes 1,348,233 752,591 595,642 39,642 88,423 137,235 302,731 186,756 28,808 29,639 83,570 206,007 248,763
I   Communicable diseases, maternal
and neonatal conditions 66,546 40,039 26,507 13,753 5,362 9,401 6,740 4,782 10,706 1,376 2,444 4,531 7,450
A. Infectious & parasitic diseases 28,018 20,399 7,619 1,093 5,009 8,214 3,934 2,147 558 813 1,311 2,320 2,618
 1. Tuberculosis 742 444 298 30 21 223 170 28 169 101
2. Sexually transmitted diseases
(apart from HIV/AIDS) 82 60 22 — 55 — — 4 — — — 16 5
a. Syphilis 60 60 — — 55 — — 4 — — — — —
b. Chlamydia 22 — 22 — — — — — — — — 16 5
c. Gonorrhoea — — — — — — — — — — — — —
d. Other STDs — — — — — — — — — — — — —
3. HIV/AIDS 12,009 11,594 415 — 4,267 6,577 743 8 — 223 159 33 —
4. Diarrhoeal diseases 686 260 426 91 — 23 34 113 — 28 21 110 267
5. Childhood immunisable diseases 286 196 90 92 26 — 55 23 — 30 43 12 5
a. Diphtheria — — — — — — — — — — — — —
b. Whooping cough 61 61 — 61 — — — — — — — — —
c. Tetanus — — — — — — — — — — — — —
d. Polio 138 78 60 — — — 55 23 — — 43 12 5
e. Measles 56 26 30 — 26 — — — — 30 — — —
f.  Rubella 31 31 — 31 — — — — — — — — —
g. Haemophilus influenzae type b — — — — — — — — — — — — —
6. Meningitis 1,605 943 662 607 112 163 43 17 249 203 62 75 73
7. Septicaemia 4,833 2,359 2,474 122 53 213 855 1,116 93 58 183 568 1,571
8. Arbovirus infection (Ross River etc.) — — — — — — — — — — — — —
9. Hepatitis 4,783 2,955 1,828 — 220 844 1,424 467 — 95 594 794 346
a. Hepatitis A 45 29 16 — — 21 — 8 — — — 16 —
b. Hepatitis B 1,729 955 775 — 156 388 337 74 — 35 438 230 71
c. Hepatitis C 3,009 1,972 1,037 — 65 435 1,087 385 — 59 156 547 275
10. Malaria 41 41 — — 26 — 14 — — — — — —
11. Trachoma — — — — — — — — — — — — —
12. Other infectious and parasitic 2,951 1,547 1,404 151 249 374 542 231 215 148 248 543 250
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Annex Table F (continued): YLL by age, sex and cause, Australia, 1996
Male Female
Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
B. Acute respiratory infections 15,795 7,379 8,416 732 353 1,186 2,671 2,436 651 285 916 2,097 4,466
1. Lower respiratory tract infections 15,318 7,177 8,141 610 353 1,165 2,637 2,410 559 256 868 2,072 4,387
2. Upper respiratory tract infections 300 101 200 31 — 21 33 16 61 — 48 14 76
3. Otitis media 177 102 75 91 — — — 10 31 30 — 12 3
C. Maternal conditions 318 — 318 — — — — — — 192 126 — —
1. Maternal haemorrhage 54 — 54 — — — — — — 28 25 — —
2. Maternal sepsis 52 — 52 — — — — — — 27 25 — —
3. Hypertension in pregnancy 57 — 57 — — — — — — 57 — — —
4. Obstructed labour — — — — — — — — — — — — —
5. Abortion 24 — 24 — — — — — — — 24 — —
6. Other maternal conditions 131 — 131 — — — — — — 81 51 — —
D. Neonatal causes 21,472 11,928 9,544 11,928 — — — — 9,498 — 47 — —
1. Birth trauma and asphyxia 6,381 3,517 2,864 3,517 — — — — 2,817 — 47 — —
2. Low birthweight 8,484 4,710 3,774 4,710 — — — — 3,774 — — — —
3. Neonatal infections 2,213 1,223 989 1,223 — — — — 989 — — — —
4. Other neonatal causes 4,394 2,477 1,917 2,477 — — — — 1,917 — — — —
E. Nutritional deficiencies 943 333 610 — — — 135 198 — 85 45 115 366
1. Protein-energy malnutrition 535 231 305 — — — 94 137 — 27 45 63 170
2. Iron-deficiency anaemia 374 89 284 — — — 31 58 — 58 — 37 189
3. Other nutritional deficiencies 34 13 21 — — — 10 4 — — — 14 7
II. Non—communicable diseases 1,129,412 597,858 531,554 18,279 24,334 93,555 283,634 178,057 14,015 14,710 70,193 195,812 236,823
F. Malignant neoplasms 399,863 211,001 188,862 2,455 6,462 36,933 117,897 47,254 1,852 6,070 44,910 90,315 45,716
1. Mouth and oropharynx cancers 9,962 7,140 2,821 — 85 1,707 4,735 613 — 28 637 1,441 715
2. Oesophagus cancer 10,848 7,181 3,667 — — 1,401 4,277 1,504 — — 453 1,862 1,352
3. Stomach cancer 14,400 8,646 5,754 — 201 1,862 4,573 2,010 — 87 985 2,860 1,823
4. Colorectal cancer 55,372 29,223 26,149 — 257 4,871 18,422 5,674 — 460 4,572 13,400 7,718
5. Liver cancer 4,568 3,312 1,256 60 — 775 2,077 399 31 21 69 833 301
6. Gall bladder cancer 3,890 1,196 2,694 — — 241 650 305 — — 438 1,371 885
7. Pancreas cancer 18,334 8,861 9,474 — 84 1,497 5,263 2,017 — 88 1,106 4,519 3,761
8. Lung cancer 83,146 55,030 28,117 — 56 7,889 35,907 11,178 — 141 5,289 16,409 6,278
9. Bone and connective tissue cancers 4,626 2,392 2,234 207 729 341 797 318 94 537 556 653 393
10. Melanoma 13,114 8,164 4,950 — 830 2,837 3,211 1,286 31 349 2,036 1,602 933
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Annex Table F (continued): YLL by age, sex and cause, Australia, 1996
Male Female
Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
11. Non-melanoma skin cancers 3,558 2,391 1,166 — — 331 1,149 911 — — 133 501 533
12. Breast cancer 40,684 — 40,684 — — — — — — 1,083 15,524 17,732 6,346
13. Cervix cancer 5,037 — 5,037 — — — — — — 426 2,133 1,787 692
14. Uterus cancer 3,458 — 3,458 — — — — — — — 466 1,985 1,007
15. Ovary cancer 11,699 — 11,699 — — — — — 31 345 2,979 5,953 2,391
16. Prostate cancer 22,474 22,474 — — — 606 11,145 10,723 — — — — —
17. Testicular cancer 700 700 — — 400 236 51 12 — — — — —
18. Bladder cancer 7,600 5,180 2,419 30 84 467 2,585 2,014 — 28 198 980 1,213
19. Kidney cancer 9,914 5,579 4,335 60 — 1,046 3,262 1,211 64 59 704 2,204 1,303
20. Brain cancer 16,713 9,636 7,076 538 1,319 3,321 3,672 786 668 791 2,005 2,868 745
21. Thyroid cancer 823 362 461 — 28 106 161 67 — — 117 136 208
22. Lymphoma 19,535 9,848 9,687 178 717 2,625 4,595 1,733 30 527 1,945 4,639 2,545
23. Multiple myeloma 7,065 3,707 3,359 — — 760 2,045 901 — 30 455 1,884 990
24. Leukemia 17,301 10,045 7,256 927 1,297 1,967 3,902 1,953 746 813 1,144 2,528 2,026
25. Other malignant neoplasms 15,041 9,933 5,107 454 375 2,046 5,419 1,639 158 258 964 2,169 1,558
G. Other neoplasms 5,557 2,844 2,713 211 221 378 1,001 1,033 156 198 423 713 1,222
1. Uterine myomas 94 94 94
2. Benign brain tumour 1,376 628 747 60 54 175 202 138 63 55 177 260 193
3. Other benign neoplasms 4,087 2,216 1,871 150 168 203 800 895 93 143 151 454 1,030
H. Diabetes mellitus 31,109 16,019 15,090 — 249 2,219 8,331 5,220 61 180 1,642 6,463 6,744
1. Type 1 diabetes 2,368 1,113 1,256 — 209 421 337 145 61 106 395 395 299
2. Type 2 diabetes 28,740 14,906 13,834 — 40 1,798 7,993 5,075 — 74 1,247 6,068 6,445
I. Endocrine and metabolic disorders 14,626 7,363 7,263 607 782 1,778 2,873 1,323 771 865 1,268 2,239 2,120
1. Non-deficiency anaemia 1,588 652 936 91 111 46 214 189 31 114 157 255 380
2. Cystic fibrosis 1,080 466 614 89 336 42 — — 183 383 48 — —
3. Haemophilia 468 235 234 31 — 89 74 40 — — 90 75 69
4. Other endocrine and metabolic 11,490 6,010 5,479 396 335 1,601 2,585 1,094 557 369 973 1,909 1,671
J. Mental disorders 18,216 13,014 5,202 59 7,061 4,086 1,343 465 — 1,657 1,276 1,101 1,167
1. Substance use disorders 17,056 12,612 4,445 29 7,034 4,000 1,233 316 — 1,513 1,091 970 870
a. Alcohol dependence/harmful use 4,308 3,390 918 — 515 1,478 1,169 228 — 115 429 300 74
b. Heroin or polydrug dependence
and harmful use
10,457 8,556 1,901 — 6,162 2,360 33 — — 1,342 559 — —
c. Sedative dependence/abuse 143 84 59 — 26 44 14 — — — 49 — 9
d. Cannabis dependence/abuse — — — — — — — — — — — — —
e. Other drug dependence/abuse 2,149 582 1,567 29 330 118 16 88 — 56 54 670 787
220
Annex Table F (continued): YLL by age, sex and cause, Australia, 1996
Male Female
Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
2. Schizophrenia 272 113 160 — 27 42 29 15 — — 46 59 55
3. Affective disorders 258 91 167 — — — 10 81 — — — 19 149
a. Depression 221 91 130 — — — 10 81 — — — — 130
b. Bipolar affective disorder 37 — 37 — — — — — — — — 19 18
4. Anxiety disorders 4 — 4 — — — — — — — — — 4
a. Panic disorder 4 — 4 — — — — — — — — — 4
b. Agoraphobia — — — — — — — — — — — — —
c. Social phobia — — — — — — — — — — — — —
d. Generalised anxiety disorder — — — — — — — — — — — — —
e. Obsessive-compulsive disorder — — — — — — — — — — — — —
f.  Post-traumatic stress disorder — — — — — — — — — — — — —
g. Separation anxiety disorder — — — — — — — — — — — — —
5. Borderline personality disorder — — — — — — — — — — — — —
6. Eating disorders 255 16 239 — — — — 16 — 113 93 12 22
7. Childhood conditions — — — — — — — — — — — — —
a. Attention-deficit disorder — — — — — — — — — — — — —
b. Autism and Asperger’s syndrome — — — — — — — — — — — — —
 8. Mental retardation 66 4 63 — — — — 4 — 30 21 12 —
9. Other mental disorders 305 180 124 30 — 44 72 34 — — 25 31 68
K. Nervous system and sense organ
 disorders 48,206 22,257 25,949 2,005 2,644 2,902 5,981 8,725 1,051 1,452 1,914 5,460 16,072
1. Dementia 23,887 8,217 15,670 272 27 38 1,932 5,948 155 85 90 2,111 13,230
2. Epilepsy 5,212 3,337 1,875 416 1,208 1,160 436 117 126 815 431 335 168
3. Parkinsons’s disease 4,921 2,819 2,102 — — 19 1,046 1,754 — — 21 460 1,621
4. Multiple sclerosis 1,657 402 1,255 — — 215 151 36 — 55 594 503 102
5. Motor neuron disease 4,168 2,546 1,622 — 57 668 1,467 353 — 30 235 1,018 339
6. Huntington’s chorea 554 343 211 — — 186 122 35 — — 47 117 47
7. Muscular dystrophy 1,065 925 140 177 572 143 24 9 — 58 41 33 7
 8. Sense organ disorders — — — — — — — — — — — — —
a. Glaucoma — — — — — — — — — — — — —
b. Cataracts — — — — — — — — — — — — —
c. Age-related vision disorders — — — — — — — — — — — — —
d. Adult-onset hearing loss — — — — — — — — — — — — —
9. Other nervous system, sense organ 6,743 3,668 3,074 1,141 780 473 803 472 771 408 455 883 558
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Annex Table F (continued): YLL by age, sex and cause, Australia, 1996
Male Female
Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
L. Cardiovascular disease 446,756 237,844 208,912 688 4,318 34,439 111,185 87,213 524 1,971 11,544 62,256 132,617
1. Rheumatic heart disease 3,892 1,423 2,469 30 196 234 629 335 31 56 333 1,282 767
2. Ischaemic heart disease 275,778 158,378 117,399 — 1,712 23,930 77,920 54,816 — 540 5,188 36,891 74,780
3. Stroke 98,523 41,863 56,660 89 736 4,605 16,636 19,797 91 536 3,584 14,470 37,979
4. Inflammatory heart disease 15,111 9,686 5,425 413 754 2,936 4,144 1,439 246 483 1,057 1,834 1,805
5. Hypertensive heart disease 11,310 4,627 6,684 — 83 432 1,715 2,397 — 1 132 1,513 5,038
6. Non-rheumatic valvular disease 7,658 3,769 3,889 — 80 488 1,696 1,505 32 30 287 1,031 2,509
7. Aortic aneurysm 12,721 8,113 4,608 — 111 678 4,357 2,966 — 27 109 1,849 2,624
8. Peripheral arterial disease 4,976 2,257 2,719 — — 69 1,038 1,151 — — 107 698 1,914
9. Other cardiovascular disease 16,785 7,727 9,059 155 646 1,067 3,051 2,807 125 297 748 2,687 5,202
M. Chronic respiratory disease 75,999 41,737 34,262 452 703 2,345 20,792 17,446 432 634 2,670 15,952 14,574
1. COPD 54,494 31,429 23,065 61 57 1,104 16,661 13,546 187 112 1,201 12,113 9,452
2. Asthma 8,732 3,620 5,112 269 508 668 1,463 712 122 438 1,124 1,914 1,514
3. Other chronic respiratory diseases 12,774 6,689 6,085 122 138 572 2,668 3,189 123 84 345 1,925 3,608
N. Diseases of the digestive system 40,596 23,068 17,528 360 645 7,138 10,268 4,656 94 364 2,914 6,142 8,014
1. Peptic ulcer disease 5,114 2,372 2,742 — — 260 1,132 981 — — 150 771 1,821
2. Cirrhosis of the liver (non-hepatitis) 18,824 13,053 5,771 29 404 5,827 5,924 869 — 163 1,962 2,503 1,143
3. Appendicitis 316 184 132 30 — 48 55 51 — 30 48 23 30
4. Intestinal obstruction 2,587 1,078 1,509 120 26 40 356 535 32 28 134 169 1,146
5. Diverticulitis 1,565 632 933 — 26 110 279 216 — — 62 321 550
6. Gall bladder and bile duct disease 1,909 929 980 — 54 59 390 426 — 30 70 318 562
7. Pancreatitis 1,837 1,092 745 30 26 278 520 238 — — 96 318 331
8. Inflammatory bowel disease 402 207 195 — — 82 79 46 — — 41 98 55
9. Vascular insufficiency of intestine 3,071 1,197 1,873 — 27 57 671 442 — 30 62 738 1,043
10. Other digestive system diseases 4,972 2,323 2,648 150 81 379 862 852 62 84 288 882 1,332
O. Genitourinary diseases 14,656 6,383 8,273 31 216 466 2,018 3,652 58 39 418 2,419 5,339
1. Nephritis and nephrosis 10,500 4,644 5,856 31 188 316 1,191 2,918 27 39 237 1,358 4,195
2. Benign prostatic hypertrophy 258 258 — — — — 106 152 — — — — —
3. Urinary incontinence — — — — — — — — — — — — —
4. Other genitourinary diseases 3,898 1,481 2,417 — 27 150 721 582 31 — 181 1,062 1,144
P. Skin diseases 1,249 419 831 — — 63 132 224 — 27 21 175 608
1. Eczema 10 6 4 — — — — 6 — — — — 4
2. Other skin diseases 1,240 413 827 — — 63 132 218 — 27 21 175 604
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Annex Table F (continued): YLL by age, sex and cause, Australia, 1996
Male Female
Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
Q. Musculoskeletal diseases 7,266 2,126 5,140 — 27 232 1,237 630 91 333 383 1,936 2,397
1. Rheumatoid arthritis 1,999 524 1,475 — — 19 365 140 — 54 62 681 679
2. Osteoarthritis 567 168 399 — — 19 60 88 — — — 26 373
3. Chronic back pain 48 24 24 — — — 19 4 — — — 12 12
4. Slipped disc 39 15 23 — — — 10 6 — — — 14 9
5. Occupational overuse syndrome — — — — — — — — — — — — —
6. Osteoporosis 561 78 483 — — — 31 47 — — — 98 385
7. Other musculoskeletal disorders 4,052 1,317 2,736 — 27 194 751 344 91 279 321 1,106 938
R. Congenital anomalies 18,697 10,035 8,661 7,681 1,005 573 564 212 6,106 919 811 623 202
1. Anencephaly 369 184 186 184 — — — — 186 — — — —
2. Spina bifida 437 224 212 153 55 — 17 — 186 27 — — —
3. Congenital heart disease 6,851 3,721 3,130 2,802 474 308 117 19 2,135 545 303 124 22
4. Cleft lip and/or palate — — — — — — — — — — — — —
5. Digestive system malformations 576 213 363 152 29 — 14 17 280 30 23 30 —
6. Urogenital tract malformations 1,914 1,137 777 577 82 46 272 159 282 3 75 267 150
7. Abdominal wall defect 61 61 — 61 — — — — — — — — —
8. Down syndrome 1,008 492 516 214 57 84 132 6 186 — 180 143 7
9. Other chromosomal disorders 1,400 551 849 551 — — — — 807 — 25 16 —
10. Other congenital anomalies 6,082 3,453 2,629 2,987 309 135 12 10 2,045 314 205 42 23
S. Oral health 58 15 43 — — — 12 3 — — — 12 31
1. Dental caries 7 — 7 — — — — — — — — — 7
2. Periodontal disease — — — — — — — — — — — — —
3. Edentulism — — — — — — — — — — — — —
4. Other oral health problems 51 15 36 — — — 12 3 — — — 12 24
V. Ill—defined conditions 6,550 3,731 2,819 3,731 — — — — 2,819 — — — —
1. Sudden infant death syndrome 6,550 3,731 2,819 3,731 — — — — 2,819 — — — —
2. Chronic fatigue syndrome — — — — — — — — — — — — —
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Annex Table F (continued): YLL by age, sex and cause, Australia, 1996
Male Female
Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
III. Injuries 152,283 114,696 37,587 7,518 58,637 33,826 11,214 3,502 4,087 13,464 10,734 5,094 4,209
T. Unintentional injuries 89,068 65,161 23,907 6,835 32,397 16,774 6,407 2,748 3,484 7,817 5,012 3,631 3,962
1. Road traffic accidents 45,928 33,685 12,243 2,783 20,094 7,675 2,405 728 1,602 5,511 2,798 1,676 656
2. Other transport accidents 5,392 4,692 700 550 2,354 1,290 448 49 185 256 168 82 9
3. Poisoning 8,708 6,374 2,334 156 3,883 2,142 139 54 31 1,051 992 201 59
4. Falls 10,165 5,964 4,201 214 1,153 1,525 1,499 1,574 30 198 219 899 2,854
5. Fires/burns/scalds 2,801 1,980 821 499 577 570 245 89 217 198 180 103 122
6. Drowning 6,074 4,560 1,513 1,439 1,562 1,126 380 54 898 256 199 141 19
7. Sports injuries 141 141 — — 141 — — — — — — — —
8. Natural and environmental factors 1,026 619 407 62 192 249 88 28 61 113 119 57 58
9. Machinery accidents 1,235 1,205 30 94 353 490 253 16 30 — — — —
10. Suffocation and foreign bodies 3,162 2,417 745 701 670 670 319 57 244 116 100 223 62
11. Adverse effects of medical treatment 777 391 386 33 54 106 160 38 — 29 115 179 63
a. Surgical/medical misadventure 485 234 251 — 28 65 123 18 — — 71 139 41
b. Adverse effects of drugs in
therapeutic use
292 157 135 33 26 41 37 20 — 29 44 40 22
12. Other unintentional injuries 3,658 3,132 527 304 1,364 932 471 61 185 88 122 71 61
U. Intentional injuries 63,215 49,535 13,680 683 26,239 17,052 4,807 754 603 5,647 5,721 1,463 247
1. Suicide and self-inflicted injuries 55,458 44,278 11,180 230 23,382 15,587 4,356 723 208 4,564 4,931 1,261 216
2. Homicide and violence 7,599 5,127 2,472 453 2,751 1,441 451 31 395 1,055 790 202 31
3. Legal intervention and war 158 130 27 — 106 24 — — — 27 — — —
Australian population (’000) 18,272 9,106 9,165 2,005 2,795 2,574 1,387 346 1,906 2,707 2,545 1,446 562
YLL per 1,000 population 73.8 82.6 65.0 19.7 31.6 53.1 217.4 539.0 15.1 10.9 32.8 142.1 442.1
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Annex Table G: YLD by age, sex and cause, Australia, 1996
Male Female
Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
All causes 1,162,041 578,720 583,321 81,157 130,699 132,796 165,985 68,084 63,754 152,437 134,438 135,360 97,331
I   Communicable diseases, maternal
and neonatal conditions 51,152 22,310 28,843 11,716 4,523 3,339 1,927 804 11,650 9,287 5,000 2,060 846
A. Infectious & parasitic diseases 17,122 7,867 9,255 2,028 2,694 2,105 759 281 2,504 3,273 2,107 1,135 235
 1. Tuberculosis 156 83 73 3 21 26 22 12 2 27 20 15 8
2. Sexually transmitted diseases
(apart from HIV/AIDS) 1,823 39 1,784 9 17 11 2 0 21 1,287 437 33 6
a. Syphilis 24 15 8 8 4 2 1 0 2 5 1 0 0
b. Chlamydia 1,086 19 1,068 0 9 9 1 0 12 771 262 20 3
c. Gonorrhoea 25 5 20 0 4 1 0 0 0 15 5 0 0
d. Other STDs 687 — 687 — — — — — 7 495 170 13 2
3. HIV/AIDS 2,486 2,291 195 22 1,252 931 78 7 13 134 43 5 0
4. Diarrhoeal diseases 3,353 1,681 1,672 822 376 206 175 102 652 519 243 217 41
5. Childhood immunisable diseases 326 138 188 118 11 6 2 1 164 10 9 2 2
a. Diphtheria — — — — — — — — — — — — —
b. Whooping cough 92 41 51 27 6 6 2 1 32 8 8 2 1
c. Tetanus 0 0 0 — — — 0 — — — — 0 —
d. Polio — — — — — — — — — — — — —
e. Measles 13 6 7 5 1 0 0 0 6 1 0 0 0
f.  Rubella 76 40 36 35 4 1 0 0 35 1 0 0 0
g. Haemophilus influenzae type b 145 51 94 51 0 0 0 0 93 0 0 — 2
6. Meningitis 805 489 316 339 50 57 34 9 175 41 52 40 8
7. Septicaemia 746 404 342 44 35 66 158 101 32 34 58 109 108
8. Arbovirus infection (Ross River etc.) 1,724 639 1,089 13 167 331 117 12 26 323 540 178 23
9. Hepatitis 894 537 357 152 205 163 15 2 152 110 80 13 2
a. Hepatitis A 226 152 74 23 89 34 6 1 23 34 12 4 2
b. Hepatitis B 122 63 59 45 13 4 0 0 46 8 3 2 0
c. Hepatitis C 366 229 137 3 91 124 9 1 3 62 64 8 0
10. Malaria 2 1 1 0 1 0 0 0 0 0 0 0 0
11. Trachoma 1,064 332 732 184 44 56 40 7 186 57 199 275 14
12. Other infectious and parasitic 3,888 1,333 2,555 400 537 251 115 30 1,119 740 427 248 22
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Annex Table G (continued): YLD by age, sex and cause, Australia, 1996
Male Female
Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
B. Acute respiratory infections 13,842 7,106 6,736 3,150 1,561 988 945 463 2,944 1,510 1,105 665 512
1. Lower respiratory tract infections 5,199 2,667 2,532 570 501 469 711 416 447 553 613 446 473
2. Upper respiratory tract infections 4,388 2,281 2,107 901 738 436 170 35 766 728 395 178 40
3. Otitis media 4,256 2,158 2,097 1,678 321 83 64 12 1,731 229 97 41 —
C. Maternal conditions 3,107 — 3,107 — — — — — 9 2,800 298 — —
1. Maternal haemorrhage 97 — 97 — — — — — 0 82 14 — —
2. Maternal sepsis 99 — 99 — — — — — 0 95 4 — —
3. Hypertension in pregnancy 575 — 575 — — — — — 0 486 89 — —
4. Obstructed labour 168 — 168 — — — — — 0 143 25 — —
5. Abortion 1,148 — 1,148 — — — — — 8 1,094 45 — —
6. Other maternal conditions 1,021 — 1,021 — — — — — — 901 120 — —
D. Neonatal causes 8,682 4,674 4,341 4,674 — — — — 4,341 — — — —
1. Birth trauma and asphyxia 1,779 1,007 772 1,007 — — — — 772 — — — —
2. Low birthweight 4,483 2,182 2,301 2,182 — — — — 2,301 — — — —
3. Neonatal infections 884 503 380 503 — — — — 380 — — — —
4. Other neonatal causes 1,869 981 888 981 — — — — 888 — — — —
E. Nutritional deficiencies 8,066 2,662 5,404 1,864 268 247 223 60 1,852 1,703 1,490 260 98
1. Protein-energy malnutrition 142 73 69 73 — — — — 69 — — — —
2. Iron-deficiency anaemia 7,906 2,586 5,319 1,791 268 246 221 60 1,783 1,701 1,484 255 96
3. Other nutritional deficiencies 18 3 15 — 0 1 1 0 — 2 6 5 2
II. Non—communicable diseases 1,053,262 519,981 533,281 61,829 110,819 121,480 159,781 66,071 47,551 137,068 124,644 129,930 94,088
F. Malignant neoplasms 78,716 41,117 37,599 369 1,437 6,216 22,417 10,678 285 1,708 10,175 16,362 9,069
1. Mouth and oropharynx cancers 4,342 3,040 1,302 4 147 849 1,568 471 9 64 319 530 381
2. Oesophagus cancer 876 513 363 — 6 70 302 135 0 — 21 145 198
3. Stomach cancer 1,643 1,107 535 1 14 203 553 336 1 10 90 217 218
4. Colorectal cancer 11,579 6,288 5,291 2 43 836 3,686 1,721 — 42 657 2,642 1,950
5. Liver cancer 174 118 56 3 2 28 62 24 1 3 5 29 18
6. Gall bladder cancer 293 132 161 — 2 9 71 50 — — 10 69 81
7. Pancreas cancer 676 341 336 — 3 43 199 96 0 3 37 137 158
8. Lung cancer 7,375 4,970 2,405 0 18 436 3,233 1,283 — 4 359 1,309 733
9. Bone and connective tissue cancers 1,601 887 714 106 174 254 253 99 85 113 243 202 72
10. Melanoma 6,896 3,696 3,200 10 345 1,161 1,579 601 5 440 1,138 1,128 489
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Annex Table G (continued): YLD by age, sex and cause, Australia, 1996
Male Female
Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
11. Non-melanoma skin cancers 1,002 626 376 — 8 92 296 231 — 10 70 149 148
12. Breast cancer 13,424 — 13,424 — — — — — — 359 4,987 5,945 2,134
13. Cervix cancer 1,008 — 1,008 — — — — — 1 144 445 311 108
14. Uterus cancer 1,408 — 1,408 — — — — — — 21 290 771 325
15. Ovary cancer 924 — 924 — — — — — 5 59 283 405 172
16. Prostate cancer 9,974 9,974 — — — 380 6,191 3,403 — — — — —
17. Testicular cancer 489 489 — 5 253 205 22 4 — — — — —
18. Bladder cancer 2,222 1,703 520 1 13 130 914 644 1 9 33 226 250
19. Kidney cancer 1,498 896 602 18 10 164 504 200 11 14 88 306 183
20. Brain cancer 1,060 663 397 4 — 201 351 108 5 1 95 195 101
21. Thyroid cancer 682 145 538 1 28 54 45 16 3 136 257 108 33
22. Lymphoma 3,915 2,116 1,799 42 184 565 867 457 26 140 337 706 590
23. Multiple myeloma 618 379 239 — 5 44 221 108 — 2 31 114 93
24. Leukemia 2,125 1,142 983 94 103 151 476 318 107 62 163 327 325
25. Other malignant neoplasms 2,918 1,893 1,025 79 79 340 1,024 370 25 75 223 397 304
G. Other neoplasms 1,796 468 1,328 32 43 109 162 121 26 136 697 282 187
1. Uterine myomas 717 — 717 — — — — — 0 93 541 75 9
2. Benign brain tumour 522 193 329 9 19 79 69 16 6 25 131 133 34
3. Other benign neoplasms 557 276 282 23 24 30 94 105 20 18 26 74 144
H. Diabetes mellitus 43,823 23,419 20,404 1,056 1,225 12,129 7,722 1,287 1,041 2,423 9,109 6,463 1,368
1. Type 1 diabetes 5,076 2,533 2,544 1,056 897 451 111 18 1,041 916 443 112 30
2. Type 2 diabetes 38,747 20,886 17,860 — 328 11,678 7,611 1,269 — 1,507 8,665 6,351 1,337
I. Endocrine and metabolic disorders 15,493 8,933 6,559 1,347 450 1,950 3,499 1,687 1,127 596 1,083 1,933 1,820
1. Non-deficiency anaemia 4,469 2,054 2,415 566 87 211 691 499 310 347 425 643 690
2. Cystic fibrosis 724 284 440 284 — — — — 440 — — — —
3. Haemophilia 66 66 — 66 — — — — — — — — —
4. Other endocrine and metabolic 10,233 6,529 3,704 430 364 1,739 2,808 1,188 377 249 658 1,291 1,130
J. Mental disorders 315,685 151,216 164,469 20,808 79,568 43,534 6,916 390 13,114 91,313 46,212 13,442 388
1. Substance use disorders 62,487 41,120 21,367 — 28,437 11,218 1,367 97 — 16,544 3,813 909 100
a. Alcohol dependence/harmful use 41,065 28,163 12,901 — 16,942 9,928 1,211 82 — 9,430 3,116 323 33
b. Heroin or polydrug dependence
and harmful use
12,719 7,764 4,955 — 7,149 615 — — — 4,851 105 — —
c. Sedative dependence/abuse 2,968 1,574 1,394 — 946 559 68 — — 727 452 216 —
d. Cannabis dependence/abuse 4,416 3,092 1,324 — 3,072 20 — — — 1,268 56 — —
e. Other drug dependence/abuse 1,319 527 792 — 328 97 87 15 — 269 85 370 68
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Annex Table G (continued): YLD by age, sex and cause, Australia, 1996
Male Female
Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
2. Schizophrenia 17,416 8,847 8,569 — 7,543 1,305 — — — 6,262 2,211 96 —
3. Affective disorders 110,457 44,613 65,844 2,961 21,665 16,831 3,044 113 3,361 34,831 18,921 8,714 18
a. Depression 92,795 35,816 56,979 2,961 12,868 16,831 3,044 113 3,361 25,966 18,921 8,714 18
b. Bipolar affective disorder 17,661 8,797 8,865 — 8,797 — — — — 8,865 — — —
4. Anxiety disorders 75,672 29,705 45,967 1,612 16,029 10,049 1,836 180 1,669 21,673 19,071 3,284 270
a. Panic disorder 5,588 1,197 4,391 — 777 386 34 — — 2,882 1,338 171 —
b. Agoraphobia 4,600 1,224 3,376 — 628 550 45 — — 1,979 1,057 340 —
c. Social phobia 18,613 8,428 10,185 — 6,184 1,788 402 55 — 7,640 2,357 160 28
d. Generalised anxiety disorder 31,830 11,342 20,488 — 4,929 5,349 938 126 — 6,067 11,870 2,408 142
e. Obsessive-compulsive disorder 4,699 2,440 2,259 — 1,240 1,002 198 — — 972 983 204 99
f.  Post-traumatic stress disorder 7,693 3,717 3,976 255 2,270 974 218 — 378 2,132 1,465 — —
g. Separation anxiety disorder 2,648 1,357 1,291 1,357 — — — — 1,291 — — — —
5. Borderline personality disorder 16,371 10,274 6,097 — 5,474 4,132 669 — — 3,460 2,197 440 —
6. Eating disorders 10,921 516 10,405 95 421 — — — 1,861 8,544 — — —
7. Childhood conditions 18,856 14,119 4,737 14,119 — — — — 4,737 — — — —
a. Attention-deficit disorder 12,959 9,369 3,590 9,369 — — — — 3,590 — — — —
b. Autism and Asperger’s syndrome 5,897 4,749 1,147 4,749 — — — — 1,147 — — — —
 8. Mental retardation 3,506 2,022 1,484 2,022 — — — — 1,484 — — — —
9. Other mental disorders — — — — — — — — — — — — —
K. Nervous system and sense organ
 disorders 187,179 85,093 102,086 3,342 3,674 7,976 41,717 28,384 2,702 3,408 6,636 33,816 55,524
1. Dementia 65,091 25,251 39,840 — — 1,017 11,523 12,712 — — 1,110 15,261 23,470
2. Epilepsy 6,307 3,331 2,976 934 1,010 692 556 139 752 849 608 557 210
3. Parkinsons’s disease 20,655 8,445 12,210 — — — 5,352 3,094 — — — 4,420 7,790
4. Multiple sclerosis 2,786 857 1,929 22 414 386 34 — 48 967 813 101 —
5. Motor neuron disease 391 248 142 — 3 60 157 28 — 1 25 79 37
6. Huntington’s chorea 892 555 336 — — 420 135 — — — 205 131 —
7. Muscular dystrophy 249 212 37 212 — — — — 37 — — — —
 8. Sense organ disorders 76,855 39,214 37,641 3 764 4,500 22,433 11,515 115 665 2,843 11,265 22,753
a. Glaucoma 1,850 408 1,442 — — — 128 281 — — 139 140 1,163
b. Cataracts 5,779 1,438 4,341 3 4 33 577 821 2 3 271 893 3,172
c. Age-related vision disorders 21,056 4,356 16,700 — — — 1,045 3,311 — — 720 1,567 14,412
d. Adult-onset hearing loss 48,170 33,012 15,158 1 759 4,467 20,683 7,102 114 662 1,712 8,664 4,006
9. Other nervous system, sense organ 13,954 6,979 6,975 2,170 1,483 900 1,528 897 1,748 926 1,033 2,002 1,265
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Annex Table G (continued): YLD by age, sex and cause, Australia, 1996
Male Female
Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
L. Cardiovascular disease 101,829 60,823 41,006 511 1,775 12,325 32,746 13,466 561 1,426 5,588 17,988 15,443
1. Rheumatic heart disease 165 55 110 0 4 11 31 9 0 4 17 62 27
2. Ischaemic heart disease 35,552 22,252 13,300 0 357 6,058 11,994 3,843 1 169 1,549 6,749 4,833
3. Stroke 38,055 22,467 15,588 230 709 3,064 12,017 6,449 177 645 2,244 6,389 6,132
4. Inflammatory heart disease 7,288 4,858 2,430 137 255 1,192 2,644 631 141 143 452 1,058 636
5. Hypertensive heart disease 1,731 373 1,358 — 2 12 97 262 — — 8 163 1,187
6. Non-rheumatic valvular disease 1,027 586 441 2 15 78 290 202 3 6 28 151 253
7. Aortic aneurysm 366 258 108 0 1 7 135 115 0 0 2 41 64
8. Peripheral arterial disease 13,357 7,895 5,462 41 160 1,538 4,633 1,522 42 233 884 2,598 1,705
9. Other cardiovascular disease 4,288 2,079 2,209 101 272 367 905 433 197 226 403 777 606
M. Chronic respiratory disease 102,796 53,286 49,510 23,602 5,409 10,809 11,931 1,535 18,646 11,522 9,133 7,952 2,258
1. COPD 38,894 24,438 14,456 — 3,648 9,213 10,394 1,183 — 2,119 5,552 5,076 1,709
2. Asthma 55,791 24,661 31,130 21,395 1,468 1,142 577 80 17,097 8,692 3,016 1,897 428
3. Other chronic respiratory diseases 8,112 4,188 3,924 2,207 294 454 960 272 1,549 710 565 978 122
N. Diseases of the digestive system 23,805 10,841 12,963 838 3,461 2,867 2,775 901 533 4,429 3,624 2,937 1,439
1. Peptic ulcer disease 2,822 1,251 1,571 — 239 456 434 123 — 345 709 314 202
2. Cirrhosis of the liver (non-hepatitis) 777 447 330 6 56 153 181 51 12 53 94 93 77
3. Appendicitis 425 223 202 56 105 43 16 3 44 105 38 12 4
4. Intestinal obstruction 2,351 1,084 1,267 75 95 266 506 141 48 100 401 507 210
5. Diverticulitis 2,947 1,302 1,645 0 50 309 692 250 0 8 318 854 465
6. Gall bladder and bile duct disease 1,330 429 902 3 30 118 192 85 3 185 300 287 127
7. Pancreatitis 227 134 93 2 23 55 41 14 1 17 26 31 19
8. Inflammatory bowel disease 8,905 4,266 4,639 351 2,240 1,272 375 29 357 2,544 1,362 327 49
9. Vascular insufficiency of intestine 454 227 226 5 34 51 98 40 14 34 37 94 47
10. Other digestive system diseases 3,565 1,478 2,087 339 589 145 240 165 54 1,038 339 417 239
O. Genitourinary diseases 47,313 28,157 19,157 152 4,623 5,281 13,700 4,401 236 8,956 6,253 2,030 1,682
1. Nephritis and nephrosis 2,004 1,193 811 38 229 363 426 137 18 166 235 287 105
2. Benign prostatic hypertrophy 16,821 16,821 — 1 123 2,186 11,151 3,360 — — — — —
3. Urinary incontinence 8,820 2,547 6,273 — — 822 1,402 322 — 2,985 2,327 540 420
4. Other genitourinary diseases 19,669 7,596 12,073 112 4,271 1,909 721 582 218 5,805 3,690 1,203 1,157
P. Skin diseases 9,707 4,195 5,513 765 1,845 1,031 453 100 1,064 2,364 1,347 580 158
1. Eczema 2,998 1,001 1,998 405 302 182 87 24 521 783 499 168 27
2. Other skin diseases 6,709 3,194 3,515 360 1,543 849 366 76 542 1,580 849 412 132
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Annex Table G (continued): YLD by age, sex and cause, Australia, 1996
Male Female
Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
Q. Musculoskeletal diseases 82,649 32,408 50,242 862 3,913 12,170 12,911 2,551 1,419 4,435 18,039 22,586 3,762
1. Rheumatoid arthritis 9,990 3,122 6,868 607 641 1,052 700 123 1,174 1,308 2,215 1,698 473
2. Osteoarthritis 55,738 22,442 33,296 — 1,113 8,306 10,923 2,099 — 893 10,969 18,614 2,820
3. Chronic back pain 3,968 2,065 1,903 20 392 978 477 198 13 437 744 462 247
4. Slipped disc 3,836 2,285 1,551 7 637 1,142 429 70 9 291 818 355 77
5. Occupational overuse syndrome 3,449 112 3,337 — 7 74 31 — — 766 2,140 431 —
6. Osteoporosis 1,994 236 1,757 — 48 95 89 4 — 147 677 860 73
7. Other musculoskeletal disorders 3,675 2,145 1,530 229 1,075 523 261 57 223 593 476 166 71
R. Congenital anomalies 13,635 7,542 6,093 7,542 — — — — 6,093 — — — —
1. Anencephaly 0 0 0 0 — — — — 0 — — — —
2. Spina bifida 634 325 309 325 — — — — 309 — — — —
3. Congenital heart disease 2,237 1,109 1,127 1,109 — — — — 1,127 — — — —
4. Cleft lip and/or palate 151 84 67 84 — — — — 67 — — — —
5. Digestive system malformations 56 39 18 39 — — — — 18 — — — —
6. Urogenital tract malformations 165 111 54 111 — — — — 54 — — — —
7. Abdominal wall defect 84 37 47 37 — — — — 47 — — — —
8. Down syndrome 2,770 1,469 1,301 1,469 — — — — 1,301 — — — —
9. Other chromosomal disorders 6,158 3,590 2,569 3,590 — — — — 2,569 — — — —
10. Other congenital anomalies 1,379 778 601 778 — — — — 601 — — — —
S. Oral health 23,934 11,087 12,848 499 3,059 4,126 2,832 570 473 3,113 4,777 3,494 990
1. Dental caries 13,456 6,649 6,807 499 2,519 2,057 1,248 327 473 2,468 2,032 1,303 531
2. Periodontal disease 7,250 3,495 3,755 — 465 1,543 1,244 243 — 460 1,526 1,347 421
3. Edentulism 3,228 942 2,286 — 76 526 340 — — 186 1,219 843 38
4. Other oral health problems — — — — — — — — — — — — —
V. Ill—defined conditions 4,901 1,396 3,505 105 333 957 — — 231 1,238 1,971 65 —
1. Sudden infant death syndrome — — — — — — — — — — — — —
2. Chronic fatigue syndrome 4,901 1,396 3,505 105 333 957 — — 231 1,238 1,971 65 —
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Annex Table G (continued): YLD by age, sex and cause, Australia, 1996
Male Female
Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
III. Injuries 57,627 36,429 21,197 7,611 15,357 7,976 4,277 1,208 4,553 6,081 4,794 3,370 2,398
T. Unintentional injuries 54,052 33,691 20,360 7,500 13,401 7,362 4,223 1,205 4,502 5,505 4,607 3,353 2,393
1. Road traffic accidents 9,781 6,620 3,161 1,128 3,682 1,438 318 54 620 1,650 607 229 55
2. Other transport accidents 1,977 1,591 386 357 889 272 70 4 115 210 44 9 8
3. Poisoning 280 131 149 35 67 20 8 2 70 39 26 6 9
4. Falls 13,437 7,222 6,215 2,640 2,021 1,276 748 538 1,826 838 798 1,083 1,670
5. Fires/burns/scalds 1,905 1,331 575 483 559 246 40 3 297 136 96 37 8
6. Drowning 121 80 41 34 10 37 0 0 32 5 2 1 0
7. Sports injuries 2,319 1,838 481 454 1,179 150 45 10 124 234 87 26 11
8. Natural and environmental factors 633 399 234 77 166 106 46 5 52 70 72 30 11
9. Machinery accidents 3,140 2,856 283 160 1,380 948 338 30 58 76 123 25 1
10. Suffocation and foreign bodies 135 116 19 39 41 30 6 1 15 2 2 1 0
11. Adverse effects of medical treatment 1,019 553 466 71 168 128 151 34 36 152 152 68 59
a. Surgical/medical misadventure 368 208 160 7 42 76 73 11 3 61 66 20 10
b. Adverse effects of drugs in
therapeutic use
651 345 306 64 127 53 78 23 32 91 86 47 49
12. Other unintentional injuries 19,304 10,952 8,351 2,022 3,241 2,712 2,454 524 1,260 2,094 2,600 1,839 560
U. Intentional injuries 3,575 2,738 837 112 1,956 614 53 3 51 576 187 18 5
1. Suicide and self-inflicted injuries 472 253 219 3 203 39 7 1 3 155 55 4 2
2. Homicide and violence 3,098 2,482 617 109 1,750 575 46 2 48 421 131 13 3
3. Legal intervention and war 5 3 1 0 3 0 0 0 0 1 1 — 0
Australian population (’000) 18,272 9,106 9,165 2,005 2,795 2,574 1,387 346 1,906 2,707 2,545 1,446 562
YLD per 1,000 population 63.6 63.6 63.7 40.5 46.8 51.6 119.7 196.8 33.5 56.3 52.9 93.7 172.9
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Annex Table H: DALYs by age, sex and cause, Australia, 1996
Male Female
Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
All causes 2,510,274 1,331,311 1,178,963 120,707 219,032 269,575 467,573 254,425 92,562 181,987 217,808 340,792 345,814
I   Communicable diseases, maternal
and neonatal conditions 117,698 62,348 55,350 25,470 9,886 12,740 8,667 5,586 22,356 10,663 7,443 6,592 8,296
A. Infectious & parasitic diseases 45,140 28,266 16,874 3,122 7,703 10,319 4,693 2,428 3,062 4,086 3,418 3,455 2,853
 1. Tuberculosis 898 527 370 33 21 47 245 182 2 55 20 184 109
2. Sexually transmitted diseases
(apart from HIV/AIDS) 1,904 99 1,806 9 72 11 2 5 21 1,287 437 50 11
a. Syphilis 84 75 8 8 60 2 1 5 2 5 1 0 0
b. Chlamydia 1,108 19 1,089 0 9 9 1 0 12 771 262 36 9
c. Gonorrhoea 25 5 20 0 4 1 0 0 0 15 5 0 0
d. Other STDs 687 — 687 — — — — — 7 495 170 13 2
3. HIV/AIDS 14,495 13,885 610 22 5,519 7,508 821 15 13 357 202 37 0
4. Diarrhoeal diseases 4,040 1,941 2,098 913 376 229 209 214 652 548 263 327 308
5. Childhood immunisable diseases 467 283 184 210 37 6 57 24 164 40 52 14 8
a. Diphtheria — — — — — — — — — — — — —
b. Whooping cough 154 102 51 88 6 6 2 1 32 8 8 2 1
c. Tetanus 0 0 0 — — — 0 — — — — 0 —
d. Polio 138 78 60 — — — 55 23 — — 43 12 5
e. Measles 69 33 36 5 27 0 0 0 6 31 0 0 0
f.  Rubella 106 70 36 65 4 1 0 0 35 1 0 0 0
g. Haemophilus influenzae type b 145 51 94 51 0 0 0 0 93 0 0 — 2
6. Meningitis 2,410 1,432 978 946 162 220 78 26 425 245 114 115 80
7. Septicaemia 5,579 2,763 2,816 167 87 279 1,014 1,217 125 93 242 677 1,679
8. Arbovirus infection (Ross River etc.) 1,728 639 1,089 13 167 331 117 12 26 323 540 178 23
9. Hepatitis 5,677 3,492 2,186 152 425 1,007 1,440 469 152 205 673 807 348
a. Hepatitis A 271 181 91 23 89 55 6 9 23 34 12 21 2
b. Hepatitis B 1,851 1,018 833 45 169 392 337 74 46 43 441 232 71
c. Hepatitis C 3,375 2,200 1,175 3 155 559 1,097 386 3 121 221 555 275
10. Malaria 43 42 1 0 27 0 14 0 0 0 0 0 0
11. Trachoma 1,064 332 732 184 44 56 40 7 186 57 199 275 14
12. Other infectious and parasitic 6,927 2,891 4,037 562 787 625 657 260 1,411 887 675 791 273
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Annex Table H (continued): DALYs by age, sex and cause, Australia, 1996
Male Female
Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
B. Acute respiratory infections 29,637 14,485 15,152 3,882 1,914 2,174 3,616 2,899 3,595 1,796 2,021 2,763 4,979
1. Lower respiratory tract infections 20,516 9,844 10,673 1,181 854 1,634 3,349 2,826 1,006 809 1,481 2,518 4,860
2. Upper respiratory tract infections 4,688 2,381 2,307 932 738 457 203 51 827 728 443 192 116
3. Otitis media 4,433 2,260 2,173 1,770 321 83 64 22 1,762 259 97 52 3
C. Maternal conditions 3,425 — 3,425 — — — — — 9 2,993 423 — —
1. Maternal haemorrhage 150 — 150 — — — — — 0 111 40 — —
2. Maternal sepsis 151 — 151 — — — — — 0 122 29 — —
3. Hypertension in pregnancy 632 — 632 — — — — — 0 542 89 — —
4. Obstructed labour 168 — 168 — — — — — 0 143 25 — —
5. Abortion 1,172 — 1,172 — — — — — 8 1,094 69 — —
6. Other maternal conditions 1,152 — 1,152 — — — — — — 981 171 — —
D. Neonatal causes 30,487 16,602 13,885 16,602 — — — — 13,838 — 47 — —
1. Birth trauma and asphyxia 8,160 4,524 3,635 4,524 — — — — 3,589 — 47 — —
2. Low birthweight 12,967 6,892 6,075 6,892 — — — — 6,075 — — — —
3. Neonatal infections 3,096 1,727 1,370 1,727 — — — — 1,370 — — — —
4. Other neonatal causes 6,264 3,458 2,805 3,458 — — — — 2,805 — — — —
E. Nutritional deficiencies 9,009 2,996 6,014 1,864 268 247 358 259 1,852 1,788 1,535 375 464
1. Protein-energy malnutrition 678 303 374 73 — — 94 137 69 27 45 63 170
2. Iron-deficiency anaemia 8,279 2,676 5,603 1,791 268 246 253 118 1,783 1,759 1,484 293 285
3. Other nutritional deficiencies 52 16 36 — 0 1 11 4 — 2 6 19 9
II. Non—communicable diseases 2,182,674 1,117,839 1,064,835 80,108 135,153 215,035 443,416 244,128 61,566 151,778 194,837 325,742 330,911
F. Malignant neoplasms 478,579 252,118 226,461 2,824 7,899 43,149 140,315 57,932 2,136 7,778 55,085 106,677 54,785
1. Mouth and oropharynx cancers 14,304 10,180 4,124 4 232 2,556 6,304 1,084 9 92 956 1,970 1,097
2. Oesophagus cancer 11,725 7,694 4,030 — 6 1,471 4,578 1,639 0 — 474 2,007 1,550
3. Stomach cancer 16,042 9,753 6,289 1 215 2,065 5,126 2,346 1 96 1,075 3,077 2,041
4. Colorectal cancer 66,951 35,511 31,440 2 300 5,707 22,108 7,395 — 502 5,229 16,041 9,668
5. Liver cancer 4,742 3,431 1,312 63 2 804 2,139 423 32 24 74 862 320
6. Gall bladder cancer 4,183 1,328 2,855 — 2 249 722 355 — — 449 1,440 966
7. Pancreas cancer 19,011 9,201 9,809 — 87 1,539 5,463 2,112 0 91 1,143 4,656 3,919
8. Lung cancer 90,522 60,000 30,521 0 74 8,325 39,140 12,462 — 145 5,648 17,718 7,011
9. Bone and connective tissue cancers 6,228 3,279 2,948 313 903 595 1,050 418 179 650 799 855 465
10. Melanoma 20,010 11,860 8,150 10 1,174 3,998 4,790 1,887 36 789 3,174 2,730 1,422
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Annex Table H (continued): DALYs by age, sex and cause, Australia, 1996
Male Female
Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
11. Non-melanoma skin cancers 4,560 3,017 1,543 — 8 423 1,445 1,142 — 10 203 650 681
12. Breast cancer 54,109 — 54,109 — — — — — — 1,442 20,510 23,677 8,480
13. Cervix cancer 6,045 — 6,045 — — — — — 1 570 2,577 2,097 800
14. Uterus cancer 4,866 — 4,866 — — — — — — 21 756 2,757 1,332
15. Ovary cancer 12,623 — 12,623 — — — — — 36 405 3,262 6,357 2,563
16. Prostate cancer 32,448 32,448 — — — 986 17,335 14,126 — — — — —
17. Testicular cancer 1,189 1,189 — 5 653 441 73 16 — — — — —
18. Bladder cancer 9,822 6,883 2,939 31 97 598 3,499 2,658 1 37 231 1,207 1,463
19. Kidney cancer 11,412 6,475 4,937 78 10 1,209 3,766 1,412 75 73 792 2,511 1,486
20. Brain cancer 17,773 10,299 7,474 542 1,319 3,522 4,023 894 673 792 2,100 3,064 846
21. Thyroid cancer 1,505 507 998 1 56 161 206 83 3 136 374 244 241
22. Lymphoma 23,451 11,964 11,487 220 901 3,190 5,462 2,190 56 667 2,283 5,345 3,136
23. Multiple myeloma 7,683 4,085 3,598 — 5 805 2,266 1,010 — 31 486 1,998 1,083
24. Leukemia 19,427 11,187 8,240 1,021 1,400 2,118 4,378 2,271 853 875 1,306 2,855 2,351
25. Other malignant neoplasms 17,958 11,826 6,132 533 454 2,387 6,443 2,009 183 333 1,188 2,566 1,863
G. Other neoplasms 7,353 3,313 4,041 243 265 487 1,163 1,154 182 334 1,120 995 1,409
1. Uterine myomas 812 — 812 — — — — — 0 93 635 75 9
2. Benign brain tumour 1,897 821 1,077 70 72 254 270 154 69 80 308 393 227
3. Other benign neoplasms 4,645 2,492 2,153 173 192 233 893 1,000 113 162 177 527 1,174
H. Diabetes mellitus 74,931 39,438 35,493 1,056 1,474 14,348 16,053 6,507 1,102 2,603 10,750 12,927 8,111
1. Type 1 diabetes 7,445 3,645 3,799 1,056 1,106 872 448 163 1,102 1,022 838 508 329
2. Type 2 diabetes 67,487 35,792 31,694 — 368 13,476 15,605 6,344 — 1,581 9,912 12,419 7,782
I. Endocrine and metabolic disorders 30,119 16,297 13,822 1,954 1,232 3,728 6,372 3,010 1,898 1,461 2,351 4,173 3,939
1. Non-deficiency anaemia 6,057 2,706 3,351 658 198 257 905 688 341 460 583 898 1,069
2. Cystic fibrosis 1,804 751 1,054 373 336 42 — — 623 383 48 — —
3. Haemophilia 534 301 234 97 — 89 74 40 — — 90 75 69
4. Other endocrine and metabolic 21,723 12,539 9,184 827 698 3,340 5,392 2,282 934 618 1,630 3,200 2,801
J. Mental disorders 333,901 164,230 169,671 20,868 86,630 47,619 8,259 855 13,114 92,970 47,488 14,544 1,555
1. Substance use disorders 79,543 53,731 25,812 29 35,472 15,218 2,600 413 — 18,058 4,905 1,879 970
a. Alcohol dependence/harmful use 45,372 31,553 13,819 — 17,457 11,406 2,380 310 — 9,545 3,545 623 107
b. Heroin or polydrug dependence
and harmful use
23,175 16,319 6,856 — 13,311 2,975 33 — — 6,193 663 — —
c. Sedative dependence/abuse 3,111 1,658 1,453 — 973 603 83 — — 727 501 216 9
d. Cannabis dependence/abuse 4,416 3,092 1,324 — 3,072 20 — — — 1,268 56 — —
e. Other drug dependence/abuse 3,468 1,109 2,359 29 659 215 103 103 — 325 140 1,040 854
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Annex Table H (continued): DALYs by age, sex and cause, Australia, 1996
Male Female
Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
2. Schizophrenia 17,688 8,960 8,728 — 7,570 1,346 29 15 — 6,262 2,257 154 55
3. Affective disorders 110,715 44,704 66,011 2,961 21,665 16,831 3,054 194 3,361 34,831 18,921 8,733 166
a. Depression 93,016 35,907 57,109 2,961 12,868 16,831 3,054 194 3,361 25,966 18,921 8,714 148
b. Bipolar affective disorder 17,698 8,797 8,902 — 8,797 — — — — 8,865 — 19 18
4. Anxiety disorders 75,676 29,705 45,971 1,612 16,029 10,049 1,836 180 1,669 21,673 19,071 3,284 274
a. Panic disorder 5,592 1,197 4,395 — 777 386 34 — — 2,882 1,338 171 4
b. Agoraphobia 4,600 1,224 3,376 — 628 550 45 — — 1,979 1,057 340 —
c. Social phobia 18,613 8,428 10,185 — 6,184 1,788 402 55 — 7,640 2,357 160 28
d. Generalised anxiety disorder 31,830 11,342 20,488 — 4,929 5,349 938 126 — 6,067 11,870 2,408 142
e. Obsessive-compulsive disorder 4,699 2,440 2,259 — 1,240 1,002 198 — — 972 983 204 99
f.  Post-traumatic stress disorder 7,693 3,717 3,976 255 2,270 974 218 — 378 2,132 1,465 — —
g. Separation anxiety disorder 2,648 1,357 1,291 1,357 — — — — 1,291 — — — —
5. Borderline personality disorder 16,371 10,274 6,097 — 5,474 4,132 669 — — 3,460 2,197 440 —
6. Eating disorders 11,176 532 10,644 95 421 — — 16 1,861 8,657 93 12 22
7. Childhood conditions 18,856 14,119 4,737 14,119 — — — — 4,737 — — — —
a. Attention-deficit disorder 12,959 9,369 3,590 9,369 — — — — 3,590 — — — —
b. Autism and Asperger’s syndrome 5,897 4,749 1,147 4,749 — — — — 1,147 — — — —
 8. Mental retardation 3,572 2,025 1,547 2,022 — — — 4 1,484 30 21 12 —
9. Other mental disorders 305 180 124 30 — 44 72 34 — — 25 31 68
K. Nervous system and sense organ
 disorders 235,385 107,350 128,035 5,347 6,318 10,878 47,698 37,109 3,753 4,860 8,550 39,276 71,596
1. Dementia 88,978 33,468 55,510 272 27 1,055 13,454 18,660 155 85 1,199 17,371 36,700
2. Epilepsy 11,519 6,668 4,851 1,350 2,219 1,852 991 255 878 1,664 1,039 892 378
3. Parkinsons’s disease 25,576 11,264 14,312 — — 19 6,397 4,848 — — 21 4,880 9,411
4. Multiple sclerosis 4,443 1,259 3,184 22 414 601 185 36 48 1,022 1,407 604 102
5. Motor neuron disease 4,559 2,794 1,764 — 60 729 1,624 382 — 32 260 1,097 375
6. Huntington’s chorea 1,446 899 547 — — 606 258 35 — — 252 248 47
7. Muscular dystrophy 1,314 1,137 177 389 572 143 24 9 37 58 41 33 7
 8. Sense organ disorders 76,855 39,214 37,641 3 764 4,500 22,433 11,515 115 665 2,843 11,265 22,753
a. Glaucoma 1,850 408 1,442 — — — 128 281 — — 139 140 1,163
b. Cataracts 5,779 1,438 4,341 3 4 33 577 821 2 3 271 893 3,172
c. Age-related vision disorders 21,056 4,356 16,700 — — — 1,045 3,311 — — 720 1,567 14,412
d. Adult-onset hearing loss 48,170 33,012 15,158 1 759 4,467 20,683 7,102 114 662 1,712 8,664 4,006
9. Other nervous system, sense organ 20,696 10,647 10,049 3,311 2,263 1,373 2,332 1,369 2,519 1,334 1,489 2,885 1,822
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Annex Table H (continued): DALYs by age, sex and cause, Australia, 1996
Male Female
Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
L. Cardiovascular disease 548,584 298,667 249,918 1,198 6,094 46,764 143,931 100,679 1,085 3,398 17,132 80,244 148,060
1. Rheumatic heart disease 4,057 1,479 2,579 30 200 245 660 343 31 61 350 1,344 794
2. Ischaemic heart disease 311,330 180,630 130,700 0 2,069 29,988 89,914 58,659 1 709 6,737 43,641 79,613
3. Stroke 136,579 64,330 72,248 318 1,445 7,669 28,653 26,246 268 1,181 5,828 20,859 44,112
4. Inflammatory heart disease 22,399 14,544 7,855 550 1,009 4,127 6,788 2,070 387 626 1,509 2,892 2,441
5. Hypertensive heart disease 13,041 4,999 8,042 — 85 443 1,811 2,660 — 1 140 1,676 6,225
6. Non-rheumatic valvular disease 8,685 4,355 4,331 2 95 566 1,986 1,707 35 36 316 1,182 2,762
7. Aortic aneurysm 13,087 8,371 4,716 0 112 685 4,491 3,082 0 27 111 1,890 2,688
8. Peripheral arterial disease 18,333 10,152 8,181 41 160 1,607 5,671 2,673 42 233 991 3,296 3,620
9. Other cardiovascular disease 21,073 9,806 11,267 256 919 1,434 3,957 3,240 321 523 1,151 3,464 5,807
M. Chronic respiratory disease 178,796 95,024 83,772 24,053 6,112 13,154 32,723 18,981 19,078 12,156 11,802 23,904 16,832
1. COPD 93,387 55,866 37,521 61 3,704 10,318 27,055 14,729 187 2,232 6,753 17,190 11,160
2. Asthma 64,523 28,281 36,242 21,663 1,976 1,810 2,040 792 17,219 9,130 4,140 3,811 1,942
3. Other chronic respiratory diseases 20,886 10,876 10,009 2,329 432 1,026 3,628 3,460 1,673 794 910 2,903 3,730
N. Diseases of the digestive system 64,400 33,909 30,491 1,198 4,106 10,005 13,042 5,557 627 4,793 6,538 9,079 9,453
1. Peptic ulcer disease 7,936 3,623 4,313 — 239 716 1,565 1,103 — 345 859 1,086 2,023
2. Cirrhosis of the liver (non-hepatitis) 19,601 13,500 6,101 36 460 5,980 6,105 920 12 216 2,057 2,596 1,220
3. Appendicitis 741 407 334 86 105 91 71 54 44 134 86 36 34
4. Intestinal obstruction 4,938 2,162 2,776 195 122 306 862 677 80 128 536 676 1,357
5. Diverticulitis 4,512 1,934 2,578 0 76 420 971 467 0 8 380 1,175 1,015
6. Gall bladder and bile duct disease 3,239 1,357 1,882 3 84 176 582 512 3 215 371 605 688
7. Pancreatitis 2,065 1,226 838 32 50 332 561 251 1 17 122 349 350
8. Inflammatory bowel disease 9,307 4,473 4,834 351 2,240 1,353 454 75 357 2,544 1,403 425 105
9. Vascular insufficiency of intestine 3,524 1,424 2,100 5 61 107 769 482 14 64 99 833 1,090
10. Other digestive system diseases 8,537 3,802 4,735 490 670 524 1,102 1,016 116 1,123 626 1,299 1,571
O. Genitourinary diseases 61,969 34,539 27,430 182 4,839 5,747 15,717 8,053 294 8,995 6,670 4,449 7,021
1. Nephritis and nephrosis 12,503 5,837 6,666 69 418 679 1,616 3,055 45 205 472 1,645 4,300
2. Benign prostatic hypertrophy 17,079 17,079 — 1 123 2,186 11,257 3,511 — — — — —
3. Urinary incontinence 8,820 2,547 6,273 — — 822 1,402 322 — 2,985 2,327 540 420
4. Other genitourinary diseases 23,568 9,077 14,491 112 4,298 2,059 1,443 1,164 249 5,805 3,871 2,264 2,301
P. Skin diseases 10,957 4,614 6,343 765 1,845 1,094 585 324 1,064 2,391 1,368 755 766
1. Eczema 3,008 1,006 2,002 405 302 182 87 29 521 783 499 168 30
2. Other skin diseases 7,949 3,607 4,341 360 1,543 912 498 294 542 1,607 869 587 735
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Annex Table H (continued): DALYs by age, sex and cause, Australia, 1996
Male Female
Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
Q. Musculoskeletal diseases 89,916 34,534 55,382 862 3,941 12,402 14,148 3,181 1,511 4,768 18,422 24,521 6,159
1. Rheumatoid arthritis 11,989 3,646 8,343 607 641 1,070 1,065 264 1,174 1,362 2,277 2,378 1,152
2. Osteoarthritis 56,305 22,610 33,695 — 1,113 8,325 10,984 2,187 — 893 10,969 18,640 3,193
3. Chronic back pain 4,016 2,089 1,927 20 392 978 497 202 13 437 744 474 260
4. Slipped disc 3,875 2,301 1,574 7 637 1,142 438 76 9 291 818 369 87
5. Occupational overuse syndrome 3,449 112 3,337 — 7 74 31 — — 766 2,140 431 —
6. Osteoporosis 2,555 315 2,240 — 48 95 121 51 — 147 677 958 458
7. Other musculoskeletal disorders 7,727 3,462 4,265 229 1,102 717 1,013 401 315 872 797 1,272 1,010
R. Congenital anomalies 32,332 17,577 14,754 15,223 1,005 573 564 212 12,199 919 811 623 202
1. Anencephaly 369 184 186 184 — — — — 186 — — — —
2. Spina bifida 1,071 550 522 478 55 — 17 — 495 27 — — —
3. Congenital heart disease 9,087 4,830 4,257 3,911 474 308 117 19 3,263 545 303 124 22
4. Cleft lip and/or palate 151 84 67 84 — — — — 67 — — — —
5. Digestive system malformations 632 251 381 191 29 — 14 17 298 30 23 30 —
6. Urogenital tract malformations 2,079 1,248 830 689 82 46 272 159 336 3 75 267 150
7. Abdominal wall defect 145 98 47 98 — — — — 47 — — — —
8. Down syndrome 3,778 1,961 1,817 1,683 57 84 132 6 1,486 — 180 143 7
9. Other chromosomal disorders 7,558 4,140 3,418 4,140 — — — — 3,376 — 25 16 —
10. Other congenital anomalies 7,461 4,231 3,230 3,765 309 135 12 10 2,646 314 205 42 23
S. Oral health 23,992 11,102 12,890 499 3,059 4,126 2,844 573 473 3,113 4,777 3,505 1,021
1. Dental caries 13,463 6,649 6,814 499 2,519 2,057 1,248 327 473 2,468 2,032 1,303 539
2. Periodontal disease 7,250 3,495 3,755 — 465 1,543 1,244 243 — 460 1,526 1,347 421
3. Edentulism 3,228 942 2,286 — 76 526 340 — — 186 1,219 843 38
4. Other oral health problems 51 15 36 — — — 12 3 — — — 12 24
V. Ill—defined conditions 11,451 5,127 6,324 3,836 333 957 — — 3,051 1,238 1,971 65 —
1. Sudden infant death syndrome 6,550 3,731 2,819 3,731 — — — — 2,819 — — — —
2. Chronic fatigue syndrome 4,901 1,396 3,505 105 333 957 — — 231 1,238 1,971 65 —
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Annex Table H (continued): DALYs by age, sex and cause, Australia, 1996
Male Female
Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
III. Injuries 209,910 151,126 58,784 15,129 73,993 41,802 15,491 4,710 8,640 19,545 15,528 8,464 6,607
— — — — — — — — — — — — —
T. Unintentional injuries 143,120 98,853 44,267 14,335 45,798 24,136 10,631 3,953 7,986 13,323 9,620 6,984 6,355
1. Road traffic accidents 55,709 40,305 15,403 3,911 23,776 9,113 2,723 782 2,222 7,161 3,404 1,905 711
2. Other transport accidents 7,369 6,284 1,086 907 3,243 1,562 518 53 300 466 212 91 18
3. Poisoning 8,988 6,505 2,483 191 3,949 2,162 146 56 100 1,090 1,018 207 68
4. Falls 23,602 13,186 10,416 2,854 3,174 2,801 2,246 2,112 1,856 1,037 1,017 1,982 4,525
5. Fires/burns/scalds 4,707 3,311 1,395 982 1,136 815 285 92 514 334 276 140 130
6. Drowning 6,195 4,641 1,554 1,473 1,572 1,162 380 54 930 261 202 142 19
7. Sports injuries 2,460 1,979 481 454 1,320 150 45 10 124 234 87 26 11
8. Natural and environmental factors 1,660 1,019 641 140 358 355 134 33 113 183 191 86 69
9. Machinery accidents 4,375 4,061 313 254 1,733 1,438 591 46 88 76 123 25 1
10. Suffocation and foreign bodies 3,298 2,533 764 740 711 700 325 58 259 118 102 223 62
11. Adverse effects of medical treatment 1,795 944 852 105 222 234 310 73 36 181 267 246 122
a. Surgical/medical misadventure 853 442 411 7 69 141 196 29 3 61 136 159 51
b. Adverse effects of drugs in
therapeutic use
943 502 441 97 153 93 115 44 32 120 131 87 70
12. Other unintentional injuries 22,962 14,084 8,878 2,325 4,604 3,644 2,925 585 1,444 2,182 2,722 1,910 621
U. Intentional injuries 66,790 52,273 14,517 794 28,195 17,666 4,860 758 654 6,223 5,908 1,480 252
1. Suicide and self-inflicted injuries 55,930 44,531 11,399 232 23,585 15,626 4,363 724 210 4,719 4,987 1,265 218
2. Homicide and violence 10,698 7,608 3,089 562 4,500 2,016 497 34 443 1,476 921 215 34
3. Legal intervention and war 163 134 29 0 109 25 0 0 0 28 1 — 0
Australian population (’000) 18,272 9,106 9,165 2,005 2,795 2,574 1,387 346 1,906 2,707 2,545 1,446 562
DALYs per 1,000 population 137.4 146.2 128.7 60.2 78.4 104.7 337.1 735.3 48.6 67.2 85.7 235.8 615.1
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Annex Table I: Undiscounted DALYs by age, sex and cause, Australia, 1996
Undiscounted DALYs Male Female
Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
All causes 3,567,292 2,008,051 1,560,142 234,466 369,334 411,584 661,394 331,272 175,095 259,676 306,373 430,559 388,439
I   Communicable diseases, maternal
and neonatal conditions 203,830 115,336 88,494 57,585 16,564 21,236 12,554 7,396 47,748 13,335 9,913 8,226 9,271
A. Infectious & parasitic diseases 72,896 48,784 24,112 6,506 13,936 17,852 7,072 3,418 4,320 6,949 5,090 4,412 3,341
 1. Tuberculosis 1,253 784 469 87 21 63 371 243 2 86 21 237 122
2. Sexually transmitted diseases
(apart from HIV/AIDS) 1,518 170 1,348 9 142 11 2 6 30 1,620 459 57 12
a. Syphilis 155 146 9 9 129 2 1 6 2 6 1 0 0
b. Chlamydia 1,334 19 1,315 0 9 9 1 0 17 971 275 43 9
c. Gonorrhoea 29 5 24 0 4 1 0 0 0 18 5 0 0
d. Other STDs 830 — 830 — — — — — 11 625 178 13 2
3. HIV/AIDS 26,648 25,599 1,049 32 10,713 13,544 1,291 19 19 650 329 51 1
4. Diarrhoeal diseases 4,388 2,181 2,207 1,076 376 249 227 254 652 579 275 361 339
5. Childhood immunisable diseases 917 588 329 451 65 6 89 33 252 80 79 17 8
a. Diphtheria — — — — — — — — — — — — —
b. Whooping cough 301 229 72 215 6 6 2 1 52 8 8 2 1
c. Tetanus 0 0 0 — — — 0 — — — — 0 —
d. Polio 209 119 90 — — — 87 32 — — 70 14 6
e. Measles 152 68 84 12 55 0 0 0 13 71 0 0 0
f.  Rubella 255 171 84 167 4 1 0 0 82 1 0 0 0
g. Haemophilus influenzae type b 163 57 106 57 0 0 0 0 105 0 0 — 2
6. Meningitis 5,210 3,222 1,988 2,399 325 360 106 32 1,078 510 163 146 91
7. Septicaemia 7,615 4,077 3,538 389 143 452 1,469 1,624 283 161 373 855 1,865
8. Arbovirus infection (Ross River etc.) 1,773 670 1,103 13 190 336 119 12 26 327 547 180 23
9. Hepatitis 8,882 5,648 3,233 223 777 1,763 2,234 651 236 390 1,137 1,073 398
a. Hepatitis A 297 200 97 23 89 71 6 12 23 34 12 27 2
b. Hepatitis B 3,359 1,904 1,454 189 364 722 525 104 203 96 761 312 82
c. Hepatitis C 5,226 3,544 1,682 12 324 969 1,703 535 10 260 363 734 314
10. Malaria 80 79 1 1 55 0 23 0 1 0 0 0 0
11. Trachoma 1,768 585 1,182 372 76 84 46 7 409 106 310 343 14
12. Other infectious and parasitic 11,854 5,125 6,729 1,455 1,053 984 1,096 537 1,330 2,440 1,399 1,092 466
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Annex Table I (continued): Undiscounted DALYs by age, sex and cause, Australia, 1996
Undiscounted DALYs Male Female
Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
B. Acute respiratory infections 38,382 19,703 18,679 5,506 2,356 3,134 5,051 3,656 5,044 2,132 2,673 3,405 5,426
1. Lower respiratory tract infections 28,057 14,454 13,603 2,278 1,265 2,575 4,761 3,575 1,960 1,097 2,095 3,153 5,299
2. Upper respiratory tract infections 4,936 2,480 2,456 987 739 473 225 56 927 729 480 197 124
3. Otitis media 5,389 2,769 2,620 2,241 352 86 65 25 2,156 307 98 55 3
C. Maternal conditions 2,830 — 2,830 — — — — — 4 2,342 483 — —
1. Maternal haemorrhage 204 — 204 — — — — — 0 142 62 — —
2. Maternal sepsis 231 — 231 — — — — — 0 179 52 — —
3. Hypertension in pregnancy 714 — 714 — — — — — 0 623 91 — —
4. Obstructed labour 168 — 168 — — — — — 0 143 25 — —
5. Abortion 477 — 477 — — — — — 4 418 56 — —
6. Other maternal conditions 1,035 — 1,035 — — — — — — 838 197 — —
D. Neonatal causes 79,953 43,528 36,424 43,528 — — — — 36,345 — 80 — —
1. Birth trauma and asphyxia 21,907 12,158 9,750 12,158 — — — — 9,670 — 80 — —
2. Low birthweight 34,265 18,202 16,063 18,202 — — — — 16,063 — — — —
3. Neonatal infections 7,146 3,988 3,158 3,988 — — — — 3,158 — — — —
4. Other neonatal causes 16,634 9,181 7,453 9,181 — — — — 7,453 — — — —
E. Nutritional deficiencies 9,769 3,320 6,449 2,044 272 250 432 322 2,036 1,912 1,587 409 505
1. Protein-energy malnutrition 942 437 505 111 — — 144 182 108 54 75 80 189
2. Iron-deficiency anaemia 8,764 2,861 5,902 1,933 272 249 272 135 1,928 1,856 1,506 306 306
3. Other nutritional deficiencies 63 22 41 — 0 1 16 5 — 2 6 23 10
— — — — — — — — — — — — —
II. Non—communicable diseases 2,958,950 1,592,513 1,366,437 140,002 193,163 315,378 626,131 317,839 106,607 205,804 270,686 411,454 371,886
— — — — — — — — — — — — —
F. Malignant neoplasms 682,476 377,497 304,980 6,916 15,691 72,433 206,241 76,215 5,178 14,546 86,020 137,792 61,444
1. Mouth and oropharynx cancers 19,997 14,735 5,262 4 337 3,960 9,088 1,346 10 124 1,410 2,498 1,220
2. Oesophagus cancer 16,674 11,708 4,966 — 6 2,552 6,932 2,219 0 — 750 2,534 1,681
3. Stomach cancer 22,952 14,752 8,201 1 446 3,536 7,647 3,122 1 190 1,714 4,012 2,284
4. Colorectal cancer 92,727 52,153 40,574 2 589 9,498 32,469 9,595 — 984 8,226 20,599 10,765
5. Liver cancer 7,164 5,437 1,727 166 2 1,428 3,262 579 87 48 115 1,115 362
6. Gall bladder cancer 5,715 1,997 3,718 — 2 439 1,082 473 — — 736 1,892 1,090
7. Pancreas cancer 26,661 14,105 12,556 — 177 2,686 8,357 2,886 0 189 1,867 6,068 4,432
8. Lung cancer 130,591 90,146 40,445 0 134 14,299 58,893 16,820 — 284 9,037 23,192 7,931
9. Bone and connective tissue cancers 10,015 5,417 4,598 640 1,859 876 1,502 542 352 1,356 1,213 1,133 544
10. Melanoma 28,579 17,693 10,887 11 2,155 6,409 6,701 2,417 81 1,202 4,673 3,352 1,579
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Undiscounted DALYs Male Female
Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
11. Non-melanoma skin cancers 6,125 4,258 1,867 — 8 688 2,078 1,484 — 10 283 823 752
12. Breast cancer 74,041 — 74,041 — — — — — — 2,577 31,590 30,391 9,483
13. Cervix cancer 8,803 — 8,803 — — — — — 1 1,011 4,172 2,715 903
14. Uterus cancer 6,037 — 6,037 — — — — — — 22 1,088 3,441 1,485
15. Ovary cancer 17,403 — 17,403 — — — — — 81 789 5,246 8,377 2,910
16. Prostate cancer 43,318 43,318 — — — 1,465 23,666 18,187 — — — — —
17. Testicular cancer 1,926 1,926 — 6 1,137 661 102 21 — — — — —
18. Bladder cancer 13,183 9,617 3,566 81 188 963 4,951 3,434 1 66 352 1,511 1,637
19. Kidney cancer 16,220 9,706 6,514 182 11 2,033 5,604 1,877 179 147 1,272 3,244 1,673
20. Brain cancer 29,751 17,818 11,933 1,443 2,865 6,224 6,087 1,199 1,763 1,694 3,445 4,078 953
21. Thyroid cancer 1,924 737 1,187 1 88 246 295 108 3 147 472 294 270
22. Lymphoma 34,010 18,577 15,433 509 1,768 5,346 8,071 2,883 107 1,271 3,609 6,914 3,532
23. Multiple myeloma 10,873 6,184 4,689 — 5 1,420 3,408 1,351 — 64 776 2,621 1,227
24. Leukemia 31,093 18,839 12,254 2,547 2,999 3,739 6,533 3,021 2,058 1,767 2,119 3,681 2,629
25. Other malignant neoplasms 26,689 18,364 8,325 1,323 916 3,963 9,510 2,652 455 606 1,859 3,311 2,095
G. Other neoplasms 10,361 5,162 5,199 623 548 797 1,700 1,494 466 574 1,423 1,206 1,529
1. Uterine myomas — — 901 — — — — — 0 98 719 75 9
2. Benign brain tumour 1,681 728 953 9 19 280 297 122 6 138 343 317 149
3. Other benign neoplasms 7,780 4,434 3,346 613 529 518 1,403 1,372 460 338 362 814 1,372
H. Diabetes mellitus 111,537 59,690 51,848 2,748 2,947 18,725 24,745 10,525 3,023 4,488 13,979 18,656 11,701
1. Type 1 diabetes 15,620 7,768 7,853 2,748 2,418 1,551 775 276 3,023 2,333 1,502 749 246
2. Type 2 diabetes 95,917 51,922 43,995 — 529 17,174 23,970 10,249 — 2,155 12,477 17,907 11,455
I. Endocrine and metabolic disorders 41,120 22,628 18,491 3,776 2,212 5,161 7,972 3,507 3,689 2,476 3,229 4,878 4,219
1. Non-deficiency anaemia 7,797 3,732 4,065 1,310 337 299 1,027 760 687 589 690 978 1,121
2. Cystic fibrosis 3,570 1,535 2,035 703 757 75 — — 1,104 846 85 — —
3. Haemophilia 891 562 329 224 — 166 115 56 — — 149 101 79
4. Other endocrine and metabolic 28,861 16,799 12,062 1,539 1,119 4,621 6,829 2,691 1,898 1,041 2,305 3,798 3,020
J. Mental disorders 411,333 208,582 202,751 29,711 112,421 55,888 9,516 1,046 17,154 113,188 54,920 15,769 1,720
1. Substance use disorders 101,259 70,469 30,791 73 46,707 19,756 3,399 534 — 21,408 6,066 2,236 1,080
a. Alcohol dependence/harmful use 51,573 36,254 15,319 — 19,169 13,552 3,133 401 — 10,314 4,138 748 119
b. Heroin or polydrug dependence
and harmful use 37,069 27,381 9,688 — 22,146 5,180 55 — — 8,574 1,114 — —
c. Sedative dependence/abuse 3,408 1,828 1,580 — 1,059 674 95 — — 771 569 229 11
d. Cannabis dependence/abuse 4,686 3,281 1,405 — 3,260 21 — — — 1,346 59 — —
e. Other drug dependence/abuse 4,524 1,725 2,799 73 1,073 329 116 134 — 403 185 1,260 951
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Undiscounted DALYs Male Female
Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
2. Schizophrenia 33,512 16,809 16,704 — 14,642 2,102 46 19 — 12,785 3,650 206 62
3. Affective disorders 119,833 49,015 70,818 2,990 25,279 17,377 3,144 225 3,433 38,878 19,384 8,939 183
a. Depression 95,337 36,942 58,395 2,990 13,207 17,377 3,144 225 3,433 26,503 19,384 8,912 163
b. Bipolar affective disorder 24,496 12,073 12,423 — 12,073 — — — — 12,376 — 27 20
4. Anxiety disorders 91,203 35,465 55,739 1,660 19,493 12,030 2,088 193 1,726 26,719 23,162 3,838 294
a. Panic disorder 6,955 1,482 5,473 — 970 473 40 — — 3,620 1,648 200 4
b. Agoraphobia 5,701 1,509 4,192 — 787 669 53 — — 2,489 1,303 400 —
c. Social phobia 23,197 10,459 12,738 — 7,751 2,185 464 59 — 9,618 2,902 188 30
d. Generalised anxiety disorder 39,191 13,941 25,249 — 6,171 6,553 1,082 135 — 7,622 14,646 2,827 154
e. Obsessive-compulsive disorder 5,175 2,688 2,488 — 1,369 1,104 215 — — 1,074 1,085 223 105
f.  Post-traumatic stress disorder 8,281 4,000 4,281 275 2,445 1,046 234 — 407 2,296 1,578 — —
g. Separation anxiety disorder 2,704 1,385 1,319 1,385 — — — — 1,319 — — — —
5. Borderline personality disorder 17,679 11,096 6,582 — 5,826 4,544 726 — — 3,683 2,419 480 —
6. Eating disorders 12,488 601 11,887 107 473 — — 21 2,043 9,646 160 14 24
7. Childhood conditions 26,953 20,400 6,553 20,400 — — — — 6,553 — — — —
a. Attention-deficit disorder 14,726 10,647 4,079 10,647 — — — — 4,079 — — — —
b. Autism and Asperger’s syndrome 12,227 9,753 2,474 9,753 — — — — 2,474 — — — —
 8. Mental retardation 7,914 4,402 3,512 4,398 — — — 4 3,398 67 32 14 —
9. Other mental disorders 492 327 165 84 — 80 115 48 — — 48 41 77
K. Nervous system and sense organ
 disorders 297,458 142,419 155,039 9,025 10,629 17,188 60,471 45,106 5,834 7,856 12,621 48,335 80,393
1. Dementia 103,546 40,146 63,400 736 60 1,485 16,465 21,399 417 183 1,796 21,372 39,633
2. Epilepsy 18,033 10,881 7,152 2,181 3,955 3,072 1,361 313 1,212 2,816 1,561 1,141 422
3. Parkinsons’s disease 32,087 14,494 17,593 — — 32 8,517 5,945 — — 32 6,569 10,991
4. Multiple sclerosis 6,686 1,915 4,771 38 636 912 277 51 85 1,620 2,135 815 117
5. Motor neuron disease 6,670 4,355 2,315 — 133 1,264 2,446 511 — 69 401 1,420 424
6. Huntington’s chorea 2,004 1,283 721 — — 869 367 47 — — 343 324 54
7. Muscular dystrophy 2,758 2,452 306 804 1,325 274 37 12 61 127 65 45 8
 8. Sense organ disorders 98,511 52,289 46,222 3 1,282 7,509 28,218 15,278 253 1,199 4,474 13,454 26,842
a. Glaucoma 2,119 455 1,663 — — — 152 303 — — 214 184 1,265
b. Cataracts 6,580 1,582 4,998 3 4 33 574 967 2 3 394 697 3,903
c. Age-related vision disorders 23,608 4,823 18,785 — — — 1,249 3,573 — — 1,110 1,996 15,680
d. Adult-onset hearing loss 66,205 45,429 20,775 — 1,277 7,476 26,242 10,434 251 1,196 2,756 10,577 5,994
9. Other nervous system, sense organ 27,164 14,604 12,560 5,263 3,239 1,771 2,783 1,549 3,806 1,843 1,814 3,195 1,902
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Undiscounted DALYs Male Female
Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
L. Cardiovascular disease 732,372 431,608 300,765 2,576 11,632 75,861 208,611 132,928 2,145 6,114 26,201 101,488 164,818
1. Rheumatic heart disease 5,868 2,442 3,426 80 447 435 1,011 469 76 124 568 1,761 897
2. Ischaemic heart disease 421,393 265,095 156,297 0 4,017 49,231 133,244 78,603 1 1,325 10,470 55,673 88,829
3. Stroke 175,321 88,749 86,573 672 2,704 12,356 39,418 33,599 601 2,197 8,977 26,016 48,783
4. Inflammatory heart disease 32,043 21,599 10,445 1,268 1,923 6,536 9,265 2,606 794 1,165 2,264 3,546 2,675
5. Hypertensive heart disease 16,366 7,172 9,194 — 176 790 2,729 3,477 — 3 223 2,150 6,818
6. Non-rheumatic valvular disease 11,538 6,296 5,242 2 183 943 2,913 2,255 90 74 505 1,502 3,072
7. Aortic aneurysm 18,134 12,451 5,684 0 250 1,212 6,808 4,180 0 54 179 2,418 3,033
8. Peripheral arterial disease 23,574 13,446 10,128 48 238 2,050 7,597 3,513 48 303 1,327 4,151 4,298
9. Other cardiovascular disease 28,134 14,357 13,777 505 1,693 2,307 5,626 4,226 535 870 1,688 4,271 6,414
M. Chronic respiratory disease 244,102 132,778 111,324 30,806 10,503 19,903 46,163 25,403 24,704 19,230 17,930 30,568 18,893
1. COPD 129,994 80,134 49,860 170 6,538 15,584 38,097 19,745 507 4,118 10,546 22,142 12,547
2. Asthma 87,607 38,058 49,549 27,938 3,341 2,778 2,943 1,058 22,201 14,162 6,190 4,821 2,174
3. Other chronic respiratory diseases 26,502 14,586 11,916 2,698 624 1,541 5,123 4,600 1,996 950 1,194 3,605 4,172
N. Diseases of the digestive system 96,310 53,784 42,526 2,767 7,786 16,856 19,156 7,219 1,443 8,984 10,044 11,564 10,491
1. Peptic ulcer disease 9,857 4,862 4,995 — 256 955 2,210 1,440 — 372 1,038 1,340 2,246
2. Cirrhosis of the liver (non-hepatitis) 31,335 22,538 8,797 81 947 10,714 9,548 1,248 13 407 3,471 3,527 1,377
3. Appendicitis 968 549 419 136 105 134 100 74 44 174 123 41 37
4. Intestinal obstruction 6,800 3,172 3,628 492 218 452 1,147 863 198 242 836 850 1,502
5. Diverticulitis 5,454 2,457 2,997 0 141 600 1,175 541 0 11 511 1,375 1,099
6. Gall bladder and bile duct disease 3,946 1,814 2,132 3 144 220 786 661 3 255 423 697 754
7. Pancreatitis 2,958 1,910 1,047 85 78 559 848 340 1 17 196 441 393
8. Inflammatory bowel disease 17,315 8,156 9,159 826 4,472 2,167 598 93 873 5,258 2,350 562 117
9. Vascular insufficiency of intestine 4,743 2,096 2,648 11 125 175 1,143 642 37 140 156 1,086 1,229
10. Other digestive system diseases 12,935 6,231 6,704 1,133 1,299 881 1,599 1,318 274 2,109 940 1,644 1,737
O. Genitourinary diseases 78,728 42,965 35,763 387 5,734 7,786 19,541 9,517 674 12,693 8,879 5,672 7,845
1. Nephritis and nephrosis 16,113 8,164 7,949 134 677 986 2,291 4,076 95 281 671 2,091 4,811
2. Benign prostatic hypertrophy 20,568 20,568 — 2 223 3,168 13,497 3,678 — — — — —
3. Urinary incontinence 14,739 3,403 11,337 — — 1,295 1,754 353 — 6,178 3,996 697 465
4. Other genitourinary diseases 27,308 10,830 16,477 251 4,834 2,337 1,999 1,410 579 6,233 4,212 2,884 2,568
P. Skin diseases 12,043 5,119 6,925 827 1,938 1,258 695 401 1,149 2,549 1,513 866 848
1. Eczema 3,190 1,068 2,122 430 321 193 92 32 553 832 528 176 32
2. Other skin diseases 8,853 4,050 4,803 397 1,617 1,065 603 369 596 1,717 985 689 816
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Undiscounted DALYs Male Female
Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
Q. Musculoskeletal diseases 114,724 44,527 70,197 1,117 5,374 17,013 17,418 3,605 2,131 6,529 24,955 29,874 6,708
1. Rheumatoid arthritis 15,375 4,746 10,629 835 855 1,362 1,373 322 1,628 1,877 2,951 2,895 1,277
2. Osteoarthritis 73,073 29,623 43,450 — 1,820 11,985 13,402 2,416 — 1,472 15,796 22,737 3,445
3. Chronic back pain 4,031 2,100 1,931 20 392 978 506 204 13 437 744 476 261
4. Slipped disc 5,225 3,133 2,093 13 972 1,556 511 81 19 445 1,107 430 92
5. Occupational overuse syndrome 3,607 117 3,490 — 7 77 32 — — 801 2,238 450 —
6. Osteoporosis 3,573 462 3,111 — 88 148 159 67 — 283 1,076 1,244 507
7. Other musculoskeletal disorders 9,840 4,347 5,493 250 1,240 907 1,435 515 472 1,214 1,041 1,641 1,125
R. Congenital anomalies 77,006 42,096 34,909 37,618 2,257 1,052 883 287 30,469 1,984 1,385 843 228
1. Anencephaly 1,033 516 516 516 — — — — 516 — — — —
2. Spina bifida 2,678 1,340 1,338 1,194 119 — 27 — 1,285 54 — — —
3. Congenital heart disease 22,282 12,015 10,266 10,175 1,061 568 185 27 8,362 1,183 527 169 24
4. Cleft lip and/or palate 391 211 179 211 — — — — 179 — — — —
5. Digestive system malformations 1,533 594 939 478 70 — 23 23 790 70 37 42 —
6. Urogenital tract malformations 4,318 2,757 1,561 1,857 179 82 423 215 904 7 123 358 169
7. Abdominal wall defect 342 244 98 244 — — — — 98 — — — —
8. Down syndrome 8,577 4,416 4,161 3,922 130 150 207 8 3,653 — 304 197 8
9. Other chromosomal disorders 17,274 9,252 8,022 9,252 — — — — 7,951 — 48 23 —
10. Other congenital anomalies 18,577 10,749 7,828 9,766 698 253 18 14 6,729 670 346 55 27
S. Oral health 25,950 11,710 14,240 500 3,144 4,459 3,020 588 475 3,307 5,542 3,868 1,049
1. Dental caries 13,502 6,668 6,834 500 2,526 2,063 1,252 328 475 2,474 2,038 1,307 541
2. Periodontal disease 7,559 3,642 3,917 — 479 1,602 1,308 253 — 474 1,584 1,420 439
3. Edentulism 4,826 1,379 3,448 — 140 794 442 3 — 359 1,920 1,127 42
4. Other oral health problems 62 22 41 — — — 18 3 — — — 14 26
V. Ill—defined conditions 23,416 11,944 11,472 10,605 346 993 — — 8,074 1,285 2,046 67 —
1. Sudden infant death syndrome 18,330 10,496 7,834 10,496 — — — — 7,834 — — — —
2. Chronic fatigue syndrome 5,085 1,448 3,638 109 346 993 — — 240 1,285 2,046 67 —
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Disease category Total Male Female 0–14 15–34 35–54 55–74 75+ 0–14 15–34 35–54 55–74 75+
III. Injuries 405,425 300,206 105,218 36,879 159,607 74,975 22,709 6,037 20,739 40,537 25,774 10,886 7,282
— — — — — — — — — — — — —
T. Unintentional injuries 272,866 195,055 77,811 34,793 97,960 42,257 15,057 4,988 19,054 27,374 15,511 8,879 6,993
1. Road traffic accidents 114,488 84,214 30,274 9,911 52,531 16,542 4,171 1,059 5,608 15,446 5,849 2,563 808
2. Other transport accidents 15,047 12,820 2,227 2,231 6,932 2,791 794 72 759 965 359 125 20
3. Poisoning 18,063 13,429 4,634 459 8,627 4,044 223 75 232 2,295 1,749 280 78
4. Falls 37,377 22,724 14,652 6,027 6,195 4,636 3,204 2,663 3,792 1,951 1,526 2,433 4,951
5. Fires/burns/scalds 9,483 6,774 2,709 2,482 2,300 1,437 431 124 1,291 656 435 180 147
6. Drowning 13,995 10,359 3,637 4,010 3,531 2,142 601 74 2,518 568 346 184 21
7. Sports injuries 4,513 3,690 823 921 2,492 212 55 10 217 427 135 32 11
8. Natural and environmental factors 3,037 1,892 1,145 338 701 617 194 42 273 367 316 111 78
9. Machinery accidents 8,047 7,431 616 641 3,491 2,415 829 55 226 154 202 33 1
10. Suffocation and foreign bodies 6,963 5,479 1,484 2,019 1,583 1,287 512 80 684 259 180 291 69
11. Adverse effects of medical treatment 2,946 1,616 1,330 269 443 381 433 90 84 365 434 312 135
a. Surgical/medical misadventure 1,323 707 616 16 138 233 283 37 7 123 225 204 58
b. Adverse effects of drugs in
therapeutic use
1,622 909 714 253 305 148 150 53 77 242 209 108 77
12. Other unintentional injuries 38,908 24,627 14,281 5,486 9,133 5,753 3,611 643 3,372 3,922 3,979 2,334 674
U. Intentional injuries 132,559 105,151 27,408 2,085 61,647 32,717 7,652 1,049 1,685 13,163 10,263 2,007 289
1. Suicide and self-inflicted injuries 110,879 89,673 21,206 586 52,103 29,098 6,883 1,004 517 10,032 8,689 1,717 250
2. Homicide and violence 21,335 15,193 6,141 1,500 9,308 3,572 769 46 1,167 3,072 1,573 290 39
3. Legal intervention and war 345 285 60 0 237 48 0 0 0 59 1 — 0
Australian population (’000) 18,272 9,106 9,165 2,005 2,795 2,574 1,387 346 1,906 2,707 2,545 1,446 562
DALYs per 1,000 population 195.2 220.5 170.2 116.9 132.1 159.9 476.8 957.3 91.9 95.9 120.5 297.8 690.8
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